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ABSTRACT 
Asthma is a chronic airway disease with high prevalence worldwide. Symptoms – including wheeze, 
cough, shortness of breath and chest tightness – can be life-threatening and long-lasting. Yet, asthma 
remains without cure, and the need for improved treatments is clear. In a genome-wide association 
study (GWAS) performed in 2011,1 a variant (rs4129267) in the interleukin-6 (IL-6) receptor gene 
(IL6R) was reported to associate with asthma risk. That study showed that asthmatics are more likely 
to carry the rs4129267:T allele that correlates with increased serum levels of the soluble IL-6 receptor 
(sIL-6R), which in turn appears to extend the inflammatory effects of IL-6 through a pathway called 
trans-signalling. Subsequently, a variant in high linkage disequilibrium with rs4129267:T was shown 
to associate with poor lung function and severe asthma. Together with functional studies that 
implicated the IL-6 pathway in asthma, these findings suggested that anti-IL-6R therapy – specifically 
inhibition of IL-6 trans-signalling – might represent a new treatment option for asthma.  
The goal of this thesis was to study that hypothesis and to understand the significance of the IL-6 
pathway in asthma. Specifically, four main questions were addressed:  
1. What characterises asthma patients likely to benefit from anti-IL-6R therapy?  
2. Is IL-6 trans-signalling more likely to be promoted by some allergen types?  
3. Are there other genes that associate with IL-6 signalling that are also risk factors for asthma?  
4. Can asthma symptoms be attenuated by a drug that blocks IL-6 signalling? 
To address the first question (Chapter 2), sputum IL-6 and sIL-6R levels were tested for association 
with relevant clinical information available for 33 asthmatics. Sputum levels of IL-6 and sIL-6R were 
largely independent of levels measured in matched serum samples. On the other hand, sputum levels 
of IL-6 and sIL-6R associated with the total number of immune cells measured in the same samples. 
High sputum levels of IL-6 and sIL-6R – which promotes IL-6 trans-signalling – were more likely to 
be observed in patients with neutrophilic and mixed granulocytic sputum inflammatory subtypes. 
To assess whether some allergen types were more likely to trigger airway inflammation that is 
associated with IL-6 trans-signalling (Chapter 3), the frequency of sputum subtypes observed after 
allergen challenge was studied in 129 asthma patients exposed to different allergen types. Overall, 
baseline sputum inflammatory subtypes shifted towards eosinophilic and mixed granulocytic 
  
inflammation after allergen inhalation. However, no difference was observed in the frequency of 
sputum inflammatory subtypes between the different allergen types used in the allergen challenge. 
In Chapter 4, data from gene expression studies and asthma GWAS were analysed to study gene 
networks associated with IL-6 signalling in asthma. Specifically, genes co-expressed with IL6R were 
screened for nearby variants that associated both with the expression of that gene and asthma risk. 
Five such genes were identified, including one which had not previously been implicated in disease 
pathophysiology: STOML2. This gene plays a key role in mitochondrial function and T-cell 
activation. Follow-up analyses (Chapter 5) of the STOML2 risk variant showed that it has a stronger 
effect in early-onset asthma, while it also associates with the risk of hay fever.  
Finally, two approaches were used to determine if tocilizumab – a drug that blocks IL-6 classic and 
trans-signalling and is approved to treat rheumatoid arthritis – represents a promising new treatment 
for asthma.  
First, data from a proof-of-concept clinical trial were analysed to assess the effect of a single dose of 
tocilizumab on allergen-induced asthma exacerbations (Chapter 6). Eleven participants with mild 
asthma completed the trial. Lung function, airway hyperresponsiveness, pathology results and 
inflammatory cells and mediators were compared between the tocilizumab and placebo groups. 
Overall, the drug did not inhibit allergen-induced airway responses. One participant with 
mixed-granulocytic sputum, rs4129267:TT genotype and treated with tocilizumab did not develop a 
late asthmatic response, but this should not be over-interpreted. Second, using data from the 
Australian Pharmaceutical Benefits Scheme (Chapter 7), individuals who were treated regularly with 
tocilizumab and were also likely to suffer from asthma were identified (N = 88). Then, in these 
individuals and a group of matched controls (N = 440), the number of asthma-related prescriptions 
was compared one year before against one year after the onset of tocilizumab treatment. Results 
showed no significant differences in the number and frequency of inhaled corticosteroids, suggesting 
that regular tocilizumab is unlikely to have an effect in asthma symptoms. 
In summary, (1) IL-6 trans-signalling was associated with mixed-granulocytic sputum; (2) different 
allergens were unlikely to influence sputum inflammatory subtype; (3) STOML2 was identified as an 
IL6R-associated gene with suggestive association with early-onset allergic disease; and (4) 
tocilizumab treatment did not reduce allergen-induced bronchoconstriction, nor the frequency of 
asthma-related prescriptions.  
  
DECLARATION BY AUTHOR 
This thesis is composed of my original work, and contains no material previously published or written 
by another person except where due reference has been made in the text. I have clearly stated the 
contribution by others to jointly-authored works that I have included in my thesis. 
I have clearly stated the contribution of others to my thesis as a whole, including statistical assistance, 
survey design, data analysis, significant technical procedures, professional editorial advice, financial 
support and any other original research work used or reported in my thesis. The content of my thesis 
is the result of work I have carried out since the commencement of my higher degree by research 
candidature and does not include a substantial part of work that has been submitted to qualify for the 
award of any other degree or diploma in any university or other tertiary institution. I have clearly 
stated which parts of my thesis, if any, have been submitted to qualify for another award. 
I acknowledge that an electronic copy of my thesis must be lodged with the University Library and, 
subject to the policy and procedures of The University of Queensland, the thesis be made available 
for research and study in accordance with the Copyright Act 1968 unless a period of embargo has 
been approved by the Dean of the Graduate School.  
I acknowledge that copyright of all material contained in my thesis resides with the copyright 
holder(s) of that material. Where appropriate I have obtained copyright permission from the copyright 
holder to reproduce material in this thesis and have sought permission from co-authors for any jointly 
authored works included in the thesis. 
  
  
PUBLICATIONS DURING CANDIDATURE 
1. Ullah MA, Revez JA, Loh Z, Simpson J, Zhang V, Bain L, Varelias A, Rose-John S, 
Blumenthal A, Smyth MJ, Hill GR, Sukkar MB, Ferreira MA, Phipps S: Allergen-induced 
IL-6 trans-signaling activates gammadelta T cells to promote type 2 and type 17 airway 
inflammation. J Allergy Clin Immunol 2015;136:1065-1073. 
2. Revez JA, Matheson MC, Hui J, Baltic S, Australian Asthma Genetics Consortium c, James 
A, Upham JW, Dharmage S, Thompson PJ, Martin NG, Hopper JL, Ferreira MA: 
Identification of STOML2 as a putative novel asthma risk gene associated with IL6R. Allergy 
2016;71:1020-1030. 
3. Ferreira MA, Jansen R, Willemsen G, Penninx B, Bain LM, Vicente CT, Revez JA, Matheson 
MC, Hui J, Tung JY, Baltic S, Le Souef P, Montgomery GW, Martin NG, Robertson CF, 
James A, Thompson PJ, Boomsma DI, Hopper JL, Hinds DA, Werder RB, Phipps S, 
Australian Asthma Genetics Consortium C: Gene-based analysis of regulatory variants 
identifies 4 putative novel asthma risk genes related to nucleotide synthesis and signaling. J 
Allergy Clin Immunol 2017;139:1148-1157.  
4. Ferreira MA, Vonk JM, Baurecht H, Marenholz I, Tian C, Hoffman JD, Helmer Q, Tillander 
A, Ullemar V, van Dongen J, Lu Y, Ruschendorf F, Esparza-Gordillo J, Medway CW, 
Mountjoy E, Burrows K, Hummel O, Grosche S, Brumpton BM, Witte JS, Hottenga JJ, 
Willemsen G, Zheng J, Rodriguez E, Hotze M, Franke A, Revez JA, Beesley J, Matheson 
MC, Dharmage SC, Bain LM, Fritsche LG, Gabrielsen ME, Balliu B, andMe Research T, 
collaborators A, consortium B, LifeLines Cohort S, Nielsen JB, Zhou W, Hveem K, 
Langhammer A, Holmen OL, Loset M, Abecasis GR, Willer CJ, Arnold A, Homuth G, 
Schmidt CO, Thompson PJ, Martin NG, Duffy DL, Novak N, Schulz H, Karrasch S, Gieger 
C, Strauch K, Melles RB, Hinds DA, Hubner N, Weidinger S, Magnusson PKE, Jansen R, 
Jorgenson E, Lee YA, Boomsma DI, Almqvist C, Karlsson R, Koppelman GH, Paternoster 
L: Shared genetic origin of asthma, hay fever and eczema elucidates allergic disease biology. 
Nat Genet 2017;49:1752-1757. 
5. Vicente CT, Revez JA, Ferreira MAR: Lessons from ten years of genome-wide association 
studies of asthma. Clin Transl Immunol 2017;6:e165. 
  
6. Revez JA, Killian KJ, O'Byrne PM, Boulet LP, Upham JW, Gauvreau GM, Ferreira MAR: 
Sputum cytology during late-phase responses to inhalation challenge with different allergens. 
Allergy 2018 (in press). 
PUBLICATIONS INCLUDED IN THIS THESIS 
Ullah MA, Revez JA, Loh Z, Simpson J, Zhang V, Bain L, Varelias A, Rose-John S, Blumenthal A, 
Smyth MJ, Hill GR, Sukkar MB, Ferreira MA, Phipps S: Allergen-induced IL-6 trans-signaling 
activates gammadelta T cells to promote type 2 and type 17 airway inflammation. J Allergy Clin 
Immunol 2015;136:1065-1073 – partially incorporated as Chapter 2. 
Contributor Statement of contribution 
Ullah MA  Conception and design: 40% 
Analysis and interpretation: 40% 
Drafting and production: 35% 
Revez JA (Candidate) Conception and design: 30% 
Analysis and interpretation: 35% 
Drafting and production: 30% 
Loh Z Conception and design: 0% 
Analysis and interpretation: 1% 
Drafting and production: 0% 
Simpson J Conception and design: 0% 
Analysis and interpretation: 1% 
Drafting and production: 0% 
Zhang V Conception and design: 0% 
Analysis and interpretation: 1% 
Drafting and production: 0% 
Bain L Conception and design: 0% 
Analysis and interpretation: 1% 
Drafting and production: 0% 
Varelias A Conception and design: 5% 
Analysis and interpretation: 1% 
Drafting and production: 5%  
Rose-John S Conception and design: 1% 
Analysis and interpretation: 1% 
Drafting and production: 2% 
  
Blumenthal A Conception and design: 1% 
Analysis and interpretation: 1% 
Drafting and production: 0% 
Smyth MJ Conception and design: 1% 
Analysis and interpretation: 1% 
Drafting and production: 2% 
Hill GR Conception and design: 1% 
Analysis and interpretation: 1% 
Drafting and production: 5% 
Sukkar MB Conception and design: 1% 
Analysis and interpretation: 1% 
Drafting and production: 1% 
Ferreira MA Conception and design: 10% 
Analysis and interpretation: 5% 
Drafting and production: 10% 
Phipps S Conception and design: 10% 
Analysis and interpretation: 10% 
Drafting and production: 10% 
 
Revez JA, Killian KJ, O'Byrne PM, Boulet LP, Upham JW, Gauvreau GM, Ferreira MAR: Sputum 
cytology during late-phase responses to inhalation challenge with different allergens. Allergy 2018 
(in press) - incorporated as Chapter 3. 
Contributor Statement of contribution 
Revez J. A (Candidate) Conception and design: 60% 
Analysis and interpretation: 70% 
Drafting and production: 80% 
K. J. Killian Conception and design: 5% 
Analysis and interpretation: 2% 
Drafting and production: 1% 
P. M. O’Byrne Conception and design: 5% 
Analysis and interpretation: 5% 
Drafting and production: 2% 
L. Boulet Conception and design: 5% 
Analysis and interpretation: 2% 
Drafting and production: 1% 
J. W. Upham Conception and design: 5% 
Analysis and interpretation: 1% 
Drafting and production: 1% 
  
G. M. Gauvreau Conception and design: 10% 
Analysis and interpretation: 10% 
Drafting and production: 5% 
M. A. R. Ferreira Conception and design: 10% 
Analysis and interpretation: 10% 
Drafting and production: 10% 
 
Revez JA, Matheson MC, Hui J, Baltic S, Australian Asthma Genetics Consortium, James A, Upham 
JW, Dharmage S, Thompson PJ, Martin NG, Hopper JL, Ferreira MA: Identification of STOML2 as 
a putative novel asthma risk gene associated with IL6R. Allergy 2016;71:1020-1030 – incorporated 
as Chapter 4. 
Contributor Statement of contribution 
Revez JA (Candidate) Conception and design: 70% 
Analysis and interpretation: 80% 
Drafting and production: 90% 
Matheson MC Conception and design: 0% 
Analysis and interpretation: 1% 
Drafting and production: 0% 
Hui J Conception and design: 0% 
Analysis and interpretation: 1% 
Drafting and production: 0% 
Baltic S Conception and design: 0% 
Analysis and interpretation: 1% 
Drafting and production: 0% 
Australian Asthma Genetics 
Consortium 
Conception and design: 0% 
Analysis and interpretation: 1% 
Drafting and production: 0% 
James A Conception and design: 0% 
Analysis and interpretation: 1% 
Drafting and production: 0% 
Upham JW Conception and design: 0% 
Analysis and interpretation: 1% 
Drafting and production: 2% 
  
Dharmage S Conception and design: 0% 
Analysis and interpretation: 1% 
Drafting and production: 0% 
Thompson PJ Conception and design: 0% 
Analysis and interpretation: 1% 
Drafting and production: 0% 
Martin NG Conception and design: 0% 
Analysis and interpretation: 1% 
Drafting and production: 2% 
Hopper JL Conception and design: 0% 
Analysis and interpretation: 1% 
Drafting and production: 1% 
Ferreira MA Conception and design: 30% 
Analysis and interpretation: 10% 
Drafting and production: 5% 
CONTRIBUTIONS BY OTHERS TO THE THESIS  
Chapter 2 is part of a manuscript published in the Journal of Allergy and Clinal Immunology. The 
publication included results from (1) experimental mouse models of asthma, and (2) human 
association studies. Author individual contributions to that publication are listed in the “Publications 
included in this thesis” section. Contributions to the subset of results included in this thesis (human 
association results, only) were exclusively made by myself, Ms. Lisa Bain and Dr. Manuel Ferreira. 
Chapter 6 includes results from a clinical trial to which the following contributions were made:  
 Porf. Gail M Gauvreau: led the clinical trial site at McMaster University, being responsible 
for ethical and regulatory approval, supervision of participant recruitment and clinical testing. 
She also developed and provided the clinical protocol used in the trial and trained the Brisbane 
team. 
 Prof. Paul O’Byrne: Developed the clinical protocol used in the trial. 
 Mr. Rick Watson: recruited and clinically tested all the participants at McMaster University. 
 Ms. Lisa Bain: Responsible for ethics and regulatory approval of the trial protocol in Brisbane, 
sourcing all the material and equipment for the trial, recruiting participants, clinical testing, 
  
assisting clinical nurses at both Brisbane sites, measuring inflammatory mediators in 
biological samples. 
 Ms. Michelle Towers: clinical nurse at the Princess Alexandra Hospital (Brisbane) who was 
responsible for all clinical procedures involving drug administration. 
 Ms. Tina Collins: clinical nurse at the Princess Alexandra Hospital (Brisbane) who performed 
clinical procedures involving drug administration. 
 Dr. Manuel Ferreira: led the clinical trial site at Q-Pharm and Princess Alexandra Hospital, 
being responsible for ethical and regulatory approval, supervision of participant recruitment 
and clinical testing. 
 Prof. John Upham: clinical leader of the tocilizumab trial, responsible for all clinical decisions 
at the Brisbane sites and direct supervision of clinical trial staff at the Princess Alexandra 
Hospital 
All other contributions to this thesis are individually listed for each author in the “Publications 
included in this thesis” section. 
STATEMENT OF PARTS OF THE THESIS SUBMITTED TO QUALIFY FOR THE 
AWARD OF ANOTHER DEGREE 
None 
RESEARCH INVOLVING HUMAN OR ANIMAL SUBJECTS  
Research projects included in this thesis that involved human subjects were performed under the 
following ethics approvals: 
 Chapter 2. Clinical features of patients with a microenvironment in the airways that promotes 
IL-6 trans-signalling – Project P710 
 Chapter 3. Sputum cytology during late phase responses to inhalation challenge with different 
allergens – Project P710 
 Chapter 6. Prevention of allergen-induced asthma exacerbations with tocilizumab – Projects 
P2025, P2103 and 14-790 
 Chapter 7. Frequency of asthma prescriptions in patients on regular tocilizumab treatment – 
Project P2242 
Copies of the ethics approval letters are included in the “Ethics approval letters” section. 
  
ACKNOWLEDGEMENTS 
First and foremost, I would like to express my deepest gratitude to my supervisor Dr. Manuel Ferreira. 
This thesis would not have been possible without you. Thank you for the opportunity you have given 
me to come to Australia, for your support, guidance and for always being available when I needed 
advice. Learning from you was inspiring and a great pleasure. Thank you also to my co-supervisors. 
Prof. Nick Martin, to whom I looked up to for all his knowledge. Thank you for your support 
throughout my candidature and for always correcting my English. Without you, I would have 
mispronounced the word “signalling” in all my talks. To Prof. John Upham, thank you for your 
valuable input to my thesis, for all the supervisor meetings and for all your support throughout the 
clinical trial.  
I would like to thank my scholarship providers for their financial support during the period of my 
candidature. Fundação para a Ciência e Tecnologia, for my living stipend (SFRH/BD/92907/2013), 
and The University of Queensland, for the UQI tuition fee scholarship. Thank you also to the 
remaining members of the Asthma Genetics group. To Lisa Bain, a special thank you for the patience 
in training me in the lab and answering all my trial questions. To Cristina, thank you for the 
companionship over the years we spent in this lab, and a big thank you for all the fun times we shared 
while living in Brisbane. 
Last, and most importantly, I would like to thank my family. My husband, Manuel Varandas, for 
being by my side for the last nine years and making me want to excel since we met. Thank you for 
your encouragement, for always listening to my rehearsals before I had a talk and for always cheering 
me up. Thank you to my parents, for without them I would not have had the opportunity to come this 
far in my academic journey. Thank you to my father for teaching me to be methodical and organised 
from an early age – it has helped me greatly throughout my PhD. Thank you to my mother for being 
a role model in perseverance and for spoiling me with countless trips to the post office when I was 
homesick. I am forever grateful to both of you for all the love and support you have given me 
throughout my life. Thank you also to my brother Afonso, for his everlasting friendship and company, 
even from the other side of the world. And finally, a special thank you to my parents-in-law, for all 
their encouragement, support and for inspiriting me to be more determined and work towards my 
goals. 
  
FINANCIAL SUPPORT 
This research was supported by a PhD scholarship granted by the Fundação para a Ciência e 
Tecnologia (SFRH/BD/92907/2013), and a UQI tuition fee scholarship. 
KEYWORDS 
allergy, allergen, asthma, genes, genetics, gwas, interleukin-6, il-6r, slp2, tocilizumab 
AUSTRALIAN AND NEW ZEALAND STANDARD RESEARCH CLASSIFICATIONS 
(ANZSRC) 
ANZSRC code: 060408 Genomics, 40% 
ANZSRC code: 060405 Gene Expression (incl. Microarray and other genome-wide approaches), 
30% 
ANZSRC code: 110701 Allergy, 30% 
FIELDS OF RESEARCH (FOR) CLASSIFICATION 
FoR code: 0604 Genetics, 70% 
FoR code: 1107 Immunology, 30% 
 
  
  
TABLE OF CONTENTS 
 
 
INTRODUCTION .............................................................................................................................. 2 
CHAPTER 1. THE CONTRIBUTION OF THE IL-6 SIGNALLING PATHWAY TO 
ASTHMA PATHOPHYSIOLOGY .................................................................................................. 6 
Introduction .................................................................................................................................. 6 
Asthma .......................................................................................................................................... 7 
Epidemiology ....................................................................................................................................................... 7 
Pathophysiology ................................................................................................................................................... 7 
Genetics ................................................................................................................................................................ 9 
The role of interleukin-6 and its receptor in asthma ................................................................. 10 
IL-6 in asthma .................................................................................................................................................... 10 
The IL-6 receptor: two forms that activate the IL-6 classic- or trans-signalling pathways ................................ 12 
Genetic variants in the IL-6 receptor and the risk of asthma .............................................................................. 14 
Targeting the IL-6 pathway as a treatment strategy for asthma................................................ 15 
Conclusions ................................................................................................................................ 15 
CHAPTER 2. CLINICAL FEATURES OF PATIENTS WITH A MICROENVIRONMENT IN 
THE AIRWAYS THAT PROMOTES IL-6 TRANS-SIGNALLING ......................................... 18 
Introduction ................................................................................................................................ 18 
Methods ...................................................................................................................................... 19 
Study Participants ............................................................................................................................................... 19 
Sputum induction and analysis ........................................................................................................................... 19 
Measurement of IL-6 and sIL-6R levels ............................................................................................................. 20 
Effect of sputum treatment with DTT on IL-6 and sIL-6R levels ...................................................................... 20 
Statistical analyses .............................................................................................................................................. 22 
Results ........................................................................................................................................ 22 
Discussion .................................................................................................................................. 27 
CHAPTER 3. SPUTUM CYTOLOGY DURING LATE PHASE RESPONSES TO 
INHALATION CHALLENGE WITH DIFFERENT ALLERGENS ......................................... 30 
Introduction ................................................................................................................................ 30 
Methods ...................................................................................................................................... 32 
Study design and participants ............................................................................................................................. 32 
Skin-prick tests ................................................................................................................................................... 32 
Methacholine inhalation challenge ..................................................................................................................... 34 
Allergen inhalation challenge ............................................................................................................................. 34 
  
Sputum collection and classification of inflammatory subtype .......................................................................... 35 
Statistical analyses .............................................................................................................................................. 35 
Results ........................................................................................................................................ 36 
Dataset and subject characteristics at baseline ................................................................................................... 36 
Overall effect of allergen challenge on sputum granulocyte counts and inflammatory subtype ........................ 37 
Effect of allergen type on sputum granulocyte counts and inflammatory subtype ............................................. 44 
Discussion .................................................................................................................................. 45 
CHAPTER 4. GENES CO-EXPRESSED WITH IL6R THAT ALSO ASSOCIATE WITH 
ASTHMA RISK  ............................................................................................................................ 50 
Introduction ................................................................................................................................ 50 
Methods ...................................................................................................................................... 51 
Analysis of gene expression levels in 373 Europeans studied by the Geuvadis consortium .............................. 52 
Analysis of gene expression levels in 38 cell types from the DMAP project ..................................................... 53 
Identification of SNPs associated with asthma risk and variation in gene expression ....................................... 54 
Selection of cut-off to prioritize IL6R-associated genes for downstream analyses ............................................ 54 
Validation of genetic associations with asthma risk ........................................................................................... 55 
Comparison with a random selection of genes ................................................................................................... 55 
Results ........................................................................................................................................ 56 
Identification of genes with expression levels associated with those of IL6R ................................................... 56 
Identification of asthma risk SNPs near IL6R-associated genes ........................................................................ 57 
Regulation of gene expression by asthma risk SNPs near IL6R-associated genes ............................................. 57 
Replication of the association between asthma and eSNPs for IL6R-associated genes ..................................... 57 
Association between STOML2 expression, IL6R expression and asthma risk .................................................. 60 
Other genes near STOML2 regulated by rs7039317 .......................................................................................... 62 
Comparison with a random selection of genes ................................................................................................... 63 
Discussion .................................................................................................................................. 63 
CHAPTER 5. ASSOCIATION BETWEEN STOML2 AND ALLERGIC DISEASE ................ 69 
Introduction ................................................................................................................................ 69 
Methods ...................................................................................................................................... 70 
Selection of cases and controls for association analysis from the UK Biobank study ....................................... 70 
Age-of-onset of allergic disease ......................................................................................................................... 71 
Statistical analyses .............................................................................................................................................. 71 
Results ........................................................................................................................................ 71 
Replication of the association between rs7039317 and asthma with hay fever .................................................. 71 
Effect of age-of-onset on the association between rs7039317 and asthma with hay fever ................................. 72 
Association between rs7039317 and the risk of individual allergic diseases ..................................................... 74 
Discussion .................................................................................................................................. 75 
  
CHAPTER 6. PREVENTION OF ALLERGEN-INDUCED ASTHMA EXACERBATIONS 
WITH TOCILIZUMAB .................................................................................................................. 78 
Introduction ................................................................................................................................ 78 
Methods ...................................................................................................................................... 80 
Study design ....................................................................................................................................................... 80 
Procedure used for participant recruitment......................................................................................................... 83 
Summary of participant inclusion and exclusion criteria ................................................................................... 85 
Clinical procedures ............................................................................................................................................. 86 
Procedure used to randomise participants to tocilizumab or placebo treatment ................................................. 89 
Infusion of tocilizumab or placebo ..................................................................................................................... 90 
Primary and secondary endpoints ....................................................................................................................... 90 
Determination of target sample size ................................................................................................................... 91 
Statistical analyses .............................................................................................................................................. 91 
Medical monitor, data safety and monitoring board (DSMB) and study monitoring ......................................... 91 
Interim analysis .................................................................................................................................................. 91 
Ethics statement .................................................................................................................................................. 91 
Results ........................................................................................................................................ 92 
Recruitment rate ................................................................................................................................................. 92 
Number of participants who enrolled the study prior to the interim analysis ..................................................... 92 
Interim analysis .................................................................................................................................................. 93 
Analysis of safety endpoints ............................................................................................................................... 94 
Analysis of primary efficacy endpoints ............................................................................................................ 102 
Analysis of secondary efficacy endpoints ........................................................................................................ 103 
Serum and sputum inflammatory mediators ..................................................................................................... 106 
Sputum subtype after allergen challenge .......................................................................................................... 110 
A single individual did not develop a LAR after treatment .............................................................................. 111 
Discussion ................................................................................................................................ 112 
CHAPTER 7. FREQUENCY OF ASTHMA PRESCRIPTIONS IN PATIENTS ON REGULAR 
TOCILIZUMAB TREATMENT.................................................................................................. 117 
Introduction .............................................................................................................................. 117 
Methods .................................................................................................................................... 118 
Data source ....................................................................................................................................................... 118 
Study design ..................................................................................................................................................... 119 
Primary analysis ............................................................................................................................................... 120 
Secondary analyses ........................................................................................................................................... 123 
Statistical analyses ............................................................................................................................................ 124 
Results ...................................................................................................................................... 124 
  
Frequency of asthma prescriptions before and after the start of TCZ therapy .................................................. 124 
Frequency of asthma prescriptions before and after the start of adalimumab therapy ..................................... 127 
Frequency of asthma prescriptions before and after the start of therapy with a stronger asthma medication .. 129 
Discussion ................................................................................................................................ 131 
CONCLUSION............................................................................................................................... 136 
REFERENCES ............................................................................................................................... 142 
APPENDIX  .................................................................................................................................. 155 
Supplementary Tables .............................................................................................................. 155 
Ethics approval letters ............................................................................................................. 210 
  
  
LIST OF FIGURES 
Figure 2.1. Correlation between the estimated concentration of assay standards treated with 
dithiothreitol (DTT, y-axis) and control standards (x-axis). ...................................................... 21 
Figure 2.2. Correlation between IL-6 and sIL-6R levels in induced sputum samples from 33 mild to 
moderate asthmatics (A) and proportion of individuals with both high (above median) sputum 
IL-6 and high sputum sIL-6R (B). ............................................................................................. 23 
Figure 2.3. Correlation between sputum IL-6 and serum IL-6 (A) and between sputum sIL-6R and 
serum sIL-6R (B) in 33 mild-to-moderate asthmatics. .............................................................. 25 
Figure 2.4. Correlation between sputum total cell count and sputum levels of IL-6 (A) and sIL-6R 
(B) in 33 mild-to-moderate asthmatics. ..................................................................................... 25 
Figure 3.1. Summary of steps used to obtain the dataset analysed. ................................................... 36 
Figure 3.2. Eosinophil and neutrophil cell counts in sputum collected before (-24 h) and after (7 h and 
24 h) allergen inhalation challenge. ........................................................................................... 40 
Figure 3.3. Proportion of sputum inflammatory subtypes before (-24 h) and after (7 h and 24 h) an 
allergen inhalation challenge. Sample sizes for each time point are shown on the left. ............ 42 
Figure 3.4. Eosinophils and neutrophil cell proportions in sputum collected before (-24h) and after (7 
h and 24 h) allergen inhalation challenge. ................................................................................. 43 
Figure 3.5. Eosinophil and neutrophil cell counts in sputum collected before (-24 h) and after (7 and 
24 h) allergen inhalation challenge, stratified by allergen. ........................................................ 44 
Figure 3.6. Change in sputum eosinophil and neutrophil cell counts from baseline (-24 h) to 7 and 24 
h post allergen inhalation challenge, stratified by allergen. ....................................................... 45 
Figure 4.1. Flowchart of IL6R co-expression analysis. ..................................................................... 51 
Figure 4.2. Comparison of GC content effect on gene expression levels of two representative 
individuals (two left panels) and histogram of GC covariate values. ........................................ 52 
Figure 4.3. Genes that are co-expressed with IL6R and have a reproducible association with asthma 
or allergies. ................................................................................................................................. 60 
  
Figure 4.4. Expression of IL6R and STOML2 across 38 hematopoietic cell types. ......................... 61 
Figure 5.1. Age of onset of allergic disease. ...................................................................................... 73 
Figure 5.2. Summary of rs7039317:T associations with allergic diseases. ....................................... 74 
Figure 6.1. Schematic of the 10 clinical trial clinical visits performed in the trial. ........................... 81 
Figure 6.2. White blood cell counts measured before, and after infusion with placebo or tocilizumab.
 .................................................................................................................................................... 96 
Figure 6.3. Haematology results before, and after infusion with placebo or tocilizumab. ................ 98 
Figure 6.4. Blood biochemistry results before, and after infusion with placebo or tocilizumab. .... 100 
Figure 6.5. Comparison of LAR %fallmax (A) and AUC3-7h (B) between patients treated with placebo 
or tocilizumab. ......................................................................................................................... 102 
Figure 6.6. Spirometry measurements in the pre- and post-treatment allergen challenges. ............ 103 
Figure 6.7. EAR %fallmax (A) and AUC0-3h (B) in patients treated with placebo or tocilizumab. ... 104 
Figure 6.8. ∆PC20 measured pre- and post-allergen challenge. ....................................................... 105 
Figure 6.9. Comparison of ∆ immune cell counts in sputum between tocilizumab and placebo groups.
 .................................................................................................................................................. 106 
Figure 6.10. Serum IL-6 and sIL-6R levels in allergen inhalation challenge tests. ......................... 107 
Figure 6.11. Sputum IL-6 and sIL-6R levels in allergen inhalation challenge tests. ....................... 107 
Figure 6.12. Serum cytokine levels before and after infusion with placebo or tocilizumab. .......... 108 
Figure 6.13. Sputum cytokine levels before and after infusion with placebo or tocilizumab. ........ 109 
Figure 6.14. Sputum levels of IL-6 and sIL-6R measured in the pre-treatment phase, before (V2) and 
after (V3 and V4) allergen inhalation challenge. ..................................................................... 111 
Figure 7.1. Number of unique patients with each of the four main prescription drugs analysed between 
April 2010 and March 2015, inclusive. ................................................................................... 119 
  
Figure 7.2. Study design .................................................................................................................. 120 
Figure 7.3. Number of ICS prescriptions (A) and proportion of patients with ICS prescriptions (B) 
before and after the start of regular TCZ therapy. ................................................................... 125 
Figure 7.4. Number of salbutamol prescriptions (A) and proportion of patients with salbutamol 
prescriptions (B) before and after the start of regular TCZ therapy. ....................................... 126 
Figure 7.5. Number of OCS prescriptions (A) and proportion of patients with OCS prescriptions (B) 
before and after the start of regular TCZ therapy. ................................................................... 127 
Figure 7.6. Number of ICS prescriptions (A) and proportion of patients with ICS prescriptions (B) 
before and after the start of regular adalimumab therapy. ....................................................... 128 
Figure 7.7. Number of salbutamol prescriptions (A) and proportion of patients with salbutamol 
prescriptions (B) before and after the start of regular adalimumab therapy. ........................... 128 
Figure 7.8. Number of OCS prescriptions (A) and proportion of patients with OCS prescriptions (B) 
before and after the start of regular adalimumab therapy. ....................................................... 129 
Figure 7.9. Number of salbutamol prescriptions (A) and proportion of patients with salbutamol 
prescriptions (B) before and after the start of regular ICS therapy. ......................................... 130 
Figure 7.10. Number of ICS prescriptions (A) and proportion of patients with ICS prescriptions (B) 
before and after the start of regular OCS therapy. ................................................................... 132 
LIST OF TABLES 
Table 2.1. Clinical and sputum characteristics of 33 mild-to-moderate asthmatics who participated in 
this study. ................................................................................................................................... 24 
Table 2.2. Association between normalised sputum IL-6 and sIL-6R levels and sputum immune cell 
counts from 33 mild-to-moderate asthmatics............................................................................. 26 
Table 2.3. Association between normalised asthma clinical outcomes and the pro-IL-6-trans-
signalling phenotype. ................................................................................................................. 27 
Table 3.1. Demographics of participants from 21 clinical trials of experimental asthma. ................ 33 
  
Table 3.2. Demographics and clinical characteristics of the study participants, stratified by allergen 
type inhaled. ............................................................................................................................... 38 
Table 3.3. Proportion of sputum inflammatory subtypes before (-24 h) and after (7 h and 24 h) an 
allergen inhalation challenge. .................................................................................................... 39 
Table 3.4. Change in eosinophil and neutrophil cell counts from baseline (-24 h) to 7 and 24 h post 
allergen inhalation challenge. .................................................................................................... 41 
Table 3.5. Proportion of sputum inflammatory subtypes observed 24 h before allergen inhalation 
challenge, stratified by the sputum subtype developed 7 h post challenge................................ 41 
Table 3.6. Association between the severity of the LAR and sputum granulocyte counts and 
inflammatory subtype. ............................................................................................................... 43 
Table 4.1. Fourteen SNPs that are eSNPs for genes that are co-expressed with IL6R and also have a 
reproducible association with asthma risk. ................................................................................ 58 
Table 4.2. Meta-analysis of the Ferreira 2,014 and GABRIEL GWAS for the 14 SNPs with validated 
asthma risk association. ............................................................................................................. 59 
Table 4.3. Effect of asthma-associated SNPs on gene expression ..................................................... 62 
Table 5.1. Demographics of study participants.................................................................................. 70 
Table 5.2. Association results between rs7039317 and asthma with hay fever ................................. 72 
Table 5.3. Association between rs7039317 and age-of-onset of allergic disease. ............................. 73 
Table 5.4. rs7039317 association results with individual allergic phenotypes. ................................. 75 
Table 6.1. List of tests performed in the screening phase to assess eligibility for the study. ............ 82 
Table 6.2. Eligibility criteria for the study. ........................................................................................ 84 
Table 6.3. Number of participants enrolled in the study in each study visit. ..................................... 92 
Table 6.4. Patient demographics and inflammatory features in screening phase. ............................. 93 
Table 6.5. Endpoints compared between TCZ and placebo groups in the interim analysis. ............. 94 
  
Table 6.6. List of adverse events (AEs) and serious AEs (SAEs) reported in subjects enrolled in the 
study. .......................................................................................................................................... 95 
Table 6.7. Differences in white blood cell (WBC) counts before and after tocilizumab. .................. 97 
Table 6.8. Differences in haematology results before and after tocilizumab. ................................... 99 
Table 6.9. Differences in haematology results before and after tocilizumab. ................................. 102 
Table 6.10. Comparison of ∆ immune cell counts in sputum between tocilizumab and placebo groups.
 .................................................................................................................................................. 105 
Table 6.11. Inflammatory mediators measured in serum. ................................................................ 109 
Table 6.12. Inflammatory mediators measured in sputum............................................................... 110 
Table 6.13. List of sputum inflammatory subtypes in each study visit where sputum was induced.
 .................................................................................................................................................. 111 
Table 7.1. Study cohort inclusion criteria. ....................................................................................... 121 
Table 7.2. Demographics of cases studied. ...................................................................................... 122 
Table 7.3. Comparison of average number of prescriptions in the baseline phase, between cases and 
matched controls. ..................................................................................................................... 131 
LIST OF ABBREVIATIONS IN THE THESIS 
ACQ Asthma Control Questionnaire 
ADA Adalimumab 
AE Adverse event 
AIHW Australian Institute of Health and Welfare 
ATC Anatomical Therapeutic Chemical 
BMI Body Mass Index 
CNTF Ciliary Neurotrophic Factor 
COPD Chronic obstructive pulmonary disease 
DMAP Differentiation Map Portal 
DTT Dithiothreitol 
  
EAR Early asthmatic response 
ELISA Enzyme-linked immunosorbent assay 
eSNP SNP associated with gene expression levels 
FDR False discovery rate 
feNO Fraction of exhaled Nitric Oxide 
FEV1 Forced Expiratory Volume in 1 sec 
gp130 Glycoprotein 130 
GWAS Genome-wide Association Study 
HDM House dust mite 
HREC Human research ethics committee 
ICS Inhaled corticosteroid 
IL Interleukin 
IL-6R Interleukin-6 receptor 
IQR Interquartile range 
LAR Late asthmatic response 
LCL Lymphoblastoid cell line 
mIL-6R Membrane-bound interleukin-6 receptor 
OCS Oral corticosteroid 
OR Odds ratio 
PBMC Peripheral blood mononuclear cell 
PBS Pharmaceutical Benefits Scheme 
PC20 Provocative concentration causing a 20% decrease in lung function 
RA Rheumatoid arthritis 
SABA Short-acting beta agonist 
SAE Serious adverse event 
sIL-6R Soluble interleukin-6 receptor 
SNP Single-nucleotide polymorphism 
STAT Signal transducer and activator of transcription 
STOML2 Stomatin-like 2 protein 
TCZ Tocilizumab 
TIO Tiotropium 
  
 
 
 
 
 
 
 
Introduction  
Introduction 
The Role of the Interleukin-6 Pathway in Asthma | 2 
INTRODUCTION 
Asthma is a chronic disease of the airways that affects about 235 million people worldwide2 and over 
2.5 million people in Australia.3 It is characterized by enhanced bronchial reactivity, airway 
inflammation and reversible airflow obstruction.4 Briefly, when exposed to environmental stimuli 
such as allergens or cigarette smoke, the airways of asthmatics tighten and get inflamed,5 reducing 
the air that reaches the lungs. This leads to the most common symptoms of asthma, which include 
wheeze, cough, shortness of breath and chest tightness.5 These symptoms can be life-threatening and 
long-lasting, representing a health burden that significantly decreases the quality of life of asthmatics. 
Yet, despite its significant burden, asthma remains prevalent and without cure. Current treatments 
provide relief to some patients, but have several limitations. Short- and long-term medications are the 
two major classes of existing treatments to relieve and control asthma.4 Short-term medications are 
widely used, regardless of disease severity, and act fast on acute symptoms. For instance, short-acting 
bronchodilators re-open tightened airways and allow air to flow. However, despite providing 
symptom relief, short-term medications fail to treat ongoing airway inflammation. Conversely, 
long-term medications attenuate inflammation, hence being able to control persistent asthma and 
prevent exacerbations. For example, inhaled corticosteroids (ICS), a first-line treatment for patients 
with persistent asthma, act by simultaneously activating and suppressing the expression of several 
genes involved in inflammatory responses, and reduce the number of inflammatory cells in the 
airways.6 Yet, these too have limitations: they are not effective for all asthmatics; they need to be 
taken regularly, which can result in long-term adverse effects such as osteoporosis or suppression of 
immune responses against infections;7,8 and their effectiveness partly relies on patient adherence to 
treatment,9-11 which is often inadequate.11-13 
The need to develop improved treatments for asthma is clear. However, two major challenges need 
to be addressed: (1) the heterogeneous nature of the disease, and (2) the low success rate in drug 
development. Asthma heterogeneity is well recognised14-16 – subtypes that share similar phenotypes 
are underpinned by different molecular mechanisms, and do not respond to the same therapies. 
Importantly, there is an unmet need to develop new treatments for poorly-controlled asthma subtypes, 
which do not respond to current medicines and, despite being the minority, represent the largest 
healthcare and economic burdens.17 Monoclonal antibodies (mAbs) are a promising class of drugs to 
address the individual needs of different asthma subtypes. Unlike conventional treatments, mAbs 
target key inflammatory components. For example, omalizumab – the first mAb to be approved for 
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asthma treatment – targets immunoglobulin E (IgE), a key player in allergic asthma, which was one 
of the first recognized asthma subtypes.18 MAbs against interleukin-5 (IL-5) have also been recently 
introduced into clinical practice to treat eosinophilic asthma subtypes,19 and other mAbs, like 
anti-TSLP,20 are currently in drug development to target other cytokines involved in the initiation and 
persistence of airway inflammation.21 These examples illustrate both the importance of (1) better 
characterising asthma subtypes, and (2) developing personalised treatments for those subtypes. 
However, as previously mentioned, a major challenge in drug development is the low attrition rate.22 
Most drugs that reached human clinical trials in the last decade have failed to show adequate efficacy 
in phase II and III studies.23 In asthma, this may partly be addressed by identifying drug candidates 
that are more appropriate for specific disease subtypes.  
An effective way to narrow down drug candidates is through genetic studies. Specifically, 
genome-wide association studies (GWAS) identify genetic variants that are associated with disease 
risk at stringent significance thresholds, providing new leads for the study of underlying disease 
mechanisms. Importantly, GWAS have been estimated to pinpoint targets that are twice more likely 
to succeed in clinical drug development.24 Thus, variants identified in these studies represent the most 
promising candidates to prioritise for functional studies and drug development.  
Between 2007 and 2016, 39 asthma risk variants in low linkage disequilibrium (LD) with each other 
were identified through GWAS.25 Of these, rs4129267 is a promising finding,1 supported by 
observational and functional studies. This variant is located in the interleukin-6 receptor (IL6R) gene 
and the rs4129267:T risk allele, which was estimated to increase asthma risk by 1·09-fold 
(P = 2.4×10–8),1  has been shown to associate with low lung function, severe asthma,26 and high serum 
levels of the soluble isoform of IL-6R (sIL-6R).27 Interleukin-6 (IL-6) can bind to sIL-6R, as it would 
to the membrane-bound receptor (mIL6R); the IL-6-sIL-6R complex then signals through the 
membrane-bound glycoprotein gp130. While gp130 is ubiquitously expressed, mIL-6R is only 
present in certain cells.28,29 Thus, cells that do not express mIL-6R can only be stimulated by IL-6 in 
the presence of sIL-6R, a process termed trans-signalling.29,30 Remarkably, higher concentrations of 
sIL-6R have been found in the serum31 and airways32 of asthmatic patients, when compared to healthy 
individuals. In addition, airway sIL-6R levels have been reported to increase further in asthma 
exacerbations.31 Thus, as sIL-6R widens the number of IL-6 target cells, these observations highlight 
the significance of the IL-6 pathway in asthma pathology, and suggest that blockade of the IL-6 
pathway may represent a treatment option for asthma. Functional studies that tested this hypothesis 
in mouse models of asthma have shown that anti-IL-6R treatment is able to attenuate airway 
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inflammation.32,33 Yet, it is unlikely that this approach will be effective for all asthma subtypes. For 
example, Ullah et al. showed that the anti-inflammatory effects IL-6R blockade was specific to 
models with elevated airway expression of IL-6 and sIL-6R.33 Thus, when translating these findings 
to humans, it is important to identify the group of patients that will more likely benefit from such 
treatment. As previously noted, the rs4129267:T risk allele is associated with increased sIL-6R levels 
and severe asthma.26,27 Accordingly, these may be features that characterise the asthma subtypes 
prone to respond to anti-IL-6R therapy. Further studies are required to test this hypothesis. 
Lastly, the fact that IL-6R is the target of a drug approved to treat rheumatoid arthritis (tocilizumab 
[TCZ]) further supports the study of this pathway as a treatment option for asthma. Drug repositioning 
is an approach that has been shown to have increased chances of successful drug development.34 
Thus, given its well-known safety and pharmacokinetics, TCZ represents a promising candidate to 
repurpose for asthma treatment.  
The overarching aim of this thesis was to understand the significance of the IL-6 pathway in asthma 
and to evaluate whether its blockade represents a promising new treatment option.  
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CHAPTER 1. THE CONTRIBUTION OF THE IL-6 SIGNALLING PATHWAY TO 
ASTHMA PATHOPHYSIOLOGY  
The goal of this chapter was to review the epidemiology and biology of asthma, as well as the 
evidence that IL-6 signalling contributes to disease pathophysiology. This was important to help plan 
the proposed research projects and adequately interpret their results. 
Introduction 
Interleukins are small signalling proteins from the cytokine family that play a central role in 
cell-to-cell communication. Particularly, interleukins were named after first being found to mediate 
communication between (“inter-“) leukocytes (“-leukin”),35, but they were later reported to promote 
communication in a wider group of cells. Once produced, these soluble molecules can be released 
from cells and act in a paracrine or autocrine fashion. They bind to their target cells through cognate 
receptors and trigger intracellular pathways that modulate the activity of the cell. In certain 
circumstances – such as inflammatory or immune responses – target cells are activated, differentiate 
and proliferate in response to these stimuli. Accordingly, it is crucial that this communication is finely 
regulated to avoid improper outcomes, such as cells being activated at the wrong time or by 
inappropriate stimuli. Often, dysregulation of interleukin signalling results in disease pathology, and 
for that reason interleukins have been the focus of a wide range of studies. 
Interleukin-6 (IL-6) was first described as a stimulatory factor released by T cells to induce antibody 
production by B cells, known previously as B cell stimulating factor 2 (BSF-2).36 However, given its 
multiple roles, BSF-2 was studied in parallel under other names such as interferon β-2 and hepatocyte 
stimulating factor.37 It was not until their aminoacid sequence was analysed that it became clear that 
these proteins were the same, and so were subsequently all integrated in the interleukin family under 
the IL-6 name. Indeed, depending on the circumstances, IL-6 can play diverse roles, which sometimes 
can even be opposing. For instance, IL-6 is well-known for its pro-inflammatory activities, such as 
promoting differentiation of immune cells,38,39 but in certain situations it also possesses anti-
inflammatory properties40,41. The numerous ways in which IL-6 acts are the reason why this cytokine 
is critical for many diseases, particularly immune-related diseases, such as rheumatoid arthritis and 
Crohn’s disease. 
Asthma is yet another immune-related disease with mounting evidence of IL-6 involvement. Several 
studies support the causal role IL-6 plays in disease development, rather than merely acting as a 
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biomarker of the underlying inflammatory process. Genetic data also support a causal role for IL-6 
dysregulation in asthma risk. Nonetheless, how exactly IL-6 contributes to asthma is still not fully 
understood; importantly, it is unclear whether blocking IL-6 signalling might prevent or treat asthma 
symptoms. In this review, I will outline the role played by IL-6 in the pathology of allergic asthma 
and discuss the possible outcomes of targeting this pathway for asthma treatment. 
Asthma  
Epidemiology 
Asthma is a common inflammatory disease of the respiratory system. Asthma affects approximately 
235 million people worldwide2 and has a particularly high incidence in developed countries. Asthma 
is the cause of an estimated 250 000 deaths per year,42 which occur mainly in under-developed 
countries. Compared with other chronic diseases, mortality rate is relatively low. However, the 
prevalence of asthma continues to rise globally42 and the biggest burden associated with this disease 
is its morbidity. The symptoms of asthma are frequent and need to be controlled constantly and 
effectively. Symptoms worsen by night-time and with physical activity, affecting essential activities 
such as sleep, exercise, work and school. Moreover, asthma is often accompanied by co-morbidities 
such as rhinitis43,44, which aggravate asthma’s effect on daily life. Despite the significant 
disease-associated morbidity, asthma patients with poorly controlled symptoms are common and, as 
a consequence, the number of hospitalizations and health care costs associated with asthma 
exacerbations are high.45,46  Thus, while no cure currently exists for asthma, the significant disease 
burden despite existing treatments justifies the development of new and improved therapeutic 
strategies. This can only be achieved through a better understanding of the disease pathophysiology. 
Pathophysiology 
Asthma is a complex disorder that can be broadly characterized by three features of the airways: 
hyperreactivity, inflammation and reversible obstruction.4  Asthmatics have hyperreactive airways, 
and so experience recurrent acute reactions to a wide variety of stimuli. Different stimuli nonetheless 
trigger a broadly similar inflammatory response, which involves acute inflammation, which with time 
can lead to airway remodelling (“scarring”); contraction of airway smooth muscle; and an increase in 
mucous production. As a result of these inflammatory processes, the airway lumen narrows, the air 
that reaches the lungs diminishes and asthma symptoms develop, including cough, wheeze (a 
whistling sound mainly heard with exhalation), shortness of breath and chest tightness.5 Nonetheless, 
despite its core features, asthma is a highly complex disease with variable onset, severity, genetic 
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make-up, pathophysiology and response to treatments. As such, classifying asthma into more 
homogeneous subtypes is required to study the disease in more detail. 
Numerous classifications systems have been developed in an attempt to categorize the heterogeneous 
facets of asthma. One of the first classifications opposed extrinsic to intrinsic asthma47 – now 
respectively known as allergic (or atopic) and non-allergic asthma. The first described a subtype of 
asthma with early onset and triggered by inhaled substances (allergens) like pollens and house dust 
mites. Typically, these asthmatics produce antibodies against allergens (atopy) and subsequently 
develop an immune response. Intrinsic asthma, on the other hand, is generally characterised by the 
development of symptoms late in life and in the absence of a particular environmental trigger. This 
dual categorization seemed convenient to work with, both in clinical and laboratory settings. 
However, mounting evidence gradually revealed a similar inflammatory profile behind extrinsic and 
intrinsic asthma: allergen-specific TH2-type T cells that were initially believed to associate only with 
atopic asthma, as well as the cytokines they produced, were soon shown to participate in non-atopic 
asthma as well.48 It became clear that in both subtypes, the balance between effector and regulatory 
T cells was compromised, contributing to initiation and maintenance of airway inflammation.49 This 
explained why the power to predict response to treatment based on this classification was low.  
Many other classification methods were developed since then, with the goal of achieving improved 
diagnosis and response to treatment.50 Subtypes based on observable clinical characteristics are often 
preferred by practitioners to classify patients and assign treatment. However, when it comes to 
asthma, this approach leads to an inconsistent classification, with overlapping subtypes and low 
predictive power regarding response to treatment. On the other hand, cellular and molecular 
phenotypes have the potential to more adequately characterize the pathways underlying the disease 
on a given patient and are more likely to provide guidance in treatment development and assignment. 
Indeed, in a clustering analysis performed in three asthma cohorts, Halder et al. found that a 
symptom-led approach was effective to assign treatment to some, but not all patients.51 Specifically, 
patients with discordance between symptoms and eosinophilic inflammation were the ones that 
usually fail to respond to conventional treatment regimens. Thus, measuring airway inflammation 
(both at the cellular and cytokine level) appears critical to predict treatment response with greater 
accuracy.  
The Halder et al. analysis also showed the value of multivariate approaches to dissect the 
heterogeneous nature of asthma. Indeed, the utility of integrating multidimensional information has 
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been demonstrated in a number of studies. For example, using a range of clinical variables in an 
agglomerative cluster approach, Moore et al. identified five groups of patients that differed clinically, 
physiologically and in terms of inflammatory parameters.52 
Thus, as previously proposed,53 a combined characterization at a phenotypic, cellular and molecular 
level represents a more reliable way of defining and targeting different asthma subtypes. 
Genetics  
Familial and twin studies have long demonstrated that environmental risk factors alone are not 
sufficient for asthma to develop; instead, a genetic predisposition is also required, which is estimated 
to explain >50% of disease liability.54-56 However, unlike monogenic diseases, where one gene alone 
is responsible for the development of the disease, asthma is a complex disorder associated with many 
genetic risk factors, each with a relatively small effect. Thus, finding these genetic variants that are 
associated with asthma risk is not straightforward. Nonetheless, the significance of the genetic basis 
of asthma has prompted much research to identify specific risk loci. 
Two main approaches have been used to identify asthma risk variants: candidate-gene studies and 
genome-wide association studies (GWAS).57 Candidate-gene studies test genetic variants from genes 
that are believed to be associated with the disease. When the presence of an allele is more common 
among cases than controls (or vice-versa), the genetic variant is said to be associated with disease 
risk. This approach is useful to confirm the association with previously suggested risk variants, 
particularly if their effect is small. However, it is limited by a priori knowledge of which variants to 
test. GWAS on the other hand, represent a proven hypothesis-free approach to find genetic variants 
associated with asthma.58 In these studies, hundreds of thousands (sometimes millions) of variants 
across the genome are compared between cases and controls. As this approach is not focused on 
previously suggested regions or genes, it can identify associations with variants that are located in 
new risk loci, with the potential to provide novel insights into the molecular mechanisms underlying 
the disease. 
The first asthma GWAS was published in 2007.59 Thousands of variants were tested for association 
with childhood asthma and a new susceptibility locus on chromosome 17q21 was identified, 
containing the ORMDL3 gene. Since then, the association of this locus with asthma has been 
replicated in several studies1,60-63 and functional analyses suggest that the protein coded by ORMDL3 
plays a role in several cellular processes that likely contribute to the pathology of asthma.64 Numerous 
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other GWAS in asthma were subsequently published, and SNP-based heritability, which represents 
the variance explained by all single nucleotide polymorphisms (SNPs) included in a GWAS,65 was 
estimated to range between 7 - 14%.25,66 Importantly, in the 10 years following the first asthma 
GWAS, 73 unique genetic variants were reported to associate with asthma risk at genome-wide 
significance level (P < 5 x 10-8) across 25 GWAS.25 Of those, 31 variants, which were (1) in low 
linkage disequilibrium (LD) with each other (r2 < 0.05) and (2) reported in GWAS of European 
ancestry, were estimated to explain 2.5% of the variation in asthma liability.25 
Interestingly, many loci containing cytokine-coding genes and genes involved in the regulation of 
cytokines were identified, suggesting that dysregulation of cytokine signalling is critical for the 
development of asthma. In this review, I will focus on the role played by IL-6 in asthma and review 
studies that provide evidence for the pathogenesis of this cytokine. 
The role of interleukin-6 and its receptor in asthma 
IL-6 in asthma 
IL-6 is a small signalling molecule that certain cells release to interact with neighbouring cells. It is 
mainly produced by immune cells such as T- and B-lymphocytes, macrophages, eosinophils and 
granulocytes, but it can also be produced by other cell types such as fibroblasts and bronchial 
epithelial cells.67-69 Both its synthesis and release occur when the cell is harmed or exposed to stress 
by stimuli such as pro-inflammatory cytokines or allergens.70-72 For a long time, IL-6 was seen as a 
general marker of inflammation, but growing evidence now suggests that instead, it plays a causal 
role in inflammatory diseases and in some cases, like rheumatoid arthritis, inhibition of this signalling 
pathway has therapeutic efficacy.73-75 
The role of IL-6 signalling in chronic inflammatory diseases is extensively reviewed in the 
literature.76-78 IL-6 is a key player in acute phase responses79,80 and dysregulation of IL-6 signalling 
has been shown to underlie diseases like rheumatoid arthritis (RA),81,82 Castleman’s disease,83,84 and 
Crohn’s disease.85,86 Several studies have reported elevated levels of IL-6 in circulation and in the 
inflammatory microenvironment of these diseases,87-90 which explains the association between this 
cytokine and multiple disease features. For instance, in RA, IL-6 mediates local inflammation, which 
causes destruction of the joints,81 and in Crohn’s disease high IL 6 levels associated with the severity 
of endoscopical and histopathological findings.86 
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IL-6 promotes CD4+ T cell differentiation, and dysregulation of the IL-6 pathway has been shown to 
affect the balance between TH1/TH2 cells and TH17/Treg,
38,91 which are key players in chronic 
inflammatory diseases. IL-6 is also known to promote angiogenesis and increased vascular 
permeability, both of which are pathological features of diseases like asthma, RA and Crohn’s 
disease.92-95 Importantly, blockade of the IL-6 signalling pathway showed anti-inflammatory 
properties in several disease models,32,33,96-100 which prompted the start of clinical trials to study the 
effects of anti-IL-6 therapy in humans. Remarkably, several studies demonstrated the safety, 
tolerability and efficacy of tocilizumab – a humanized monoclonal antibody that blocks IL 6R – in 
RA patients, and tocilizumab is now approved for the treatment of RA in over 90 countries.78 
Tocilizumab is also approved for the treatment of systemic juvenile idiopathic arthritis (JIA), and 
Castleman’s disease, and represents a promising drug to reposition for the treatment of other 
inflammatory diseases.78 
Asthma is among the diseases that may benefit from anti-IL-6 therapies like tocilizumab. In 1995, 
Yokoyama et al. not only showed that asthma patients had higher serum IL-6 levels than healthy 
controls, but also that there was a further increase in IL-6 levels after an asthma exacerbation.101 High 
levels of IL-6 were also observed in the airways of asthmatics in a number of studies75,102 and sputum 
levels of IL-6 have been shown to correlate negatively with FEV1 (forced expiratory volume in one 
second)102,103 and positively with the Asthma Control Questionnaire (ACQ) – a scoring system that 
assigns higher grades to poorer controlled asthma.102 These findings implicated the presence of IL-6 
in the inflammatory environment of asthma, but further studies showed that IL-6 is not merely a 
by-product of inflammation, but rather a cytokine that acts independently of inflammation.75 
IL-6 actively contributes to asthma inflammation by interfering with the balance between effector 
and regulatory T cells. Specifically, IL-6 has been shown to suppress the activity of regulatory 
T cells104 and to promote differentiation of T helper 2 (TH2) cells over TH1.
38,105 TH2 cells have long 
been associated with allergic asthma.106 These cells release pro-inflammatory cytokines (e.g. IL-4, 
IL-5 and IL-13) that contribute to asthma pathophysiology through several mechanisms, including B 
cell isotype switching and IgE secretion; recruitment and differentiation of eosinophils; increased 
bronchial hyperresponsiveness; and mucus production.  
IL-6 drives IL-4 production in CD4+ naive T cells, promoting their differentiation to TH2 cells.
107 In 
addition, IL-6 modulates the inflammatory responses of differentiated TH2 cells. For example, IL-6 
produced by alveolar macrophages (AM) has been shown to promote CD4+ T-cell IL-5 production 
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upon allergen stimulation.69 Interestingly, compared to AM from non-asthmatic subjects, AM from 
patients with atopic asthma produce increased amounts of IL-6,69 and in mouse models of asthma, 
blockade of IL-6 signalling (either through knockout or antibody-mediated neutralization) markedly 
decreased allergen-induced IL-5 production, which abrogated the recruitment of eosinophils and 
neutrophils into the airways.108 Likewise, blockade of IL-6 signalling has been shown to deplete 
allergen-induced production of IL-13,33 which associated with attenuated airway 
hyperresponsiveness and mucus production. 
In addition, recent studies provided evidence of IL-6 involvement in the regulation of TH17 
cells,78,109,110 a distinct type of effector T cells that contributes to the inflammatory responses in 
asthma. Thus, altogether, these studies support a contribution of IL-6 to core features of asthma and 
to symptom variability observed amongst patients.102,111 
The IL-6 receptor: two forms that activate the IL-6 classic- or trans-signalling pathways 
As a soluble molecule, IL-6 exerts its biological actions by binding to a receptor anchored to the 
membrane of its target cells. Specifically, the IL-6 receptor is a complex composed of two subunits: 
a ligand-binding component, IL-6R, and a signal-transducing unit, gp130.29,30,112 When IL-6 binds to 
IL-6R, two molecules of gp130 are recruited to form the complex and the signal is transduced into 
the cell.113 The subsequent steps of this signalling pathway are extensively characterised in the 
literature.74,114 Briefly, once IL-6 binds to its receptor, homodimerization of the gp130 molecules 
leads to activation of two intracellular signalling pathways – the JAK/STAT (Janus Kinase/Signal 
Transducer and Activator of Transcription) and the Ras/MAPK (Mitogen-Activated Protein Kinase) 
pathways. Activation of these pathways causes the translocation of specific transcription factors to 
the nucleus, which regulate the expression of IL-6 responsive genes, such as those coding for acute 
phase proteins. Thus, understanding the regulation of the IL-6 receptor complex has been critical to 
characterise the signalling pathway of this cytokine. 
In part, the study of the IL-6 receptor complex has clarified the roles played by the cytokine itself. 
First, while IL-6R is exclusive to the IL-6 receptor complex – binding to IL-6 only – the 
signal-transducing subunit gp130 is shared with receptor complexes of other cytokines of the IL-6 
family, such as LIF (Leukaemia Inhibitory Factor), OSM (Oncostatin M) and CNTF (Ciliary 
Neurotrophic Factor),115. This explains the redundancy of some activities of IL-6 and other cytokines 
from the same family. Second, while IL-6R is selectively expressed by a restricted group of cells, 
such as lymphocytes and macrophages, gp130 is ubiquitously expressed.28,29 Since IL-6 does not 
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directly bind to gp130, only cells with IL-6R on their membrane can be stimulated directly by IL-6, 
a process called classical signalling. However, IL-6 can also stimulate cells through a soluble version 
of IL-6R (sIL-6R) – a process known as the trans-signalling pathway. In this pathway, IL-6 binds to 
sIL-6R and in turn, this complex is recognised by gp130, which initiates the intracellular signalling 
cascades. Thus, in the presence of sIL-6R, a wide range of cell types that express gp130 can be 
activated by IL-6, which underlies some of the pleiotropic effects of this cytokine. 
Unlike other soluble receptors, sIL-6R does not counter the role of its membrane-bound version. 
Instead, it works agonistically with mIL-6R and widens the range of cell types that IL-6 can target. 
This is particularly relevant to interpret the reports of high systemic and airway levels of sIL-6R 
observed in asthmatic patients.31,32 These observations raise the hypothesis that the trans-signalling 
pathway may play a role in the pathogenesis of asthma. Indeed, that hypothesis has been 
experimentally demonstrated in animal studies. Doganci et al.32 showed that sgp130-Fc, a fusion 
protein that inhibits trans- but not classic IL-6 signalling, significantly reduced eosinophilia and Th2 
cytokine levels in bronchoalveolar lavage fluid (BALF) after OVA challenge. Similarly, Ullah et al.33 
found that both neutrophilia and eosinophilia were attenuated by sgp130-Fc, which was mirrored in 
significant decreases in IL-13, IL-17A and IL-17F levels in BALF.  
The soluble version of IL-6R is thought to arise due to at least three mechanisms: (1) proteolytic 
shedding of the membrane bound form of IL-6R (mIL-6R),116 which accounts for most variation in 
sIL-6R levels; (2) differential splicing of exon 9, which produces an isoform that directly encodes 
sIL-6R117; and (3) release of microvesicle-associated IL-6R.118 Shedding of sIL-6R from the 
membrane of cells can be induced by various proteases like ADAM10 or PMA. Importantly, certain 
bacterial proteases have been shown to induce shedding of IL-6R, suggesting that certain types of 
allergens that contain bacteria may promote inflammation through a significant increase of the levels 
of sIL-6R in the airways. Indeed, in our own animal studies,33 we found that two of the most common 
types of allergens – house dust mite (HDM) and cockroach – affect mIL-6R shedding differently. 
Specifically, while HDM allergen only increased IL-6 levels, cockroach increased both IL-6 and sIL-
6R, suggesting that not all allergens contribute to an increase in IL-6 trans-signalling. 
Undoubtedly, animal studies have greatly contributed to our understanding of the pathogenicity of 
the IL-6 pathway in asthma. Nonetheless, translating these findings to humans is not always 
straightforward. Thus, it would be interesting to replicate some of these experiments in human cell 
lines, to determine whether IL-6 trans-signalling is also triggered differently in response to different 
Chapter 1. The contribution of the IL-6 signalling pathway to asthma pathophysiology 
The Role of the Interleukin-6 Pathway in Asthma | 14 
stimuli in humans. Furthermore, determining exactly which stimuli present in airborne allergens are 
responsible for activating the IL-6 trans-signalling pathway could provide some clues as to how 
activation of this pathway might be prevented. 
Genetic variants in the IL-6 receptor and the risk of asthma 
Evidence for an association between variants in IL6R and asthma was first published in a GWAS 
meta-analysis, which included 57,800 individuals.1 In that study, asthma risk was estimated to 
increase by 1.09-fold for each copy of the rs4129267:T allele, which has a frequency of 36% in 
Europeans. The SNP rs4129267 maps to an intronic region of the IL6R gene, and is also associated 
with variation in serum levels of sIL-6R.27,119 Specifically, the rs4129267:T asthma risk allele is 
associated with increased sIL-6R levels, due to its effect on two separate mechanisms: first, it is 
associated with increased shedding of mIL-6R; second, it promotes the transcription of an IL6R 
isoform that directly encodes for sIL-6R. 119,120 The former association is thought to arise because 
rs4129267:T is in strong LD with rs2228145:C (LD r2 = 0.99 in Europeans), which corresponds to 
the 358Ala amino-acid variant that is located within the main mIL-6R cleavage site121 and that 
increases receptor shedding by ADAM proteases.120 As a result, the asthma rs4129267:T predisposing 
allele is associated with increased sIL-6R serum levels, which in turn have been shown to be elevated 
in asthma patients.31 In addition, rs4129267:T was subsequently found to be associated with poor 
lung function and severe asthma.26 Hence, these results strongly suggested that IL6R was indeed the 
target gene underlying the association observed between rs4129267 and asthma risk in the Ferreira et 
al. GWAS. 
Unlike for other asthma risk variants (e.g. rs3771166 in the IL18R1 gene), the association between 
rs4129267 and asthma has not been replicated at genome-wide significance level (P < 5 x 10-8). 
However, strong associations, with consistent direction of effect (i.e. with rs4129267:T as the 
predisposing allele) have been reported independent samples, including the UK Biobank GWAS 
(P = 5.8 x 10-6).25 In addition, we found that a second independent but less common SNP in IL6R 
(rs12083537, minor allele frequency of 19%) was also associated with the expression of IL6R and 
asthma risk (OR = 1.05 122). Together, these findings suggested that increased asthma risk was 
associated with increased IL-6 trans-signalling and decreased IL-6 classical signalling. However, it 
is important to recognise that many more genes are part of (or interact with) the IL-6 pathway. The 
extent to which such genes might also represent risk factors for asthma is largely unknown. This 
information is important, as it could provide new targets (other than IL-6R) to inhibit the IL-6 
signalling pathway in asthma. 
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Targeting the IL-6 pathway as a treatment strategy for asthma 
As summarised above, there is extensive evidence linking the IL-6 pathway and asthma, suggesting 
that its inhibition might be an effective new treatment for this disease. Thus, tocilizumab – the anti-
IL-6R drug approved for RA treatment – is a good candidate to reposition for the treatment of asthma. 
Tocilizumab (TCZ) binds to both the soluble and the membrane-bound forms of IL-6R, thereby 
inhibiting both the classical and trans-signalling pathways.  
In RA, human genetic studies suggest that TCZ is effective in reducing disease symptoms because it 
inhibits IL-6 classical signalling. This is because the rs4129267:T allele that associates with inhibition 
of IL-6 classical signalling (while it promotes trans-signalling), reduces the risk of developing RA.123 
In asthma, unlike for RA, human genetic studies show that the rs4129267:T increases disease risk.1 
Because rs4129267:T not only reduces mIL-6R but simultaneously also increases sIL-6R, this 
protective effect on disease risk can be explained by either reduced IL-6 classic signalling or, 
alternatively, increased IL-6 trans-signalling. It is critical to determine which of these two alternatives 
is correct, because they imply opposing clinical effects of TCZ in asthma patients. Specifically, if 
rs4129267:T increases asthma risk because it reduces classic signalling, then TCZ would be expected 
to worsen asthma symptoms. Conversely, if rs4129267:T increases asthma risk because it increases 
trans-signalling, TCZ would be expected to improve asthma symptoms. 
Experiments with animal models,32 including our own,33 suggest that the latter alternative is true. 
Anti-IL-6R drugs attenuated airway inflammation, suggesting that increased trans-signalling (rather 
than reduced classical signalling) is a risk factor for asthma. Therefore, although there is convincing 
evidence that TCZ is a promising new drug for asthma, clinical trials are now required to formally 
test this possibility. 
Conclusions 
Until recently, asthma management strategies have broadly consisted of three approaches: (1) 
prevention of disease onset and/or symptoms by avoiding/minimizing the exposure to recognised 
environmental risk factors; (2) prevention of symptoms with corticosteroids; and (3) symptom relieve 
with bronchodilators. However, given the complexity and heterogeneity of asthma, these are 
wide-ranging measures to which many individuals do not respond. A more efficient approach to 
manage this disease is to break it into more homogeneous subgroups, characterised based on the 
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underlying cellular and molecular components. To this end, the support of genetic studies that can 
identify new asthma risk genes is essential. Such genes point to pathways that are causally related to 
the inflammatory mechanisms underlying asthma. Targeting components of these pathways directly 
may prove particularly effective for asthma treatment.  
Growing evidence supports the involvement of IL-6 in asthma, including that of genetic studies. 
Importantly, an association has been reported between sIL-6R and several asthma features. Given 
that this soluble version of the receptor is the only mechanism through which IL-6 is able to stimulate 
a wide range of relevant cell types, it is possible that the high concentrations of sIL-6R observed in 
asthmatics reflect an underlying genetically-caused dysregulation of gene expression that leads to 
disease. Thus, it is important to comprehensively characterise asthma patients with high IL-6 
trans-signalling. Importantly, a multivariate approach combining information of clinical features 
(which may overlap with those of distinct groups of asthma) and biomarkers of this asthma subtype 
could give new insights into a specific type of asthma that could be targeted by anti-IL-6R drugs, 
such as tocilizumab. 
It is important to also acknowledge that asthma is a complex disease at several levels, from phenotype 
down to genotype. Therefore, it is essential to integrate information from the several components that, 
together, contribute to the disease state. For instance, at the molecular level, regardless of our 
understanding of how the IL-6 pathway contributes to disease development, it is worth noting that 
this pathway does not act on its own. It is linked to other pathways that simultaneously contribute to 
disease pathophysiology, and which may explain other important clinical features. Thus, exploring 
those pathways is equally important, as it may provide further insight to the networks underlying 
disease risk.  
Lastly, additional studies are needed to determine whether treatments such as tocilizumab may be 
used to treat asthma. So far, evidence suggests that this drug is a promising candidate to treat a subtype 
of asthma that involves activation of the IL-6 trans-signalling pathway. Thus, characterizing such a 
group of asthmatics, as well as testing whether they respond to such a treatment, is warranted. 
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CHAPTER 2. CLINICAL FEATURES OF PATIENTS WITH A MICROENVIRONMENT 
IN THE AIRWAYS THAT PROMOTES IL-6 TRANS-SIGNALLING  
The goal of this chapter was to identify clinical subtypes of asthma with an underlying 
pathophysiology that is likely to involve the activation of the IL-6 trans-signalling pathway. Results 
from these analyses were included in a manuscript published in the Journal of Allergy and Clinical 
Immunology: 
Ullah, M. A., J. A. Revez, Z. Loh, J. Simpson, V. Zhang, L. Bain, A. Varelias, S. Rose-John, A. 
Blumenthal, M. J. Smyth, G. R. Hill, M. B. Sukkar, M. A. Ferreira and S. Phipps (2015). "Allergen-
induced IL-6 trans-signaling activates gammadelta T cells to promote type 2 and type 17 airway 
inflammation." J Allergy Clin Immunol 136(4): 1065-1073. 
Introduction 
The pathophysiology of asthma is not homogenous across all patients. Several attempts have been 
made to classify and discriminate distinct clinical phenotypes to help diagnosis and treatment.53 For 
instance, asthma can be characterized based on the proportion of inflammatory cell types present in 
the lung. Relying exclusively on the proportion of sputum eosinophils and neutrophils, four distinct 
phenotypes can be distinguished:124 eosinophilic (characterized by a high proportion of eosinophils), 
neutrophilic (high proportion of neutrophils), mixed granulocytic (high proportion of both cell types) 
and paucigranulocytic (low proportion of both cell types). These phenotypes reflect the type of 
ongoing inflammation and this information may be used to assign targeted treatments.125 However, 
the mechanisms behind the different granulocytic infiltrations are not well understood but could be 
informative to develop novel asthma treatments. 
Recent experiments with a mouse model of asthma have shown that allergic immune responses in the 
airways that are associated with high airway expression of IL-6 and sIL-6R – which promotes IL-6 
trans-signalling – can be attenuated by IL-6R blockade.33 Specifically, an allergen-induced 
inflammatory response characterized by mixed granulocytic infiltration and high IL-6 and sIL-6R 
levels in the airways was shown to respond to treatment with IL-6R inhibitors. Yet, it remained 
unclear if those findings extended to humans. It is possible that asthmatics with airway IL-6 
trans-signalling define a clinically distinct group of asthma, exhibiting clinical features that either 
mediate or result from the presence of high levels of IL-6 and sIL-6R in the airways. Here, to 
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investigate whether IL-6 trans-signalling underlies a clinically distinct group of asthma, we 
phenotypically characterized asthmatics with high airway levels of IL-6 and sIL-6R. 
Methods 
We measured IL-6 and sIL-6R levels in induced sputum samples of asthma patients, and tested these 
for association with clinical phenotypes.  
Study Participants 
A total of 158 subjects with a doctor diagnosis of asthma were recruited from the greater Brisbane 
area between October 2012 and December 2013 and completed the clinical protocol. The participants 
were non-smokers, aged 12-60, and had no respiratory infection in the week preceding clinical testing. 
Clinical testing included completing a detailed questionnaire about asthma history, symptoms, 
severity, medication and triggers; skin prick testing against six common allergens; spirometry 
(Micromedical Microlab Mk 8); measurement of fractional exhaled nitric oxide (feNO, NIOX 
MINO); sputum induction; and blood collection. Participants were asked to withhold anti-histamines 
for 72 hours, inhaled steroids for 48 hours, non-steroidal preventers or symptom controllers for 24 
hours and reliever medication for 8 hours before testing. For the present study, only individuals who 
reported still suffering from asthma were considered for analysis (n = 138). This study was approved 
by the QIMR Berghofer Human Research Ethics Committee and all subjects gave written informed 
consent. 
Sputum induction and analysis  
Sputum induction and processing were performed as described previously.126 Briefly, a saline 
solution was inhaled for doubling periods (30 sec, 1 min, 2 min, and 4 min) from a DeVilbiss 
Ultrasonic nebulizer (UltraNeb) connected to a Hans Rudolph 2700 two-way valve box with rubber 
mouthpiece and nose clips. Forced expiratory volume in 1 sec (FEV1) was measured 60 sec after each 
saline dose, after which participants were asked to expectorate into a sterile container. The test was 
stopped when either the FEV1 had fallen by more than 20% or 15.5 cumulative minutes nebulisation 
time had elapsed. Sputum plugs were selected, dispersed with dithiothreitol (DTT) for a minimum of 
30 minutes (maximum 70 min) at room temperature and filtered through a 60 μm nylon filter. A total 
cell count was then performed with a light microscope. The sample was then centrifuged at 400 g for 
10 minutes; the supernatant was stored at -80 ºC and cytospin slides prepared and stained with May 
Grunwald and Giemsa. A differential cell count of 400 non-squamous cells was then performed. 
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Based on the differential cell count, the sputum inflammatory subtype was classified into four groups, 
as proposed previously124: eosinophilic (≥ 1% eosinophils), neutrophilic (≥ 61% neutrophils), mixed 
granulocytic (≥ 1% eosinophils and ≥ 61% neutrophils) and paucigranulocytic (< 1% and < 61% 
neutrophils). 
Measurement of IL-6 and sIL-6R levels 
Of the 138 current asthmatics tested, 68 provided an induced sputum sample. Of these, we excluded 
from analysis 35 sputum samples with high saliva contamination (> 40% squamous cells) or low cell 
viability (< 40%), thus resulting in 33 samples available for analysis. A 10-ml serum sample was 
collected from 32 of these 33 individuals immediately after sputum induction. The sample was 
centrifuged at 805 g for 10 min, and the serum layer extracted and stored at -80 ºC until analysis. 
ELISA assays (R&D Systems, Minneapolis, MN, USA) were used to measure IL-6 and sIL-6R levels 
according to the manufacturer’s procedures. The optical density was determined using a BioTek 
PowerWave XS2 microplate spectrophotometer (BioTek Instruments, Inc., Winooski, VT, USA) at 
both 450 and 540 nm wavelengths. Results and standard curves were acquired with BioTek Gen5 2.0 
Data Analysis Software.  
The sIL-6R ELISA kit (catalog number DR600) is insensitive to IL-6, i.e. sIL-6R levels measured 
with this assay reflect the total amount of sIL-6R (free or bound to IL-6). The IL-6 kit (catalog number 
HS600B) is affected by concentration of sIL-6R is ≥ 20 ng/ml. 
Effect of sputum treatment with DTT on IL-6 and sIL-6R levels 
To determine if treatment of sputum samples with DTT might have affected the ELISA assays used, 
we first treated the assay standards for IL-6 with DTT and used these as test samples in the ELISA 
assay as done for the sputum samples. We found that the concentration of IL-6 in DTT-treated 
standards was severely underestimated (Figure 2.1 A), as previously reported.127 Similar results were 
obtained with the sIL-6R assay (Figure 2.1 B). 
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Figure 2.1. Correlation between the estimated concentration of assay standards treated with 
dithiothreitol (DTT, y-axis) and control standards (x-axis). 
To prepare the DTT-treated standards (n = 6), the lyophilised assay standard included in the kit was 
first reconstituted at a higher concentration to allow for the subsequent addition of four volumes of 
0.1% DTT to 1 volume of assay standard (4:1). Doubling dilutions were mixed, and the 0.1% DTT 
was added to each dilution. For comparison, a set of standards with the same concentration was 
prepared without DTT. Diagonal line indicates equality between the estimated concentrations of the 
two sets of standards. 
Despite this, median IL-6 levels measured in sputum with the ELISA assay used in our study have 
been shown to be comparable between DTT-treated and DTT-untreated samples, suggesting that the 
activity of DTT is neutralized during the process of mucolysis, thus reducing its effect on the IL-6 
immunoassay.127 Furthermore, we found that if we used the standard curve obtained from the 
DTT-treated assay standards to determine IL-6 and sIL-6R concentrations in sputum samples, the 
resulting median sputum concentration levels (213 pg/ml and 788 pg/ml, respectively) were 
considerably higher than those reported in the literature for sputum or bronchoalveolar lavage fluid 
of asthmatics,32,128-131 suggesting that they were overestimated. Collectively, these results are 
consistent with a significant effect of DTT on the detection of the assay standards but not (or less so) 
on the detection of the mediators in sputum samples. Therefore, we analysed IL-6 and sIL-6R sputum 
levels based on the standard curve obtained from the DTT-untreated assay standards. 
Chapter 2. Clinical features of patients with a microenvironment in the airways that promotes IL-6 trans-signalling 
The Role of the Interleukin-6 Pathway in Asthma | 22 
Statistical analyses 
Two sets of analyses were performed to assess the association between asthma clinical features and 
sputum levels of IL-6 and sIL-6R. First, we analysed sputum IL-6 and sIL-6R levels individually for 
association with clinical information. Second, we classified patients into two groups: those with high 
(i.e. above the median) IL-6 and sIL-6R (pro–IL-6–trans-signalling phenotype), and those with low 
IL-6 and/or sIL-6R sputum levels. Clinical features were then compared between these groups.  
The association between sputum IL-6 and sIL-6R levels and clinical features of asthma was tested 
using linear regression, after normalising both dependent and independent variables with a 
non-parametric transformation. There were no significant effects of age, BMI or sex on IL-6 or 
sIL-6R levels. The association between the pro–IL-6–trans-signalling phenotype and clinical features 
was tested using a logistic regression. Results were considered significant at a P-value threshold of 
0.05. 
Power calculations were performed with the pwr R package to determine the effect size that our 
sample was able to detect with 80% power at a 0.05 significance level.  
Analyses were performed with R version 3.2.3. 
Results 
To understand whether high airway levels of IL-6 and sIL-6R define a clinically distinct group of 
asthmatic patients – a potential target group for clinical trials of IL-6 inhibitors – we measured both 
IL-6 and sIL-6R levels in induced sputum samples of 33 patients with mild-to-moderate asthma 
(Table 2.1) and correlated this information with sputum immune cell counts and relevant clinical 
parameters. This sample was powered to detect effect sizes of 0.25 (i.e. r2 = 0.2, or r = 45) with 80% 
power at a 0.05 significance level. 
Sputum levels of IL-6 and sIL-6R were weakly correlated with each other (Figure 2.2 A), and largely 
independent of levels measured in matched serum samples (Figure 2.3), suggesting that they are 
determined by local (and not systemic) inflammatory responses.  
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Figure 2.2. Correlation between IL-6 and sIL-6R levels in induced sputum samples from 33 
mild to moderate asthmatics (A) and proportion of individuals with both high (above median) 
sputum IL-6 and high sputum sIL-6R (B). 
Circle colours indicate sputum inflammatory subtype while vertical and horizontal black lines show 
overall median sIL-6R and IL-6 levels, respectively. Abbreviations: Eosino, eosinophililic; MixedG, 
mixed granulocytic; Neutro, neutrophilic; Pauci, paucigranulocytic.
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 Eosinophilic Mixed granulocytic Neutrophilic Paucigranulocytic 
N 14 10 4 5 
Female % 50 30 75 60 
Mean age (range) 39 (21-59) 45 (21-58) 39 (29-52) 38 (31-45) 
     
Median sputum total cell count, x106 / ml (IQR) 1.2 (0.9-1.5) 1.1 (0.8-1.5) 0.6 (0.4-0.9) 0.7 (0.6-0.8) 
Mean sputum cell viability (range) 0.69 (0.42-0.93) 0.69 (0.54-0.82) 0.74 (0.68-0.84) 0.66 (0.58-0.82) 
Mean differential cell counts, % (range)     
Squamous epithelial cells  10 (0-32) 10 (1-28) 6 (2-9) 16 (9-22) 
Columnar epithelial cells  0.2 (0-0.7) 0.2 (0-1) 0 (0-0) 0.1 (0-0.7) 
Neutrophils 42.4 (26-60) 78.5 (68-95) 76.7 (64-90) 33.1 (7-59) 
Eosinophils 12.2 (1-35) 2.8 (1-7) 0.3 (0-1) 0.5 (0-1) 
Macrophages 41.3 (12-65) 15.6 (4-27) 19.6 (8-30) 61.8 (39-89) 
Lymphocytes 3.9 (0.7-21) 2.8 (0.2-5) 3.4 (1-5) 4.5 (2-7) 
     
Mean absolute cell counts, x104 / ml (range)     
Neutrophils 57.9 (19.2-116.4) 112.7 (46.4-267.6) 61.6 (31.7-137.2) 29 (4.5-74) 
Eosinophils 15.2 (1.3-40.5) 5.2 (0.9-26) 0.3 (0-0.5) 0.5 (0-1.2) 
Macrophages 54.8 (12.9-114.8) 23.1 (3.1-56.4) 12.5 (8.6-20.2) 47.2 (24.7-61.9) 
Lymphocytes 4.1 (0.8-18.1) 4.6 (0.2-14) 2.1 (0.7-3.6) 3.3 (2.1-4.7) 
     
Mean baseline FEV1 (range) 2.8 (1.2-4.8) 2.8 (0.8-5.4) 2.7 (1.8-3.3) 2.9 (1.8-3.5) 
Mean percent predicted FEV1 (range) 75.7 (43.9-94.4) 69.6 (34.2-113.2) 81.5 (65.9-107.9) 79 (56.7-98.1) 
Mean FEV1/FVC ratio (range) 0.71 (0.43-0.93) 0.64 (0.45-0.79) 0.74 (0.6-0.86) 0.72 (0.62-0.84) 
Mean Asthma Control Questionnaire score (range) 1.73 (0.71-2.86) 1.67 (0.71-3.14) 1.96 (1.14-3.57) 1.8 (0.71-2.71) 
Median FeNO (IQR) 34 (29-80) 44 (24-81) 12 (9-16) 27 (22-49) 
Asthma severity (N in GINA steps 1:2:3:4:5) 6:0:6:2:0 2:1:5:1:1 1:0:1:2:0 2:0:0:3:0 
     
Median sputum IL-6, pg / ml (IQR) 14.2 (9.2-18.8) 26.5 (22.4-29.3) 27.2 (18.9-34.3) 8.3 (1.7-32.0) 
Median sputum sIL-6R, pg / ml (IQR) 532 (249-771) 379 (183-876) 269 (94-510) 305 (175-336) 
Table 2.1. Clinical and sputum characteristics of 33 mild-to-moderate asthmatics who participated in this study. 
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Figure 2.3. Correlation between sputum IL-6 and serum IL-6 (A) and between sputum sIL-6R 
and serum sIL-6R (B) in 33 mild-to-moderate asthmatics. 
Consistent with this hypothesis, there were significant positive correlations between the total number 
of immune cells present in induced sputum and both sIL-6R and IL-6 levels (Figure 2.4). When the 
four major immune cell types present in sputum were analysed individually, we found significant 
correlations between sIL-6R levels and absolute numbers of both neutrophils and eosinophils and 
between IL-6 levels and neutrophil numbers (Table 2.2). 
 
Figure 2.4. Correlation between sputum total cell count and sputum levels of IL-6 (A) and sIL-
6R (B) in 33 mild-to-moderate asthmatics. 
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Outcome Predictor Scale  β SE P-value 
sIL-6R Neutrophils  Absolute, x 104 / ml 0.414 0.163 0.0165 
  Relative, % 0.109 0.179 0.5460 
 Eosinophils Absolute, x 104 / ml 0.454 0.160 0.0080 
  Relative, % 0.405 0.164 0.0193 
 Lymphocytes Absolute, x 104 / ml 0.111 0.178 0.5387 
  Relative, % -0.115 0.178 0.5240 
 Macrophages Absolute, x 104 / ml 0.223 0.175 0.2116 
  Relative, % -0.130 0.178 0.4700 
      
IL-6 Neutrophils Absolute, x 104 / ml 0.540 0.151 0.0012 
  Relative, % 0.423 0.163 0.0142 
 Eosinophils Absolute, x 104 / ml 0.124 0.178 0.4924 
  Relative, % 0.070 0.179 0.6990 
 Lymphocytes Absolute, x 104 / ml -0.152 0.178 0.3998 
  Relative, % -0.282 0.172 0.1123 
 Macrophages Absolute, x 104 / ml 0.007 0.180 0.9706 
  Relative, % -0.324 0.17 0.0657 
Table 2.2. Association between normalised sputum IL-6 and sIL-6R levels and sputum immune 
cell counts from 33 mild-to-moderate asthmatics. 
To estimate the association between an IL-6 trans-signalling–promoting environment in the airways 
and the sputum inflammatory subtype, we classified asthmatic patients into two groups, those with 
high (i.e., above the median) IL-6 and high sIL-6R levels (n = 9) and those with low (below the 
median) IL-6 levels, low sIL-6R levels, or both (n = 24). The pro–IL-6–trans-signalling phenotype 
was more common in patients with neutrophilic (50%) and mixed granulocytic (40%) asthma when 
compared with those with eosinophilic (21%) and paucigranulocytic (0%) asthma (Figure 2.2). 
Consistent with this, neutrophils counts per gram of sputum were significantly (P = 0.0072) elevated 
in the pro–IL-6–trans-signalling phenotype. 
Asthma clinical outcomes were comparable between patients with and without the 
pro-IL-6-trans-signalling phenotype (Table 2.3). Among the 33 patients with mild-to-moderate 
asthma tested, four (12%) had mixed granulocytic infiltration associated with both high IL-6 and high 
sIL-6R levels in sputum (Figure 2.2).  
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Outcome β SE P-value 
FEV1  0.376 0.390 0.3420 
FEV1 % predicted 0.489 0.386 0.2139 
FEV1/FVC ratio 0.303 0.392 0.4459 
Asthma symptoms -0.185 0.394 0.6422 
FeNO 0.353 0.390 0.3724 
Asthma severity 0.391 0.389 0.3231 
Table 2.3. Association between normalised asthma clinical outcomes and the pro-IL-6-trans-
signalling phenotype. 
Discussion  
To assess the clinical implications of IL-6 trans-signalling in asthma, we studied the association 
between clinical features of asthma and both sputum IL-6 and sIL-6R levels. Sputum levels of IL-6 
and sIL-6R did not correlate with levels measured in matched serum samples. These results may have 
been confounded by IL-6 binding to sIL-6R. Specifically, the ELISA assay used to measure IL-6 is 
affected by high concentrations of sIL-6R (≥ 20 ng/ml). Consequently, the elevated concentrations of 
sIL-6R observed in sera may have affected the quantification of IL-6 in those samples. Importantly, 
measurements performed in sputum samples, which reflect the inflammations of the airways, showed 
relatively low levels of sIL-6R. Thus, it is unlikely that our measurements of IL-6 in sputum were 
affected. 
High levels of both IL-6 and sIL-6R were more common in asthmatic patients with a neutrophilic or 
mixed granulocytic sputum profile when compared with those with the eosinophilic or 
paucigranulocytic inflammatory subtypes. These results are in line with recent observations from Chu 
et al.,108 who reported elevated IL-6 levels in sputum samples of patients with mixed granulocytic 
bronchitis, and suggest that an airway environment that promotes IL-6 trans-signalling might be a 
risk factor for asthma exacerbations associated with high numbers of infiltrating neutrophils. But the 
reverse could also be true: a neutrophil-rich immune response might promote IL-6 trans-signalling in 
the airways.  
We also found that 12% of patients with mild-to-moderate asthma tested had a sputum inflammatory 
profile – mixed granulocytic infiltration with high IL-6 and high sIL-6R levels – similar to that seen 
to attenuate with IL-6 blockade in mice experiments.33 In light of this, we suggest that this is the 
group of patients most likely to respond to treatment with IL-6R inhibitors.  
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Our study does, however, have three main caveats. First, sample size was small; sputum total cell 
count and cell viability were also lower than reported in previous studies that used the same protocol 
for sputum induction and analysis,124,132,133 although this might reflect the milder asthma spectrum 
sampled in our study. Second, we did not study a population of patients with severe asthma, the most 
likely to benefit from novel directed therapies. Sputum IL-6 and sIL-6R patterns in patients with 
severe asthma might be distinct from those identified in this study. Lastly, measurements of sputum 
IL-6 and sIL-6R levels might have been affected by the use of dithiothreitol (DTT) during sample 
processing, although we note that (1) DTT treatment was shown previously to have no effect on IL-6 
levels measured in sputum127 and (2) the observed median value for sIL-6R was consistent with that 
reported in BALF of asthmatic patients.32 In addition, all samples in our study are likely to have been 
underestimated as they were all processed with DTT. Thus, the patients that we identified to have the 
highest sputum levels of IL-6 and sIL-6R are likely to be the same that would have been identified if 
samples had not been processed with DTT. 
Nevertheless, despite these limitations, our results are consistent with recent observations from a 
study that evaluated the association between epithelial IL-6 trans-signalling activation and molecular 
and clinical phenotypes in asthmatic patients.134 In that study, human bronchial epithelial cells were 
first stimulated with IL-6 and sIL-6R to identify genes induced by IL-6 trans-signalling. Then, using 
the most strongly-induced genes, the authors performed cluster analysis in a cohort of 103 asthmatic 
patients to identified the subset of patients with signs of lung epithelial IL-6 trans-signalling activation 
(n =17). The patients with the IL-6 trans-signalling gene signature were shown to have a history of 
frequent exacerbations and significantly increased infiltration of T cells and macrophages to the 
airways compared to the other asthmatics. In addition, and consistent with our results, sputum 
eosinophilia was significantly higher in that group of patients, and there was a trend, although not 
significant, towards increased sputum neutrophil counts. Thus, while our results should be interpreted 
with caution, they are supported by these observations. 
In conclusion, we demonstrate that, in human subjects, an airway microenvironment that promotes 
IL-6 trans-signalling is associated with mixed granulocytic asthma. The latter could develop, for 
example, because of a genetic predisposition and/or exposure to specific allergens that trigger a 
neutrophil-rich inflammatory response.  
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CHAPTER 3. SPUTUM CYTOLOGY DURING LATE PHASE RESPONSES TO 
INHALATION CHALLENGE WITH DIFFERENT ALLERGENS 
In the previous chapter, high airway levels of IL-6 and sIL-6R were found to be more frequent in 
subjects with mixed granulocytic and eosinophilic sputum inflammatory subtypes. In this chapter, the 
goal was to assess whether sputum inflammatory subtypes can be influenced by common asthma 
triggers. Results from these analyses were published in the Allergy journal in 2018: 
Revez JA, Killian KJ, O'Byrne PM, Boulet LP, Upham JW, Gauvreau GM, Ferreira MAR: Sputum 
cytology during late-phase responses to inhalation challenge with different allergens. Allergy 2018 
(in press). 
Introduction 
Allergic asthma is triggered by the inhalation of aero-allergens in previously sensitized individuals. 
Within hours of allergen exposure, various immune cell types infiltrate the airways, where they 
release pro-inflammatory mediators that result in narrowing of the airways and the characteristic 
symptoms of wheezing and shortness of breath.135 Amongst the most abundant cells in the airway 
immune infiltrate are eosinophils and neutrophils. The relative abundance of these cell types in 
induced sputum varies widely between asthmatics and is often used to categorize the underlying 
inflammatory response.124,136-139 Currently, four major sputum subtypes have been described124,140 (1) 
eosinophilic, with elevated eosinophils but not neutrophils; (2) neutrophilic, with elevated neutrophils 
but not eosinophils; (3) mixed granulocytic, with both eosinophils and neutrophils elevated; and (4) 
paucigranulocytic, with both eosinophils and neutrophils within the normal range. Recognising this 
heterogeneity in inflammatory subtype is important because it can help identify the subsets of patients 
that can benefit most from specific targeted therapies.141 For example, patients with eosinophilic 
asthma typically respond well to corticosteroids,142-144 which is not the case for those with non-
eosinophilic asthma144-147 However, despite its importance, the factors that contribute to the 
heterogeneity in sputum inflammatory subtype in humans remain poorly understood. 
Mouse models of asthma have provided some clues into the factors that might contribute to the type 
of sputum inflammatory subtype that develops upon allergen challenge. As in humans, airway 
inflammation can be induced in mice by challenging previously sensitized animals with a specific 
allergen. The allergen most commonly used to trigger airway inflammation in mice is ovalbumin 
(OVA), which typically induces eosinophilic inflammation. However, higher concentrations of 
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endotoxin in the OVA solution can shift the inflammation developed in the airways to a mixed 
granulocytic subtype.148,149 Furthermore, the adjuvant that is co-administered with OVA to stimulate 
the immune response also influences the inflammation that develops in the airways. For example, co-
administering alum promotes stronger eosinophilia than if no adjuvant is used.150 Similarly, house 
dust mite (HDM), a common household allergen, is frequently used in mouse models of asthma and 
triggers an airway inflammation rich in eosinophils.151,152 In contrast, cockroach and Alternaria 
allergens, to which humans are also commonly sensitized, promote an inflammation rich in both 
eosinophils and neutrophils in mice.33,153,154 Less common are allergens that induce an increase in 
neutrophils but not eosinophils in mice: 1,3-β-glucan, the major cell wall component of fungi, is one 
example.155,156 Collectively, these observations suggest that different allergen types are capable of 
promoting distinct inflammatory subtypes in mice.  
To our knowledge, no study has previously tested the hypothesis that different allergens can induce 
distinct inflammatory subtypes in humans. As in mice, the inflammatory response to allergen 
exposure can be studied in humans in a controlled setting using an allergen inhalation challenge test. 
In this test, subjects with mild allergic asthma inhale increasing concentrations of an allergen solution 
until an early asthmatic response (EAR) is triggered, typically consisting of a 20% drop in lung 
function from baseline.157 The allergen used in the inhalation challenge test is usually that which 
triggers the largest allergic response in a skin prick test.157 The primary outcome measured is often 
the late asthmatic response (LAR), which follows the natural recovery from the EAR and corresponds 
to the drop in lung function from baseline recorded between 3 and 8 h after allergen challenge. The 
magnitude of the LAR reflects the severity of airway inflammation induced by allergen exposure,158 
and can vary considerably between individuals. Importantly, Boulet et al. found that some of this 
variation in the magnitude of the LAR can be explained by the allergen type used in the challenge.159 
On the other hand, the allergen used in the inhalation challenge did not determine the absolute number 
of eosinophils or neutrophils measured in sputum, but these cell types were analysed individually and 
sputum inflammatory subtypes were not considered. Here, we extend the analysis of Boulet et al. to 
test the association between sputum inflammatory subtypes and the allergen type inhaled, based on 
information from 129 individuals with a documented EAR and LAR. 
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Methods 
Study design and participants 
We performed a retrospective analysis of data from 21 clinical trials of experimental asthma 
treatments that included an allergen inhalation challenge test. The trials (summarized in Table 3.1) 
were conducted between 2003 and 2013 in two centers (Laval University and McMaster University); 
protocols were standardized between sites. Briefly, in all studies, each participant completed an 
allergen inhalation challenge test during the screening phase of the trial, that is, prior to receiving any 
experimental treatment. The test was carried out on three consecutive days and consisted of: (1) skin 
prick titration test and methacholine challenge test on day one, to determine the dose of allergen to 
be administered in the inhalation test; (2) the allergen inhalation challenge test on day two; and (3) a 
follow-up methacholine challenge on day three. All measurements included in our analysis refer to 
data collected only in these three days. A total of 153 participants (57% female) were recruited, aged 
18 - 61 years. Subjects had mild asthma, defined by (1) a Forced Expiratory Volume in 1 sec (FEV1) 
> 70% of the predicted normal value (i.e. sufficient lung function such that a 50% fall in FEV1 would 
be safe and tolerated), (2) a provocative concentration of methacholine that caused a 20% drop in 
FEV1 (PC20) that was ≤ 16 mg/ml (see below), and (3) no requirement for anti-inflammatory 
treatments that could interfere with allergen-induced responses, with the exception of short-acting 
beta agonists (SABA) to relieve symptoms less than twice weekly. 
Skin-prick tests 
Each participant completed two skin prick tests – an allergen skin test and an allergen skin titration 
test.  
The aim of the allergen skin test, typically performed during the first clinical visit, was to determine 
the allergen type to be used subsequently in the inhalation challenge test. Briefly, skin reactivity was 
measured 15 minutes after exposure (scratching or pricking) to (1) an allergen; (2) a positive control 
(1 mg / ml histamine); and (3) a negative control (diluent). Allergens tested included alder, white 
birch, horse, Alternaria, Dermatophagoides farinae (HDMDF), ragweed, grass, cat and 
Dermatophagoides pteronyssinus (HDMDP), and were purchased from Omega Laboratories, Greer 
and ALK. Positive skin reactions were defined as a wheal (raised itchy bump) greater than 2 x 2 mm 
in size. The allergen that resulted in the largest positive skin reaction after exposure was selected for 
the inhalation challenge (the test allergen).  
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Study N participants 
Sex (% 
female) 
Age 
(years) 
BMI 
(kg/m2) 
Allergens tested (allergen type, N) 
1 22 66.7 32 ± 11.2 25 ± 4 Alternaria, 1; Cat, 5; Grass, 3; HDMDF, 1; HDMDP, 6; Horse, 4; Ragweed, 2 
2 20 50 33 ± 13.2 26 ± 4.6 Alder, 1; Cat, 8; Grass, 3; HDMDP, 6; Ragweed, 1; White birch, 1 
3 11 54.5 26 ± 8.3 24 ± 2.1 Cat, 4; Grass, 1; HDMDF, 1; HDMDP, 2; Horse, 1; Ragweed, 2 
4 24 45.8 26 ± 8.7 NA Alternaria, 1; Cat, 6; Grass, 5; HDMDP, 9; Ragweed, 3 
5 9 55.6 25 ± 9.8 NA Alternaria, 1; Cat, 2; HDMDP, 5; Ragweed, 1 
6 10 60 31 ± 12.6 NA Cat, 4; Grass, 1; HDMDF, 1; HDMDP, 4 
7 18 52.4 31 ± 13.7 25 ± 5.9 Alternaria, 2; Cat, 6; Grass, 3; HDMDF, 2; HDMDP, 7; Ragweed, 1 
8 11 54.5 38 ± 13.2 28 ± 8.7 Alternaria, 1; Cat, 5; Grass, 1; HDMDP, 4 
9 21 57.1 27 ± 10.6 NA Cat, 4; Grass, 2; HDMDF, 3; HDMDP, 10; Ragweed, 2 
10 10 30 33 ± 15.3 24 ± 2.7 Alternaria, 1; Cat, 2; HDMDF, 1; HDMDP, 4; Ragweed, 2 
11 7 28.6 29 ± 11 NA Alternaria, 1; Cat, 1; Grass, 1; HDMDP, 3; Ragweed, 1 
12 21 42.9 29 ± 10.3 NA Cat, 11; Grass, 2; HDMDF, 1; HDMDP, 7 
13 5 80 32 ± 15.4 25 ± 4.8 Alternaria, 1; Cat, 1; Grass, 1; HDMDP, 2 
14 20 52.4 36 ± 13.7 27 ± 6.3 Cat, 9; Grass, 2; HDMDP, 8; Ragweed, 2 
15 15 46.7 29 ± 10.6 NA Cat, 3; Grass, 5; HDMDF, 2; HDMDP, 5 
16 11 72.7 29 ± 10.8 NA Cat, 2; Grass, 2; HDMDF, 2; HDMDP, 5 
17 10 30 33 ± 13.3 NA Cat, 1; HDMDF, 1; HDMDP, 6; Ragweed, 2 
18 19 73.7 27 ± 11 NA Cat, 3; HDMDF, 2; HDMDP, 9; Ragweed, 5 
19 13 64.3 31 ± 13.1 27 ± 5.8 Cat, 5; Grass, 2; HDMDP, 5; Horse, 1; Ragweed, 1 
20 7 57.1 33 ± 14.9 NA Cat, 2; Grass, 3; HDMDP, 2 
21 16 75 26 ± 9.1 NA Grass, 2; HDMDF, 3; HDMDP, 9; Ragweed, 2 
Table 3.1. Demographics of participants from 21 clinical trials of experimental asthma. 
 Results are presented as means ± SD. Abbreviations: BMI, body mass index 
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The allergen skin titration test was performed the day before the inhalation challenge test. The aim of 
this test was to determine the weakest dilution of the test allergen that resulted in a positive (> 2 mm 
wheal) skin prick response. Briefly, skin reactivity was measured 10 minutes after exposure to serial 
dilutions of the test allergen. The lowest titration that caused a positive reaction corresponded to the 
‘skin test end point’, which is required to calculate the PC of the test allergen that is expected to cause 
a 20% drop in FEV1, that is, the allergen PC20.
160 
Methacholine inhalation challenge 
A methacholine challenge test was performed the day before the allergen inhalation test to quantify 
airway sensitivity, as this is required to calculate the expected allergen PC20, in addition to the skin 
test end point.160 Briefly, methacholine chloride stock was prepared at a concentration of 128 mg/ml 
in physiological saline and further diluted in physiological saline to achieve working concentrations 
from 0.031 mg/ml to 128 mg/ml. A Wright nebulizer with an output of 0.13 ml/min was used to 
produce methacholine aerosols. Participants were instructed to wear nose clips and to breathe 
normally from a Hans Rudolf valve connected to the nebulizer, during a 2-minute period. First, 
subjects inhaled normal saline, then doubling concentrations of methacholine for periods of 2 min. 
FEV1 was measured at 30, 90, 180 and 300 seconds after each inhalation, until a fall of 20% in FEV1 
was observed. The concentration at which a 20% decline in FEV1 was observed corresponds to the 
methacholine PC20.  
Allergen inhalation challenge 
The allergen PC20 was determined based on the skin test endpoint and methacholine PC20 using an 
equation developed elsewhere.160 In turn, the allergen PC20 determined the first concentration of the 
test allergen that was administered in the inhalation test, specifically corresponding to three to four 
doubling dilutions below the PC20. Starting with that concentration, allergen was inhaled at tidal 
breathing for 2 minutes, and FEV1 measured 10 minutes after challenge. Increasing doubling 
concentrations of allergen (up to 1:4) were administered until a concentration was reached that caused 
a 20% decline in FEV1, which corresponds to the observed allergen PC20. FEV1 was then recorded at 
regular intervals until 7 hours after inhalation of the last allergen dose. At 7 hours all participants 
were treated with a SABA to reverse bronchoconstriction from allergen challenge. Participants 
received no anti-inflammatory medications, including inhaled corticosteroids, before or after allergen 
challenge, with the exception of SABA to relieve symptoms less than twice weekly. 
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A positive early asthmatic response (EAR) was defined by a decline of ≥ 20% in FEV1 from baseline 
within 3 h of the last allergen inhalation. A positive LAR was defined by a decline of ≥ 15% in FEV1 
3 - 7 hours post allergen inhalation. Only individuals who experienced both an EAR and an LAR 
were selected for analysis. 
Sputum collection and classification of inflammatory subtype 
Sputum was collected at three time points: after the methacholine challenge on day one, after the 
allergen challenge on day two (7 hours post inhalation), and after the methacholine challenge on day 
three. Relative to the start of the allergen inhalation test, we refer to these time points as -24 h, 7 h 
and 24 h post-challenge. The sputum samples collected therefore reflect three different inflammatory 
states: baseline (i.e. pre-challenge), LAR and persistence of LAR. 
Sputum was induced and processed as described previously,161 which included obtaining total and 
differential cell counts. To account for differences in sputum yield, analyses of absolute cell numbers 
were performed relative to sputum weight. The proportion of eosinophils and neutrophils in sputum 
was calculated relative to the total cell count and used to categorize sputum inflammatory subtype 
into four categories as described elsewhere124: (1) eosinophilic, > 1.01% eosinophils and < 61% 
neutrophils; (2) neutrophilic, < 1.01% eosinophils and > 61% neutrophils; (3) mixed 
granulocytic, > 61% neutrophils and > 1.01% eosinophils; or (4) paucigranulocytic, < 61% 
neutrophils and < 1.01% eosinophils.  These thresholds were determined based on the 95th percentiles 
observed in a cohort of healthy individuals. 124 
Statistical analyses 
Outcome variables measured on a continuous scale (cell counts, EAR and LAR) were assessed for 
normality using the Shapiro-Wilkinson test. Neutrophil counts, eosinophil counts and LAR were not 
normally distributed and so were transformed with a rank-based inverse-normal transformation. A 
paired t-test was used to compare cell counts between pre-challenge (-24 h) and post-challenge (7 h 
and 24 h) time points. A one-way ANOVA was used to test the effect of allergen type on variation in 
outcome variables, with post-hoc comparisons between allergen types performed with the 
Tukey-Kramer test. Associations between sputum subtype, which is a categorical variable, and 
predictors of interest (e.g. allergen type) were tested with a multinomial log-linear model, using the 
multinom function from the nnet R package.162 Sputum subtype proportions were compared between 
groups using the McNemar test. All outcomes were assessed for association with covariates (age, sex, 
height, weight, and body mass index) before analysis.  
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Power analyses were performed with the pwr and the pwr2 R packages. Analyses were performed 
using R version 3.2.3. 
Results 
Dataset and subject characteristics at baseline 
The dataset available for analysis included 305 allergen challenges performed by 153 unique 
individuals and including nine allergen types (Figure 3.1).  
 
Figure 3.1. Summary of steps used to obtain the dataset analysed. 
(A) The original dataset consisted of 305 allergen challenges performed by 153 unique individuals, 
including nine different types of allergen. Most individuals (n = 92) completed a single allergen 
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challenge. Of the 61 individuals who completed two or more allergen challenges, 51 were challenged 
with the same allergen, and 10 were challenged with different allergens.  
(B) Four data management steps were applied to select individual allergen challenges for analysis. 
First, challenges performed with an allergen extract (alder, white birch, horse, Alternaria) tested 
in < 10 individuals were excluded. Second, results from challenges performed by the same individual 
with the same allergen type in different studies were averaged. Third, for individuals challenged with 
different allergen types in different studies, results for the least common allergen(s) were selected for 
analysis. Fourth, results from individuals who did not experience both an EAR and an LAR were 
excluded. 
Four allergen extracts (alder, white birch, horse and Alternaria) were tested in a small number of 
individuals (n < 10), so these data were excluded from further analysis. Sixty-one individuals 
participated in two or more clinical trials and so completed multiple allergen challenge tests. For each 
of these individuals, outcomes were averaged across allergen challenge tests performed with the same 
allergen type in different studies. If an individual was challenged with different allergens in different 
studies, data was included for the challenge performed with the allergen type that was least common 
in the dataset, to maximize the number of challenges with each allergen included in the analyses. 
Lastly, data was excluded from 16 allergen challenges with a negative EAR and/or negative LAR, as 
it was not clear if allergen challenge triggered a typical acute asthmatic response. After these 
exclusions, data were available for 129 allergen challenges performed by 129 individuals and 
including five allergen types: HDMDF (n = 12), ragweed (n = 16), grass (n = 22), cat (n = 39) and 
HDMDP (n = 40). Sputum samples were available for 118 subjects before allergen challenge (-24 h), 
and for 123 (7 h) and 124 (24 h) subjects after allergen inhalation challenge. For 111 subjects, sputum 
samples were available across all three time points. 
Subjects subsequently tested with different allergen types had similar characteristics at baseline, 
including, for example, comparable sputum subtype frequencies (Table 3.2). Age, height, weight and 
BMI, had no significant effect on variation in sputum subtype frequencies. 
Overall effect of allergen challenge on sputum granulocyte counts and inflammatory subtype 
At baseline (i.e. before allergen challenge), the sputum inflammatory subtype of most individuals was 
either paucigranulocytic (38%) or eosinophilic (43%) (Table 3.3), i.e. less than 20% of the individuals 
had a sputum subtype rich in neutrophils.
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  HDMDF Ragweed Grass Cat HDMDP 
n 12 16 22 39 40 
Sex (% female) 41.7 50 22.7 68.4 65 
Age (years) 27 ± 10.5 (19-52) 23 ± 5.9 (18-40) 29 ± 10.4 (18-48) 31 ± 13.8 (19-60) 29 ± 10.5 (19-54) 
Height (cm) 174 ± 12 (155-192) 170 ± 9.9 (150-186) 176 ± 10.9 (155-195) 170 ± 8.7 (155-187) 169 ± 8.4 (153-188) 
Weight (kg) 71 ± 6.1 (63-77) 73 ± 10.1 (59-83) 86 ± 21.3 (53-115) 75 ± 17.9 (52-113) 69 ± 13.5 (50-101) 
BMI (kg/m2) 23 ± 1.5 (21-24) 26 ± 2.1 (24-29) 27 ± 3.5 (22-32) 27 ± 6 (19-41) 24 ± 3.6 (19-32) 
LAR (% fall in FEV1) 28 ± 7.7 (15-41) 24 ± 9.2 (15-49) 24 ± 6.7 (17-42) 22 ± 6 (16-44) 26 ± 7.2 (15-44) 
      
Baseline sputum characteristics      
TCC (x 106/g mucus) 2 ± 1.3 (0-4) 5 ± 5.9 (0-24) 3 ± 4.1 (0-19) 3 ± 2.2 (1-12) 4 ± 2.8 (1-13) 
Eosinophils (x 106/g mucus) 16 ± 33.6 (0-110) 10 ± 16.8 (0-61) 4 ± 6.6 (0-26) 12 ± 20.8 (0-111) 16 ± 34.6 (0-172) 
Neutrophils (x 106/g mucus) 111 ± 52.2 (32-191) 286 ± 573.9 (2-2255) 185 ± 337.6 (4-1518) 140 ± 195.5 (1-915) 179 ± 212.7 (4-1022) 
Subtype (% Pauci, % Eos, % Neut, % 
MG) 
10, 60, 30, 0 60, 13, 13, 13 45, 35, 10, 10 31, 56, 3, 11 41, 43, 8, 8 
Table 3.2. Demographics and clinical characteristics of the study participants, stratified by allergen type inhaled. 
Results are presented as frequencies (in %) or means ± SD (range). There were no statistically significant differences in baseline characteristics between 
the groups. Abbreviations: BMI, body mass index; Eos, eosinophililic; FEV1, forced expiratory volume in 1 s; LAR, late airway response; MG, mixed 
granulocytic; Neut, neutrophilic; Pauci. paucigranulocytic; TCC, total cell counts.  
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    -24h   7h   24h 
  Subtype Proportion   Proportion P§   Proportion P§ P† 
          
   n = 118   n = 123   n = 124 
A
ll
  
al
le
rg
en
s Paucigranulocytic 0.38  0.06 2.5x10
-10  0.04 4.5x10
-9 0.4795 
Eosinophilic 0.43  0.55 0.0253  0.76 3.6x10
-7 1.0x10-4 
Neutrophilic 0.09  0.01 0.0016  0.02 0.0114 0.3173 
Mixed granulocytic 0.09  0.38 3.3x10
-7  0.19 0.0184 1.0x10
-4 
 
         
   n = 37   n = 38   n = 38 
H
D
M
D
P
 Paucigranulocytic 0.41  0.05 3.0x10
-4  0.05 3.0x10
-4 1 
Eosinophilic 0.43  0.53 0.4669  0.76 0.0047 0.0126 
Neutrophilic 0.08  0.00 0.0833  0.00 0.0833 NA 
Mixed granulocytic 0.08  0.42 0.0029  0.18 0.1573 0.0126 
 
         
   n = 36   n = 38   n = 38 
C
at
 
Paucigranulocytic 0.31  0.05 0.0016  0.00 0.0016 0.1573 
Eosinophilic 0.56  0.66 0.285  0.84 0.0067 0.0348 
Neutrophilic 0.03  0.00 0.3173  0.00 0.3173 - 
Mixed granulocytic 0.11  0.29 0.0522  0.16 0.3173 0.0956 
 
         
   n = 20   n = 19   n = 22 
G
ra
ss
 Paucigranulocytic 0.45  0.00 0.0027  0.00 0.0027 - 
Eosinophilic 0.35  0.42 0.3173  0.68 0.0196 0.1573 
Neutrophilic 0.10  0.05 0.3173  0.05 0.3173 - 
Mixed granulocytic 0.10  0.53 0.0047  0.27 0.1797 0.1573 
 
         
   n = 15   n = 16   n = 14 
R
ag
w
ee
d
 Paucigranulocytic 0.60  0.19 0.0082  0.07 0.0082 0.1573 
Eosinophilic 0.13  0.50 0.0143  0.71 0.0082 0.0833 
Neutrophilic 0.13  0.00 0.1573  0.07 1 0.3173 
Mixed granulocytic 0.13  0.31 0.0833  0.14 - 0.1573 
 
         
   n = 10   n = 12   n = 12 
H
D
M
D
F
 Paucigranulocytic 0.10  0.00 0.3173  0.17 0.5637 0.1573 
Eosinophilic 0.60  0.58 1  0.67 0.6547 0.6547 
Neutrophilic 0.30  0.00 0.0833  0.00 0.0833 - 
Mixed granulocytic 0.00   0.42 0.0455   0.17 0.3173 0.0833 
Table 3.3. Proportion of sputum inflammatory subtypes before (-24 h) and after (7 h and 24 h) 
an allergen inhalation challenge.  
§, vs. -24 h; †, vs. 7h. 
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Figure 3.2. Eosinophil and neutrophil cell counts in sputum collected before (-24 h) and after 
(7 h and 24 h) allergen inhalation challenge. 
Sample sizes are summarized in Table 3.3 (‘All allergens’ group). 
At 7 h post challenge, both eosinophils and neutrophils in sputum increased significantly (Figure 3.2; 
Table 3.4), causing the inflammatory subtype to change for most subjects (62%; Table 3.5 and 
Supplementary Table 3.1). For example, of the 44 individuals with paucigranulocytic sputum at 
baseline, 48% and 43% had eosinophilic and mixed granulocytic subtype at 7 h post challenge, 
respectively. Overall, relative to baseline, there was an increase in the proportion of individuals with 
the eosinophilic (43% to 55%) and mixed granulocytic (9% to 38%) subtypes, and a decrease in the 
proportion of individuals with the paucigranulocytic (38% to 6%) and neutrophilic subtypes (9% to 
1%) (Figure 3.3, Table 3.3). 
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    7 h post challenge   24 h post challenge 
  Allergen N Δ P-value   N Δ P-value 
E
o
si
n
o
p
h
il
s 
All allergens 112 1.2 2.0x10-30  113 1.1 1.4x10
-26 
Grass 18 1.6 1.4x10-6  20 1.3 6.5x10
-6 
Ragweed 15 1.4 5.8x10-5  13 1.2 5.0x10
-4 
HDMDF 10 1.2 0.0032  10 1.3 0.0012 
HDMDP 35 1.2 4.5x10-11  36 1.5 3.9x10
-10 
Cat 34 1.0 8.4x10-10  34 0.8 1.5x10
-7 
         
N
eu
tr
o
p
h
il
s 
All allergens 112 0.7 3.0x10-10  113 0.6 1.5x10
-10 
Ragweed 15 0.7 0.0923  13 0.3 0.0473 
Grass 18 0.7 0.0056  20 0.6 0.0123 
Cat 34 0.7 2.7x10-5  34 0.6 3.0x10
-4 
HDMDP 35 0.7 2.0x10-4  36 0.7 7.0x10
-4 
HDMDF 10 0.2 0.2385   10 0.5 0.0278 
Table 3.4. Change in eosinophil and neutrophil cell counts from baseline (-24 h) to 7 and 24 h 
post allergen inhalation challenge. 
Differences from baseline were calculated based on normalized cells counts per gram of sputum. 
Abbreviations: Δ, mean difference from baseline. 
  Baseline  
   Paucigranulocytic Eosinophilic Neutrophilic 
Mixed 
granulocytic Total at 7h 
7
 h
 p
o
st
 
ch
al
le
n
g
e 
Paucigranulocytic 9% 0% 0% 0% 4 
Eosinophilic 48% 69% 27% 60% 64 
Neutrophilic 0% 0% 9% 0% 1 
Mixed 
granulocytic 
43% 31% 64% 40% 45 
Baseline total 44 49 11 10 114 
Table 3.5. Proportion of sputum inflammatory subtypes observed 24 h before allergen 
inhalation challenge, stratified by the sputum subtype developed 7 h post challenge. 
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Figure 3.3. Proportion of sputum inflammatory subtypes before (-24 h) and after (7 h and 24 h) 
an allergen inhalation challenge. Sample sizes for each time point are shown on the left.  
* P < 0.05, ** P < 0.01, *** P < 0.001. 
At 24 h post challenge, eosinophils and neutrophils in sputum remained elevated compared to 
baseline, and largely unchanged from 7 h post challenge (Figure 3.2; Table 3.4). However, when cell 
counts were assessed as a fraction of the total cell count, there was a significant decrease in the 
proportion of neutrophils from 7 h to 24 h post challenge (Figure 3.4). This resulted in a significant 
decrease in the proportion of individuals with the mixed granulocytic subtype (38% to 19%) at 24 h, 
and a significant increase in the proportion of individuals with the eosinophilic subtype (55% to 76%) 
(Figure 3.3 and Table 3.3).  
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Figure 3.4. Eosinophils and neutrophil cell proportions in sputum collected before (-24h) and 
after (7 h and 24 h) allergen inhalation challenge. 
Sample sizes are summarized in Table 3.3 (‘All allergens’ group). 
When considering the difference in sputum cell counts between the baseline and post-challenge time 
points, which reflects how many cells entered the airways after the challenge, there was no association 
between the severity of the LAR and the number of eosinophils or neutrophils (Table 3.6). However, 
individuals with higher eosinophil (P = 0.014) and neutrophil (P = 0.018) sputum counts at baseline 
developed a more severe LAR upon allergen challenge (Table 3.6). 
 N β P-value 
Sputum subtype at baseline 118 NA 0.32388 
Neutrophils at baseline 117 0.19 0.01824 
Eosinophils at baseline 117 0.26 0.01371 
Sputum subtype at 7 h post challenge 123 NA 0.51214 
Neutrophils at 7 h post challenge 121 0.03 0.69377 
Eosinophils at 7 h post challenge 121 0.16 0.09762 
Difference in neutrophils between 7 h and baseline 112 -0.07 0.2989 
Difference in eosinophils between 7 h and baseline 112 0.03 0.76726 
Table 3.6. Association between the severity of the LAR and sputum granulocyte counts and 
inflammatory subtype. 
Sputum subtype and cell counts were assessed before (-24 h; baseline) and after (7 h) allergen 
challenge. 
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Effect of allergen type on sputum granulocyte counts and inflammatory subtype 
Compared to baseline, all allergens promoted a significant (Figure 3.5) and comparable (Figure 3.6 
and Table 3.4) increase in sputum eosinophil counts, both at 7 h and 24 h post challenge.  
 
Figure 3.5. Eosinophil and neutrophil cell counts in sputum collected before (-24 h) and after (7 
and 24 h) allergen inhalation challenge, stratified by allergen. 
Sample sizes are summarized in Table 3.3. 
On the other hand, neutrophil counts only increased significantly at 7 h post challenge for HDMDP, 
cat and grass allergens (Figure 3.5), although a similar trend was observed with HDMDF and ragweed 
(Figure 3.6 and Table 3.4). At 24 h post challenge, all allergens promoted a significant increase in 
neutrophils, suggesting a delayed infiltration of neutrophils with some allergens. 
At 7 h post challenge, the eosinophilic subtype was found at a similar frequency across allergens, 
ranging from 42% of individuals tested with grass to 66% of those tested with cat (Figure 3.3 and 
Table 3.3). The second most common subtype at this time point, mixed granulocytic sputum, also 
occurred with similar frequency across allergen types, ranging from 29% for cat to 53% for grass 
allergen. Overall, there were no significant differences in the frequency of sputum inflammatory 
subtypes between the five allergen types tested (P = 0.298).  
Chapter 3. Sputum cytology during late phase responses to inhalation challenge with different allergens 
The Role of the Interleukin-6 Pathway in Asthma | 45 
At 24 h post challenge, the eosinophilic subtype was found in 66% (HDMDF) to 84% (cat) of 
individuals, and the mixed granulocytic in 14% (ragweed) to 27% (grass) of individuals, again with 
no overall statistically significant differences in subtype frequencies between allergen types 
(P = 0.255). 
 
Figure 3.6. Change in sputum eosinophil and neutrophil cell counts from baseline (-24 h) to 7 
and 24 h post allergen inhalation challenge, stratified by allergen. 
Differences from baseline were calculated based on normalized cells counts per gram of sputum. The 
dashed line represents the overall median change from baseline. Sample sizes are summarised in 
Table 3.4. 
Discussion 
In this study, we analysed data from allergen inhalation challenges to test the hypothesis that different 
allergen types can induce distinct inflammatory profiles in the airways. The study population included 
exclusively individuals with mild allergic asthma. 
Unexpectedly, we found no association between the number of eosinophils and neutrophils that 
infiltrate into the airways after allergen challenge and the severity of the LAR.  On the other hand, 
individuals with increased eosinophil and neutrophil sputum counts at baseline had a more severe 
LAR, consistent with results from previous studies.159,163 These results suggest that the presence of 
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larger numbers of granulocytes at baseline, perhaps reflecting ongoing or chronic inflammatory 
processes, is a risk factor for a more severe asthma exacerbation upon acute allergen exposure. This 
is not surprising, given the active contribution of eosinophils and neutrophils to asthma immune 
responses. These cells produce and release proteases, cytokines and chemokines aimed at eliminating 
pathogens.164,165 Recurrent release of these mediators contributes to irreversible airway remodelling, 
which in turn is associated with progressive loss of lung function. More importantly, degranulation 
of eosinophils and neutrophils releases mediators that recruit immune cells involved in adaptive 
immune responses, and these have been shown to associate with the magnitude of the LAR.166 
Specifically, the severity of the LAR associates with allergen-specific proliferative response of 
peripheral T lymphocytes, which in turn are correlated with increased serum levels of IL-5, a cytokine 
produced by eosinophils.166 
When we compared the frequency of sputum inflammatory subtypes between individuals challenged 
with different allergen types, we found no overall significant differences. This is in contrast with 
findings from studies of experimental acute allergic asthma conducted in isogenic mice. Such 
differences could arise, for example, if there is a significant genetic contribution to variation in 
sputum subtype in humans. Blood cell counts are highly heritable in humans, with about 70% of the 
variation in eosinophil and neutrophil numbers explained by genetic factors.167 There is also a 
significant positive correlation in granulocyte counts between blood and sputum, most strongly for 
eosinophils.138,168,169 Therefore, it is possible (if not likely) that sputum cell counts are also heritable. 
On the other hand, environmental factors might also contribute to variation in sputum subtype after 
acute allergen challenge in humans but not (or less so) in mouse studies. For example, recent studies 
have shown that depending on the microbiota composition of the lungs, the airway inflammatory 
phenotype may adopt a neutrophilic- or eosinophilic-like profile.170-173 The intestinal microbiome can 
also modulate the allergic responses in the airways through the production of byproducts that regulate 
cell function and differentiation.174 Thus, unlike described in mice, allergen type is likely to have no 
(or only a small) contribution to variation in sputum subtype following acute allergen challenge. 
The changes in sputum inflammatory cells seen in the paucigranulocytic subtype warrant some 
discussion, especially as the pathogenesis of this asthma subtype is not well understood. Our findings 
indicate that individuals with paucigranulocytic asthma can readily develop an eosinophilic or mixed 
granulocytic sputum subtype after allergen exposure. This suggests that it is not correct to regard 
paucigranulocytic asthma as a static phenotype but one in which airway inflammation can develop 
dynamically in response to sensitizing allergens. 
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 There are a number of limitations that need to be considered when interpreting results from our study. 
First, the study design used does not explicitly control for many factors that could potentially 
contribute to inter-individual variation in sputum subtype. This could decrease power to detect a true 
effect of allergen type on variation in sputum subtype frequency. For example, in mouse studies, 
animals are isogenic, kept in a comparable environment, fed the same diet and challenged within days 
of each other. As such, the effect of genetic and (many) environmental factors on sputum subtype 
variability is minimized, which was not the case in our study. Therefore, in mice, allergen type might 
explain a larger fraction of sputum subtype variability, and so such effect might be detectable with 
relatively small sample sizes. A comparable and more desirable study design in humans would be to 
test if different allergens trigger different sputum subtypes in the same individual, with different 
allergens tested in a relatively narrow time frame. Such data were available for only a small number 
of individuals in our study, and so were not considered in our analyses. Second, to facilitate the 
analysis and interpretation of results, we averaged observations from individuals who completed 
multiple allergen challenges using the same allergen. Although this is unlikely to have affected the 
robustness of our findings, a more powerful approach would have been to use mixed models and 
include random effects to account for the presence of non-independent observations. We explored 
this approach but often had convergence problems, thus questioning the validity of the model 
estimates. Nonetheless, with this caveat in mind, results obtained with mixed models were consistent 
with our conclusions (not shown). Third, not all allergens tested in these analyses were equally 
represented. HDMDP, the most common allergen in the dataset, was used in 40 allergen inhalation 
tests, whereas HDMDF, the rarest allergen in the dataset, was only used in 12 allergen inhalation 
tests. Small sample sizes could affect the power to detect differences between allergens. Another 
caveat relates to the allergen groupings used in our analysis. We opted to analyse the two HDM 
species separately (instead of combining them into a broader HDM group) because known differences 
between these allergens 175,176 could potentially trigger distinct immunological responses. The same 
holds for the two types of pollen that were analysed separately in our study (ragweed and grass). 
When we repeated our analyses with only three major allergen groups (HDM, pollen and cat), results 
remained largely unchanged (not shown). Lastly, the outcome of interest in these analyses was the 
sputum subtype, which is defined by the proportion of eosinophils and neutrophils in sputum. The 
thresholds we used to classify sputum subtype were proposed by Simpson et al,124 corresponding to 
the 95th percentiles observed in healthy individuals. However, other studies have proposed slightly 
different thresholds,138,177,178 which might result in a different sputum subtype classification for some 
individuals in our study. Which thresholds are more appropriate to define the different sputum 
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subtypes is still an open question. However, when we categorized sputum subtype according to other 
published thresholds, results remained unchanged, with no significant effect of allergen type on the 
frequency of sputum subtypes (not shown). 
In conclusion, we found no association between the type of allergen used in inhalation challenge tests 
and the sputum inflammatory subtype developed. This observation is important because it suggests 
that there are no specific allergen types that can be used reliably to enrich allergen-induced responses 
for an inflammatory subtype of interest, as might be important in clinical trials of biologic therapies 
for asthma. 
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CHAPTER 4. GENES CO-EXPRESSED WITH IL6R THAT ALSO ASSOCIATE WITH 
ASTHMA RISK 
The goal of this chapter was to increase our understanding of gene networks that are perturbed in 
asthma by identifying genes that are (1) co-expressed with IL6R and (2) associated with asthma risk. 
Results from these analyses were published in the Allergy journal in 2016: 
Revez JA, Matheson MC, Hui J, Baltic S, Australian Asthma Genetics Consortium c, James A, 
Upham JW, Dharmage S, Thompson PJ, Martin NG, Hopper JL, Ferreira MA: Identification of 
STOML2 as a putative novel asthma risk gene associated with IL6R. Allergy 2016;71:1020-1030. 
Introduction 
Chapter 1 reviewed extensive evidence from both human genetic association studies1,26,122 and 
experimental animal models of asthma32,33 that suggested that dysregulation of IL6R expression 
contributes to asthma pathophysiology. However, it is important to recognize that IL6R expression is 
also associated the expression of other immune and inflammatory genes.179,180 For instance, in a study 
that evaluated the contribution of IL-6 to obesity-related inflammation, gene expression levels 
measured in adipose tissue showed that IL6R expression was positively correlated with the expression 
of inflammatory genes involved in processes such as insulin resistance, chemotaxis and infiltration 
of inflammatory cells into adipose tissue.180  
Thus, in asthma, the expression of IL6R may also be associated with the expression of other genes 
that simultaneously contribute to increased disease risk. To our knowledge, this possibility has not 
been studied systematically to date. To address that hypothesis, we first analysed two publicly 
available gene expression datasets to search for genes whose expression was correlated with that of 
IL6R (henceforth referred to as “IL6R-associated genes”). Then, this information was integrated with 
results from both asthma and transcriptome GWAS to identify the subset of IL6R-associated genes 
that are likely to be genetic risk factors for asthma. Identifying disease risk genes that are also 
associated with IL6R might provide new clues into the broader gene network that underlies the 
pathological effect of IL-6 signalling dysregulation in asthma. 
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Methods 
Our analytical procedure is summarized in Figure 4.1 and described in detail below. 
 
Figure 4.1. Flowchart of IL6R co-expression analysis. 
Steps taken for the identification of genes with expression (i) associated with that of IL6R and (ii) 
regulated by asthma risk SNPs. 
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Analysis of gene expression levels in 373 Europeans studied by the Geuvadis consortium 
To identify genes with expression levels correlated with those of IL6R, we first analysed RNA-seq 
data generated by the Geuvadis consortium for human lymphoblastoid cell lines (LCLs)181. LCLs are 
derived from peripheral blood B-cells and so represent a practical in vitro model to study gene 
expression patterns relevant to immune-related conditions.  
We downloaded from the European Bioinformatics Institute (EBI) RPKM-normalized gene 
expression levels for 53,934 transcripts measured in LCLs of 462 unrelated individuals from the 1000 
Genomes Project (accession E-GEUV-1, file GD660.GeneQuantRPKM.txt.gz). Transcripts 
expressed in > 90% of individuals (N = 18,702) were selected and distributions normalized using a 
rank-based inverse-normal transformation. We restricted our analysis to samples of European 
ancestry (N = 373) and unique transcripts (unambiguous match between HGNC symbol and 
corresponding Ensembl ID) annotated in GENCODE182 (N = 15,440). The association between IL6R 
expression levels and the expression of each of the other 15,440 genes was then tested using linear 
regression, with covariates included in the model to adjust for the effects of sex, population (CEU, 
GBR, FIN, TSI), sequencing centre and gene GC content (see below). Sixteen principal components 
(PCs) were also included as covariates to account for the effect of unmeasured confounders, as 
described below. These analyses were performed in R version 3.2.2. 
 
Figure 4.2. Comparison of GC content effect on gene expression levels of two representative 
individuals (two left panels) and histogram of GC covariate values. 
Histogram of GC correction values is based on sample of 462 individuals. 
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Gene GC content can affect RNA-seq-derived expression levels differently in different 
individuals.183,184 We tested this possibility and indeed found that in some individuals, increased gene 
GC content was associated with increased gene expression, while in others the reverse was true 
(Figure 4.2). To correct for this potential confounder, we calculated a GC correction per individual 
as follows. From the 18,702 genes expressed in more than 90% of individuals, we (1) excluded a 
subset of 3,756 highly expressed genes (RPKM > 21.48); (2) normalized the distribution of the 
remaining genes with a rank-based inverse-normal transformation; and (3) for each individual 
determined a correction value as the regression slope obtained from the regression of gene expression 
levels on gene GC content (for two examples, see Figure 4.2). GC content for each gene was obtained 
from the Conditional Quantile Normalization R package for 15,277 genes.183 To correct for the effects 
of unmeasured confounders, PC analysis was applied to the matrix of quantile-normalized gene 
expression levels using the prcomp function of the R stats package,185 and the first 16 PCs were then 
extracted and included as covariates when testing the association between IL6R expression levels and 
the expression levels of other genes.  
The top 10% of genes with expression most associated with that of IL6R were then selected for 
subsequent analyses. For a justification of how/why we selected a cut-off of 10% (instead of e.g. 5%), 
see section “Selection of cut-off to prioritize IL6R-associated genes” below. 
Analysis of gene expression levels in 38 cell types from the DMAP project 
We used a second independent approach to identify genes associated with IL6R. This approach 
differed from the analysis of the Geuvadis data in that we searched for genes correlated with IL6R 
within an individual but across immune cell types (e.g. cell types with increased expression of IL6R 
also have increased expression of gene X), instead of within a cell type but across individuals (e.g. 
individuals with increased expression of IL6R in LCLs also have increased expression of gene X). 
A file (DMap_data.gct) containing normalized gene expression levels for 8,968 genes measured in 
38 hematopoietic cell populations isolated from four to seven individuals was downloaded from the 
Differentiation Map Portal (DMAP) project186 website. We then selected 7,372 unique genes 
annotated in GENCODE,182 and measured the association of their expression with IL6R expression 
using the cosine distance metric, as implemented in the GeneNeighbors module of GenePattern.187 
As for the Geuvadis data, the top 10% of genes most associated with IL6R expression (based on the 
absolute of the distance metric) were selected for subsequent analyses. 
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Identification of SNPs associated with asthma risk and variation in gene expression  
Not all genes associated with IL6R will contribute to asthma pathophysiology. To identify the subset 
of IL6R-associated genes whose expression might be causally-related to asthma risk, we combined 
information from published GWAS of asthma and published GWAS of gene expression levels. 
Specifically, for each gene X (e.g. BCL6) that is associated with IL6R, we (1) extracted summary 
association statistics (effect, risk allele, P-value) for SNPs within 1 Mb of the gene boundaries from 
the Ferreira et al. GWAS,188 which included 6,685 asthmatics and 14,091 controls; (2) selected the 
SNP with the most significant association with asthma (amongst those with P < 0.05) in that 1 Mb 
interval; (3) identified all genes whose expression was previously reported to associate (typically, but 
not always, with FDR < 0.05 imposed by the original study) with this SNP (or a proxy, r2 > 0.8) in 
11 published GWAS of gene expression levels conducted in cells/tissues relevant to asthma181,189-198; 
and (4) retained that SNP for further analysis if one of the genes known to be regulated by this SNP 
was also gene X (i.e. BCL6). In other words, we selected a subset of IL6R-associated genes that are 
regulated by a nearby SNP that associates with asthma risk.  
We selected this approach for two main reasons. First, disease risk variants that associate with gene 
expression are more likely to reflect causal associations. This has been demonstrated in several 
studies,(23650636) including a study by Moffat et al. that showed that genome-wide significant 
variants associated with childhood asthma were consistently associated with the expression of 
ORMDL3,59 a gene that was subsequently shown to be inducible in lung epithelial cells and involved 
in airway remodelling.199,200 Second, we restricted our analysis to cis eQTLs because most GWAS of 
gene expression used here (performed in tissues relevant for asthma, e.g. B cells) had low power to 
detect trans effects, or reported cis effects only. 
We considered an alternative more comprehensive analytical strategy (selection of all SNPs 
associated with asthma in step (2) above), but found that this would result in hundreds of SNPs being 
carried forward to validation, which would decrease power given the multiple testing burden (see 
below). 
Selection of cut-off to prioritize IL6R-associated genes for downstream analyses 
In the first step of our analytical procedure (Figure 4.1 A), we used a 10% cut-off to select a group of 
genes whose expression was most strongly associated with that of IL6R. The choice of cut-off 
determined the number of genes selected for downstream analysis, and so also the number of SNPs 
that were moved to validation (see below). As such, an important consideration when deciding what 
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cut-off to use was the power provided by the validation study to replicate a significant association 
after accounting for multiple SNP testing. Cut-offs of 5% and 10% resulted in 37 and 61 SNPs 
reaching the validation step, respectively. Based on the specific effect sizes and minor allele 
frequencies observed for these SNPs in the discovery GWAS, we estimated the power provided by 
the validation study to replicate the associations at a Bonferroni-corrected threshold of 0.0014 
(0.05/37) and 0.0008 (0.05/61), respectively. The validation study was adequately powered to 
replicate 22 of the 37 (59%) SNP associations obtained with the 5% cut-off and 35 of the 61 (57%) 
associations obtained with the 10% cut-off. Therefore, the ability to replicate the associations with 
these two sets of SNPs was comparable between the two cut-offs (59% vs. 57%). The 10% cut-off 
maximised the opportunity to discover new risk SNPs, and so we selected that cut-off. 
Validation of genetic associations with asthma risk 
The previous analyses identified a set of SNPs found to regulate an IL6R-associated gene and that 
were also associated with asthma risk in the Ferreira et al. GWAS.188 We refer to these SNPs that are 
associated with variation in the expression of a nearby gene as “eSNPs”. 
Some of these might represent novel risk variants for asthma. To test this possibility, we investigated 
whether these eSNPs were also associated with asthma risk in an independent study, the GABRIEL 
consortium GWAS.62 After excluding overlapping samples (N = 1,207, Busselton cohort), results 
were based on the analysis of 12,077 asthmatics and 15,301 controls. A reproducible association was 
defined as a significant (P < 0.05) and consistent (i.e. same direction of effect as in the Ferreira et al. 
GWAS188 association in this analysis. The proportion of eSNPs for IL6R-associated genes with a 
reproducible association with asthma out of all eSNPs tested in the GABRIEL is denoted in the 
section below by fIL6R-genes. To obtain an overall measure of association between an eSNP and asthma 
risk, we used METAL201 to meta-analyse results from the Ferreira et. al GWAS and the GABRIEL 
GWAS using a fixed-effects model. 
Comparison with a random selection of genes 
We applied the same analytical approach described above (Figure 4.1) to a random set of 1,000 genes, 
instead of IL6R. This allowed us to estimate the extent to which the enrichment of significant 
associations between asthma risk and eSNPs for IL6R-associated genes was because eSNPs in general 
– and not just those specific to IL6R-associated genes – are more likely to be disease-associated than 
randomly selected SNPs.202 To this end, we (1) selected a random gene tested in both the Geuvadis 
and DMAP datasets; (2) applied steps A through D (Figure 4.1) to identify genes co-expressed with 
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that random gene (instead of IL6R); and (3) identified the proportion of eSNPs for genes co-expressed 
with that random gene that had a reproducible association asthma risk (and denote this fraction by 
frandom-genes). This procedure was repeated for 1,000 different random genes. We then calculated the 
mean frandom-genes across the 1,000 replicates, and the proportion of replicates where frandom-genes ≥ fIL6R-
genes. This proportion represents the (empirically-derived) probability of observing reproducible eSNP 
associations with asthma risk more often than observed for IL6R-associated genes when selecting a 
random gene of interest.  
Results 
Identification of genes with expression levels associated with those of IL6R 
To identify genes that were associated with IL6R, we used two complementary approaches (Figure 
4.1 A). First, we tested the association between IL6R expression and that of 15,440 genes measured 
with RNA-seq in LCLs of 373 individuals of European descent by the Geuvadis consortium.181 In 
this analysis, the expression of 1,020 genes (6.6%) was associated with the expression of IL6R at a 
P < 0.05. The most associated genes (N = 1,544; top 10%) are listed in Supplementary Table 4.1 and 
include notable genes such as ATP8B2 and IL18R1, which are respectively a gene located near IL6R 
and a gene located in an established asthma risk locus.203  
The previous analysis aimed to identify genes associated with IL6R when comparing expression 
levels measured in a single cell type across different individuals. In a separate approach, we analysed 
data from the DMAP project186 to search for genes whose expression values were correlated with 
IL6R across 38 different hematopoietic cell populations. In this analysis, the expression of 3,643 
genes (49%) was associated with that of IL6R at P < 0.05. This excess of significant associations 
likely arises because cell types analysed by the DMAP project derive from a common hematopoietic 
progenitor cell and many belong to the same lineage, and so their transcriptional profiles are highly 
correlated.186 As for the analysis of the Geuvadis data, we then selected the top 10% of genes with 
expression patterns most associated with IL6R for subsequent analysis (N = 737, Supplementary 
Table 4.1). Amongst the most IL6R-associated genes were for example LY96 and TLR2, two genes 
involved in the regulation of inflammation.204,205 
After combining the lists of genes most associated with IL6R in these two independent approaches 
(top 10% of each), we obtained 2,203 genes (Figure 4.1 A), including those identified (1) in the 
Geuvadis dataset only (N = 1,466); (2) in both the Geuvadis and DMAP datasets (N = 78) and (3) in 
the DMAP dataset only (N = 659). 
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We used the STRING v10206 online database to analyse the 78 genes identified through both 
approaches, and found a significant enrichment for cellular components involved in binding and 
present in the cell periphery or plasma membrane. In addition, this set of genes was enriched in 
biological processes involved in cellular response to stimulus, suggesting that, like IL6R, the genes 
identified through the GEUVADIS and DMAP studies code for proteins involved in cell signalling. 
Identification of asthma risk SNPs near IL6R-associated genes  
The analysis above identified 2,203 genes with expression levels associated with IL6R, either across 
different individuals and/or cell types. We hypothesized that the expression of some of these genes 
might be causally related to asthma. If so, we would expect that genetic polymorphisms that regulate 
the expression of these genes would be associated with asthma risk. To test this possibility, for each 
gene, we first identified the nearby (+/- 1 Mb) single nucleotide polymorphism (SNP) with significant 
(P < 0.05) and strongest association with asthma risk in a recently published asthma GWAS,188 that 
included 6,685 cases and 14,091 controls. For twelve genes, there were no significant SNPs within 1 
Mb, and so these were not considered further. The resulting list of 2,191 SNPs was further pruned by 
removing duplicate (i.e. same SNP selected for two or more genes; N = 1,122) or correlated (linkage 
disequilibrium r2 > 0.1; N = 79) SNPs, leaving for further analysis 990 independent SNPs that were 
associated with asthma risk and located near an IL6R-associated gene. 
Regulation of gene expression by asthma risk SNPs near IL6R-associated genes 
We then investigated if the association between each of these 990 independent SNPs and asthma risk 
could arise because these SNPs regulate the expression of the nearby IL6R-associated gene. Of the 
990 SNPs, 358 (36%) were associated with the expression of at least one nearby gene in published 
GWAS of gene expression levels (which we refer to as eSNPs), including 84 (8.5%) that were eSNPs 
for the actual gene that was correlated with IL6R (Supplementary Table 4.2). 
In total, the 84 eSNPs associated with the expression of 90 IL6R co-expressed genes. When we 
analysed these genes with the STRING v10206 online database, we observed a significant enrichment 
for genes involved in lymphocyte and leukocyte activation. In addition, these genes were enriched 
for adaptive immune responses and regulation of isotype switching to IgE isotypes.  
Replication of the association between asthma and eSNPs for IL6R-associated genes 
Eighty-four eSNPs were associated with both asthma risk in the Ferreira et al. GWAS188 and 
expression levels of an IL6R-associated gene in published GWAS of gene expression. To validate the 
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association observed between asthma risk and these 84 eSNPs, we analysed publically available 
results from the GABRIEL asthma GWAS.62 After excluding samples that overlapped with the 
Ferreira et al. GWAS, results were available for 12,077 asthmatics and 15,301 controls. Of the 84 
eSNPs, 61 were tested in the GABRIEL GWAS and for 14 of these (23%) there was a significant 
(P < 0.05) and consistent (same direction of effect) association (Table 4.1 and Figure 4.1), when only 
about two reproducible associations were expected at this significance level by chance alone given 
multiple testing (61 [eSNPs tested] x 0.05 [P < 0.05] x 0.5 [same direction] = 1.5).  
   
Co-expression with 
IL6R Ferreira, 2014 GABRIEL 
No. eSNP Chr:bp Gene Cor Study 
OR, 
allele P-value Proxy SNP 
OR*, 
allele P-value 
1 rs10197862 2:102350089 IL18R1 -0.202 G 1.24, A 4x10-11 rs13431828 1.2, C 2x10-9 
 rs10197862 2:102350089 IL18RAP -0.143 G 1.24, A 4x10
-11 rs13431828 1.2, C 2x10-9 
2 rs1464510 3:188394766 BCL6 0.324 D 0.91, A 0.0001 rs1559810 0.92, A 0.0001 
3 rs7039317 9:34964538 STOML2 -0.346 D 1.11, T 0.0003 - 1.09, T 0.0010 
4 rs324011 12:57108399 STAT6 0.415 D 1.09, T 0.0001 rs167769 1.07, T 0.0022 
5 rs4833095 4:38798089 TLR1 0.448 D 1.2, T 5x10-12 - 1.07, T 0.0044 
6 rs2357792 16:50734311 NOD2 0.648 D 1.08, A 0.0011 rs6500331 1.06, G 0.0050 
7 rs13416555 2:8301605 ID2 0.324 D 1.12, C 1x10-5 rs10178845 1.06, G 0.0120 
8 rs6511788 19:12369223 MAN2B1 0.425 D 1.07, T 0.0088 - 1.06, T 0.0160 
9 rs11265424 1:160530060 SLAMF1 0.109 G 0.91, A 0.0005 rs1055880 0.95, C 0.0178 
10 rs2435206 17:45980745 NSF 0.374 D 1.08, T 0.0014 rs2435211 1.05, T 0.0197 
11 rs1253118 14:59497301 RTN1 0.556 D 1.07, T 0.0051 rs9323348 1.05, T 0.0210 
12 rs13212921 6:27237643 BTN2A1 0.329 D 1.14, T 0.0002 rs13219354 1.08, C 0.0224 
13 rs11000805 10:73903593 NDST2 0.349 D 1.07, C 0.0145 rs17741873 1.06, T 0.0316 
14 rs9289837 3:151388204 P2RY13 0.452 D 0.88, T 1x10-5 rs7637803 0.95, T 0.0416 
 rs9289837 3:151388204 MED12L 0.129 G 0.88, T 1x10
-5 rs7637803 0.95, T 0.0416 
Table 4.1. Fourteen SNPs that are eSNPs for genes that are co-expressed with IL6R and also 
have a reproducible association with asthma risk. 
Highlighted in light grey are SNPs that had not previously been reported to associate with asthma 
risk. SNPs with significant association with asthma after correction for multiple testing (FDR < 0.05) 
in the replication analysis are represented with bold font. *The OR is reported for the allele that is 
on the same haplotype as (i.e. in phase with) the allele reported for the Ferreira, 2014 GWAS SNP. 
Proxy SNPs were chosen based on an r2 > 0.8. Abbreviations: BP, base pair; Chr, chromosome; D, 
DMAP; G, Geuvadis; OR, Odds Ratio 
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SNP A1 A2 Effect SE P-value Direction 
rs10197862 A G 0.197 0.0222 7.25x10-19 ++ 
rs4833095 T G 0.121 0.0179 1.67x10-11 ++ 
rs1464510 A G -0.086 0.0153 1.70x10-08 -- 
rs324011 T G 0.077 0.0154 5.80x10-07 ++ 
rs13416555 C G 0.082 0.017 1.54x10-06 ++ 
rs7039317 T G 0.094 0.0196 1.67x10-06 ++ 
rs9289837 T G -0.085 0.0194 1.20x10-05 -- 
rs2357792 A G 0.068 0.0158 1.82x10-05 ++ 
rs13212921 T G 0.102 0.024 2.00x10-05 ++ 
rs11265424 A G -0.068 0.0169 5.63x10-05 -- 
rs2435206 T G 0.062 0.0162 0.00015 ++ 
rs1253118 T G 0.056 0.0157 0.00033 ++ 
rs6511788 T G 0.063 0.0175 0.00034 ++ 
rs11000805 C G 0.064 0.0192 0.00094 ++ 
Table 4.2. Meta-analysis of the Ferreira 2,014 and GABRIEL GWAS for the 14 SNPs with 
validated asthma risk association. 
Abbreviations: A1, allele 1; A2, allele 2; SE, standard error. 
Of the 14 eSNPs (representing 16 genes; Figure 4.3) with a reproducible association with asthma risk 
in the replication analysis, four were significant after controlling for the 61 SNPs tested 
(FDR207 < 0.05). Three of these are established risk variants for allergic disease, specifically those 
regulating the expression of IL18R1/IL18RAP,62 BCL6 and STAT6.208 On the other hand, rs7039317 
(combined discovery and replication analysis OR = 1.10 for the T allele, P = 2 x 10-6; Table 4.2), an 
eSNP for STOML2, has not previously been reported to be associated with the risk of asthma or other 
allergic diseases. Therefore, STOML2 represents a putative novel risk gene for asthma. 
To get mechanistic insight into the function of the STOML2 eSNP (rs7039317), we queried HaploReg 
v4,209 an online tool that combines information from several GWAS annotation resources, including 
the Roadmap Epigenomics and ENCODE projects. We found that the STOML2 eSNP overlaps an 
enhancer region in skin epithelial cells. Thus, it is possible that rs7039317 affects the binding of a 
transcription factor that then determines the transcription levels of STOML2, as has been postulated 
for other non-coding variants identified through GWAS. 
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Figure 4.3. Genes that are co-expressed with IL6R and have a reproducible association with 
asthma or allergies. 
Underlined genes were significant at FDR < 5% in the replication analysis. Distance of genes to 
IL6R, and of eSNPs to genes, represent strength of association (i.e. shorter distances represent 
stronger association). 
Association between STOML2 expression, IL6R expression and asthma risk 
To further characterize the association observed between the expression of STOML2 and that of IL6R 
in the DMAP project, we examined the expression of both genes across the 38 hematopoietic cell 
types studied. There was a negative correlation between IL6R and STOML2 expression (Figure 4.4); 
for example, central memory CD4+ T Cells and neutrophilic metamyelocytes had high IL6R 
expression and low STOML2 expression, whereas megakaryocytes and erythroids had low IL6R 
expression and high STOML2 expression. 
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Figure 4.4. Expression of IL6R and STOML2 across 38 hematopoietic cell types. 
High gene expression levels are portrayed in red and low gene expression levels in white. 
Abbreviations: DDENDA2, Myeloid Dendritic Cell; TCELLA6, Naïve CD4+ T Cells; TCELLA7, 
Effective Memory CD4+ T Cell; GMP, Granulocyte-Monocyte Progenitor; TCELLA2, Naïve CD8+ 
T Cells; GRAN3, Neutrophil; MONO2, Monocyte; MONO1, Colony Forming Unit-Monocyte; 
GRAN2, Neutrophilic Metamyelocyte; TCELLA8, Central Memory CD4+ T Cell; ERY4, Erythroid 
4; ERY3, Erythroid 3; HSC1, Hematopoietic Stem Cell 1; MEGA1, Colony Forming Unit-
Megakaryocytic; HSC3, Hematopoietic Stem Cell 3; ERY5, Erythroid 5; ERY1, Erythroid 1; MEP, 
Megakaryocyte/Erythroid Progenitor; MEGA2, Megakaryocyte; BCELLA4, Mature B Cell Class 
Switched; PRE_BCELL3, Pro B Cells; NKA4, NKT; DENDA1, Plasmacytoid Dendritic cell; ERY2, 
Erythroid 2; PRE_BCELL2, Early B Cells; CMP, Common Myeloid Progenitor; EOS2, Eosinophil; 
GRAN1, Colony Forming Unit-Granulocyte; BASO1, Basophil; TCELLA4, Central Memory CD8+ 
T Cell; NKA1, Mature NK Cell 1; TCELLA1, Effective Memory RA CD8+ T Cell; TCELLA3, Effective 
Memory CD8+ T Cell; BCELLA3, Mature B Cell; BCELLA1, Naïve B Cells; NKA2, Mature NK Cell 
2; NKA3, Mature NK Cell 3; BCELLA2, Mature B Cell Class Able To Switch. 
We also combined results from the asthma and transcriptome GWAS to predict the direction of effect 
of STOML2 expression on asthma risk. The rs7039317:T allele that was associated with increased 
asthma risk was associated with increased expression of STOML2 in whole-blood195 (Table 4.3), 
suggesting that increased STOML2 expression has a predisposing effect on asthma. 
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Table 4.3. Effect of asthma-associated SNPs on gene expression 
* Corresponding to the eSNP allele that is on the same haplotype as the asthma effect allele. 
Abbreviations: LD, linkage disequilibrium; N/A, not available; OR, odds ratio; SNP, single 
nucleotide polymorphism 
Other genes near STOML2 regulated by rs7039317 
Many eSNPs are known to be associated with the expression of multiple genes, as we observed for 
rs10197862, an eSNP for both IL18R1 and IL18RAP. Although rs7039317 was only associated with 
the expression of a single gene that was correlated with IL6R, it could nonetheless be associated with 
the expression of other nearby genes unrelated to the IL-6 signalling pathway, i.e. our results do not 
exclude the possibility that another gene is the driver of the association between rs7039317 and 
asthma. When we queried results from 11 published GWAS of gene expression levels, there were an 
additional three genes whose expression was correlated with this SNP, namely VCP (P = 2 x 10-17; 
193,195), PIGO (P = 3 x 10--6; 195) and DNAJB5 (P = 6 x 10-4; 195). Therefore, in addition to STOML2, 
these three genes represent putative target genes for rs7039317 and so might also be related to asthma 
pathophysiology. 
Asthma association 
(Ferreira 2014 GWAS) 
Gene expression association 
 eSNP in LD with 
asthma SNP 
 
SNP rs ID 
Effect 
allele OR rs ID r2 Gene P-value Study Tissue 
Effect on 
expression* 
rs10197862 A 1.24 rs10197862 1.00 IL18RAP 2.8x10-137 195  Whole blood Decreased 
rs10197862 A 1.24 rs950881 0.95 IL18R1 0.00025 195  Whole blood Decreased 
rs11000805 C 1.07 rs17741873 0.86 NDST2 2.7x10-10 195  Whole blood Increased 
rs11265424 A 0.91 rs6670721 0.81 SLAMF1 3.0x10-15 195  Whole blood Decreased 
rs1253118 T 1.07 rs956901 0.87 RTN1 0.00160 195  Whole blood Decreased 
rs13212921 T 1.14 rs13217285 0.92 BTN2A1 1.7x10-15 181  LCLs N/A 
rs13416555 C 1.12 rs891058 0.99 ID2 6.1x10-08 193  PBMCs Increased 
rs1464510 A 0.91 rs9864529 0.81 BCL6 5.2x10-10 193  PBMCs Increased 
rs2357792 A 1.08 rs7342715 0.89 NOD2 3.5x10-11 193  PBMCs Decreased 
rs2435206 T 1.08 rs2435211 0.96 NSF 9.4x10-05 190  LCLs N/A 
rs324011 T 1.09 rs12368672 0.89 STAT6 9.8x10-198 195  Whole blood Decreased 
rs4833095 T 1.20 rs12233670 0.97 TLR1 2.8x10-57 197  Whole blood Increased 
rs6511788 T 1.07 rs10411986 0.98 MAN2B1 5.2x10-06 181  LCLs N/A 
rs7039317 T 1.11 rs10972275 0.93 STOML2 9.6x10-05 195  Whole blood Increased 
rs9289837 T 0.88 rs13327359 1.00 MED12L 2.4x10-37 195  Whole blood Decreased 
rs9289837 T 0.88 rs7637803 0.85 P2RY13 2.0x10-14 195  Whole blood Decreased 
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Comparison with a random selection of genes 
The aim of this study was to identify asthma risk genes amongst IL6R-associated genes. This was 
assessed by identifying eSNPs with a reproducible association with asthma risk amongst eSNPs for 
IL6R-associated genes. We found 14 such eSNPs amongst 61 eSNPs tested (23%), a significant 
enrichment over the 2.5% expectation (0.05 [P < 0.05] x 0.5 [same direction] = 0.025). It is possible 
that this enrichment of significant asthma associations amongst the eSNPs tested arose mostly 
because eSNPs in general are more likely to be disease-associated than randomly selected SNPs.202 
To test this, we applied steps A through D (Figure 4.1) to a random gene of interest in place of IL6R, 
and repeated this analysis 1,000 times (see Methods for details). On average, we found that 17.4% 
(SD = 4.7%) of eSNPs for genes co-expressed with a given random gene had a reproducible 
association with disease risk, a 1.3-fold decrease when compared to 23% for the list of 
IL6R-associated genes, but this difference was not statistically significant (empirical P = 0.120; see 
Methods for details). The observation that the enrichment of reproducible associations between 
eSNPs and asthma risk is comparable whether we considered IL6R or a random selection of genes 
does not imply that the associations are false-positives. Instead, it is consistent with previous studies 
that demonstrate that eSNPs are more likely to be associated with human traits than 
frequency-matched SNPs that are not related to gene expression.202 This observation is important to 
interpret our results but does not detract from the identification of eSNPs that are related to asthma 
risk as well as the expression of IL6R-associated genes.  
Discussion 
In this study, we investigated the possibility that genes whose expression is associated with that of 
IL6R might also be causally related to asthma pathophysiology.  
To identify genes with expression levels associated with that of IL6R, we used two complementary 
approaches, each with its own strengths and weaknesses. The RNA-seq dataset generated by the 
Geuvadis consortium181 for 373 unrelated individuals provided a unique opportunity to identify genes 
that share transcriptional regulatory mechanisms with IL6R constitutively in LCLs; for example, these 
could be shared regulatory elements (e.g. enhancers) or transcription factors. The top three genes 
most correlated with IL6R expression in this analysis were: FYN (negative correlation), which 
regulates mast cell function,210 B-cell development211 and is phosphorylated upon IL-6 binding to 
IL-6R212; CD180 (positive correlation), which belongs to the Toll-like receptor family and is involved 
in innate immune response to mycobacteria213; and ATP8B2 (positive correlation), which is located 
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in close proximity (53 kb) to IL6R, suggesting that both genes might share a nearby regulatory 
element. Our results demonstrate that the expression of these genes is to some extent coordinated 
with that of IL6R in LCLs, and is consistent with the previously suggested role for IL6R in Treg 
development,32 innate immunity214 and inflammation.215 The major caveat of this analysis was the 
use of an immortalized cell line that, although derived from a relevant cell type (B-cells), provides a 
very limited representation of gene expression patterns that are relevant for asthma. 
To partly address the limitation of using LCLs to uncover IL6R-associated genes that are relevant for 
asthma, we also analysed publicly available gene expression patterns measured in 38 different 
hematopoietic cell populations by the DMAP project.186 The strengths of this approach included the 
use of primary cells collected from volunteers (instead of cell lines) and the opportunity to identify 
genes associated with IL6R across cell types within individuals (instead of within a cell type across 
individuals). As such, the two approaches used (analyses of Geuvadis and DMAP data) shared the 
same aim but were conceptually distinct. An association between IL6R and another gene across cell 
types within an individual could arise, for example, if differentiation into specific cell lineages from 
a common progenitor requires temporal coordination of the expression of both genes (e.g. 
simultaneous expression; expression of one gene but not the other).  
In this second approach, the proportion of genes with expression associated with that of IL6R (49%) 
at P < 0.05 far exceeded the 5% nominal expectation. However, this is perhaps not too unexpected 
given that the cell types analysed by the DMAP project not only derive from a common hematopoietic 
progenitor cell (hematopoietic stem cells CD133+ CD34dim), but also include cell types that belong to 
the same lineage: for example, CD8 T cells and CD4 T cells, early B cells and pro B cells. As 
highlighted in the original DMAP publication,186 the global transcription profiles from cell types of 
related lineages are highly correlated. 
The top three genes whose expression was most closely associated with that of IL6R in the DMAP 
project were (all with a positive correlation): CD4, a cell surface antigen that is expressed on subsets 
of T cells, as well as on monocytes and macrophages, and plays an important role in T-helper cell 
development and activation216; VIPR1, a high-affinity G protein-coupled receptor for vasoactive 
intestinal peptide, a neuropeptide that controls both innate and adaptive immunity 217,218 and that has 
long been linked to asthma219; and RGL1, a downstream effector protein of the Ras pathway of IL-6 
signal transduction.  
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The clear literature links between IL-6 signalling and the function of some of the top IL6R-associated 
genes in the Geuvadis and DMAP analyses, suggests that both approaches were indeed able to 
identify specific components of the IL-6 signalling transduction pathway, its upstream regulators or 
downstream target genes. As for IL6R, we hypothesized that genetic dysregulation of the expression 
of these genes could affect asthma risk, for example by interfering with cellular differentiation or 
function in response to IL-6 stimulation. To address this hypothesis, we identified the subset of 
IL6R-associated genes whose expression was regulated by a SNP that was also a risk factor for asthma 
in a published GWAS.188 This list (90 genes) included genes directly relevant for both IL-6 signalling 
and asthma, for example TLR1,220 IL17RA221,222 and NDFIP1,223 amongst others.  
Due to multiple testing, the SNP associations with asthma for some of these 90 genes were likely to 
represent false-positive findings. To identify those with a reproducible association, we extracted 
results for these SNPs from an independent asthma GWAS62 and found that for 16 genes the SNP 
association with asthma was both significant and consistent. As such, this represents the group of 
genes which our analyses most convincingly link to both asthma aetiology and IL-6 signalling. Five 
of these genes were identified at a significance threshold that controls for multiple SNP testing in the 
replication study (FDR < 0.05): IL18R1, IL18RAP, BCL6, STAT6 and STOML2. The first four, but 
not STOML2, are known target genes of SNPs that have an established (i.e. genome-wide significant) 
association with allergic disease.62,208 
IL18R1 and IL18RAP encode the alpha and beta chains of the IL-18 receptor; IL-18 signalling through 
this receptor can activate IL-6 production,224 and IL-18 serum levels have been found to be positively 
correlated with sIL-6R levels.225 Therefore, together with these studies, our results indicate that the 
IL-18 and IL-6 signalling pathways are associated, and that this could in part be achieved by the 
coordinated transcription of IL6R, IL18R1 and IL18RAP.  
BCL6 is a transcription factor with a critical role in the activation and differentiation of germinal 
centre (GC) B cells226 and CD4 T cell differentiation into T follicular helper (Tfh) cells.227 IL-6 
stimulation is required for BCL6 expression, while in turn BCL6 induces IL6R expression.228 Thus, 
the expression of both genes is associated during specific B and T cell differentiation programs. Our 
finding that BCL6 expression is positively correlated with IL6R expression across hematopoietic cell 
types further supports the importance of coordinated transcription of these genes during normal cell 
lineage commitment. The association between SNPs that regulate the expression of these two genes 
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and asthma risk suggests that their effect on asthma pathophysiology might be related to dysregulation 
of GC B-cell and/or Tfh-cell differentiation. 
STAT6 is a transcription factor that plays a key role in adaptive immunity, by mediating IL-4 and 
IL-13 signalling through their cognate receptors,229 but also in innate immunity.230 Few studies have 
reported an association between IL-6 and STAT6, suggesting that these two signalling pathways 
might be mostly independent. However, in macrophages, IL-6 can induce the expression of the IL-4 
receptor and augment IL-4-induced STAT6 signalling.231 As such, IL6R and STAT6 co-expression 
might be important for innate immune responses. Consistent with this possibility, in the DMAP 
project, the cell types with highest expression of both IL6R and STAT6 were monocytes (not shown), 
the precursors for macrophages. 
Lastly, results from our analyses indicate that STOML2 is a putative novel asthma risk gene whose 
expression is negatively associated with that of IL6R. The overall statistical evidence we found for 
an association between the STOML2 eSNP and asthma risk (P = 2 x 10-6) would be considered 
suggestive and not genome-wide significant in the context of a GWAS. As such, validation of this 
association in a well-powered independent study is required to unambiguously confirm this eSNP as 
a novel risk factor for asthma. 
STOML2 encodes for a protein that is mostly expressed in mitochondria, is required for the correct 
development of cell respiratory chain complexes,232 and promotes T cell activation.233 In our study, 
we found that the eSNP associated with increased STOML2 expression was associated with an 
increased disease risk. Intuitively, the inverse correlation observed between STOML2 and IL6R 
expression may seem contradictory to the fact that increased expression of these genes is associated 
with variants predisposing to higher risk of asthma. Indeed, the rs4129267:T allele was estimated to 
increased asthma risk by 1.09-fold,1 and increased serum levels of sIL-6R by 1.4-fold.27 However, 
rs4129267:T is in high LD (r2 = 0.99) with rs2228145:C, which was also shown to associate with 
lower expression of IL6R in plasma and whole blood.122,234 As discussed by van Dongen et al.,234 the 
opposite effect of rs2228145 on sIL-6R protein levels and IL6R expression may be explained by the 
strong effect that the variant has on IL6R alternative splicing. Specifically, the rs2228145:C is 
associated with increased splicing of exon 9,235 which results in a differentially spliced mRNA 
presumed to directly code for sIL-6R. Consistent with this hypothesis, the rs2228145:C allele have 
been shown to associate with higher expression of the differentially spliced IL6R mRNA.119,235  
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The association of the STOML2 eSNP with increased gene expression and increased asthma risk 
suggests that STOML2 may have a pro-inflammatory effect in asthma. This is consistent with the 
observation that T cells from STOML2-deficient mice have decreased IL-2 production in response to 
cell activation, and this translated into reduced CD4+ T cell responses.236 In the DMAP project, CD4+ 
T cells had high expression of IL6R and low expression of STOML2. We speculate that in individuals 
with the rs7039317:T allele that increases STOML2 expression,195 mitochondria biogenesis and 
function in CD4+ T cells is increased, which results in stronger T cell responses to allergens, thereby 
increasing asthma risk. Functional studies that formally test this hypothesis are warranted. 
Interestingly, IL-6R blockade has been shown to attenuate the development of cachexia by promoting 
mitochondrial biogenesis and dynamics,237 which are induced by STOML2.236 These observations are 
consistent with our finding of a negative correlation between IL6R and STOML2 expression and, 
collectively, suggest that STOML2 is part of a gene network that underlies the effect of IL-6 on muscle 
loss. Of note, skeletal muscle dysfunction is common in chronic obstructive pulmonary disease238 and 
is induced by chronic intake of corticosteroids.239 
In conclusion, we identified 16 genes whose expression was associated with IL6R and that were 
regulated by common polymorphisms that had a reproducible association with asthma risk. This list 
included five known and 11 putative new asthma risk genes, of which STOML2 had the strongest 
SNP association with asthma. These genes provide new clues into broader gene networks that are 
associated with IL-6 signalling and that contribute to asthma pathophysiology. 
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CHAPTER 5. ASSOCIATION BETWEEN STOML2 AND ALLERGIC DISEASE 
The goals of this chapter were to (1) validate the association reported in the previous chapter between 
a STOML2 variant and asthma risk; and (2) to test the association between the same STOML2 variant 
and the risk of hay fever and eczema, two allergic diseases that share a large fraction of their genetic 
make-up with asthma. 
Introduction 
In the previous chapter, we identified genes associated with IL6R that also contributed to asthma risk. 
To identify genes whose expression correlated with that of IL6R, we used data from two publically 
available gene expression datasets.181,186 Then, we screened those genes for nearby SNPs associated 
with both variation in gene expression levels (eSNPs) and asthma risk. We used the Ferreira et al. 
GWAS,188 which included cases with both asthma and hay fever, to assess associations with asthma 
risk. Then, we confirmed those associations using data from the GABRIEL GWAS62 – the largest 
asthma GWAS that had been performed at the time the analyses were performed. Amongst the top 
replicated associations (false discovery rate [FDR] < 0.05) were eSNPs for four known (IL18R1, 
IL18RAP, BCL6 and STAT6) and one putative novel asthma risk gene, stomatin-like protein 2 
(STOML2).240  Specifically, STOML2 expression correlated with that of IL6R, and was up-regulated 
by an allele (rs7039317:T) that was associated with increased asthma risk.  
STOML2 encodes a protein found in mitochondria and cell membranes and has previously been 
shown to play a role in the function of T-cells, which in turn are central to allergic disease. However, 
even though our results suggest that STOML2 might contribute to IL-6 signalling in the context of 
asthma, evidence for association between rs7039317 and asthma risk did not reach the genome-wide 
significance threshold (combined discovery and replication analysis OR = 1.10 for the T allele, 
P = 2x10-6).240 Moreover, it was unclear from our results whether STOML2 was a risk factor that was 
specific to asthma or potentially shared with other allergic diseases, such as hay fever and eczema. 
Here, to address these questions, we assessed the association of rs7039317 with multiple allergic 
disease phenotypes using data from a new study that was not included in the analysis described in 
Chapter 4: the UK Biobank study. 
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Methods 
Selection of cases and controls for association analysis from the UK Biobank study 
The UK Biobank study is a prospective study of 502,682 participants recruited at 22 centres across 
the UK between 2006 and 2010.241 Data from this study was accessed through application number 
10074. We downloaded data-fields approved as part of this application on the 21st of March 2016, 
and restricted our analysis to a subset of 152,566 individuals with available genotype data at that time.  
We used information from the available data-fields as described in detail previously242 to classify 
disease status for asthma, hay fever and eczema. After restricting the analysis to individuals with 
information available for the SNP of interest near STOML2 (rs7039317), and who were unrelated to 
each other (based on an identity by descent cut-off of 0.125), we identified individuals of European 
ancestry as previously described.242 Briefly, using 847,442 directly genotyped variants from 152,566 
individuals in the UK Biobank, we selected common SNPs (MAF > 5%) in low LD (r2 > 0.1) with 
each other that were (1) present in the 1000 Genomes Project, with call rate >95% and Hardy-
Weinberg equilibrium P value >10-6, and (2) not A/T or C/G polymorphisms. Then, we merged the 
UK Biobank and 1000 Genomes project data and performed multi-dimensional scaling (MDS) 
analysis to identify individuals who clustered closely to Europeans of the 1000 Genomes project. 
Among individuals of confirmed European ancestry, we identified 16,095 cases with asthma, but no 
hay fever or eczema; 7,130 cases with hay fever, but no asthma or eczema; 2,904 cases with eczema, 
but no asthma or hay fever; and 86,986 controls who reported not suffering from any allergic disease 
(see Table 5.1 for demographics of each group). Information from asthma and hay fever was then 
used to define two new combined phenotypes: “asthma with hay fever”, with cases defined as 
individuals suffering from both diseases (n = 2,011); and “asthma and/or hay fever”, with cases 
defined as those who suffered from asthma and/or hay fever (n = 21,214). 
 Asthma Hay fever Eczema Controls 
N 16,095 7,130 2,904 86,986 
Sex (% female) 56.6 53.1 56.1 51.4 
Age (mean, SD, range) 56, 8.1, 40-70 55, 8.1, 40-70 55, 8.1, 40-70 57, 7.9, 40-73 
BMI (mean, SD, range) 28, 5.4, 15-66 27, 4.6, 16-57 27, 5, 17-67 27, 4.7, 14-67 
Smoker (% current, % ever) 10.5, 44.3 7.2, 38.1 10.7, 43.6 12.9, 47.7 
Age of onset* (mean, SD, range) 30, 18.9, 1-74 24, 15.7, 1-70 23, 19.1, 1-67 - 
Table 5.1. Demographics of study participants 
*Age of onset for hay fever and eczema was assessed under the same question in the UK Biobank 
questionnaire. Abbreviations: SD, standard deviation. 
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Age-of-onset of allergic disease 
Age-of-onset information was obtained from two data-fields: “Age asthma diagnosed” and “Age hay 
fever, rhinitis or eczema diagnosed”. For each individual, the minimum of these two was taken as the 
earliest any one allergic disease was first diagnosed. We were not able to analyse age-of-onset 
separately for hay fever and rhinitis, as there were no data-fields covering these two diseases 
separately. We considered a cut-off of 12 years old to identify cases with early disease onset, because 
it coincides with the start of the teenage period, which is associated with significant developmental 
changes (i.e. puberty). 
Statistical analyses 
We tested the association between allelic dosage of rs7039317 and case-control status using logistic 
regression. The effects of age, sex, body mass index (BMI), and smoking status (current and ever) on 
case-control status was tested with a multiple logistic regression beforehand, and variables with 
significant (P < 0.05) effect were included in the model as covariates.  
The association between rs7039317 and age-of-onset (quantitative trait) was tested using linear 
regression, after applying a rank-based inverse-normal transformation. Similarly, age, sex, BMI and 
smoking status were included in the model as covariates if their effect on age-of-onset was significant 
(P <0.05).  
Analyses were performed in R version 3.2.3. 
Results 
Replication of the association between rs7039317 and asthma with hay fever  
We previously found a significant association between rs7039317 near STOML2 and the combined 
phenotype of asthma with hay fever (OR = 1.10).188 Our first goal was to test if a consistent 
association with this same phenotype was also observed in the UK Biobank study, which was not 
included in our original analysis. We identified a total of 2,011 cases who reported having both asthma 
and hay fever, all unrelated and of European descent. On the other hand, a total of 86,986 individuals 
reported not suffering from any allergic disease and so were considered as controls. In this dataset, 
we observed a consistent (OR = 1.05 for T allele) but not significant (P = 0.2036) association between 
asthma with hay fever and rs7039317 (Table 5.2).  
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 N cases N controls OR P-value 
All asthma with hay fever cases 2,011 86,986 1.05 0.2036 
Subset of cases with early onset 849 86,986 1.09 0.1635 
Table 5.2. Association results between rs7039317 and asthma with hay fever 
Odds ratio (OR) reported for the minor allele (rs7039317:T). 
Effect of age-of-onset on the association between rs7039317 and asthma with hay fever 
We noticed that the UK Biobank cases included in the analysis above were enriched for individuals 
with late-onset asthma (e.g. median age-of-onset = 14; 54% with onset > 16), which was not the case 
in our original study (35% with onset > 16). Age-of-onset of hay fever/eczema was also relatively 
high (median age-of-onset = 20; 38% with onset > 16). Therefore, we hypothesised that the attenuated 
effect observed for rs7039317 in the UK Biobank study could reflect stronger effects for this SNP on 
early- when compared to later-onset allergic disease.  
To test this hypothesis, we first tested the association between rs7039317 and age-of-onset of allergic 
disease. The latter was defined as the earliest age-of-onset reported when considering information 
from asthma and hay fever/eczema (see Methods), which was available for 34,137 individuals (Figure 
5.1). We found that the rs7039317:T allele was significantly associated with decreased age-of-onset 
(P = 0.0175; Table 5.3). To understand if this effect was similar for asthma as compared to hay 
fever/eczema, we analysed the two age-of-onset phenotypes separately. We found a significant 
association with hay fever/eczema (P = 0.0241) but not with asthma (n = 14,014; P = 0.6843) age-
of-onset (Table 5.3). This indicates that the significant association with the combined allergic disease 
age-of-onset phenotype was mostly driven by the association with hay fever/eczema age-of-onset. 
Chapter 5. Association between STOML2 and allergic disease 
The Role of the Interleukin-6 Pathway in Asthma | 73 
 
Figure 5.1. Age of onset of allergic disease. 
Age-of-onset of: N β P-value 
Asthma 14,014 -0.01 0.6843 
Hay fever/eczema 26,161 -0.03 0.0241 
Allergic disease 34,137 -0.02 0.0175 
Table 5.3. Association between rs7039317 and age-of-onset of allergic disease.  
The results above suggest that rs7039317:T has a stronger effect on disease risk in individuals with 
early onset of allergic disease. We thus repeated the association analysis between this SNP and asthma 
with hay fever, but considered only cases with onset of allergic disease before age 12 (n = 849; see 
Methods for justification of cut-off selection). In this analysis, the effect of rs7039317 on disease risk 
was stronger (OR = 1.09) and closer to that reported in our original study (OR = 1.10). However, it 
did not reach statistical significance (P = 0.1635; Figure 5.2 and Table 5.2), a reflection of the smaller 
sample size.  
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Figure 5.2. Summary of rs7039317:T associations with allergic diseases. 
In each study, cases were defined as having the phenotype mentioned on the left. The phenotype 
“Asthma with Hay Fever” included cases affected by both diseases. The same set of controls was 
used across all UK Biobank analyses (N = 86,986). Early age-of-onset was defined as between 0-12 
years of age. Abbreviations: CI, confidence interval. 
Association between rs7039317 and the risk of individual allergic diseases 
To help understand if rs7039317 was a genetic risk factor shared between different allergic diseases, 
we then tested the association between this SNP and case-control status for asthma, hay fever and 
eczema separately. We found that the rs7039317:T allele was associated with increased risk of hay 
fever (OR = 1.04), asthma (OR = 1.02) and eczema (OR = 1.02), but all three associations were not 
statistically significant (P > 0.05; Table 5.4). Of note, the SNP effect on the individual risks of hay 
fever and asthma increased in individuals with early age-of-onset of allergic disease (OR = 1.06 and 
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OR = 1.05, respectively; Table 5.4), which was not the case for eczema (OR = 1.00). These results 
suggest that rs7039317 increases the risk of early onset asthma and early onset hay fever similarly, 
with a weaker or no effect on eczema risk. Consistent with this hypothesis, when we considered cases 
who reported suffering from asthma or hay fever and had early disease onset (n = 6,044, compared 
with n = 849 for asthma with hay fever analysis), we found a marginally significant association 
between rs7039317 and case-control status (OR = 1.05, P = 0.0333). Therefore, we conclude that 
results from the UK Biobank study do not formally replicate our original association between 
rs7039317 and asthma with hay fever but generally support the notion that this SNP is a risk factor 
for both asthma and hay fever with early onset. 
 N cases N controls OR P-value 
Asthma 16,095 86,986 1.02 0.1846 
Hay fever 7,130 86,986 1.04 0.1209 
Eczema 2,904 86,986 1.02 0.6530 
     
Cases with early onset   
Asthma 3,800 86,986 1.05 0.1385 
Hay fever 1,899 86,986 1.06 0.1532 
Eczema 967 86,986 1.00 0.9337 
Table 5.4. rs7039317 association results with individual allergic phenotypes. 
Odds ratio (OR) reported for the minor allele (rs7039317:T). Abbreviations: Y, years. 
Discussion 
In the previous chapter, we identified a variant near STOML2 (rs7039317) as a putative novel risk 
variant for asthma.240 Specifically, the rs7039317:T allele associated with increased risk of suffering 
from asthma with hay fever. Here, we studied that association in an independent study to increase 
confidence in our original results and assessed whether rs7039317 was a risk factor shared between 
allergic diseases.  
We found a weaker, but consistent, association between rs7039317 and the phenotype ‘asthma with 
hay fever’. Of note, the allele that associated with increased disease risk was also associated with 
earlier age-of-onset, and the association between rs7039317 and ‘asthma with hay fever’ was stronger 
in individuals with early age-of-onset. Risk variants associated with early onset disease have 
previously been reported to be shared between asthma, hay fever and eczema.242 Our results suggest 
that rs7039317 is one such variant.  
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Asthma, hay fever and eczema – also known as the atopic triad – are characterized by IgE-mediated 
immune responses, which in turn are induced by Th2-type cytokines. Increased expression of 
STOML2 has been shown to promote sustained T-cell responses.233 Thus, we hypothesized that the 
rs7039317:T allele, which is associated with increased STOML2 expression,195 would promote 
stronger T cell responses and so contribute to an increased risk of multiple allergic diseases. Even 
though we found no significant associations, we observed that the rs7039317:T allele was associated 
with a higher risk of each of the three individual diseases, asthma, hay fever and eczema. Of note, 
stronger associations were observed for both asthma and hay fever in individuals with early-onset 
disease. This is perhaps not surprising given that genetic burden is higher in individuals with early-
onset of these traits. 243 However, the association with eczema was weaker in individuals with early-
onset. Eczema often precedes asthma and hay fever,244 and early-onset has been shown to associate 
mainly with familial factors, as opposed to environmental exposures.245-247 In a model of allergic 
contact dermatitis, STOML2 was shown to be part of a group genes that are up-regulated by several 
sensitizers, suggesting its involvement in eczema.248 Nevertheless, our results suggest that the genetic 
regulation of this gene is not associated with disease risk.  
While the current study did not replicate our original association with asthma with hay fever, the 
effect size observed in individuals with early-onset was comparable to that reported previously. 
Together with the weaker association observed for eczema, this observation supports the notion that 
rs7039317-dependent higher STOML2 expression increases the risk of early onset asthma and hay 
fever, that is, allergic diseases of the airways. 
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CHAPTER 6. PREVENTION OF ALLERGEN-INDUCED ASTHMA EXACERBATIONS 
WITH TOCILIZUMAB 
The goal of this chapter was to test the hypothesis that asthmatics treated with a single dose of 
tocilizumab have reduced airway inflammation and bronchoconstriction after allergen challenge.  
Introduction 
Chapter 1 reviewed extensive clinical, genetic and functional evidence suggesting a pathological 
contribution of the IL-6 pathway to asthma. Briefly, clinical studies showed that, compared to healthy 
controls, asthma patients have high systemic101,249 and airway75 levels of IL-6, which in turn are 
associated with impaired lung function102,111 and worse asthma symptoms.102,250 Genetic association 
studies also showed that asthma susceptibility is greater amongst carriers of genetic variants in the 
IL6R gene that associate with increased serum levels of sIL-6R.1,122 Notably, among these is a genetic 
variant (rs4129267, or a variant in LD with it) that also associates with the risk of rheumatoid arthritis 
(RA)123 – a disease currently treated with anti-IL-6R therapy. Lastly, experiments with mouse models 
of asthma showed that anti-IL-6R therapy attenuates features of airway allergic inflammation.32,33,251 
Thus, an extensive body of evidence suggests that blockade of the IL-6 pathway may represent a new 
treatment option for asthma.  
Two main therapeutic approaches can be used to inhibit IL-6 signalling, namely targeting IL-6 itself 
or its receptor. Anti-IL-6 monoclonal antibodies (mAbs) were first reported to drastically increase 
IL-6 in circulation.252,253 Specifically, treatment was shown to induce accumulation of plasma 
monomeric IL-6 complexes that were not eliminated by renal filtration.252 Since then, improved anti-
IL-6 mAbs have been developed,254,255 and have shown promising results in several stages of clinical 
testing for inflammatory and autoimmune diseases.256 Antibodies against IL-6R have also been 
developed.257 258-260 Of these, tocilizumab – which blocks both the membrane (mIL-6R) and soluble 
(sIL-6R) forms of the receptor – was the first drug with demonstrated efficacy to be approved for RA 
treatment. Currently, it is used in over 100 countries to treat RA and other related inflammatory 
diseases such as Castleman's disease, and juvenile idiopathic arthritis.78 Tocilizumab is a promising 
drug to repurpose for the treatment of other autoimmune and inflammatory diseases with underlying 
IL-6 signalling dysregulation, such as asthma. Other drugs that block both mIL-6R and sIL-6R are 
also in clinical development, with sarilumab recently approved in the US and Canada for the treatment 
of RA.261 Lastly, an alternative treatment strategy was developed at the University of Kiel to 
selectively block sIL-6R, inhibiting IL-6 trans-signalling but not classical signalling.262 This new drug 
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(recently re-named olamkicpet) completed phase I clinical trials263 and is now being evaluated in a 
Crohn's disease phase II study sponsored by i-Mab BioPharma.  
IL-6R is therefore a unique example of a target for which clinical development in asthma is supported 
by multiple lines of evidence (observational clinical studies, genetic association studies and animal 
studies) and also by the availability of drugs that can be used in phase II trials. Based on these 
observations, in 2012 Dr Ferreira and Prof Upham obtained funding from the QLD Government to 
perform a phase II clinical trial of tocilizumab in participants with allergic asthma. Specifically, 
participants performed an allergen-inhalation challenge test before and after treatment, with endpoints 
compared between those randomized to a single dose of TCZ or placebo.  
Our primary efficacy endpoint was the magnitude of the late asthmatic response (LAR), as this is one 
of the most clinically relevant outcomes in early efficacy studies.157 The LAR is characterised by 
narrowing of the airways – also known as bronchoconstriction, which reflects underlying airway 
inflammation – that occurs typically 3 to 7 hours after allergen exposure. Allergen-inhalation 
challenge tests are a widely-used research tool to study the LAR. In these tests, increasing 
concentrations of allergen are inhaled until an early asthmatic response (EAR) is induced, typically 
consisting of an FEV1 fall of 20% from the challenge baseline FEV1. In approximately 50% of cases, 
recovery from the EAR is followed by a LAR.157 However, the prevalence of LAR is also determined 
by the allergen used in the challenge test. For instance, house dust mite (HDM) and cat allergens are 
more likely to induce LAR than grass pollen.264 Interestingly, inhalation of HDM has also been shown 
to significantly increase sIL-6R serum levels.31 This suggests that sIL-6R plays a role in 
bronchoconstriction associated with allergic inflammation. In addition, multiple lines of evidence 
suggest the involvement of IL-6 signalling in allergen-induced responses, including the LAR. First, 
allergen exposure has been shown to increase IL-6 signalling in humans, mouse models of asthma, 
and in vitro models. In humans, allergen inhalation challenge tests have been shown to promote 
exacerbations with significant increases in serum levels of IL-6 and sIL-6R.31,101 In mouse models of 
asthma, allergen inhalation challenge was also shown to increase airway levels of IL-6 and sIL-
6R,32,33,108 and blockade of IL-6 signalling abrogated airway inflammation, a key feature in LAR. In 
addition, alveolar macrophages isolated from patients who performed a bronchial provocation test 
and developed a LAR were shown to produce increased levels of IL-6 compared to those isolated 
from patients who did not develop LAR after allergen challenge.71 Second, the LAR is characterised 
by airway inflammation, and both serum and sputum levels of IL-6 have been shown to negatively 
correlated with FEV1.102,108,111 Therefore, an inhalation challenge with HDM provides an ideal 
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approach to test the hypothesis that tocilizumab can prevent bronchoconstriction, as advocated by 
others.265  
Here, we evaluated the safety and efficacy of tocilizumab in HDM-induced LAR in 11 patients 
recruited between September 2014 and July 2017. The original target sample size of the study was 
16, allocated 1:1 to placebo and tocilizumab. However, in late 2017, after reviewing blinded results 
from 11 participants who had completed the trial, the data safety and monitoring board (DSMB) of 
the study requested an interim analysis to confirm that continuing the trial to completion (i.e. to the 
target of 16) would be powered to detect a significant effect of tocilizumab on the primary endpoint 
(LAR), given the observed findings to date. Unblinded results were sent to the chair of the DSMB, 
who compared the primary endpoint between the two groups and found: (1) no significant differences 
in the LAR post-treatment; and (2) that, given the observed group means and SD, the target n of 16 
would not provide adequate power to detect a significant difference between groups. The trial was 
therefore stopped for futility and unblinded results released to the research team. In this chapter, I 
performed preliminary analyses of the safety and efficacy endpoints measured in the trial, which will 
be expanded in a future publication. 
Methods 
Study design 
We initiated a proof-of-concept phase II clinical trial of tocilizumab in 2012, with the first participant 
enrolled in September 2014 and the last in July 2017. The aim of this trial was to evaluate the safety 
and efficacy of a single dose of tocilizumab in 16 patients with mild allergic asthma. The trial used a 
double-blind, randomized, parallel-group, placebo-controlled design, with participants recruited at 
three clinical sites: Q-Pharm at the QIMR Berghofer Medical Research Institute (Brisbane, Australia); 
Princess Alexandra Hospital (Brisbane, Australia); and McMaster University (Hamilton, Canada). 
The study was divided into three phases (Figure 6.1): (1) screening (visits 1 – 4); (2) treatment (visits 
5 – 8); (3) and follow -up (visits 9 – 10).  
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Figure 6.1. Schematic of the 10 clinical trial clinical visits performed in the trial. 
We used inhaled-allergen bronchoprovocation tests to assess the efficacy of the drug in preventing 
allergen-induced airway responses. This acute challenge model is extremely safe, and has been 
extensively used to evaluate the effect of new anti-inflammatory therapies in asthma.266  
During the screening phase (visits 1 to 4), participants performed a series of tests to assess the 
inclusion and exclusion criteria for the study (Table 6.1), which are summarised here and described 
in detail below. Individuals who remained eligible after the tests performed at visit 1 were mild 
asthmatics (but otherwise in good health), with confirmed positive skin prick test for HDM and with 
rs4129267:TT or CT genotype. These participants then progressed to the first allergen inhalation 
challenge triad (visits 2 to 4), performed within 20 days of visit 1. In the first day of the triad (visit 
2), participants completed a methacholine inhalation test and a skin prick titration test (described in 
detail below). For participants with a positive methacholine test, information from both tests 
(methacholine and skin titration) was used to determine the allergen PC20 as described previously.
160 
The allergen PC20 corresponds to the allergen provocative concentration required to induce a 20% 
fall in FEV1. In the second day of the allergen triad (visit 3), an allergen inhalation challenge test was 
performed with HDM to determine the presence of an EAR and LAR. In the final day of the triad 
(visit 4), a follow-up methacholine challenge test was performed. Subjects with confirmed allergen-
induced EAR and LAR at visit 4 were eligible to enter the second phase of the study. 
 Visit Test 
Visit 1 Written informed consent 
 Demographics, medical and medication histories 
 Physical examination and vital signs 
 Spirometry 
 Chest X-ray (can be completed any time prior to starting visit 2 testing) 
 Resting 12-lead electrocardiogram (ECG) 
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 Urine and serum pregnancy test for women of childbearing potential 
 Participants who continue to meet entry criteria: 
 Complete routine laboratory tests;  
 Complete skin prick testing against house dust mite.  
 Genotype rs4129267 (or any time prior to Visit 1 if required)  
Visit 2 Spirometry 
 Methacholine challenge test 
 Participants who continue to meet entry criteria will:  
 Undergo skin titration test 
 Sputum induction 
Visit 3 Spirometry 
 Allergen inhalation challenge test 
 Sputum induction 
 Blood samples for haematology, biochemistry and biomarker assessment 
Visit 4 Spirometry 
 Methacholine challenge test 
  Sputum induction 
Table 6.1. List of tests performed in the screening phase to assess eligibility for the study. 
In the second phase of the study (visits 5 to 8), participants were randomized to receive a single dose 
of either tocilizumab or placebo (visit 5) and performed a second allergen inhalation challenge triad 
(visits 6 to 8), as summarised above and described in more detail below. The procedures used for 
randomisation and drug administration are described in detail below. Tocilizumab (or placebo) was 
administered seven days after the first allergen challenge, and seven days before the second allergen 
challenge. The timing of drug administration was decided based on the dose-dependent half-life of 
tocilizumab. Specifically, in RA, an 8 mg/kg dose of tocilizumab administered every four weeks has 
an apparent half-life of up to 13 days.267 Thus, in our study, we administered tocilizumab six to eight 
days before second allergen challenge. In turn, second allergen challenge was performed 14 days after 
the first allergen challenge, as this is the minimum recovery time shown to be successful in parallel-
group studies involving multiple allergen challenges.157 Drug efficacy was assessed based on primary 
and secondary endpoints (described in detail below) measured during this second allergen challenge. 
Lastly, two follow-up visits were carried out to assess safety endpoints, specifically 14 (visit 9) and 
28 (visit 10) days after tocilizumab/placebo infusion, in accordance with the published half-life of 
tocilizumab.268 
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Procedure used for participant recruitment 
Information from participants of asthma studies conducted prior to this trial at the QIMR Berghofer 
Medical Research Institute and the McMaster University were screened to identify those who were 
potentially eligible according to inclusion and exclusion criteria of the screening phase of this study 
(Table 6.2). Potential eligible participants identified were approached by email or postal letter to 
provide information about this trial, explain why they were considered to be eligible and invite them 
to participate. In parallel, the study was also advertised in the general community to identify 
additional potential eligible participants. 
Inclusion criteria for entry into screening phase of the study 
1. Male and female volunteers 18 through 65 years of age  
2. Females must not be actively seeking pregnancy and demonstrate a negative serum pregnancy 
test at screening 
3. Females of child-bearing potential and males with female partners of child-bearing potential 
must use adequate and effective contraception 
4. General good health 
5. History of, or current mild to moderate, stable, allergic asthma 
6. History of episodic wheeze and shortness of breath 
7. FEV1 at baseline at least 70% of the predicted value 
8. Positive skin-prick test to house dust mite 
9. Able to understand and give written informed consent and has signed a written informed 
consent form approved by the investigator’s HREC 
Inclusion criteria for entry into treatment phase of the study 
1. Positive methacholine challenge 
2. Positive allergen-induced early and late airway bronchoconstriction 
3. rs4129267 genotype TT or CT  
Exclusion criteria for both screening and treatment phases of the study 
General: 
1. History or symptoms of clinically significant autoimmune disease 
2. Lung disease other than mild to moderate allergic asthma 
3. Recent (less than 1 year) history of alcohol dependency 
4. Use of tobacco products of any kind currently or within the previous 12 months, or smoking 
history > 10 pack years 
5. Unwillingness or inability to comply with the study protocol for any other reason 
Exclusions because of previous or concomitant therapy:  
1. Use of corticosteroids, immunosuppressives, anticoagulants (warfarin or heparin) or any 
medications that may interact with drug within 28 days prior to treatment randomisation 
2. Have chronic use of any other medication for treatment of allergic lung disease other than 
short- and intermediate-acting ß2-agonists or ipratropium bromide 
3. Participation in any other investigational drug treatment protocol within the preceding 30 days 
or 5 half-lives of the drug 
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Exclusions for general safety: 
1. A worsening of asthma or a respiratory tract infection within 6 weeks preceding study entry 
2. History of clinically significant hypotensive episodes or symptoms of fainting, dizziness, or 
light-headedness 
3. History or symptoms of cardiovascular disease, particularly coronary artery disease, 
arrhythmias, hypertension, or congestive heart failure 
4. History or symptoms of significant neurologic disease, including transient ischemic attack 
(TIA), stroke, seizure disorder, or behavioural disturbances 
5. History of serious adverse reaction or hypersensitivity to any drug 
6. Abnormal chest X-ray, including evidence of latent or active TB 
7. Abnormal electrocardiogram 
8. History of clinically significant hematologic abnormality, including coagulopathy 
9. History of intestinal ulceration or diverticulitis 
10. Clinically significant abnormalities in laboratory test results (including complete blood count, 
coagulation, chemistry panel and urinalysis) 
11. Be pregnant or lactating or have positive serum pregnancy test at screening or positive urine 
pregnancy test during the study 
12. History of, or known currently active, recurrent bacterial, viral, fungal, mycobacterial or other 
infections (including but not limited to tuberculosis and atypical mycobacterial disease, 
hepatitis B and C, and herpes zoster, but excluding fungal infections of nail beds), or any 
major episode of infection requiring hospitalisation or treatment with intravenous antibiotics 
within 4 weeks of screening or oral antibiotics within 2 weeks prior to screening 
13. Primary or secondary immunodeficiency (history of or currently active) 
14. Patients with lack of peripheral venous access 
15. Concomitant disease or condition which could interfere with the conduct of the study, or for 
which the treatment might interfere with the conduct of the study, or which would, in the 
opinion of the investigator, pose an unacceptable risk to the subject in this study, including, 
but not limited to, cancer, alcoholism, drug dependency or abuse, or psychiatric disease 
16. Subject develops a severe asthma reaction during the screening allergen challenge that could 
not be rescued by bronchodilator alone 
Laboratory exclusion criteria (at screening): 
1. Serum aspartate transaminase or alanine transaminase >1.5x ULN 
2. Absolute neutrophil count < 2 x 109/l 
3. Platelet count < 100 x 109/l 
Table 6.2. Eligibility criteria for the study. 
Participants interested in taking part in the trial were contacted by phone to confirm interest in 
participating and to assess potential eligibility based on inclusion criteria for entry into the screening 
phase of the study (listed in Table 6.2). An appointment for clinical visit 1 was made for participants 
who remained potentially eligible to participate. 
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In some cases, to facilitate recruitment some participants had their rs4129267 genotype determined 
prior to trial enrolment. Participants provided a 4 ml blood sample for genotyping, and completed a 
separate Participant Information Sheet and Consent form for this collection only. 
Prior to performing any study-specific procedures (including screening procedures to determine 
eligibility), a signed consent form was obtained for each subject. The consent form described the 
purpose of the study, the procedures to be followed, and the risks and benefits of participation. The 
investigator conducted the informed consent discussion and checked that the subject comprehended 
the information provided and answered any questions about the study. Consent was voluntary and 
free from coercion. The investigator who conducted the consent discussion also signed the informed 
consent form. A copy of the consent form was given to the subject, and the outcome of the procedure 
documented. When all the inclusion and exclusion criteria were assessed and eligibility confirmed, 
subjects were randomised to treatment (phase 2). 
Summary of participant inclusion and exclusion criteria 
All inclusion and exclusion criteria assessed in the study are listed in Table 6.2. Briefly, non-smoking 
volunteers, in general good health, aged 18 to 65, with a history of episodic wheeze and shortness of 
breath were screened for participation in visit 1. 
To ensure the safety of the patients and minimise the risk of severe bronchoconstriction during the 
allergen inhalation challenge test, subjects screened in visit 1 were also required to have stable, mild 
asthma, and a baseline forced expiratory volume in 1 second (FEV1) of at least 70% of the predicted 
value. Patients were also required to have allergic asthma and a positive skin-prick test to HDM 
because of the model (allergen inhalation challenge test) that we used to test the efficacy of the drug. 
Patients enrolled in the study were required to have a positive methacholine challenge 
(≥ 20% FEV1 drop). This was essential because the methacholine concentration at which FEV1 drops 
20% (methacholine PC20) is required to determine the allergen PC20.  
In the screening phase, patients who did not develop an allergen-induced EAR before the maximum 
allergen concentration was reached were excluded from the study. Similarly, patients who did not 
develop a LAR in the screening phase were excluded from the study, as the magnitude of the LAR 
was the primary efficacy outcome assessed in the study (described in detail below).  
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Another requirement for inclusion in the study was that subjects were carriers of the rs4129267:T 
allele. Mounting evidence, including observations from genotype-specific studies, shows that 
different asthma subtypes have variable response to treatment, and support the notion of developing 
personalised treatment approaches to manage asthma.269,270 In our study, the decision to study the 
rs4129267:CT and rs4129267:TT genotypes was based on prior evidence that tocilizumab response 
to treatment is associated with polymorphisms in the IL6R gene.271 In addition, several lines of 
evidence suggest that patients with airway inflammation associated with IL-6 trans-signalling are 
more likely to benefit from anti-IL-6R treatment. The anti-inflammatory effects of blocking IL-6 
trans-signalling in asthma were demonstrated in functional studies with mouse models of 
asthma.32,33,215 The rs4129267:T asthma risk allele1 was estimated to increase serum sIL-6R (the main 
player in IL-6 trans-signalling) by 1.4-fold,27 and is in high LD (r2 = 0.99) with the rs2228145:C 
functional variant that promotes sIL-6R production. Accordingly, in this proof-of-concept study, we 
opted not to include patients with the rs412927:CC genotype. 
Subjects were excluded from the study if they experienced worsening of asthma, or a respiratory tract 
infection, within 6 weeks of study entry. Other key exclusion criteria included history or symptoms 
of autoimmune disease, lung disease (other than mild to moderate allergic asthma), and use of 
corticosteroids, immunosuppressives, anticoagulants or any medications that could interact with 
tocilizumab within 28 days of treatment randomization. 
Clinical procedures 
Medical history 
Information collected included, but it is not limited to, current and previous illnesses, hospital 
admissions, known allergies, history of anaphylaxis, participation in other investigational drug 
treatment protocols, use of tobacco products and recent (<1 year) history of alcohol consumption. 
Physical examination (including X-ray) 
The following parameters were measured: height, weight, heart rate, respiratory rate, blood pressure, 
temperature, examination of body systems, including a resting 12-lead electrocardiogram, antero-
posterior chest X-ray and collection of urine sample for analysis. 
Lung function 
A standard spirometer that complies with 1995 ATS requirements was used for lung function 
measurements (MicroLab spirometer), with the subject tested while sitting. The spirometer records a 
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trace of volume against time or volume against flow. All tracings were recorded by the spirometer’s 
software. Results were also entered on the clinical form of each participant. 
Skin prick test 
Two skin prick tests were performed, namely (1) a skin-prick challenge test, and (2) a skin-prick 
titration test. Briefly, the skin-prick challenge test was used to identify an allergic reaction to the 
house dust mite Dermatophagoides farinae. The allergen, positive (histamine) and negative controls 
were purchased from an accredited provider (HollisterStier or Greer). The test was then performed 
by applying serial dilutions of the house dust mite allergen extract to the skin (from 1:4 to 1:32768) 
scratching or pricking the skin to allow exposure. The size of the resulting skin wheal was measured 
15 minutes after (or 10 minutes after for histamine). The skin-prick titration test was used to identify 
the lowest titration of allergen causing a skin wheal of at least 2 x 2 mm in size.  
Methacholine inhalation challenge test  
Briefly, the goals of this test were three-fold: (1) determine the presence of airway 
hyperresponsiveness, consistent with the diagnosis of asthma; (2) establish the severity of airway 
hyperresponsiveness as an indirect measure of the likely severity of clinical asthma; and (3) determine 
the methacholine PC20 which is one of two parameters used for predicting the allergen PC20. The 
method consists of continuous generation of methacholine aerosols at different concentrations, as 
described by Cockcroft et al.272 Each concentration of methacholine was then inhaled by the subject 
using tidal breathing from a Wright nebulizer (Roxon Meditech, Montreal, PQ, Canada) for a duration 
of 2 minutes. This specific nebulizer is unregistered in Australia but has been extensively used in 
research studies and clinical trials by our collaborators Prof Paul O'Byrne and A/Prof Gail Gauvreau 
(McMaster University, Canada) in the last 30 years;272 its performance is very well characterised, 
being very precise, reliable and safe. FEV1 was measured after each inhaled concentration until a 
20% fall was observed. Results were expressed as a PC20, representing the provocation concentration 
of methacholine that causes a fall in FEV1 of 20%. 
Allergen inhalation challenge test 
An allergen inhalation challenge test was performed before (visit 3) and after (visit 7) treatment. 
Briefly, the goal of this test was to elicit an inflammatory response in the airways similar to that which 
follows natural exposure to allergen. The test includes measuring: (1) the magnitude of the EAR, that 
is, the largest fall in FEV1 that occurs 0-3 hours following allergen inhalation; (2) the magnitude of 
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the LAR, that is, the largest fall in FEV1 that occurs at 3 - 7 hours; (3) and airway inflammation, based 
on cell counts and inflammatory mediators measured in induced sputum. House dust mite allergen 
was inhaled by each subject using tidal breathing from a Wright nebulizer, as described by O'Byrne 
et al.273 The inhalation test was performed in a designated area, with emergency equipment and 
medical facilities readily available. The test was carried out by qualified study personnel under 
physician supervision, i.e. an investigator or delegate aware of the procedure was present in the 
laboratory or was available by phone/pager within minutes. Participants were clinically monitored 
with regular spirometry performed throughout the test. FEV1 was recorded at regular intervals up to 
7 hours post allergen inhalation. Participants who experienced a positive EAR (largest fall in FEV1 
>20%) and a positive LAR (largest fall in FEV1 >15%) were eligible to continue to the treatment 
phase of the trial  
Sputum induction and processing 
Briefly, the goal of this test was to collect an induced sputum sample for accurate non- invasive 
assessment of bronchial inflammation. A saline solution was inhaled for increasing concentrations 
from a DeVilbiss ultrasonic nebulizer (DeVilbiss Healthcare, Castle Hill, NSW, Australia). This 
nebulizer is currently used by many respiratory function laboratories across Australia, including at 
the Princess Alexandra Hospital. FEV1 was measured 60 sec after each saline dose, after which 
participants were asked to expectorate into a sterile container. Sputum was induced after 
methacholine (visits 2, 4, 6 and 8) and allergen (visits 3 and 7) inhalation challenges (Figure 6.1). 
Sputum subtypes were defined as described before, i.e. eosinophilic (≥ 1% eosinophils), neutrophilic 
(≥ 61% neutrophils), mixed granulocytic (≥ 1% eosinophils and ≥ 61% neutrophils) and 
paucigranulocytic (< 1% and < 61% neutrophils). 
Blood collection and processing 
Up to 40 ml of blood were collected at each visit for haematology, biochemistry, immune, 
inflammatory, genetic and/or pharmacodynamics analyses. Biochemistry analyses were performed 
with samples collected at visits 1, 3, 5, 7, 9, and 10. In visits where a methacholine or an allergen 
inhalation challenge test was performed (visits 2-4 and 6-8), blood was collected after the challenge. 
Measurement of cytokines in serum and sputum samples 
Enzyme-linked immunosorbent assays (ELISAs) and Cytometric Bead Arrays (CBAs) were used to 
measure inflammatory mediators in serum and sputum supernatant samples. Measurements were 
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performed according to the kit protocols. CBAs were performed with Becton Dickinson Biosciences 
kits (Hu Solbl Ptein CBA Buf Kit 100Tst, 558264; Hu TNF CBA Flex Set C4 100Tst, 560112; Hu 
IL-13 CBA Flex Set E6 100Tst, 558450; Hu IL-8 CBA Flex Set A9 100Tst, 558277; Hu IL-6 CBA 
Flex Set A7 100Tst, 558276; Hu IL-5 CBA Flex Set A6 100Tst, 558278). ELISAs were performed 
with Invitrogen (Neutrophil elastase human ELISA kit, BMS269) and R&D Systems (R&D Systems 
Human IL-6 R alpha Quantikine SixPak (6 Plates), Per Pack, RDSSR600; R&D Systems Human C-
Reactive Protein/CRP Quantikine ELISA Kit, Per Kit, RDSDCRP00) kits. 
DNA sequencing to obtain rs4129267genotype 
DNA was extracted from buffy coats, and the DNA region surrounding rs4129267 amplified and 
analysed using Sanger Sequencing to obtain genotype data for this SNP. Sequencing was performed 
by the Australian Genome Research Facility (AGRF), a facility accredited by the National 
Association of Testing Authorities, Australia (NATA). 
Procedure used to randomise participants to tocilizumab or placebo treatment 
A block randomisation method was used to allocate the study drug or placebo to the study 
participants. Briefly, we first randomised tocilizumab or placebo (50:50) to an investigational drug 
kit (numbered 1 to 16). Then each participant was randomly allocated a drug kit. This procedure was 
done independently in four blocks with four participants each. The resulting randomisation table was 
held by the DSMB Secretariat throughout the duration of the study. Based on the randomisation table, 
two envelopes were created for each participant and sent to the PAH or Q-Pharm pharmacy. Both 
envelopes contained the same information, namely the participant number, the block number, the kit 
number and the kit content. Envelope 1 was labelled with the project name, project number, 
participant number and with “Pharmacy Randomisation code” and “To be opened by trial pharmacist 
only to prepare the investigational drug”. Envelope 2 was labelled with the project name, project 
number, participant number and with “Emergency unblinding envelope” and “To be opened by 
investigator only in an emergency situation”. 1-2 days prior to visit 5 a study doctor completed a 
script requesting an investigational drug kit for the participant. The participant’s weight was included 
in this request, so that the right dose of drug could be prepared. The investigator collected the 
investigational drug kit for the participant, together with envelope 2, which remained closed for the 
duration of the study. Envelope 1 was kept at the PAH or Q-Pharm pharmacy until the conclusion of 
the study. A similar procedure was used at McMaster University. 
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Infusion of tocilizumab or placebo 
Tocilizumab (trade name Actemra) and placebo were acquired from, prepared and labelled by, the 
PAH or Q- Pharm pharmacy. At the PAH this procedure was supervised by the PAH Clinical Trial 
pharmacist at Q-Pharm this procedure was supervised by the Q-Pharm pharmacist. Tocilizumab (at a 
dose of 8mg/kg – concentration approved for RA treatment274) or placebo were administered at room 
temperature by controlled infusion into an arm vein over a one-hour period on visit 5. A sterile saline 
solution, with appearance identical to that of the drug, was used as placebo.  
Primary and secondary endpoints 
The primary outcomes used to evaluate tocilizumab safety were haematology and blood biochemistry 
results. The primary outcomes used to evaluate tocilizumab efficacy were (1) the maximum 
percentage fall in FEV1 measured during the LAR induced by allergen challenge (LAR %fallmax); and 
(2) the area under the FEV1 curve during allergen-induced LAR (AUC3-7h).  
The calculate the LAR %fallmax, for each participant, we (1) identified the largest drop in FEV1 
observed 3 to 7 hours after allergen challenge at visit 3 (LAR %fallmax,screening); (2) identified the 
largest drop in FEV1 observed 3 to 7 hours after allergen challenge at visit 7 (after treatment; LAR 
%fallmax,treatment); and (3) calculated the difference between the two as LAR %fallmax = LAR 
%fallmax,treatment - LAR %fallmax,screening. For example, in the first participant to complete the trial, LAR 
%fallmax,screening = 16% (i.e. FEV1 dropped by 16% from baseline), LAR %fallmax,treatment = 25%, and 
so LAR %fallmax = 8.75%. In this participant, allergen-induced bronchoconstriction was higher after 
treatment than at screening. The same approach was used to calculate the AUC3-7h. Specifically, for 
each participant we (1) calculated the area under the FEV1 (expressed as % from baseline) curve 
measured 3 to 7h after allergen challenge at visit 3 (AUC3-7h,screening); (2) calculated the area under the 
FEV1 curve measured 3 to 7h after allergen challenge at visit 7 (AUC3-7h,treatment); and (3) calculated 
the difference between the two as AUC3-7h = AUC3-7h,treatment - AUC3-7h,screening. AUC were calculated 
using the Bolstad2 R package.275 
The secondary outcomes used to evaluate tocilizumab efficacy were (1) the lowest FEV1 measured 
during the EAR induced by allergen challenge (EAR %fallmax); (2) airway hyperresponsiveness (i.e. 
the methacholine PC20) measured 24 hours after the allergen inhalation test; (3) changes in sputum 
inflammatory cells at 7 and 24 hours after the allergen inhalation test; and (4) serum and sputum 
inflammatory mediators at 7 and 24 hours after the allergen inhalation test. 
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EAR %fallmax was calculated for each participant in the same way as LAR %fallmax, but with FEV1 
measured 0 to 3 hours after allergen challenge, i.e. EAR %fallmax = EAR %fallmax,treatment - EAR 
%fallmax,screening. Similarly, AUC0-3h was defined as AUC0-3h = AUC0-3h,treatment – AUC0-3h,screening. 
Determination of target sample size  
Based on the mean (23.5%) and standard deviation (3.3%) of the maximum percentage fall in LAR 
FEV1 expected in placebo,
276 we estimated that 16 participants would be needed to detect a difference 
in LAR between treatment groups of at least 5% (e.g. 83.5% vs. 92.5%). 
Statistical analyses 
The primary and secondary outcomes were compared between (within) treatment groups with 
unpaired (paired) Wilcoxon tests. Sputum samples with low viability (< 40%) were removed from 
analysis of sputum cell counts. Analyses were performed with R version 3.3.2. 
Medical monitor, data safety and monitoring board (DSMB) and study monitoring 
The medical monitor for this trial was Prof. Ian Yang (Prince Charles Hospital, Brisbane). The DSMB 
was composed of Prof. Peter Sly (chair; Child Health Research Centre, University of Queensland, 
Brisbane), Prof. Peter Nash (Department of Medicine, University of Queensland, Brisbane), Prof. 
Daman Langguth (Wesley Hospital, Brisbane) and Dr. Paul Griffin (Q-Pharm, Brisbane). Adherence 
to Good Clinical Practice guidelines was monitored by Clinical Network Services (CNS) Pty Ltd.  
Interim analysis 
In August 2017, after reviewing blinded results from 11 participants who had completed the trial at 
that time point, the data safety and monitoring board (DSMB) of the study requested an interim 
analysis to confirm that continuing the trial to completion (i.e. to the target of 16) would be powered 
to detect a significant effect of tocilizumab on the primary endpoint, given the observed findings to 
date. Unblinded results were sent to the chair of the DSMB, who compared the primary endpoint 
between tocilizumab and placebo. 
Ethics statement 
All study procedures were approved by the ethics committees of the QIMR Berghofer Medical 
Research Institute (project P2025 and P2103), Metro South (HREC/14/QPAH/22 - 
SSA/14/QPAH/216) and McMaster University (project 14-790) and carried out according to the 
Declaration of Helsinki, the NHMRC National Statement on Ethical Conduct in Research Involving 
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Humans (1999) and the Notes for Guidance on Good Clinical Practice as adopted by the Australian 
Therapeutic Goods Administration (2000) (CPMP/ICH/135/95) and the ICH GCP Guidelines. All 
participants provided written informed consent before enrolling in the study. The trial was registered 
in the Australian New Zealand Clinical Trials Registry (ANZCTR), number 
ACTRN12614000123640. 
Results 
Recruitment rate 
Over 3,500 individuals were invited through social media or email to be screened at the Brisbane sites 
to participate in the trial. A total of 607 people were interested in the study, with 446 being screened 
by phone or email to assess potential eligibility. Of these, 44 were considered potentially eligible and 
attended visit 1. At McMaster, participants from previous studies were screened to identify 22 
potentially eligible participants. 
Number of participants who enrolled the study prior to the interim analysis 
Across the Brisbane and McMaster sites, a total of 66 participants consented to enrol in this study 
and completed visit 1 between September 2014 and July 2017 (Table 6.3): 10 at QIMR Berghofer, 
34 at the Princess Alexandra Hospital and 22 at McMaster University. Of these, 37 remained eligible 
for the trial after the assessments performed at visit 1. The most frequent causes of ineligibility were 
not having the required rs4129267 genotype (n = 20), and having a negative skin prick test to HDM 
(n = 7). Eight participants withdrew from the study after visit 1, while 29 completed visit 2. Of the 
latter, most (21 or 72%) went on to complete visits 3 and 4, that is, the full pre-treatment allergen 
inhalation challenge triad (visits 2 to 4). Of these, 9 were ineligible to continue, most (8 or 89%) 
because of a negative LAR after allergen challenge. Of the 12 participants who were eligible to 
continue into the treatment phase of the trial, 11 completed visit 5 (six treated with tocilizumab, five 
with placebo) and all five subsequent trial visits. 
Study visit QIMR Berghofer PA Hospital  McMaster University  Total 
1 10 34 22 66 
2 6 15 8 29 
3 4 11 6 21 
4 1 11 6 18 
5-10 1 4 6 11 
Table 6.3. Number of participants enrolled in the study in each study visit. 
Abbreviations: PA, Princess Alexandra. 
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Table 6.4 summarizes demographics and relevant inflammatory features observed before treatment 
for these 11 participants. Seven patients took Ventolin in the six months prior to entering the study 
(nPlacebo = 4; nTocilizumab = 3). No other asthma medications were taken by any of the study participants 
before enrolment. 
 Placebo Tocilizumab 
N 5 6 
Age, years 29 (19-51) 35 (25-44) 
Sex, % female 80 67 
BMI, Kg/m2 25.5 (23-32) 25 (22-31) 
FEV1, % Predicted 92.2 (87-100) 90.7 (72-101) 
EAR, % from baseline 69.1 (57-80) 68.3 (59-79) 
LAR % from baseline 74.6 (71-81) 78.1 (69-84) 
Methacholine PC20 pre-Ag, mg/ml 2.9 (0.56-5.74) 6.1 (0.44-14.45) 
Methacholine PC20 post-Ag, mg/ml 1.1 (0.21-2.15) 2.2 (0.04-8.65)    
Sputum sIL-6R, pg/ml 45.8 (0-110.8) 306.3 (0-571.3) 
Sputum IL-6, pg/ml 5 (0-11.8) 33.5 (0-75.9) 
Serum sIL-6R, ng/ml 97.8 (58.9-149.1) 150.8 (102.9-203.9) 
Serum IL-6, pg/ml 1.8 (0-7.5) 1.7 (0-10) 
Table 6.4. Patient demographics and inflammatory features in screening phase. 
Results are presented as mean and range, unless otherwise stated. Cytokine levels refer to visit 2, 
i.e. after the pre-allergen methacholine challenge. There were no significant (P < 0.05) differences 
between the groups. Abbreviations: Ag, allergen; BMI, body mass index; FEV1, forced expiratory 
volume in 1 second; PC20, provocative concentration causing a 20% decrease in FEV1. 
Interim analysis 
An interim analysis was carried out to assess whether continuing the trial to completion (i.e. to the 
target of 16) would be powered to detect a significant effect of tocilizumab on the primary endpoint, 
given the observed findings to date. Results from the 11 participants were analysed by the chair of 
the DSMB (Table 6.5) who compared the primary endpoint between tocilizumab and placebo. The 
analysis showed (1) no significant differences in the LAR post-treatment; and (2) that, given the 
observed group means and SD, the target sample size of 16 would not provide adequate power to 
detect a significant difference between groups. The trial was therefore stopped for futility and 
unblinded results released to the research team for analysis.  
  Screening Treatment   
Subject ID Treatment group FEV1,baseline LAR FEV1,baseline LAR LAR %fallmax AUC3-7h 
P210300001 Placebo 3.07 2.25 3.07 2.57 -10.42 16.9381 
P210300002 Tocilizumab 2.97 2.06 3.25 1.41 25.98 -94.0752 
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P210300003 Placebo 3.7 2.69 3.65 1.87 4.48 -34.02 
P210300004 Placebo 3.53 2.65 3.46 2.16 12.64 -18.1901 
P210300005 Tocilizumab 2.39 2.01 2.28 1.67 10.85 -37.0614 
P210300006 Tocilizumab 4.15 3.17 4.14 3.59 -10.32 18.6415 
QPS0100 Tocilizumab 4.47 3.4 4.45 3.23 3.48 -5.69 
S00013 Tocilizumab 3.17 2.67 3.1 2.34 8.75 -34.525 
S00023 Tocilizumab 2.98 2.34 2.98 2.37 -1.01 3.5235 
S00028 Placebo 3.44 2.45 3.71 2.37 7.34 -51.4178 
S00030 Placebo 3.41 2.76 3.4 2.45 8.88 -12.22 
Table 6.5. Endpoints compared between TCZ and placebo groups in the interim analysis. 
Pre-challenge FEV1 (FEV1,baseline) and the minimum FEV1 measured 3 to 7 hours post-allergen (LAR) 
from the screening and treatment challenges were used to calculate the LAR %fallmax as indicated in 
the Methods. For example, for patient P210300001, LAR %fallmax = (1-(2.57/3.07))-(1-(2.25/3.07)). 
Analysis of safety endpoints 
Adverse events (AEs) and serious adverse events (SAEs) 
Nine AEs (Table 6.6) and one SAE (campylobacter enteritis between visits 1 and 2) were recorded 
amongst the 55 participants who enrolled in the trial but did not continue to the treatment phase. 
Fifteen AEs were reported for five of the 11 participants who completed the trial (Table 6.6). Most 
of these occurred during or after drug infusion (10 or 67%) and were mild. Only one AE 
(asymptomatic neutropenia) was determined to be related to the study drug, and one other AE 
(headache) was also probably related to the drug. These are common side-effects of tocilizumab that 
have previously been reported.277,278 No SAE or malignancy was recorded in the 11 participants who 
completed the trial. 
ID Visit AE / SAE SAE IP related? Resolved? 
            
Randomised to treatment       
Placebo      
S00030 3 Vasovagal event No No Yes 
S00030 9 Sore throat No No Yes 
S00030 9 Headache No No Yes 
S00028 10 Mild fever No No Yes 
      
Tocilizumab      
S00023 1 Wisdom tooth extraction No No Yes 
S00023 3 Headache No No Yes 
QPS0100 4 Migraine No Probably Yes 
S00023 4 Headache No No Yes 
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S00023 5 Pre-syncopal event No No Yes 
S00023 6 Headache No No Yes 
QPS0100 7 Mild neutropenia No Definitely Yes 
QPS0100 7 Otitis externa (earache) No No Yes 
S00013 7 Headache No No Yes 
S00013 7 Knee injury No No Yes 
S00013 9 Medial tibial stress syndrome (shin splints) No No Yes 
Not randomised to treatment       
QPS0127 1 Campylobacter enteritis Yes No Yes 
QPS0103 2 Right eye inflammation No No Yes 
QPS0127 2 Muscle pain No No Yes 
S00002 2 Headache No No Yes 
S00019 2 Pre-syncopal event No No Yes 
S00027 2 Left knee staph infection No No Yes 
S00029 2 Suspected food poisoning No No Yes 
S00034 2 Mild fever No No Yes 
S00019 4 Headache No No Yes 
S00019 4 Suspected viral respiratory infection No No Yes 
Table 6.6. List of adverse events (AEs) and serious AEs (SAEs) reported in subjects enrolled in 
the study. 
Laboratory evaluations – blood cell counts 
In the tocilizumab group, neutrophil counts decreased significantly between the screening and 
post-treatment visits (Figure 6.2). For example, comparing visit 3 (first allergen challenge) against 
visit 7 (second allergen challenge), neutrophil counts decreased on average from 3.4 (SD = 1.22) to 
2.5 (SD = 1.50), a statistically significant difference (P = 0.0313; Table 6.7). Similar results were 
observed for total white blood cell (WBC) counts. In the placebo group, these effects were not 
observed (Table 6.7): neutrophil (and WBC) did not change significantly within-subjects between 
pre- and post-treatment visits. 
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Figure 6.2. White blood cell counts measured before, and after infusion with placebo or 
tocilizumab.  
Abbreviations: V, visit; WBC, white blood cells. 
  V1 vs. V5 V2 vs. V6 V3 vs. V7 V4 vs. V8 V5 vs. V9 
Tocilizumab      
Basophils 0, 0, 1 0, 0, 0.7893 0.1, 0, 0.1814 0.1, 0, 0.1003 0, 0, 0.3458 
Eosinophils 0.2, 0.3, 0.0591 0.2, 0.3, 0.1814 0.3, 0.2, 0.1775 0.3, 0.4, 0.0585 0.3, 0.4, 0.0313 
Lymphocytes 1.5, 1.6, 0.5992 1.9, 1.8, 0.1362 2, 1.8, 0.0938 1.8, 1.6, 0.0625 1.6, 2, 0.0313 
Monocytes 0.4, 0.5, 0.5896 0.5, 0.4, 0.0568 0.5, 0.4, 0.0579 0.5, 0.4, 0.0591 0.5, 0.5, 1 
Neutrophils 4.7, 3.4, 0.0355 3.7, 2.3, 0.0313 3.4, 2.5, 0.0313 4.1, 2.5, 0.0313 3.4, 2.7, 0.0313 
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WBC 6.9, 5.7, 0.0313 5.5, 4.8, 0.1563 6.2, 5, 0.0585 6.4, 4.9, 0.0313 5.7, 5.5, 0.5992 
      
Placebo      
Basophils 0, 0, 0.1814 0, 0, 0.1814 0, 0, - 0, 0, - 0, 0, 1 
Eosinophils 0.2, 0.3, 0.0975 0.1, 0.2, 0.4164 0.2, 0.4, 0.625 0.3, 0.5, 0.25 0.3, 0.5, 0.1814 
Lymphocytes 1.8, 1.9, 0.1696 1.7, 2.1, 0.0625 1.9, 1.7, 0.0975 1.8, 1.5, 0.4227 1.9, 2.1, 0.2012 
Monocytes 0.5, 0.5, 0.7893 0.4, 0.5, 0.1814 0.5, 0.5, 1 0.5, 0.5, 1 0.5, 0.4, 0.1003 
Neutrophils 3.7, 3.7, 0.5827 3.9, 3.8, 1 3.5, 4.7, 0.25 4.4, 4.4, 0.875 3.7, 3.7, 1 
WBC 6.1, 6.4, 0.4375 6.3, 6.6, 0.3125 6, 7.2, 0.375 7, 6.8, 0.875 6.4, 6.7, 0.1875 
Table 6.7. Differences in white blood cell (WBC) counts before and after tocilizumab.  
Results are expressed as mean at screening visit, mean at treatment visit, P-value from paired 
Wilcoxon test. Cell counts are in cell x 109/l. Abbreviations: V, visit. 
There were no noteworthy treatment effects on other white blood cell counts measured (Figure 6.2 
and Table 6.7).  
In RA and Crohn’s disease clinical trials, haemoglobin levels have been reported to increase with 
tocilizumab therapy.279-281, 282,283 IL-6 promotes hepcidin production, which in turn restricts iron 
availability.284,285 Thus, blockade of IL-6R was expected to decrease hepcidin levels and increase iron 
availability for the production of haemoglobin. In our study, haemoglobin levels were significantly 
(P = 0.0313; Figure 6.3; Table 6.8) lower on the day of infusion (visit 5) compared to the day patients 
were first assessed (visit 1). However, in visit 5 blood was drawn before infusion, so both these 
measurements were made before treatment and are not related to tocilizumab. In the post-treatment 
visits, haemoglobin levels fluctuated, but there were no significant differences compared to baseline 
visits. 
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Figure 6.3. Haematology results before, and after infusion with placebo or tocilizumab. 
Abbreviations: HB, haemoglobin (g/l); HCT, haematocrit (%); MCV, mean cell volume (fl); PLT, 
platelets (x 109/l); RBC, Red blood cells (x 1012/l); V, visit.
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  V1 vs. V5 V2 vs. V6 V3 vs. V7 V4 vs. V8 V5 vs. V9 
Tocilizumab 
     
Haemoglobin, g/l 136, 129.8, 0.0313 136.8, 133.5, 0.0938 130.5, 132, 0.2021 134.7, 132.7, 0.3613 129.8, 132, 0.1362 
Haematocrit, % 0.4, 0.4, 0.0313 0.4, 0.4, 0.2807 0.4, 0.4, 0.1056 0.4, 0.4, 1 0.4, 0.4, 0.1003 
Mean cell volume, fl 87.8, 87.7, 1 87, 87.3, 0.4227 86.6, 86.1, 0.4004 87.1, 86.8, 0.5839 87.7, 86.6, 0.0591 
Platelets, x 109/l 244.3, 233, 0.1563 241.3, 229.7, 0.0625 242.3, 228, 0.0591 243.3, 228.5, 0.4375 233, 209.5, 0.035 
Red cell count, x 1012/l 4.7, 4.4, 0.0313 4.7, 4.6, 0.2188 4.5, 4.6, 0.0313 4.6, 4.6, 0.3125 4.4, 4.6, 0.0313       
Placebo 
     
Haemoglobin, g/l 129.4, 126, 0.3125 130.4, 127.4, 0.0568 129.5, 127.2, 0.625 128.5, 124.2, 0.1814 126, 128, 0.2012 
Haematocrit, % 0.4, 0.4, 0.4375 0.4, 0.4, 0.5839 0.4, 0.4, 0.625 0.4, 0.4, 0.25 0.4, 0.4, 0.2785 
Mean cell volume, fl 90.8, 91.9, 0.1003 90.5, 91.4, 0.1041 91.3, 92.3, 0.25 90.1, 91, 0.125 91.9, 90.8, 0.1003 
Platelets, x 109/l 258.4, 258.4, 0.8125 266.8, 252, 0.125 266.5, 248.2, 0.125 252, 225.2, 0.0975 258.4, 254.4, 1 
Red cell count, x 1012/l 4.2, 4.1, 0.2785 4.3, 4.2, 0.4375 4.2, 4.1, 0.25 4.3, 4.2, 0.25 4.1, 4.2, 0.3125 
Table 6.8. Differences in haematology results before and after tocilizumab.  
Results are expressed as mean at screening visit, mean at treatment visit, P-value from paired Wilcoxon test. Abbreviations: V, visit. 
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Laboratory evaluations – blood biochemistry 
 
Figure 6.4. Blood biochemistry results before, and after infusion with placebo or tocilizumab. 
Abbreviations: Alb, albumin (g/l); ALT, alanine transaminase (U/l); AP, alkaline phosphatase (U/l); 
AST, aspartate transaminase (U/l); BG, glucose (mmol/l); Ca, calcium (mmol/l); CK, creatine kinase 
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(U/l); Cl, Chloride (mmol/l); Creat, creatinine (µmol/l); GGT, gamma-glutamyl transpeptidase (U/l); 
HCO3, bicarbonate (mmol/l); Ins, insulin (pmol/l); K, potassium (mmol/l); Mg, magnesium (mmol/l); 
Na, sodium (mmol/l); PHOS, phosphate (mmol/l); TBILI, bilirubin total (µmol/l); Urea (mmol/l); V, 
visit.   
In the tocilizumab group, albumin levels increased significantly after treatment (Figure 6.4). 
Specifically, levels measured before treatment were on average 39.5 (visit 3) and 40 g/l (visit 5), and 
increased to 42.3 (visit 7) and 42.0 g/l (visit 9) after treatment (Table 6.9). Bilirubin increased from 
visit 3 (13.3 µmol/l) to visit 7 (16.5 µmol/l). These observations are in line with reports from previous 
clinical trials of tocilizumab.283,286,287 Electrolytes were generally stable before and after treatment. 
However, at 7 hours post allergen-inhalation, sodium levels increased from pre- (138 mmol/l) to post-
treatment (139.7 mmol/l) with tocilizumab (P = 0.0335). Phosphate levels also increased from visit 5 
(1.1 mmol/l) to visit 9 (1.3 mmol/l). 
  V1 vs. V5 V3 vs. V7 V5 vs. V9 
Tocilizumab    
Alanine transaminase, U/l 17, 14.3, 0.8923 15, 15.8, 0.7874 14.3, 19.8, 0.0739 
Albumin, g/l 40.7, 40, 0.1736 39.5, 42.3, 0.0335 40, 42, 0.0345 
Alkaline phosphatase, U/l 63.3, 58, 0.1718 59, 57.7, 0.3951 58, 54.8, 0.3125 
Aspartate transaminase, U/l 17, 17, 0.5982 18.2, 16.2, 0.2809 17, 20.3, 0.4004 
Bicarbonate, mmol/l 25.3, 24.8, 0.3711 24.7, 25.5, 0.089 24.8, 25.2, 0.7103 
Bilirubin, µmol/l 13.7, 15.2, 0.1362 13.3, 16.5, 0.034 15.2, 17, 0.4375 
Calcium, mmol/l 2.3, 2.3, 0.035 2.1, 2.3, 0.2072 2.3, 2.3, 0.1056 
Chloride, mmol/l 105.3, 104.5, 1 104.8, 98.7, 0.5992 104.5, 105.5, 1 
Creatine Kinase, U/l 113.7, 255, 0.5992 409, 123.2, 1 262, 334.6, 1 
Creatinine, µmol/l 71.8, 73.2, 0.4568 72.3, 72, 0.9163 73.2, 74.3, 0.5271 
Gamma-glutamyl transpeptidase, U/l 15.5, 14.7, 0.3408 15.3, 14.5, 0.3711 14.7, 16.3, 0.0993 
Glucose, mmol/l 5.1, 4.6, 0.0938 4.6, 4.8, 0.1975 4.6, 4.4, 0.2932 
Insulin, mU/l 41, 11.1, 0.8438 18.7, 19.6, 1 11.1, 23.8, 0.4375 
Magnesium, mmol/l 0.8, 0.8, 0.034 0.9, 0.9, 1 0.8, 0.9, 1 
Phosphate, mmol/l 1.2, 1.1, 0.1563 1.2, 1.2, 0.5625 1.1, 1.3, 0.0313 
Potassium, mmol/l 4, 3.8, 0.0313 4.5, 3.8, 0.0591 3.8, 3.9, 0.0975 
Sodium, mmol/l 140.3, 138.7, 0.0568 138, 139.7, 0.0335 138.7, 138.8, 0.7728 
Urea, mmol/l 4.4, 5, 0.2012 4.4, 5.1, 0.0579 5, 4.2, 0.1148 
    
Placebo    
Alanine transaminase, U/l 13.4, 12, 0.089 14.5, 12.8, 0.625 12, 13.8, 0.5807 
Albumin, g/l 39.8, 39.6, 0.7728 39.8, 40.2, 0.7893 39.6, 40.8, 0.0947 
Alkaline phosphatase, U/l 64.4, 66.2, 0.5879 70.5, 70.2, 0.875 66.2, 65.8, 1 
Aspartate transaminase, U/l 14.8, 12.8, 0.6845 15.2, 15.2, 1 12.8, 16.2, 0.4375 
Bicarbonate, mmol/l 25.8, 25.4, 0.3458 26.2, 25.2, 0.3458 25.4, 25.6, 0.7728 
Bilirubin, µmol/l 8.4, 7, 0.089 9, 8, 0.3458 7, 7.4, 0.3458 
Calcium, mmol/l 2.4, 2.3, 0.0625 2.4, 2.3, 0.4227 2.3, 2.3, 0.3125 
Chloride, mmol/l 104.4, 103.8, 0.5807 104.7, 105.7, 0.3711 103.8, 104.2, 0.3458 
Creatine Kinase, U/l 97.4, 81, 1 102.5, 118, 1 81, 105, 0.0625 
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Creatinine, µmol/l 70.4, 72.4, 0.5879 72.5, 73.8, 0.8539 72.4, 72.4, 0.8923 
Gamma-glutamyl transpeptidase, U/l 12.8, 12.4, 0.5862 14.5, 14.2, 1 12.4, 11.6, 0.4227 
Glucose, mmol/l 4.8, 4.4, 0.1875 4.4, 4.1, 0.4227 4.4, 4.5, 0.4982 
Insulin, mU/l 14.7, 6.6, 0.625 11, 6.8, 0.125 6.5, 9.3, 0.3125 
Magnesium, mmol/l 0.8, 0.8, 1 0.8, 0.8, 0.125 0.8, 0.9, 0.0625 
Phosphate, mmol/l 1.2, 1.2, 0.0625 1.2, 1.2, 0.7893 1.2, 1.3, 0.25 
Potassium, mmol/l 3.9, 4, 0.8551 3.9, 3.7, 0.25 4, 3.9, 0.625 
Sodium, mmol/l 139.2, 138, 0.129 139.7, 139.3, 0.7728 138, 138.4, 0.8501 
Urea, mmol/l 5.2, 4.9, 0.5839 5.4, 6.1, 0.2693 4.9, 5.1, 0.625 
Table 6.9. Differences in haematology results before and after tocilizumab. 
Results are expressed as mean at screening visit, mean at treatment visit, P-value from paired 
Wilcoxon test. Abbreviations: V, visit. 
Analysis of primary efficacy endpoints 
Bronchoconstriction during the LAR induced by allergen challenge 
We analysed two primary efficacy endpoints, both of which measure the magnitude of 
bronchoconstriction recorded between 3 and 7 hours after allergen challenge (i.e. during the LAR): 
LAR %fallmax and AUC3-7h. Details on how these were calculated for each individual are provided in 
detail in the Methods section. Briefly, LAR %fallmax was calculated as the difference between the 
largest drop in FEV1 measured 3 – 7h in post- and pre-treatment allergen challenges. 
 
Figure 6.5. Comparison of LAR %fallmax (A) and AUC3-7h (B) between patients treated with 
placebo or tocilizumab.   
LAR %fallmax was not significantly different between the tocilizumab (n = 6, mean= 6.3%, 
SD = 12.3%) and placebo (n = 6, mean = 4.5%, SD = 8.9%) groups (P = 1; Figure 6.5 A). Similarly, 
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there were no significant differences between groups for the AUC3-7h (Figure 6.5 B). Thus, 
tocilizumab did not significantly influence the primary endpoints measured in this study. 
Overall, FEV1 fluctuations throughout the pre- a post-treatment allergen inhalation challenges tests 
were comparable between the two treatment groups (Figure 6.6). 
 
Figure 6.6. Spirometry measurements in the pre- and post-treatment allergen challenges. 
Solid lines represent average FEV1. Shading represents 95% CI around the mean. Abbreviations: 
EAR, early asthmatic response; LAR, late asthmatic response. 
Analysis of secondary efficacy endpoints 
Bronchoconstriction induced during the early asthmatic response (EAR) 
To test if tocilizumab improved the immediate bronchoconstriction triggered by allergen challenge, 
for each individual we measured the EAR %fallmax, that is, the difference between the post- and 
pre-treatment allergen challenges in the largest FEV1 % drop measured 0 - 3h after allergen challenge 
(see Methods for details). As for EAR %fallmax, we found that EAR %fallmax was not significantly 
different between the placebo and tocilizumab groups (P = 0.5368; Figure 6.7 A). Similarly, no 
differences were observed between groups when bronchoconstriction during the EAR was measured 
using AUC0-3h (P = 0.3290; Figure 6.7 B). 
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Figure 6.7. EAR %fallmax (A) and AUC0-3h (B) in patients treated with placebo or tocilizumab. 
Airway hyperresponsiveness (AHR) to methacholine, before and after allergen challenge 
The methacholine PC20 measured 24 hours prior to allergen challenge provides a measure of AHR 
that is independent of an inflammatory response triggered by allergen exposure. To test if tocilizumab 
had any effect on AHR, for each participant we calculated ∆PC20 as the difference in PC20 between 
the post- and pre-treatment allergen challenges. We found no significant differences in ∆PC20 
between the tocilizumab and placebo groups (P = 0.3290, Figure 6.8).  
We then repeated the same analysis but considered the methacholine PC20 observed 24 hours after 
the allergen challenge, which now also captures the persistence of airway inflammation triggered by 
the allergen challenge in the previous day. Again, we observed no difference in the delta PC20 after 
allergen challenge between tocilizumab and placebo groups (P = 0.6857; Figure 6.8). 
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Figure 6.8. ∆PC20 measured pre- and post-allergen challenge.  
∆PC20 was calculated for each participant as the difference between the PC20 measured after 
treatment and before treatment (e.g. ∆PC20 Pre-allergen = PC20 Pre-allergen,treatment - PC20 Pre-allergen,screening). 
Immune cell counts in induced sputum samples 
We also compared immune cell counts from sputum samples obtained before and after treatment. 
When we compared visit 2 against visit 6, there were no significant differences in Δ cell counts 
between tocilizumab and placebo groups for any of the four immune cell types analysed (Table 6.10; 
Figure 6.9). Similar results were obtained when comparing visit 3 against visit 7, and visit 4 against 
visit 8.  
 V6-V2 V7-V3 V8-V4 
 TCZ Placebo P-value TCZ Placebo P-value TCZ Placebo P-value 
Macrophages -0.78 0.75 0.40 0.20 -1.26 0.80 -0.38 -1.69 0.70 
Neutrophils 0.06 -1.61 1.00 -5.35 0.93 0.20 -1.89 -5.09 0.40 
Eosinophils -0.02 2.17 0.15 -0.42 0.22 0.40 -0.24 -0.71 0.70 
Lymphocytes -0.09 -0.08 0.86 -0.07 -0.02 0.40 -0.13 -0.28 1 
Table 6.10. Comparison of ∆ immune cell counts in sputum between tocilizumab and placebo 
groups.  
The difference between visits (i.e. ∆) was calculated using number of cells per g of sputum. 
Abbreviations: TCZ, tocilizumab. 
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Figure 6.9. Comparison of ∆ immune cell counts in sputum between tocilizumab and placebo 
groups.  
∆ cell counts were calculated for each participant as the difference between the cell count measured 
after treatment and the cell count measured before treatment in the matching visit 
(e.g. ∆V6 V2,eosinophils= Eosinophil counts measured at visit 6 - Eosinophil counts measured at visit 2). 
Serum and sputum inflammatory mediators 
When comparing inflammatory mediators before and after treatment, large increases were observed 
in the tocilizumab group for serum IL-6 levels (Figure 6.10 and Figure 6.12). For example, in the 
pre-treatment phase, serum IL-6 levels were 0.2 and 0 pg/ml at 7 and 24 hours post allergen inhalation, 
respectively. After treatment, these figures changed to 12.2 and 13.4 pg/ml, respectively.  
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Figure 6.10. Serum IL-6 and sIL-6R levels in allergen inhalation challenge tests. 
Solid lines represent average protein levels. Shading represents 95% CI around the mean. 
Abbreviations: A, allergen challenge; M, methacholine challenge. 
We also observed decreases in C-reactive protein (CRP) serum levels, which were not seen with 
placebo. (Figure 6.12) However, none of these differences was statistically significant (Table 6.11). 
We did, however, observe a significant decrease in serum sIL-6R levels from visit 5 to visit 9 (130.2 
vs. 16.2, P = 0.0313). Similarly, sIL-6R levels decreased from pre- to post-treatment in all other visits, 
but these differences were not statistically significant (Table 6.11). Conversely, sIL-6R levels 
measured in sputum increased from pre- to post-treatment (Figure 6.11 and Figure 6.13). For 
example, sputum sIL-6R levels measured 7 hours after allergen inhalation were 357.3 pg/ml before 
treatment, and increased to 1,005.5 pg/ml after treatment. However, these differences were also not 
significant (Table 6.12) No other relevant differences were observed in sputum. 
 
Figure 6.11. Sputum IL-6 and sIL-6R levels in allergen inhalation challenge tests. 
Solid lines represent average protein levels. Shading represents 95% CI around the mean. 
Abbreviations: A, allergen challenge; M, methacholine challenge. 
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Figure 6.12. Serum cytokine levels before and after infusion with placebo or tocilizumab. 
CRP and sIL-6R levels are presented in ng/ml. All other cytokines are presented in pg/ml. CRP, 
C-reactive protein; IL, interleukin; sIL-6R, IL-6 soluble receptor; TNF, tumour necrosis factor  
  V2 vs. V6 V3 vs. V7 V4 vs. V8 V5 vs. V9 
Tocilizumab    
CRP 2069.3, 471.7, 0.0625 1057.5, 128.8, 0.1003 2029.5, 437.4, 0.0625 2205.4, 822.3, 0.0625 
IL-13 0.5, 1.6, 0.1814 1, 0.5, 0.7893 1, 0.9, 0.8551 1, 1.2, 0.8551 
IL-5 0.1, 0.2, 1 0.3, 0.6, 0.4185 0.8, 3.1, 0.1056 0.1, 0.2, 0.3711 
IL-6 1.7, 4.3, 0.1814 0.2, 12.2, 0.1056 0, 13.4, 0.1003 0, 5.5, 0.1003 
sIL-6R 133.8, 54.8, 0.0938 146.7, 53.2, 0.0938 135, 53.3, 0.1563 130.2, 16.2, 0.0313 
IL-8 4.4, 5.8, 0.4185 4.6, 3.7, 0.7874 4.9, 5.1, 1 5.9, 5.6, 1 
TNF 3, 2.9, 0.8551 2.8, 3.8, 0.7874 3, 2.6, 0.5896 3.3, 3.3, 1 
     
Placebo    
CRP 2588.8, 1672.5, 0.1875 2524.5, 1612.6, 1 1477.1, 1420.2, 1 2078.7, 2241.1, 1 
IL-13 0.1, 0.3, 0.3711 0.3, 0.2, 1 0.2, 0.3, 0.3711 0.3, 0.2, 1 
IL-5 0.1, 0, 1 0.1, 0.9, 0.4227 1.5, 5.5, 0.1814 0.6, 0, 1 
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IL-6 1.8, 0.2, 0.4227 1.7, 0.4, 1 0.2, 0.1, 1 0.1, 0.1, 1 
sIL-6R 78.3, 111.6, 0.4375 72.4, 122.3, 0.125 71.9, 92.6, 0.3125 106.4, 135.3, 0.125 
IL-8 2.6, 2.3, 1 2.1, 1.8, 1 1.2, 2.3, 0.4227 1.6, 1.9, 0.3711 
TNF 35.9, 47.7, 0.4375 57.6, 59.6, 0.875 47.4, 46.4, 1 56.6, 42, 1 
Table 6.11. Inflammatory mediators measured in serum.  
Results are expressed as mean at screening visit, mean at treatment visit, P-value from paired 
Wilcoxon test. CRP and sIL-6R levels are presented in ng/ml. All other cytokines are presented in 
pg/ml. Abbreviations: CRP, C-reactive protein; IL, interleukin; sIL-6R, IL-6 soluble receptor; TNF, 
tumour necrosis factor; V, visit. 
 
Figure 6.13. Sputum cytokine levels before and after infusion with placebo or tocilizumab.  
NE levels are presented in ng/ml. All other cytokines are presented in pg/ml. IL, interleukin; sIL-6R, 
IL-6 soluble receptor; NE, neutrophil elastase; TNF, tumour necrosis factor. 
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  V2 vs. V6 V3 vs. V7 V4 vs. V8 
Tocilizumab   
IL-13 0.2, 0.2, 1 0.6, 1.2, 1 0.2, 0.3, 0.3711 
IL-5 0, 0, 1 0.5, 3.5, 0.3711 0.5, 0.8, 1 
IL-6 41.8, 35.1, 0.875 22.7, 31.7, 0.3711 47.9, 52.5, 0.875 
sIL-6R 382.9, 708.2, 0.625 357.3, 1005.5, 0.5 451.7, 975.7, 0.25 
IL-8 1206, 2321.1, 0.875 419.1, 1002.3, 0.25 4192.1, 7558.5, 0.625 
NE 117.6, 72.4, 0.125 206.4, 152.7, 1 100.3, 103.7, 0.875 
TNF 2.8, 3.1, 0.875 3.8, 3.8, 1 3, 5.5, 0.25 
    
Placebo   
IL-13 0.5, 0.3, 0.1814 0.7, 0.7, 1 0.3, 0.4, 0.4227 
IL-5 0.2, 0.1, 1 0.6, 2.2, 1 0.1, 1.6, 0.5839 
IL-6 5, 6.8, 0.4375 17.2, 31.7, 0.625 55.3, 32.6, 1 
sIL-6R 45.8, 118.2, 0.1003 209, 144.8, 0.625 146, 187.9, 0.4375 
IL-8 181.5, 414.7, 0.125 677.7, 1737.2, 0.4375 951.6, 1191, 0.8125 
NE 31.4, 14.8, 0.1814 46.2, 97.7, 0.8125 36.7, 32.9, 0.4375 
TNF 2, 2.2, 0.8125 2.3, 2.6, 0.625 2.9, 2.7, 1 
Table 6.12. Inflammatory mediators measured in sputum.  
Results are expressed as mean at screening visit, mean at treatment visit, P-value from paired 
Wilcoxon test. NE levels are presented in ng/ml. All other cytokines are presented in pg/ml. 
Abbreviations: IL, interleukin; sIL-6R, IL-6 soluble receptor; NE, neutrophil elastase; TNF, tumour 
necrosis factor; V, visit. 
Sputum subtype after allergen challenge 
Of the 11 participants who completed the trial, 8 provided a sputum sample 7 hours after allergen 
challenge in the screening phase. Sputum subtypes were eosinophilic (n = 7) or mixed granulocytic 
(n = 1). At 24 hours, 9 participants provided a sputum sample: paucigranulocytic, n = 1; eosinophilic, 
n = 5; neutrophilic, n = 1; and mixed granulocytic, n = 2. Sputum subtypes observed after treatment 
are listed in Table 6.13. 
  Visit 2 Visit 3 Visit 4 Visit 6 Visit 7 Visit 8 
P210300001 Pauci - Neutro Pauci Neutro Pauci 
P210300002 Pauci Eosino Eosino Pauci Pauci Pauci 
P210300003 Pauci Eosino Eosino Pauci Eosino Eosino 
P210300004 Pauci Eosino Eosino Eosino Pauci Eosino 
P210300005 - Eosino MG - - Eosino 
P210300006 Pauci Eosino MG MG MG MG 
QPS0100 Eosino Eosino - Eosino Eosino Eosino 
S00013 Neutro - Eosino Pauci - Eosino 
S00023 - - - - - - 
S00028 Eosino MG Eosino Eosino Eosino Pauci 
S00030 Pauci Eosino Pauci Pauci Pauci Pauci 
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Table 6.13. List of sputum inflammatory subtypes in each study visit where sputum was 
induced. 
Subjects treated with tocilizumab are represented in bold font. Abbreviations: Eosino, eosinophilic; 
Neutro, neutrophilic; MG, mixed granulocytic; Pauci, paucigranulocytic. 
A single individual did not develop a LAR after treatment 
Of note, one participant in the trial did not develop a LAR after treatment (LAR %fallmax  < 15%). 
The subject was the only participant who (1) had mixed granulocytic sputum after the screening 
allergen challenge (when considering the sputum sample collected at 24 hours post challenge); (2) 
had the rs4129267:TT genotype; and (3) was in the tocilizumab group. No other participant met all 
three criteria. Furthermore, before treatment, the patient had the highest levels of sputum sIL-6R, and 
the highest, or second highest, levels of IL-6 in sputum collected at 7 and 24 hours post allergen 
inhalation (Figure 6.14). Specifically, sputum sIL-6R was 2- and 3.9-fold higher than average at 7 
and 24 hours post-allergen, respectively. Sputum IL-6 was 2.2- and 3.9-fold higher than average at 7 
and 24 hours post-allergen, respectively.  
 
Figure 6.14. Sputum levels of IL-6 and sIL-6R measured in the pre-treatment phase, before 
(V2) and after (V3 and V4) allergen inhalation challenge.  
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The square represents cytokine levels from the only patient who did not have a LAR after treatment. 
Triangles represent cytokine levels from other patients with the rs4129267:TT genotype. Circles 
represent cytokine levels from subjects with the rs4129267:CT genotype. One patient with the 
rs4129267:TT genotype (rs4129267:TT_03) did not produce sputum in any of the study visits, and so 
has no cytokine measurements. 
Discussion 
An extensive body of evidence has implicated IL-6 signalling in asthma pathophysiology. 
Tocilizumab is a monoclonal antibody that blocks IL-6 signalling by binding to both mIL-6R and 
sIL-6R. In the current study, we evaluated the safety and efficacy of a single dose of 8 mg/kg of 
tocilizumab in allergen-induced asthmatic responses. 
Safety assessment showed that the drug was generally well tolerated by asthma patients. A single 
drug-related adverse event was recorded, asymptomatic neutropenia. In addition, white blood cell 
counts were lower in tocilizumab-treated patients than in placebo-controls, mostly due to a 
significantly lower neutrophil count. Previous studies have reported significant decreases in 
neutrophil counts with tocilizumab treatment.277,278 Thus, these were expected drug effects. Overall, 
our results show that tocilizumab is safe to treat patients with asthma. This is important because 
tocilizumab is now widely used to treat patients with rheumatoid arthritis – 1-7% of whom have been 
estimated to also suffer from asthma.11,288,289  
In line with previous reports,274,279,286 we also observed significant increases in serum IL-6 and sIL-
6R levels after tocilizumab infusion. The high concentrations of IL-6 could be explained by an 
increase in free IL-6, i.e. IL-6 that is not bound to mIL-6R or sIL-6R. There is contradicting evidence 
on the possible effect of tocilizumab in dissociating IL-6 from IL-6/IL-6R complexes.258,290 
Nevertheless, continued production of IL-6 would be expected to drive increases in free IL-6, given 
that the remaining IL-6R would be blocked by tocilizumab. Another possible explanation for the 
increase in IL-6 levels is that tocilizumab blocks the IL-6R mediated clearance of IL-6. This 
hypothesis is supported by observations in models of experimental asthma.290 Specifically, Uchiyama 
et al. showed that a single injection of tocilizumab in monkeys with collagen-induced arthritis did not 
induce IL-6 production synthesis (measured through IL-6 messenger RNA levels), but an anti-IL-6R 
antibody inhibited IL-6 clearance in IL-6 deficient mice continuously infused with human IL-6.290 
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The increase in serum levels of sIL-6R after tocilizumab treatment may be an artefact caused by 
tocilizumab binding to the ELISA assay that was used to measure sIL-6R levels. To our knowledge, 
this has not been tested. Another possible explanation, suggested by Nishimoto et al.,291 is that 
tocilizumab increases the half-life of sIL-6R when sIL-6R/tocilizumab complexes are formed. This 
hypothesis is in line with previous observations that the half-life of antigens was increased in 
antibody/antigen complexes.292 
Serum IL-6 levels measured in the screening phase were very low (Table 6.4), considering the 
concentrations observed in sputum and the correlation that we previously observed between serum 
and sputum levels of IL-6 (Figure 2.3). Two possible explanations for this include the timing of 
sample collection or biases in cytokine measurements. In the current study, baseline sputum 
measurements were performed in samples that were collected after the first methacholine challenge. 
Conversely, in chapter 2, serum and sputum collection were not preceded by any challenge tests. 
Thus, the timing of sample collection could have affected cytokine levels. This hypothesis is, 
however, unlikely. Firstly, methacholine challenge has been shown to have no effect on sputum 
inflammatory cell counts and biochemical biomarkers.293 Secondly, blood samples were collected 
immediately after the methacholine challenge; thus, it is unlikely that cytokine levels measured in 
serum have been affected in that time frame. A more plausible explanation is that IL-6 concentrations 
were not accurately measured. Specifically, high concentrations of sIL-6R (> 20 ng/ml) may interfere 
with the detection of IL-6 in the ELISA kits used in this study. Thus, given the elevated concentration 
of sIL-6R observed in serum samples (?̿?Placebo = 91.6 ng / ml; ?̿?Tocilizumab = 147.8 ng / ml), it is likely 
that IL-6 levels measured in serum are underestimated.  
The primary efficacy outcome assessed in this study was the LAR %fallmax, taken as the difference 
between post- and pre-treatment maximum FEV1 % drop measured 3 – 7h after allergen inhalation. 
Overall, there were no differences in LAR %fallmax between the tocilizumab and placebo groups. 
After treatment, all but one participant experienced a LAR, defined by an FEV1 fall > 15% from 
baseline, between 3 and 7 hours post allergen-inhalation. The exception was a patient with mixed 
granulocytic sputum after allergen challenge, homozygous for rs4129267:T and treated with 
tocilizumab. Interestingly, the participant also had higher airway levels of IL-6 and sIL-6R after 
allergen challenge. This is consistent with previous evidence from mouse models of experimental 
asthma that showed that IL-6R blockade is able to attenuate airway inflammation that is associated 
with elevated levels of IL-6 and sIL-6R. Our findings support the hypothesis that the pathological 
contribution of IL-6 to asthma is mainly due to the trans-signalling pathway. Curiously, a recent 
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evaluation of tocilizumab affinity suggests that the drug might be more efficient at blocking the 
classical signalling pathway. Specifically, tocilizumab affinity was found to be three times greater to 
mIL-6R than to sIL-6R.294 This observation raises the possibility that at the dose used (8-mg/kg), 
tocilizumab might not have efficiently blocked sIL-6R. Previously, fortnightly intravenous infusions 
of 8 mg/kg of tocilizumab were shown to increase serum levels of sIL-6R and, while free tocilizumab 
(i.e. not bound to IL-6R) remained detectable in serum (i.e. above 1 μg/ml), over 95% of sIL-6R was 
found in the form of sIL-6R/tocilizumab immune complexes.291 Although the degree of mIL-6R 
blockade was not assessed in that study, the recent observations on tocilizumab affinity suggest that 
most, if not all, mIL-6R will also be blocked with an 8 mg/kg monthly dose of tocilizumab, as long 
as the drug remains above 1 μg/ml in serum. In our study, free tocilizumab in serum was not measured. 
However, pharmacodynamics was monitored through the levels of serum IL-6, sIL-6R, and C-
reactive protein (CRP). In line with previous reports,256,291,295 we observed significant increases in IL-
6 and sIL-6R, and decreases in CRP, after tocilizumab infusion. Therefore, our observations suggest 
that mIL-6R and sIL-6R were efficiently targeted at systemic level. However, it is possible that the 
amount of tocilizumab that reached the airways was lower than that observed at systemic level. This 
hypothesis is corroborated by the fact that there was no increase in airway levels of IL-6 after 
tocilizumab infusion. Thus, if tocilizumab levels were lower in the airways, we would expect mIL-6R 
to be preferentially targeted, which could explain why the drug only improved allergen-induced 
bronchoconstriction in the subject with higher airway levels of sIL-6R (and consequently lower 
mIL-6R levels). An alternative way to test the effect of tocilizumab in asthma patients would be to 
administrate the drug directly to the airways, for example through aerosol inhalation. However, the 
only two routes currently approved for tocilizumab administration are intravenous (used in this study) 
or subcutaneous infusions. Further studies are required to assess the feasibility of targeting the IL-6 
pathway directly in the airways. 
A relevant observation in the results above is that the subject who responded to tocilizumab had two 
copies of the rs4129267:T allele, which is estimated to increase serum sIL-6R levels by about 1.4-fold 
per copy,27 and asthma risk by 1·09-fold.1 Based on the effects of this variant, we previously 
hypothesised that tocilizumab could either worsen or improve asthma symptoms, depending on which 
pathway (classical or trans-signalling) was underlying the association between rs4129267 and asthma 
risk. Specifically, if rs4129267:T increases asthma risk because it decreases classical signalling, then 
we would expect asthma symptoms to worsen with tocilizumab, which blocks signalling through this 
pathway. On the other hand, if rs4129267:T increases asthma risk because it increases IL-6 
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trans-signalling, we would expect tocilizumab to improve asthma symptoms, because it blocks 
sIL-6R. As previously discussed, in mice allergen-induced responses improved after tocilizumab 
treatment, thereby supporting the second hypothesis. Thus, a more appropriate approach to target 
IL-6 trans-signalling would be to use a drug such as olamkicept, which specifically blocks sIL-6R 
and has no effect on the classical signalling pathway.  
Overall, the current study design was appropriate for a proof-of-concept assessment of the effect of a 
single dose of tocilizumab in asthma patients. Allergen inhalation challenge tests are routinely used 
to assess the efficacy of new experimental treatments for asthma. Moreover, the main efficacy 
endpoint that we analysed (the magnitude of the LAR after treatment) was objectively measured 
before and after treatment, providing the opportunity to correct for intra-individual variability that 
was not related to the study drug. Another advantage in our study was the recruitment of patients with 
the rs4129267:T allele. As discussed above, this variant is associated with increased serum levels of 
sIL-6R and an extensive body of evidence suggests that its blockade has anti-inflammatory effects. 
Our study did, however, have some limitations. First, by blocking both the mIL-6R and sIL-6R, 
tocilizumab may have opposing effect in airway inflammation. Second, with the current study design, 
we were not able to test the effect of tocilizumab in patients with more severe asthma, who are more 
likely to benefit from new therapies, and in particular from blockade of IL-6 signalling. Lastly, in the 
screening phase, only one of the 11 participants developed a mixed granulocytic inflammatory 
response after allergen challenge. Importantly, that patient also had the highest sputum level of IL-6 
and sIL-6R, and was the only subject who did not experience a LAR after treatment with tocilizumab. 
We previously showed that individuals with mixed-granulocytic sputum subtype are more likely to 
have IL-6 trans-signalling in the airways (Chapter 2), perhaps because neutrophils are a main source 
of sIL-6R.296 Accordingly, the asthma sub-group that is more likely to benefit from the anti-
inflammatory effects of IL-6 trans-signalling blockade are those who also have a mixed granulocytic 
sputum subtype. Further studies are required to test this hypothesis. 
In conclusion, we show that a single intravenous infusion of tocilizumab at a dose of 8-mg/kg does 
not inhibit allergen-induced airway responses in mild asthmatics. However, our results suggest that 
blockade of airway IL-6 trans-signalling in patients with elevated sputum levels of IL-6 and sIL-6R 
might provide a more promising therapeutic strategy to attenuate allergen-induced immune responses. 
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CHAPTER 7. FREQUENCY OF ASTHMA PRESCRIPTIONS IN PATIENTS ON 
REGULAR TOCILIZUMAB TREATMENT 
The goal of this chapter was to assess whether long-term (i.e. 12 months) treatment with TCZ 
influenced the frequency of prescriptions for asthma-related medications using data from the 
Pharmaceutical Benefits Scheme (PBS). 
Introduction 
In the previous chapter, we presented results from a phase II clinical trial performed to assess the 
effect of single dose tocilizumab (TCZ) in the prevention of allergen-induced responses. The study 
design used in that study is very powerful to detect drug effects on acute exacerbations. However, it 
has two important limitations. First, the allergen inhalation challenge test used can only be performed 
in subjects with mild asthma, who at baseline have lung function within 30% of the predicted value. 
This ensures that allergen challenge does not cause a drop in lung function that is unsafe for the 
participants. As such, that study design cannot be used to assess the effect of new experimental drugs 
in patients who have severe asthma and, therefore, who have the greatest need for new treatments. 
This is particularly relevant if, for example, the pathway being targeted by the new treatment is 
specific to an inflammatory subtype that is common amongst patients with severe but not mild 
asthma. The second limitation of the clinical trial reported in the previous chapter is that it does not 
address the possibility that prolonged treatment with TCZ might be required to observe a clinically-
significant effect on airway inflammation. 
In this chapter, we conceived a study that could potentially address these limitations, at least partly. 
Specifically, we identified individuals who (1) were likely to have asthma, including some expected 
to have moderate to severe asthma symptoms, based on the number of inhaled corticosteroid 
prescriptions taken; and (2) were treated regularly with TCZ, which was prescribed for a different 
condition, most likely rheumatoid arthritis (RA). Based on co-morbidity studies, 1-7% of RA patients 
also suffer from asthma.288,289,297 Thus, if TCZ has an effect on asthma – improving or worsening 
disease symptoms – then we hypothesised that the onset of TCZ therapy in these patients is associated 
with a significant change in the pattern of asthma-related prescriptions.  
In Australia, information recorded in the Pharmaceutical Benefits Scheme (PBS) can be used to test 
this hypothesis. The PBS is a comprehensive program through which the Australian Government 
provides residents with affordable access to a wide range of medicines. Electronic records of claims 
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through the PBS are collected by the Department of Human Services, and include information on 
quantity, strength, and date the subsidized medicines were dispensed. Access to these data can be 
requested for specific research projects, thereby providing a unique opportunity to study outcomes of 
medicines that have been approved for particular diseases or conditions. 
TCZ was approved by the Therapeutic Goods Administration for the treatment of rheumatoid arthritis 
(RA) in Australia in 2009. In this chapter, we analyse PBS data collected during a 5-year period to 
study the pattern of asthma-related prescriptions after the onset of regular TCZ treatment in 
individuals who were likely to suffer from both RA and asthma. Specifically, our hypothesis was that 
regular treatment with TCZ is associated with a decreased frequency of asthma prescriptions, 
reflecting an improvement in asthma symptoms. 
Methods 
Data source 
We conducted a retrospective study of de-identified PBS individual-level data of prescription drugs 
subsidized by the Australian Government. Data were extracted by the Australian Institute of Health 
and Welfare (AIHW) for prescriptions supplied between April 2010 and March 2015, inclusive. The 
dataset obtained from the AIHW included six fields: (1) de-identified patient ID, (2) sex, (3) age as 
of 1 July 2016, (4) prescription supply date (year and month), (5) PBS item code, and (6) number of 
scripts issued. Four groups of drugs were included in this dataset, namely (1) TCZ, (2) inhaled 
corticosteroids (ICS), to identify individuals who were likely to suffer from asthma, (3) tiotropium 
(TIO), to exclude individuals who were likely to suffer from chronic obstructive pulmonary disease 
(COPD); and (4) adalimumab (ADA), a monoclonal antibody that blocks TNF-alpha and is also used 
to treat RA, which was used to assess if any changes in the pattern of asthma prescriptions were 
specific to TCZ. Figure 7.1 summarizes the number of unique individuals with prescriptions for each 
drug in this dataset. 
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Figure 7.1. Number of unique patients with each of the four main prescription drugs analysed 
between April 2010 and March 2015, inclusive.  
ADA, adalimumab; ICS, inhaled corticosteroids; TIO, tiotropium; TCZ, tocilizumab. 
Records for all other drugs prescribed between April 2010 and June 2015 to subjects included in the 
dataset above were also obtained. As some items in this list were rare and potentially identifiable, 
these data were aggregated by the AIHW into two groups, using the Anatomical Therapeutic 
Chemical (ATC) classification system. Specifically, drugs for obstructive airway diseases (ATC2 
code ‘R03’) were grouped at the ATC5 code level, and other drugs grouped at the ATC2 code level. 
No scripts under co-payment were included in any of the datasets. Data were exclusively derived 
from the PBS dataset, i.e. no linkage to other datasets was performed. 
Study design  
Figure 7.2 summarizes the approach used to study the effect of regular TCZ therapy on the frequency 
of asthma prescriptions. The number of asthma prescriptions was compared between two consecutive 
periods, designated as ‘baseline’ and ‘treatment’ phases. The baseline phase consisted of a 12-month 
period with no TCZ scripts. The treatment phase consisted of a 12-month period comprising at least 
10 months with a prescription of TCZ, which is taken monthly. 
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Figure 7.2. Study design 
The number of ICS scripts were compared between two consecutive periods of 12 months. The first 
12-month period (baseline) comprised no TCZ scripts. The second 12-month period (treatment) 
included at least 10 months with a TCZ script. Abbreviations: ICS, inhaled corticosteroid; TCZ, 
tocilizumab. 
Analyses were performed in a ‘case group’ and in a ‘control group’ (specific inclusion criteria below). 
The case group consisted of patients treated with TCZ who were also likely to suffer from asthma. 
The control group consisted of subjects who were not treated with TCZ but were likely to suffer from 
asthma  
Primary analysis 
Inclusion criteria to define cases 
In broad terms, we considered that an individual was likely to suffer from asthma if he/she had (1) 
prescriptions of ICS, which are used almost exclusively to treat asthma and COPD; and (2) no 
prescriptions of TIO, which is almost exclusively used to treat COPD (Table 7.1). 
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Table 7.1. Study cohort inclusion criteria. 
ICS, inhaled corticosteroids; TIO, tiotropium; TCZ, tocilizumab. 
More specifically, we first identified individuals who between April 2010 and March 2015 were 
issued (1) any number of prescriptions for TCZ; (2) any number of prescriptions for ICS; and (3) no 
prescriptions of TIO. Next, we identified the subset of individuals who had a 12-month period of no 
TCZ prescriptions (this constitutes the ‘baseline phase), which was followed by a 12-month period 
with 10 or more months with a TCZ script (‘treatment phase’). Lastly, we selected for inclusion in 
the ‘case group’ individuals with three or more ICS prescriptions during the 24-month period of 
analysis (i.e. baseline plus treatment phases) – this threshold was used to minimize the probability 
that ICS were prescribed seasonally to treat viral coughs and not necessarily asthma.  
Three sub-groups of cases (Groups 1 to 3) were defined base on the frequency of ICS scripts in the 
24-month period of analysis: (1) 3 to 5; (2) 6 to 11; or (3) 12 to 24 months. These groups are likely 
to represent individuals with different severity of disease. Demographics for individuals included in 
the case group are summarized in Table 7.2. 
Intervention drug Outcome drug Group N Age Sex 
Number of 
outcome 
prescriptions 
TCZ ICS All 88 61, 11.1, 27-84 81.8 10, 6.7, 3-28 
  Group 1 37 58, 10.6, 32-81 75.7 4, 0.9, 3-6 
  Group 2 31 62, 10.3, 41-82 87.1 9, 3.7, 6-22 
  Group 3 20 64, 12.7, 27-84 85 20, 4.3, 13-28 
 Salbutamol All 49 61, 12, 27-84 85.7 8, 6, 3-33 
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  Group 1 22 63, 12.5, 32-82 77.3 4, 2.1, 3-12 
  Group 2 19 58, 10.7, 27-73 94.7 9, 3.4, 6-20 
  Group 3 8 65, 13.3, 47-84 87.5 18, 6.8, 12-33 
 OCS All 422 59, 14.2, 5-92 76.1 14, 9.6, 3-58 
  Group 1 122 55, 15.2, 5-92 76.2 5, 2.3, 3-15 
  Group 2 131 60, 13.2, 7-89 77.1 11, 3.6, 6-22 
  Group 3 169 62, 13.7, 19-88 75.1 23, 8, 12-58 
ADA ICS All 272 54, 15.2, 5-85 69.5 9, 6.4, 3-45 
  Group 1 110 53, 15.3, 16-78 70 4, 1.7, 3-13 
  Group 2 106 54, 15.9, 5-85 70.8 9, 2.6, 6-19 
  Group 3 56 56, 13.9, 23-79 66.1 19, 6.5, 12-45 
 Salbutamol All 141 54, 14.3, 2-78 70.9 9, 7.2, 3-42 
  Group 1 72 57, 12.6, 22-78 70.8 4, 1.5, 3-10 
  Group 2 46 52, 14.4, 5-75 73.9 10, 2.6, 6-18 
  Group 3 23 50, 17.7, 2-76 65.2 22, 8, 12-42 
 OCS All 942 55, 17.2, 3-89 67.6 12, 8.1, 3-62 
  Group 1 345 51, 18.4, 4-89 65.8 5, 2.2, 3-21 
  Group 2 330 55, 17.5, 3-87 67 11, 3.6, 6-30 
  Group 3 267 61, 13.1, 18-85 70.8 21, 7.7, 12-62 
ICS Salbutamol All 3088 57, 24, 0-103 58.1 12, 12, 3-297 
  Group 1 1027 59, 23.2, 0-98 62.1 4, 1.6, 3-31 
  Group 2 1278 55, 24.9, 0-103 57.4 10, 4.2, 6-58 
  Group 3 783 57, 23.4, 0-102 54 25, 16.8, 12-297 
OCS ICS All 849 68, 15.8, 0-100 59.4 10, 7.1, 3-44 
  Group 1 313 67, 15.6, 0-100 56.9 4, 1.7, 3-26 
  Group 2 292 67, 16.5, 1-98 59.2 10, 3.3, 6-35 
  Group 3 244 70, 14.9, 8-100 62.7 19, 5.4, 12-44 
Table 7.2. Demographics of cases studied. 
Age and sex were assessed at the day of the first prescription of the intervention drug. The number of 
outcome prescriptions represents the total number of prescriptions observed in the 24-month period 
of analysis. Matched controls had the same demographics but had no prescriptions for the 
intervention drug. Age and number of outcome prescriptions are presented as mean, standard 
deviation and range. Sex is presented as percentage of female. ICS, inhaled corticosteroids; OCS, 
oral corticosteroids; TCZ, tocilizumab. 
Inclusion criteria to define controls 
To create a group of controls for the TCZ analysis, we selected individuals who were likely to suffer 
from asthma but who were not treated with TCZ. We identified up to five matched controls for each 
case. Controls were matched on age, sex and number of ICS scripts issued during the same 24-month 
period of analysis. For example, a male who (1) was born in 1958, (2) started regular TCZ therapy in 
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January 2014, and (2) had nine ICS prescriptions from January 2013 to January 2015, was matched 
with up to five males born in 1958, who had nine ICS prescriptions between January 2013 and January 
2015, but none of TCZ. 
Secondary analyses 
Effect of TCZ on other asthma medications 
We conducted secondary analyses with the same analytical approach used in the primary analysis, 
but defined cases based on different outcome drugs.  
First, we identified a group of cases with the exact same selection criteria as before, but the outcome 
drug was salbutamol instead of ICS, i.e. we selected individuals with (1) ≥ 3 months with salbutamol 
prescriptions in the 24 months analysed, (2) no tiotropium prescriptions ever, and (3) a period of 12 
months with no TCZ (baseline), followed by a period of 12 months with ≥ 10 TCZ prescriptions 
(treatment). We identified 49 individuals with these characteristics, and defined three sub-groups 
based on the frequency of salbutamol prescriptions, as before.  
Second, we identified a group of cases with (1) ≥ 3 months with OCS prescriptions in the 24 months 
analysed, (2) no tiotropium prescriptions ever, and (3) a period of 12 months with no TCZ (baseline), 
followed by a period of 12 months with ≥ 10 TCZ prescriptions (treatment). A total of 942 individuals 
met these criteria and were divided into three sub-groups based on the frequency of OCS 
prescriptions. 
These groups were used to compare the number of salbutamol or OCS prescriptions before and after 
the onset of regular TCZ therapy. Matched controls were defined with the exact same criteria and 
approach described in the primary analysis. 
Demographics for individuals included in these analyses are summarized in Table 7.2. 
Effect of ADA on ICS or other asthma medications 
To assess if TCZ-associated changes in the pattern of asthma prescriptions were specific to TCZ, we 
performed the same analyses as before (i.e. with ICS, salbutamol or OCS as the outcome drug) but 
selected cases that were treated with ADA instead of TCZ. A matched control group was also 
identified in each analysis using the exact same criteria and approach described above. Demographics 
for individuals included in these analyses are summarized in Table 7.2. 
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Effect of strong asthma medications on other asthma medications 
Lastly, we evaluated the ability of our study design to identify changes in the number of asthma 
prescriptions, based on the assumption that stronger asthma medications (e.g. ICS), which help 
control asthma, may result in a decrease in the number of other asthma prescriptions (e.g. salbutamol). 
Specifically, we performed two analyses. First, we compared the number of salbutamol prescriptions 
before and after the onset of ICS therapy. Second, we compared the number of ICS prescriptions 
before and after the onset of OCS therapy. Cases were defined with the same criteria used in the 
primary analysis, except that the intervention (TCZ) and outcome (ICS) drugs were respectively 
replaced by ICS and salbutamol in the first analysis, and OCS and ICS in the second analysis. In both 
analyses matched controls were defined with the exact same criteria as before. Demographics for 
individuals included in these analyses are summarized in Table 7.2. 
Statistical analyses 
A Wilcoxon signed rank test was used to compare (1) the number of asthma prescriptions between 
the baseline and treatment phases, and (2) the number of asthma prescriptions issued at baseline 
between the case and control groups. Analyses were conducted using R version 3.4.1. 
Results 
Frequency of asthma prescriptions before and after the start of TCZ therapy 
Between April 2010 and March 2015, a total of 132,780 TCZ prescriptions were issued to 4,104 
unique individuals. Of these, 88 (2.1%) were included in the ‘case group’ because they (1) were 
prescribed TCZ for at least 10 of 12 consecutive months; (2) in the preceding 12 months had no TCZ 
prescription; (3) had three or more ICS prescriptions in the combined 24-month period; and (4) had 
no TIO prescriptions in the 5-year period. The 88 individuals were then divided into three case sub-
groups according to the number of months with an ICS prescription across the 24-month period: (1) 
3 – 5 months (Group 1; n = 37); (2) 6 – 11 months (Group 2; n = 31); and (3) 12 – 24 months (Group 3; 
n = 20).  
First, for each case group, we compared the frequency of ICS prescriptions between the baseline and 
treatment phases, that is, before and after the onset of regular TCZ treatment. We found that the 
number of ICS prescriptions taken in the 12 months that followed the onset of TCZ therapy was 
comparable to that observed in the preceding 12 months without TCZ treatment (Figure 7.3 A). This 
indicates that the pattern of ICS use did not significantly change in these individuals after the onset 
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of TCZ therapy. To help visualize this, for each month, we estimated the proportion of individuals 
with an ICS prescription, and plotted these estimates across the 24-month period considered (Figure 
7.3 B). For example, in Group 3 cases (i.e. those with this greatest number of ICS prescriptions over 
the 24-month period; n = 20), 70% of individuals had an ICS prescription on average per month in 
the baseline period, and this increased to 73% in the treatment period. These figures were comparable 
to what was observed in the matched control group (69% vs. 74%; n = 100), indicating that the small 
increase in proportion of individuals taking ICS observed in the treatment phase was unlikely to be 
related to TCZ treatment. Broadly similar results were observed in Group 1 and 2 cases.  
 
Figure 7.3. Number of ICS prescriptions (A) and proportion of patients with ICS prescriptions 
(B) before and after the start of regular TCZ therapy. 
Dashed lines represent the mean. Light grey shading represents the 95% margin of error of 
proportions. Red vertical line indicates date of first TCZ script. Group 1, 3-5 months with ICS; Group 
2, 6-11 months with ICS; Group 3, 12-24 months with ICS. B, baseline phase; ICS, inhaled 
corticosteroids; T, treatment phase. 
Next, we used the exact same approach to assess the impact of regular TCZ therapy on the frequency 
of two other asthma medications:  salbutamol and oral corticosteroids (OCS). We found that the onset 
of TCZ therapy did not have a significant effect on salbutamol use (Figure 7.4). Because salbutamol 
is used almost exclusively to treat asthma, these results suggest that TCZ therapy did not have a 
significant effect on asthma symptoms, as observed for ICS. 
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Figure 7.4. Number of salbutamol prescriptions (A) and proportion of patients with salbutamol 
prescriptions (B) before and after the start of regular TCZ therapy. 
Dashed lines represent the mean. Light grey shading represents the 95% margin of error of 
proportions. Red vertical line indicates date of first TCZ script. Group 1, 3-5 months with salbutamol; 
Group 2, 6-11 months with salbutamol; Group 3, 12-24 months with salbutamol. B, baseline phase; 
T, treatment phase. 
On the other hand, we found the number of OCS prescriptions dropped significantly (P = 5.9 x 10-7) 
in the 12 months that followed the onset of TCZ therapy in the case group that had the lowest overall 
number of OCS prescriptions (Figure 7.5 A). This was a reflection of a reduction in the proportion of 
patients taking OCS prescriptions, from 22% at baseline to 10% in the treatment phase (Figure 7.5 
B). This pattern of change was not observed in the matched controls (Figure 7.5 A and B), indicating 
that it was indeed related to the onset of TCZ treatment. A similar trend was observed in those with 
intermediate (Group 2; P = 0.03) but not highest (Group 3; P = 0.83) overall use of OCS. These 
results indicate that in patients with a low to intermediate number of OCS scripts (possibly prescribed 
for the treatment of RA), the onset of TCZ therapy is associated with a reduction in OCS intake. 
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Figure 7.5. Number of OCS prescriptions (A) and proportion of patients with OCS 
prescriptions (B) before and after the start of regular TCZ therapy. 
Dashed lines represent the mean. Light grey shading represents the 95% margin of error of 
proportions. Red vertical line indicates date of first TCZ script. Group 1, 3-5 months with OCS; 
Group 2, 6-11 months with OCS; Group 3, 12-24 months with OCS. B, baseline phase; OCS, oral 
corticosteroids; T, treatment phase. 
Frequency of asthma prescriptions before and after the start of adalimumab therapy 
To determine the extent to which the results above were specific to TCZ therapy, we analysed data 
from subjects who started regular treatment with adalimumab (ADA) – another monoclonal antibody 
used to treat RA – instead of TCZ.  
We found that the effect of ADA treatment on the frequency of ICS (Figure 7.6), salbutamol (Figure 
7.7) and OCS (Figure 7.8) was very similar to that observed with TCZ. The only exception was that 
OCS prescriptions decreased during the treatment phase in all three case groups, including those with 
highest use of OCS (Group3). Thus, as for TCZ, our results suggest that ADA therapy results in a 
significant improvement in RA symptoms which prompts the reduction in OCS prescriptions. The 
lack of a significant effect on the frequency of medications that are typically used to treat asthma 
(ICS and salbutamol) suggests that ADA too (as TCZ) does not significantly influence asthma 
symptoms. 
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Figure 7.6. Number of ICS prescriptions (A) and proportion of patients with ICS prescriptions 
(B) before and after the start of regular adalimumab therapy.  
Dashed lines represent the mean. Light grey shading represents the 95% margin of error of 
proportions. Red vertical line indicates date of first adalimumab script. Group 1, 3-5 months with 
ICS; Group 2, 6-11 months with ICS; Group 3, 12-24 months with ICS. B, baseline phase; ICS, 
inhaled corticosteroids; T, treatment phase. 
 
Figure 7.7. Number of salbutamol prescriptions (A) and proportion of patients with salbutamol 
prescriptions (B) before and after the start of regular adalimumab therapy.  
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Dashed lines represent the mean. Light grey shading represents the 95% margin of error of 
proportions. Red vertical line indicates date of first adalimumab script. Group 1, 3-5 months with 
salbutamol; Group 2, 6-11 months with salbutamol; Group 3, 12-24 months with salbutamol. B, 
baseline phase; T, treatment phase. 
 
Figure 7.8. Number of OCS prescriptions (A) and proportion of patients with OCS 
prescriptions (B) before and after the start of regular adalimumab therapy.  
Dashed lines represent the mean. Light grey shading represents the 95% margin of error of 
proportions. Red vertical line indicates date of first adalimumab script. Group 1, 3-5 months with 
OCS; Group 2, 6-11 months with OCS; Group 3, 12-24 months with OCS. B, baseline phase; OCS, 
oral corticosteroids; T, treatment phase. 
Frequency of asthma prescriptions before and after the start of therapy with a stronger asthma 
medication 
Lastly, we determined if our study design was indeed able to identify a change in the frequency of 
asthma-related prescriptions when such an effect was expected. To this end, we analysed the 
frequency of prescriptions for a particular asthma treatment (e.g. salbutamol) before and after the 
onset of stronger asthma treatment (e.g. ICS). For example, after the start of ICS, which help prevent 
asthma symptoms, we hypothesised that the frequency of salbutamol prescriptions would decrease. 
Unexpectedly, we observed that the number of salbutamol prescriptions increased markedly after the 
start of ICS treatment, in all three case groups considered (Figure 7.9 A). For example, in Group 1, 
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the proportion of patients with salbutamol scripts per month increased from 8% to 25%, whereas 
marginal increases (16% to 17%) were observed in matched controls (Figure 7.9 B). Notably, the 
number of salbutamol prescriptions was consistently higher in the baseline phase in matched controls, 
who by definition did not start ICS treatment (Table 7.3). A similar pattern of results was observed 
when we assessed the effect of OCS therapy on the frequency of ICS prescriptions (Figure 7.10 A). 
Possible explanations for this unexpected finding are discussed below. 
 
Figure 7.9. Number of salbutamol prescriptions (A) and proportion of patients with salbutamol 
prescriptions (B) before and after the start of regular ICS therapy.  
Dashed lines represent the mean. Light grey shading represents the 95% margin of error of 
proportions. Red vertical line indicates date of first ICS script. Group 1, 3-5 months with salbutamol; 
Group 2, 6-11 months with salbutamol; Group 3, 12-24 months with salbutamol. B, baseline phase; 
ICS, inhaled corticosteroids; T, treatment phase. 
  
Number or prescriptions 
in baseline phase  
Intervention drug Outcome drug Group Cases 
Matched 
controls P-value 
TCZ ICS 1 1.89 2.17 0.3572 
  2 5.23 4.32 0.2251 
  3 9.45 9.76 0.8507 
 Salbutamol 1 2.86 1.81 0.0417 
  2 4.53 4.41 0.4338 
  3 8.75 10.43 0.4415 
 OCS 1 3.48 2.31 9 x 10
-10 
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  2 5.88 5.11 0.0100 
  3 11.63 10.83 0.0572 
ADA ICS 1 2.02 2.02 0.7636 
  2 4.12 4.27 0.8018 
  3 9.11 8.96 0.7854 
 Salbutamol 1 2.15 2.01 0.4735 
  2 4.37 4.98 0.3738 
  3 9.87 11.02 0.3696 
 OCS 1 3.01 2.2 2 x 10
-12 
  2 6.26 5.06 3 x 10
-9 
  3 11.46 10.29 0.0001 
ICS Salbutamol 1 1.07 2.15 1 x 10-89 
  2 2.07 4.55 8 x 10
-195 
  3 10.46 10.03 0.5854 
OCS ICS 1 1.88 2.14 0.0216 
  2 4.08 4.66 0.0001 
  3 9.27 9.5 0.8662 
Table 7.3. Comparison of average number of prescriptions in the baseline phase, between cases 
and matched controls. 
Group 1, 3-5 months with outcome drug; Group 2, 6-11 months with outcome drug; Group 3, 12-24 
months with outcome drug. ADA, adalimumab; ICS, inhaled corticosteroids; OCS, oral 
corticosteroids; TCZ, tocilizumab. 
Discussion 
In the current study, we used a nation-wide database of medical prescriptions to analyse the effect of 
long-term exposure to TCZ on the frequency of asthma prescriptions, as an indirect measure of 
asthma symptoms. 
ICS were prioritized as the main outcome in our analyses, as this class of drugs is primarily used to 
treat asthma and COPD patients. To enrich our case group for patients with asthma, we excluded 
patients who had ever been prescribed tiotropium, a drug specifically used for the treatment of COPD. 
We identified 88 patients who started regular TCZ therapy and who were regularly prescribed ICS. 
In this cohort, there were no differences in the frequency of ICS use before and after TCZ onset. As 
discussed in the previous chapter, this may be a consequence of the administration route currently 
used to deliver TCZ, which may not be adequate to target the airways, and consequently, might not 
provide symptom relieve. 
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Figure 7.10. Number of ICS prescriptions (A) and proportion of patients with ICS prescriptions 
(B) before and after the start of regular OCS therapy.  
Dashed lines represent the mean. Light grey shading represents the 95% margin of error of 
proportions. Red vertical line indicates date of first OCS script. Group 1, 3-5 months with ICS; Group 
2, 6-11 months with ICS; Group 3, 12-24 months with ICS. B, baseline phase; ICS, inhaled 
corticosteroids; OCS, oral corticosteroids; T, treatment phase. 
On the other hand, we observed a significant decrease in oral steroid use after the start of TCZ 
treatment. OCS are anti-inflammatory drugs that are prescribed to asthma patients with severe, hard-
to-control symptoms. However, OCS are also used to treat other conditions such as arthritis, severe 
allergies and skin conditions. Thus, unlike ICS, these data could potentially represent treatments for 
conditions other than asthma. Indeed, previous studies that evaluated the efficacy of TCZ in various 
forms of arthritis, including RA and systemic juvenile idiopathic arthritis (two conditions that are 
currently treated with TCZ), have shown that OCS use decreases in patients treated with TCZ.298-300 
Thus, it is likely that the decreases in number of OCS prescriptions that we observed in our study 
corresponded to a decrease in OCS use by arthritis patients who were OCS-users and became less 
dependent on these drugs after TCZ onset. This is further corroborated by the observation that the 
start of therapy with ADA – another drug used to treat arthritis – was also accompanied by a decreased 
in OCS use.   
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The study design used here was able to detect plausible changes in the frequency of use of arthritis 
treatments after the start of TCZ and ADA – two biologic agents used to treat more severe cases of 
disease. To determine whether similar changes would be observed in asthma treatment plans after the 
introduction of stronger asthma medications, we also assessed the patterns of salbutamol use before 
and after the start of ICS treatment. ICS are preventer drugs used to control asthma symptoms. 
Typically, these medications are prescribed as-needed or when regular use of reliever medications is 
not sufficient to control asthma symptoms. We expected ICS onset to result in an improvement in 
symptom control and, consequently, to be associated with a decrease in the use of reliever drugs, such 
as salbutamol. Instead, we observed a large increase in the frequency of salbutamol prescriptions after 
the start of regular ICS treatment. Interestingly, these increases were not observed in matched 
controls, who had higher rates of ICS use in the baseline phase. These observations suggest that, in 
controls, regular use of reliever medication contributed to well-controlled asthma, and consequently 
no step-up was required in their treatment plan. This hypothesis is corroborated by extensive evidence 
that treatment adherence is associated with a decreased frequency of asthma symptoms.301-304 On the 
other hand, patients who required adding ICS to their treatment plan were likely to have experienced 
a worsening of symptoms due to poor-controlled asthma, in which case medical advice would have 
been sought. This hypothesis is supported by the fact that the increase in salbutamol use started before 
ICS onset. On the other hand, the sharp increase in salbutamol use coinciding with the first ICS dose, 
suggests that the use of reliever medication was part of a new treatment plan outlined by a clinician. 
Another possibility is that, when compared to matched controls, individuals who started ICS 
treatment were more likely to be asymptomatic (rather than have poorly-controlled symptoms) during 
the baseline period.  
An appropriate negative control for our analyses would have been a group of individuals not likely 
to have asthma but with records of asthma prescriptions (e.g. ICS). This would allow us to assess the 
effect of TCZ on the frequency of asthma-related prescriptions. Our approach to select asthma 
patients was to select individuals treated with asthma prescriptions and exclude individuals with 
tiotropium prescriptions, as those are exclusively prescribed to COPD patients. Thus, using the same 
criteria, a control group taking asthma prescriptions and TCZ but not likely to have asthma would 
include the subjects with tiotropium prescriptions (not exclude them), i.e. COPD patients. 
Unfortunately, this is not a good negative control because, as for asthma, there is compelling evidence 
that the IL-6 trans-signalling pathway may contribute to the pathophysiology of COPD.256,305,306 Thus, 
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TCZ could potentially have the same effects in the use of medications like ICS in the group of ‘likely 
asthmatics’ and the group of ‘likely non-asthmatics’. 
Instead, our negative control were individuals that were likely to be asthmatics and who started 
regular therapy with ADA (instead of TCZ). We recognise that this is not a perfect negative control. 
Single-case reports have provided evidence of asthma-like symptoms in RA patients  after the onset 
of ADA therapy.307-309 Thus, asthma may be an adverse event of ADA therapy. Importantly, the 
patients in these reports were treated with asthma medications, including ICS and salbutamol, so if 
our analyses included cases like these our results could be biased. Nevertheless, ADA was tested in 
thousands of patients with different conditions (including RA, juvenile idiopathic arthritis, psoriatic 
arthritis, psoriasis, ulcerative colitis, ankylosing spondylitis, and Crohn's disease) and asthma was not 
a common adverse event in those studies.310 In RA clinical trials, common adverse events reported 
(> 10% incidence) included infections, injection site reactions, headaches and rashes.311-315 More 
importantly, the incidence at which asthma-related symptoms were reported in these studies was less 
than 5%.316 Thus, we performed our analyses based on the assumption that the low incidence of these 
cases would not affect our results. We did not observe any increases in asthma prescriptions after the 
onset of adalimumab therapy. Thus, it is unlikely that cases like the ones mentioned above biased our 
results. 
A few considerations need to be taken when interpreting the results of this study. First, it is important 
to note that the results presented here are exclusively based on medical prescription data. Thus, case 
ascertainment may not be as specific as if diagnostic information were available. In addition, when 
assessing the changes in medical prescriptions, it is important to note that prescription data may not 
be an exact representation of drug use. Second, the study design that we used is more likely to detect 
upgrades in asthma treatment than downgrades or no changes, as patients are more likely to visit the 
doctor (and so to be prescribed ICS or OCS) when their symptoms worsen. In addition, while 
clinicians aim to prescribe the lowest doses required to control patient symptoms, there is typically 
greater caution when reducing treatment. Nevertheless, the results obtained for OCS use suggest that 
this study design can be used to monitor long-term drug effects on the condition they were approved 
for.  
In conclusion, our results suggest that long-term treatment with TCZ does not improve (or worsen) 
asthma symptoms, assessed through the number and frequency of use of ICS and salbutamol 
prescriptions. 
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CONCLUSION 
The overall goal of this dissertation was to evaluate the role of the IL-6 signalling pathway in asthma 
and to evaluate whether its blockade represents a potential new treatment option for asthma. 
Specifically, four main questions were addressed: 
1. What characterises asthma patients who are likely to benefit from anti-IL-6R therapy?  
2. Is IL-6 trans-signalling more likely to be promoted by some allergen types?  
3. Are there other genes that associate with IL-6 signalling that are also risk factors for asthma?  
4. Can asthma symptoms be attenuated by a drug that blocks IL-6 signalling? 
This section presents a synthesis of how each research question was addressed and outlines the main 
findings and implications of each study.  
Chapter 2: What characterises asthma patients who are likely to benefit from anti-IL-6R 
therapy? 
Overview: Previous studies suggested that blockade of the IL-6 pathway could represent a new 
treatment option for asthma. Tocilizumab – a drug that blocks IL-6R – was already approved to treat 
a different condition, and so represented the ideal candidate to test this hypothesis in a phase IIA (i.e. 
proof-of-concept) clinical trial of asthma. Phase IIA trials are designed to assess the efficacy of a 
given drug in a selected disease or condition. Typically, these studies have small sample sizes to 
reduce patient exposure to unexpected drugs effects that might be specific (or more common) in a 
patient group for which the drug was not developed for. It is at this stage of drug development that 
most drugs fail to show a clinically significant effect in the disease that they were originally designed 
for.317,318 An approach that can increase the success rate of phase II trials is to test drugs in a selected 
group of patients who are most likely to respond to the new intervention. The first aim of this thesis 
was to identify the group of asthmatics most likely to benefit from anti-IL-6R therapy, as this 
information could then help design subsequent phase II trials of tocilizumab. A key strength of this 
study was the use of a combined phenotype that integrated information from both IL-6 and sIL-6R 
levels (the two key components of IL-6 trans-signalling) measured in sputum. As previously noted, 
using multivariate approaches and well defined phenotypes is essential to identify the subsets of 
asthma patients that are more likely to respond to specific treatments. 
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Main findings and conclusions: High levels of IL-6 and sIL-6R in sputum were observed more 
frequently in asthmatics with neutrophilic or mixed granulocytic airway inflammation. Therefore, 
asthma exacerbations are likely to include activation of IL-6 trans-signalling in patients with a sputum 
subtype that is rich in neutrophils. Sputum neutrophilia is associated with more severe 
symptoms,139,319 and so anti-IL-6R treatments might be useful to treat patients who have the greatest 
need for new therapies. The small sample size of the cohort analysed, and the potential effect of DTT 
in sputum cytokine measurements are caveats of this study. Nevertheless, our results are in line with 
recent observations that patients with a gene signature of IL-6 trans-signalling activation in the 
airways produce sputum rich in eosinophils and neutrophils.134 
Future directions: The association between neutrophil-rich airway inflammation and IL-6 
trans-signalling should be validated in patients with severe asthma. Future studies are also needed to 
identify biomarkers of IL-6 trans-signalling in the airways. 
Chapter 3: Is IL-6 trans-signalling more likely to be promoted by some allergen types? 
Overview: Mice exposed to cockroach but not house-dust mite (HDM) allergens develop airway 
inflammation that includes neutrophilia and activation of IL-6 trans-signalling.33 In this chapter, we 
tested if this observation might also extend to humans. Specifically, we compared the frequency of 
sputum inflammatory subtypes between asthmatics (n = 129) exposed to different allergens in 
inhalation challenge tests performed in previous clinical trials. Five allergen types were represented: 
the house dust mites Dermatophagoides pteronyssinus and Dermatophagoides farinae, ragweed, 
grass, and cat. The breadth of allergens tested and the reasonable sample size in which each one was 
tested is a key strength of this study. 
Main findings and conclusions: We found no significant differences in the frequency of sputum 
inflammatory subtypes between different allergen types. Thus, unlike reported in mice, our findings 
indicate that in humans the sputum inflammatory subtype observed after an allergen-induced asthma 
exacerbation is unlikely to be influenced by the type of allergen use. Together with our previous 
findings (Chapter 2), these results suggest that activation of IL-6 trans-signalling in human airways 
is not triggered more frequently by a specific allergen type. 
Future directions: A major caveat of this study was that sputum levels of IL-6 and sIL-6R were not 
measured in the original clinical trials. This can be addressed in future studies that directly test 
whether airway IL-6 trans-signalling is associated with exposure to different allergens. Ideally, these 
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studies should be based on a repeated-measures design to minimize the effect of potential 
confounders; that is, IL-6 and sIL-6R levels should be measured in the same individuals after 
exposure to different allergens. 
Chapters 4 and 5: Are there other genes that associate with IL-6 signalling that are also risk 
factors for asthma? 
Overview: Despite extensive evidence supporting the involvement of the IL-6 signalling pathway in 
asthma, little was known about the extent to which the IL-6 pathway also included other genes whose 
expression might also have a causal role in disease pathophysiology. In Chapters 4 and 5 we tested 
the hypothesis that genes related to IL-6 signalling (other than IL6R) also harbour risk variants for 
asthma. Specifically, we first searched for genes that satisfied two criteria (Chapter 4): (i) gene 
expression associated with IL6R expression; and (ii) gene expression associated with a SNP that was 
also associated with asthma risk. We then studied the association between a SNP of interest and 
asthma risk in an independent study (Chapter 5). A key strength these analyses were the different 
levels of evidence that linked the genes to asthma and the IL-6 signalling. Namely, genes expression 
levels (measured across different cell types and different individuals), eQTL studies and three 
independent asthma GWAS. 
Main findings and conclusions: We identified five genes that satisfied both criteria: IL18R1, 
IL18RAP, BCL6, STAT6 and STOML2 (Chapter 4). Of these, the latter represents a potential new 
player in asthma pathophysiology, with a known role in T-cell activation. We noted that CD4+ T cells 
of healthy individuals have high expression of IL6R and low expression of STOML2. On the other 
hand, SNPs that increased the expression of STOML2 were associated with an increased risk of 
asthma and hay fever, most notably amongst individuals with early disease onset (Chapter 5). Based 
on these observations, we postulated that high expression of both IL6R and STOML2 might result in 
stronger T-cell responses to allergens, thereby increasing asthma risk.  
Future directions: Functional studies are required to (1) validate the contribution of STOML2 to IL-
6 signalling; and (2) test our prediction that high expression of both IL6R and STOML2 results in 
stronger T-cell responses. 
Chapters 6 and 7: Can asthma symptoms be attenuated by a drug that blocks IL-6 signalling? 
Overview: The final question addressed in this thesis was whether blockade of the IL-6 signalling 
pathway with tocilizumab could potentially attenuate asthma symptoms. First, we analysed results 
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from a clinical trial that evaluated the safety and efficacy of a single dose of tocilizumab in allergen-
induced responses. Eleven patients with mild allergic asthma were randomized to receive an 
intravenous infusion of either tocilizumab (n = 6) or placebo (n = 5). Participants performed an 
allergen inhalation challenge test before and after infusion. Then, allergen-induced responses were 
compared before and after tocilizumab. Second, we analysed data from the Pharmaceutical Benefits 
Scheme (PBS) to assess the effect of regular tocilizumab treatment on the frequency of asthma-related 
prescriptions, the latter used as a proxy for the severity of asthma symptoms.  
Main findings and conclusions: Results from the clinical trial showed that tocilizumab was well 
tolerated but did not significantly attenuate allergen-induced bronchoconstriction. However, of note, 
the only individual who did not develop a late asthmatic response after treatment was in the 
tocilizumab group, had the rs4129267:TT genotype, mixed granulocytic sputum, and high sputum 
levels of IL-6 and sIL-6R. The latter observation broadly supports findings from previous chapters 
that anti-IL-6R therapy might be effective in attenuating an inflammatory response that includes 
activation of IL-6 trans-signalling. The study design used is particularly strong as it used screening 
measurements to correct for intra-individual variability that is unrelated to the investigational drug, 
and a placebo control group to distinguish drug-specific effects. On the other hand, the study was 
limited by the drug selected to block IL-6 signalling (tocilizumab), as it blocks two pathways 
(classical and trans-signalling pathway) that may have opposing effects in inflammatory 
responses.32,33,40,41 In addition, mounting evidence supports the association between severe asthma 
and the IL-6 pathway.26,102,103 Thus, a limitation of our study was the inability to test the effect of 
tocilizumab in patients with more severe asthma. Results from the PBS study demonstrated that, in 
individuals who were likely to suffer from asthma as well as rheumatoid arthritis, regular treatment 
with tocilizumab was not associated with a significant change in the frequency of ICS or salbutamol 
prescriptions. This suggests that regular tocilizumab treatment does not significantly attenuate or 
exacerbate asthma symptoms. In this analysis, cases likely included patients with more severe asthma. 
However, since the analysis was exclusively based on medical prescription data, we had no means of 
confirming our definitions of cases and controls, and the patterns of prescriptions analysed may not 
be an exact representation of medication use. 
Future directions: Results from our clinical trial can be used to help design future trials with more 
refined hypotheses. For example, these could focus on drugs that specifically block IL-6 
trans-signalling (e.g. olamkicept), and/or specifically address the possibility that anti-IL-6R therapy 
Conclusion 
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is only effective in patients with rs4129267:TT genotype and mixed-granulocytic sputum subtype 
after challenge. 
Overall conclusion 
Collectively, the studies described in this thesis have (1) increased our understanding of how IL-6 
signalling may contribute to asthma pathophysiology; and (2) provided new insights that can inform 
the design of future clinical studies of anti-IL-6R therapies in asthma. 
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APPENDIX 
Supplementary Tables 
Supplementary Table 3.1. Sputum inflammatory subtypes observed before (-24 h) and after     
(7 h and 24 h) allergen inhalation challenge. 
N/A, no sputum sample available. 
Participant -24 h 7 h 24 h Allergen 
1 Eosinophilic Eosinophilic Eosinophilic Cat 
2 Eosinophilic Eosinophilic Eosinophilic Cat 
3 Eosinophilic Eosinophilic Eosinophilic Cat 
4 Eosinophilic Eosinophilic Eosinophilic Cat 
5 Eosinophilic Eosinophilic Eosinophilic Cat 
6 Eosinophilic Eosinophilic Eosinophilic Cat 
7 Eosinophilic Eosinophilic Eosinophilic Cat 
8 Eosinophilic Eosinophilic Eosinophilic Cat 
9 Eosinophilic Eosinophilic Eosinophilic Cat 
10 Eosinophilic Eosinophilic Eosinophilic Cat 
11 Eosinophilic Eosinophilic Eosinophilic Cat 
12 Eosinophilic Eosinophilic Eosinophilic Cat 
13 Eosinophilic Eosinophilic Eosinophilic Cat 
14 Eosinophilic Eosinophilic Eosinophilic Cat 
15 Eosinophilic Eosinophilic Eosinophilic Cat 
16 Eosinophilic Eosinophilic Eosinophilic Grass 
17 Eosinophilic Eosinophilic Eosinophilic Grass 
18 Eosinophilic Eosinophilic Eosinophilic Grass 
19 Eosinophilic Eosinophilic Eosinophilic Grass 
20 Eosinophilic Eosinophilic Eosinophilic HDMDF 
21 Eosinophilic Eosinophilic Eosinophilic HDMDF 
22 Eosinophilic Eosinophilic Eosinophilic HDMDF 
23 Eosinophilic Eosinophilic Eosinophilic HDMDP 
24 Eosinophilic Eosinophilic Eosinophilic HDMDP 
25 Eosinophilic Eosinophilic Eosinophilic HDMDP 
26 Eosinophilic Eosinophilic Eosinophilic HDMDP 
27 Eosinophilic Eosinophilic Eosinophilic HDMDP 
28 Eosinophilic Eosinophilic Eosinophilic HDMDP 
29 Eosinophilic Eosinophilic Eosinophilic HDMDP 
30 Eosinophilic Eosinophilic Eosinophilic Ragweed 
31 Eosinophilic Eosinophilic Eosinophilic Ragweed 
32 Eosinophilic Eosinophilic Mixed granulocytic Grass 
33 Eosinophilic Eosinophilic Mixed granulocytic HDMDP 
34 Eosinophilic Eosinophilic Paucigranulocytic HDMDF 
35 Eosinophilic Mixed granulocytic Eosinophilic Cat 
36 Eosinophilic Mixed granulocytic Eosinophilic Cat 
37 Eosinophilic Mixed granulocytic Eosinophilic Cat 
38 Eosinophilic Mixed granulocytic Eosinophilic Cat 
39 Eosinophilic Mixed granulocytic Eosinophilic Grass 
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40 Eosinophilic Mixed granulocytic Eosinophilic HDMDF 
41 Eosinophilic Mixed granulocytic Eosinophilic HDMDP 
42 Eosinophilic Mixed granulocytic Eosinophilic HDMDP 
43 Eosinophilic Mixed granulocytic Eosinophilic HDMDP 
44 Eosinophilic Mixed granulocytic Eosinophilic HDMDP 
45 Eosinophilic Mixed granulocytic Eosinophilic HDMDP 
46 Eosinophilic Mixed granulocytic Mixed granulocytic Cat 
47 Eosinophilic Mixed granulocytic Mixed granulocytic HDMDF 
48 Eosinophilic Mixed granulocytic Mixed granulocytic HDMDP 
49 Eosinophilic Mixed granulocytic Mixed granulocytic HDMDP 
50 Eosinophilic N/A Eosinophilic Grass 
51 Eosinophilic N/A Eosinophilic HDMDP 
52 Mixed granulocytic Eosinophilic Eosinophilic Cat 
53 Mixed granulocytic Eosinophilic Eosinophilic HDMDP 
54 Mixed granulocytic Eosinophilic Eosinophilic HDMDP 
55 Mixed granulocytic Eosinophilic Mixed granulocytic Cat 
56 Mixed granulocytic Eosinophilic Mixed granulocytic Cat 
57 Mixed granulocytic Eosinophilic Mixed granulocytic HDMDP 
58 Mixed granulocytic Mixed granulocytic Mixed granulocytic Cat 
59 Mixed granulocytic Mixed granulocytic Mixed granulocytic Grass 
60 Mixed granulocytic Mixed granulocytic Mixed granulocytic Ragweed 
61 Mixed granulocytic Mixed granulocytic Mixed granulocytic Ragweed 
62 Mixed granulocytic N/A Eosinophilic Grass 
63 Neutrophilic Eosinophilic Eosinophilic HDMDF 
64 Neutrophilic Eosinophilic Eosinophilic Ragweed 
65 Neutrophilic Eosinophilic Paucigranulocytic HDMDF 
66 Neutrophilic Mixed granulocytic Eosinophilic HDMDF 
67 Neutrophilic Mixed granulocytic Eosinophilic HDMDP 
68 Neutrophilic Mixed granulocytic Mixed granulocytic Cat 
69 Neutrophilic Mixed granulocytic Mixed granulocytic Grass 
70 Neutrophilic Mixed granulocytic Mixed granulocytic HDMDP 
71 Neutrophilic Mixed granulocytic Mixed granulocytic HDMDP 
72 Neutrophilic Mixed granulocytic N/A Ragweed 
73 Neutrophilic Neutrophilic Neutrophilic Grass 
74 Paucigranulocytic Eosinophilic Eosinophilic Cat 
75 Paucigranulocytic Eosinophilic Eosinophilic Cat 
76 Paucigranulocytic Eosinophilic Eosinophilic Cat 
77 Paucigranulocytic Eosinophilic Eosinophilic Cat 
78 Paucigranulocytic Eosinophilic Eosinophilic Cat 
79 Paucigranulocytic Eosinophilic Eosinophilic Cat 
80 Paucigranulocytic Eosinophilic Eosinophilic Grass 
81 Paucigranulocytic Eosinophilic Eosinophilic Grass 
82 Paucigranulocytic Eosinophilic Eosinophilic HDMDP 
83 Paucigranulocytic Eosinophilic Eosinophilic HDMDP 
84 Paucigranulocytic Eosinophilic Eosinophilic HDMDP 
85 Paucigranulocytic Eosinophilic Eosinophilic HDMDP 
86 Paucigranulocytic Eosinophilic Eosinophilic HDMDP 
87 Paucigranulocytic Eosinophilic Eosinophilic HDMDP 
88 Paucigranulocytic Eosinophilic Eosinophilic HDMDP 
Appendix 
The Role of the Interleukin-6 Pathway in Asthma | 157 
89 Paucigranulocytic Eosinophilic Eosinophilic Ragweed 
90 Paucigranulocytic Eosinophilic Eosinophilic Ragweed 
91 Paucigranulocytic Eosinophilic Eosinophilic Ragweed 
92 Paucigranulocytic Eosinophilic Eosinophilic Ragweed 
93 Paucigranulocytic Eosinophilic Mixed granulocytic Grass 
94 Paucigranulocytic Eosinophilic N/A Ragweed 
95 Paucigranulocytic Mixed granulocytic Eosinophilic Cat 
96 Paucigranulocytic Mixed granulocytic Eosinophilic Cat 
97 Paucigranulocytic Mixed granulocytic Eosinophilic Cat 
98 Paucigranulocytic Mixed granulocytic Eosinophilic Grass 
99 Paucigranulocytic Mixed granulocytic Eosinophilic Grass 
100 Paucigranulocytic Mixed granulocytic Eosinophilic Grass 
101 Paucigranulocytic Mixed granulocytic Eosinophilic Grass 
102 Paucigranulocytic Mixed granulocytic Eosinophilic Grass 
103 Paucigranulocytic Mixed granulocytic Eosinophilic HDMDF 
104 Paucigranulocytic Mixed granulocytic Eosinophilic HDMDP 
105 Paucigranulocytic Mixed granulocytic Eosinophilic HDMDP 
106 Paucigranulocytic Mixed granulocytic Eosinophilic HDMDP 
107 Paucigranulocytic Mixed granulocytic Eosinophilic HDMDP 
108 Paucigranulocytic Mixed granulocytic Eosinophilic Ragweed 
109 Paucigranulocytic Mixed granulocytic Mixed granulocytic Grass 
110 Paucigranulocytic Mixed granulocytic Mixed granulocytic HDMDP 
111 Paucigranulocytic Mixed granulocytic Neutrophilic Ragweed 
112 Paucigranulocytic Mixed granulocytic Paucigranulocytic HDMDP 
113 Paucigranulocytic Mixed granulocytic N/A Cat 
114 Paucigranulocytic Paucigranulocytic Eosinophilic HDMDP 
115 Paucigranulocytic Paucigranulocytic Eosinophilic Ragweed 
116 Paucigranulocytic Paucigranulocytic Paucigranulocytic HDMDP 
117 Paucigranulocytic Paucigranulocytic Paucigranulocytic Ragweed 
118 Paucigranulocytic N/A Mixed granulocytic Cat 
119 N/A Eosinophilic Eosinophilic Cat 
120 N/A Eosinophilic Eosinophilic HDMDF 
121 N/A Eosinophilic Eosinophilic HDMDP 
122 N/A Eosinophilic N/A HDMDP 
123 N/A Mixed granulocytic Mixed granulocytic Grass 
124 N/A Mixed granulocytic Mixed granulocytic HDMDF 
125 N/A Paucigranulocytic Eosinophilic Cat 
126 N/A Paucigranulocytic Eosinophilic Cat 
127 N/A Paucigranulocytic Eosinophilic Ragweed 
128 N/A N/A Eosinophilic Grass 
129 N/A N/A N/A HDMDP 
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Supplementary Table 4.1. 2,203 genes co-expressed with IL6R in the GEUVADIS and DMAP 
studies. 
Abbreviations: Chr, chromosome; Cor, correlation. 
  Geuvadis DMAP 
Gene Chr Cor P-value Cor P-value 
FYN 6 -0.236 3.95E-06 0.413 4.14E-10 
CD180 5 0.234 4.70E-06 0.181 0.0083 
ATP8B2 1 0.230 6.89E-06 0.027 0.6949 
NEURL3 2 0.230 7.52E-06 NA NA 
CCL22 16 0.221 1.59E-05 0.056 0.4144 
CASK-AS1 X 0.219 1.95E-05 NA NA 
SYBU 8 0.213 3.27E-05 NA NA 
TRIM47 17 0.211 3.92E-05 NA NA 
FAM104A 17 -0.207 5.49E-05 NA NA 
CACNA1A 19 0.206 6.11E-05 -0.313 3.62E-06 
NCR2 6 -0.205 6.90E-05 NA NA 
TBKBP1 17 -0.203 7.71E-05 NA NA 
IL18R1 2 -0.202 8.25E-05 -0.008 0.9073 
RNF213 17 0.199 0.0001 NA NA 
KYNU 2 0.197 0.0001 0.262 0.0001 
KLF10 8 0.196 0.0001 0.023 0.7387 
RARRES3 11 0.193 0.0002 0.175 0.0110 
FAM65B 6 0.193 0.0002 NA NA 
B3GNT2 2 -0.193 0.0002 -0.335 6.45E-07 
ITM2C 2 0.193 0.0002 -0.179 0.0092 
RGS2 1 -0.191 0.0002 0.237 0.0005 
BCL9L 11 0.189 0.0002 NA NA 
DPYSL2 8 0.188 0.0003 0.186 0.0066 
NCK2 2 0.188 0.0003 0.195 0.0045 
SPSB1 1 0.188 0.0003 NA NA 
CISH 3 0.187 0.0003 0.318 2.51E-06 
ATPIF1 1 -0.185 0.0003 -0.042 0.5476 
CUEDC1 17 0.185 0.0003 0.084 0.2216 
STX5 11 -0.184 0.0004 0.097 0.1605 
RIN3 14 -0.183 0.0004 0.357 9.63E-08 
EEF1A1P38 16 0.182 0.0004 NA NA 
GFPT1 2 -0.182 0.0004 0.114 0.0984 
ARHGAP11A 15 -0.181 0.0004 -0.123 0.0748 
RPL3P9 8 0.180 0.0005 NA NA 
MOXD1 6 -0.180 0.0005 -0.174 0.0115 
KLHL29 2 0.180 0.0005 NA NA 
PLCL2 3 -0.180 0.0005 0.068 0.3232 
ZNF697 1 0.179 0.0005 NA NA 
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AHNAK 11 0.179 0.0005 0.238 0.0005 
CBLB 3 -0.178 0.0006 -0.010 0.8903 
HIPK2 7 0.178 0.0006 -0.063 0.3610 
ZFP91 11 -0.177 0.0006 NA NA 
CPNE5 6 0.177 0.0006 NA NA 
ITPR3 6 0.176 0.0006 -0.031 0.6506 
KLF2 19 0.175 0.0007 0.275 5.27E-05 
EPS8 12 0.175 0.0007 0.429 7.80E-11 
PTGIR 19 0.175 0.0007 NA NA 
FAM8A1 6 0.175 0.0007 0.093 0.1802 
SLC25A5P5 7 0.173 0.0008 NA NA 
MAP3K5 6 -0.172 0.0009 0.261 0.0001 
VDR 12 0.171 0.0009 0.391 4.15E-09 
TBX21 17 -0.171 0.0009 -0.175 0.0107 
ZNF329 19 -0.171 0.0009 -0.080 0.2486 
BICD1 12 0.171 0.0009 -0.310 4.39E-06 
CORO1B 11 0.171 0.0009 0.469 6.50E-13 
CEACAM1 19 0.171 0.0009 0.185 0.0071 
ZNF84 12 -0.170 0.0010 -0.053 0.4419 
LIMK1 7 -0.170 0.0010 0.040 0.5633 
COLGALT2 1 0.169 0.0010 NA NA 
HNF4G 8 0.169 0.0010 NA NA 
SLC25A37 8 0.169 0.0010 -0.090 0.1945 
ZNF570 19 -0.169 0.0010 NA NA 
LRRC32 11 0.169 0.0010 NA NA 
SLC25A32 8 -0.169 0.0011 0.002 0.9769 
MPZL2 11 0.169 0.0011 NA NA 
MSN X 0.169 0.0011 0.180 0.0087 
AQR 15 0.168 0.0011 0.209 0.0023 
UBAC2 13 -0.168 0.0012 NA NA 
SAMSN1 21 -0.167 0.0012 0.333 7.46E-07 
AP3D1 19 -0.167 0.0012 0.184 0.0074 
PSIP1 9 -0.167 0.0012 -0.012 0.8620 
RPL5P35 22 0.167 0.0012 NA NA 
MFHAS1 8 0.166 0.0013 -0.024 0.7248 
EEF1A1P14 1 0.166 0.0013 NA NA 
PRKCH 14 -0.165 0.0014 0.155 0.0243 
APBB1IP 10 0.165 0.0014 0.288 2.19E-05 
RPL7AP31 4 0.165 0.0014 NA NA 
SEMA4B 15 0.165 0.0014 NA NA 
TMCC2 1 0.164 0.0015 -0.171 0.0128 
MYL12AP1 8 0.164 0.0015 NA NA 
ARID3A 19 0.162 0.0017 0.091 0.1877 
FECH 18 -0.162 0.0018 -0.188 0.0063 
FAM46C 1 0.161 0.0018 -0.301 8.60E-06 
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TBC1D23 3 -0.161 0.0018 NA NA 
ANKRD33B 5 0.161 0.0018 NA NA 
CTSZ 20 0.161 0.0019 0.210 0.0021 
UFL1 6 -0.161 0.0019 NA NA 
TOMM70A 3 -0.160 0.0019 0.074 0.2816 
PLEKHM2 1 -0.160 0.0019 NA NA 
GPR18 13 -0.160 0.0019 0.189 0.0058 
G0S2 1 0.160 0.0020 0.302 8.23E-06 
MBOAT2 2 0.159 0.0021 -0.254 0.0002 
RAB37 17 -0.159 0.0021 NA NA 
BCL7A 12 0.158 0.0022 -0.360 7.78E-08 
CD1C 1 0.158 0.0023 0.300 9.24E-06 
CLINT1 5 0.158 0.0023 0.030 0.6605 
TLE1 9 0.158 0.0023 -0.305 6.50E-06 
CAMK2D 4 -0.156 0.0025 -0.001 0.9882 
ABCA5 17 -0.156 0.0025 -0.020 0.7723 
SORBS3 8 0.156 0.0025 NA NA 
SEMA6A 5 0.156 0.0025 -0.092 0.1835 
ECHS1 10 -0.156 0.0026 0.070 0.3123 
FEZ1 11 -0.155 0.0026 -0.018 0.7953 
ZFP41 8 0.155 0.0026 NA NA 
SMIM3 5 -0.155 0.0027 NA NA 
ERICH5 8 0.155 0.0027 NA NA 
RPL17P50 10 0.155 0.0027 NA NA 
FCHO1 19 0.154 0.0028 NA NA 
GOLGA6L5P 15 -0.154 0.0028 NA NA 
SYCP2 20 -0.154 0.0028 NA NA 
RPL7P26 6 0.154 0.0029 NA NA 
PABPC1P1 4 0.154 0.0029 NA NA 
BIRC3 11 0.154 0.0029 0.286 2.46E-05 
NAPSB 19 0.153 0.0030 NA NA 
C3orf20 3 -0.153 0.0030 NA NA 
RILPL2 12 -0.153 0.0031 NA NA 
RGS14 5 0.152 0.0032 0.340 4.32E-07 
F13A1 6 -0.152 0.0032 0.295 1.34E-05 
DNAH17 17 -0.152 0.0032 0.357 1.01E-07 
GHITM 10 -0.151 0.0035 0.012 0.8673 
GNGT2 17 -0.150 0.0036 0.212 0.0020 
CLSTN1 1 -0.150 0.0036 0.175 0.0109 
LAMB3 1 0.150 0.0037 NA NA 
FRMD3 9 0.150 0.0038 NA NA 
TM6SF1 15 -0.149 0.0038 0.292 1.59E-05 
SMIM10 X 0.149 0.0040 NA NA 
MAPK6PS3 13 -0.149 0.0040 NA NA 
GLUD2 X -0.149 0.0040 0.273 5.75E-05 
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EFNB2 13 0.149 0.0040 NA NA 
MYO1D 17 0.149 0.0040 NA NA 
FAM129C 19 0.148 0.0041 NA NA 
CDC42EP4 17 0.148 0.0042 -0.015 0.8234 
HCG27 6 0.148 0.0042 NA NA 
NUDT8 11 -0.147 0.0043 NA NA 
GBF1 10 -0.147 0.0043 -0.030 0.6657 
SLC14A1 18 -0.147 0.0044 -0.215 0.0017 
MYO5C 15 0.147 0.0045 -0.210 0.0022 
RBMS3 3 0.147 0.0045 NA NA 
NIPAL1 4 0.147 0.0046 NA NA 
CAPG 2 0.146 0.0046 0.274 5.35E-05 
POU5F1B 8 0.146 0.0046 NA NA 
MSNP1 5 0.146 0.0046 NA NA 
PARM1 4 0.146 0.0047 NA NA 
ALOX12-AS1 17 -0.146 0.0047 NA NA 
DSTYK 1 0.146 0.0048 NA NA 
ABI3 17 -0.146 0.0048 NA NA 
FZR1 19 -0.146 0.0048 -0.062 0.3693 
ATL1 14 0.145 0.0049 NA NA 
DNMBP-AS1 10 -0.145 0.0050 NA NA 
SLC25A19 17 0.145 0.0050 NA NA 
YRDC 1 -0.145 0.0051 -0.060 0.3880 
NPIPP1 16 -0.144 0.0052 NA NA 
CDC20P1 9 -0.144 0.0052 NA NA 
SESN3 11 0.144 0.0052 NA NA 
SIRPB1 20 0.144 0.0053 0.570 0 
ARHGAP31 3 0.144 0.0053 NA NA 
RPL3P1 21 0.144 0.0053 NA NA 
DPF3 14 -0.144 0.0053 NA NA 
HIST1H3PS1 6 0.144 0.0053 NA NA 
GLDC 9 0.144 0.0053 -0.084 0.2221 
PSD3 8 0.144 0.0053 -0.207 0.0025 
SOAT1 1 -0.144 0.0053 0.463 1.36E-12 
TPMT 6 0.144 0.0055 0.240 0.0004 
MGAT4A 2 0.143 0.0055 0.308 5.24E-06 
IL18RAP 2 -0.143 0.0057 -0.143 0.0373 
CREB3 9 -0.142 0.0059 NA NA 
NRD1 1 -0.142 0.0059 0.100 0.1470 
HLTF 3 -0.142 0.0059 -0.215 0.0017 
GLTPP1 11 -0.142 0.0060 NA NA 
NR3C1 5 0.142 0.0061 0.220 0.0013 
TCL6 14 0.141 0.0062 -0.176 0.0106 
RASGRP2 11 0.141 0.0064 0.131 0.0584 
ZNF425 7 0.141 0.0064 NA NA 
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CXCR5 11 0.141 0.0065 NA NA 
TBC1D17 19 -0.141 0.0065 NA NA 
RAP1GDS1 4 -0.141 0.0065 0.158 0.0218 
RBBP4P2 3 0.140 0.0067 NA NA 
HMGB3P6 1 -0.140 0.0067 NA NA 
ITM2A X -0.140 0.0067 -0.130 0.0591 
SIGIRR 11 0.140 0.0069 0.236 0.0006 
MALT1 18 -0.140 0.0069 0.367 4.14E-08 
RELA 11 -0.140 0.0069 0.189 0.0059 
KL 13 0.140 0.0070 0.116 0.0941 
SUPT5H 19 -0.139 0.0070 0.165 0.0161 
GCAT 22 -0.139 0.0071 NA NA 
EFCAB7 1 0.139 0.0072 NA NA 
ZNF540 19 -0.139 0.0072 NA NA 
PPP3CA 4 -0.139 0.0073 -0.103 0.1365 
YIF1B 19 -0.139 0.0073 NA NA 
IER5L 9 0.139 0.0073 NA NA 
TNS1 2 0.139 0.0073 -0.200 0.0035 
C9orf142 9 0.139 0.0074 NA NA 
CALHM1 10 0.138 0.0074 NA NA 
HCAR1 12 0.138 0.0074 NA NA 
SNHG10 14 0.138 0.0074 NA NA 
USP46 4 0.138 0.0074 0.089 0.1993 
HSPD1P2 8 0.138 0.0075 NA NA 
ETV4 17 -0.138 0.0076 NA NA 
BORA 13 -0.138 0.0076 NA NA 
ZBED3-AS1 5 0.138 0.0076 NA NA 
FKBP8 19 -0.138 0.0076 -0.145 0.0355 
LRRC42 1 -0.138 0.0077 NA NA 
FAM207BP 13 0.138 0.0078 NA NA 
FAM174B 15 -0.137 0.0079 NA NA 
PFKFB1 X -0.137 0.0079 NA NA 
AQP3 9 0.137 0.0079 0.184 0.0074 
RPL18AP16 X 0.137 0.0079 NA NA 
RPL7AP73 13 0.137 0.0081 NA NA 
SUPT3H 6 0.137 0.0082 0.083 0.2289 
TMC8 17 -0.137 0.0082 NA NA 
NDFIP1 5 -0.137 0.0083 0.439 2.40E-11 
TET2 4 -0.136 0.0083 NA NA 
JUN 1 0.136 0.0085 -0.075 0.2800 
TMEM51 1 -0.136 0.0085 0.207 0.0025 
PPM1M 3 0.136 0.0085 NA NA 
SFR1P1 X 0.136 0.0085 NA NA 
DSC2 18 -0.136 0.0085 0.388 5.45E-09 
EEF1A1P30 X 0.136 0.0085 NA NA 
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SS18L1 20 -0.136 0.0085 0.238 0.0005 
NR4A3 9 0.136 0.0086 -0.032 0.6488 
NDUFS1 2 -0.136 0.0086 0.169 0.0142 
CCDC26 8 -0.136 0.0086 NA NA 
TMEM147 19 0.136 0.0086 0.121 0.0804 
ACTG1P2 Y 0.136 0.0086 NA NA 
NFIB 9 0.136 0.0087 -0.185 0.0069 
WDFY1 2 -0.136 0.0087 NA NA 
C9orf156 9 0.136 0.0087 0.267 8.77E-05 
KLF3 4 -0.136 0.0087 0.117 0.0903 
LTA 6 0.136 0.0088 0.039 0.5715 
TRAFD1 12 0.136 0.0088 0.336 5.63E-07 
ARF4 3 -0.136 0.0088 -0.010 0.8881 
CDK9 9 -0.135 0.0088 NA NA 
KLHL36 16 -0.135 0.0088 NA NA 
SLFN11 17 0.135 0.0088 NA NA 
C21orf91 21 -0.135 0.0088 0.017 0.8051 
PDZD2 5 0.135 0.0088 -0.240 0.0004 
CKB 14 0.135 0.0088 NA NA 
TBC1D16 17 -0.135 0.0090 -0.140 0.0422 
RPL36AP13 2 0.135 0.0090 NA NA 
NCR3LG1 11 -0.135 0.0090 NA NA 
VAMP5 2 -0.135 0.0090 NA NA 
MED11 17 0.135 0.0090 NA NA 
SGMS1-AS1 10 -0.135 0.0091 NA NA 
ASB2 14 0.135 0.0091 NA NA 
ATP1B2 17 0.135 0.0091 -0.179 0.0092 
CACYBPP1 10 0.135 0.0092 NA NA 
FOXA3 19 0.135 0.0092 NA NA 
PIK3R5 17 0.134 0.0093 0.235 0.0006 
YBX1P10 9 -0.134 0.0094 NA NA 
PA2G4P1 X 0.134 0.0094 NA NA 
MAP4 3 -0.134 0.0094 0.104 0.1309 
H3F3AP5 X 0.134 0.0094 NA NA 
EEF1A1P17 12 0.134 0.0096 NA NA 
DNASE1L3 3 -0.134 0.0096 -0.038 0.5826 
DTX3L 3 0.134 0.0096 NA NA 
TRGV2 7 0.134 0.0097 NA NA 
HMSD 18 0.134 0.0098 NA NA 
ATAD2B 2 0.134 0.0098 0.146 0.0340 
NUAK2 1 0.134 0.0098 NA NA 
SYNGR3 16 -0.134 0.0098 NA NA 
SMAGP 12 0.134 0.0098 NA NA 
MCL1 1 0.133 0.0099 0.478 2.03E-13 
FCRL3 1 -0.133 0.0099 NA NA 
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VEZF1 17 0.133 0.0099 0.194 0.0047 
VDAC3 8 -0.133 0.0099 0.025 0.7143 
MORF4L1P1 1 -0.133 0.0100 NA NA 
INPP5F 10 0.133 0.0101 0.101 0.1423 
WDR33 2 -0.133 0.0101 0.142 0.0393 
ORC6 16 -0.133 0.0101 NA NA 
EPB41L5 2 0.133 0.0101 -0.072 0.2965 
HIVEP3 1 0.133 0.0101 -0.037 0.5889 
ERCC6L X -0.133 0.0102 NA NA 
B4GALT2 1 -0.133 0.0102 -0.079 0.2513 
TBC1D9 4 0.133 0.0102 0.149 0.0305 
ANKRD13B 17 0.133 0.0102 NA NA 
PTBP3 9 -0.133 0.0103 NA NA 
LINC01358 1 0.133 0.0104 NA NA 
ZFR 5 -0.132 0.0105 0.059 0.3951 
ZMYM5 13 -0.132 0.0105 0.017 0.8032 
KLF7 2 0.132 0.0106 0.313 3.65E-06 
BTF3P8 X 0.132 0.0107 NA NA 
PRDX1P1 9 0.132 0.0107 NA NA 
CDC20 1 -0.132 0.0107 -0.308 5.13E-06 
HMX3 10 0.132 0.0107 NA NA 
STT3B 3 -0.132 0.0110 NA NA 
POU3F1 1 0.132 0.0110 -0.097 0.1591 
ENSA 1 0.131 0.0110 -0.211 0.0020 
PPP6R1 19 -0.131 0.0111 NA NA 
DENND1C 19 -0.131 0.0111 0.226 0.0010 
CHM X 0.131 0.0111 NA NA 
PQLC2 1 0.131 0.0111 NA NA 
PPP1R14BP3 4 -0.131 0.0112 NA NA 
ESR1 6 0.131 0.0114 0.151 0.0282 
HMGB3 X -0.131 0.0114 -0.226 0.0009 
MYO1F 19 0.131 0.0116 0.297 1.13E-05 
LHFPL2 5 0.130 0.0117 -0.203 0.0031 
TMEM140 7 0.130 0.0117 NA NA 
KLHDC2 14 -0.130 0.0117 -0.049 0.4814 
R3HDM4 19 0.130 0.0118 NA NA 
SHE 1 0.130 0.0118 NA NA 
ACBD4 17 -0.130 0.0119 NA NA 
SERPINH1P1 9 -0.130 0.0119 NA NA 
RPS3AP25 7 0.130 0.0119 NA NA 
MTMR9LP 1 0.130 0.0121 NA NA 
PURB 7 -0.130 0.0121 NA NA 
SNIP1 1 0.130 0.0121 0.056 0.4202 
ARHGEF2 1 0.130 0.0122 0.069 0.3195 
IQCH 15 -0.130 0.0122 NA NA 
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SLC22A23 6 0.130 0.0122 NA NA 
COMMD8 4 -0.130 0.0123 0.385 7.08E-09 
ZBP1 20 0.129 0.0123 0.097 0.1613 
PYCARD 16 0.129 0.0123 0.313 3.66E-06 
PLA1A 3 0.129 0.0124 0.092 0.1816 
CFAP57 1 0.129 0.0125 NA NA 
TSKU 11 0.129 0.0125 NA NA 
LAMA3 18 0.129 0.0125 NA NA 
NDUFAF4 6 -0.129 0.0126 NA NA 
GRB2 17 0.129 0.0126 0.208 0.0024 
BIRC5 17 -0.129 0.0126 -0.322 1.82E-06 
OSBPL3 7 0.129 0.0126 0.017 0.8029 
TMEM173 5 0.129 0.0127 NA NA 
SEMA3F-AS1 3 -0.129 0.0127 NA NA 
MICAL1 6 -0.129 0.0127 0.330 9.50E-07 
SLC20A1 2 0.129 0.0127 0.107 0.1213 
FAM78B 1 0.129 0.0127 NA NA 
RPL26P37 Y 0.129 0.0128 NA NA 
DCTN3 9 -0.129 0.0128 0.027 0.6916 
MRGBP 20 -0.129 0.0128 NA NA 
SH3PXD2A 10 0.129 0.0128 -0.011 0.8715 
MED12L 3 0.129 0.0129 NA NA 
MOB3B 9 0.129 0.0129 NA NA 
GAPDHP70 11 0.129 0.0129 NA NA 
TMED9 5 -0.128 0.0130 0.157 0.0226 
CTDSP2 12 0.128 0.0130 0.165 0.0166 
NCOA1 2 -0.128 0.0131 0.193 0.0050 
TTYH3 7 -0.128 0.0131 NA NA 
TMEM80 11 -0.128 0.0132 0.158 0.0218 
UHMK1 1 -0.128 0.0132 NA NA 
ATP6V1G1 9 0.128 0.0132 0.137 0.0474 
MAD2L1 4 -0.128 0.0132 -0.244 0.0004 
PKIG 20 -0.128 0.0133 -0.468 7.26E-13 
GAS2 11 0.128 0.0133 -0.007 0.9169 
KIAA0232 4 -0.128 0.0133 0.235 0.0006 
GALNT10 5 -0.128 0.0133 0.018 0.7937 
WNT5B 12 0.128 0.0135 NA NA 
FOXD2-AS1 1 0.128 0.0135 NA NA 
HIST2H2BF 1 0.128 0.0136 NA NA 
GRAMD4 22 0.128 0.0136 NA NA 
RASAL2 1 0.128 0.0136 -0.083 0.2301 
CYBB X 0.128 0.0136 0.296 1.26E-05 
HECW2 2 -0.128 0.0136 NA NA 
IFNGR2 21 0.128 0.0137 0.329 1.04E-06 
HMX2 10 0.128 0.0137 NA NA 
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MED28 4 -0.128 0.0137 -0.094 0.1725 
GLT1D1 12 -0.127 0.0138 NA NA 
GABARAP 17 -0.127 0.0138 0.196 0.0043 
DAB2IP 9 -0.127 0.0139 NA NA 
YARS 1 -0.127 0.0139 -0.105 0.1285 
RPL23AP12 21 0.127 0.0139 NA NA 
HABP4 9 0.127 0.0140 0.188 0.0063 
DUX4L50 9 0.127 0.0140 NA NA 
METTL18 1 -0.127 0.0140 NA NA 
DIS3 13 -0.127 0.0140 NA NA 
RPL5P11 4 0.127 0.0141 NA NA 
BMP6 6 0.127 0.0141 -0.055 0.4305 
ZBTB12 6 -0.127 0.0141 NA NA 
SLC4A1AP 2 -0.127 0.0141 0.129 0.0615 
IFI27L1 14 -0.127 0.0142 NA NA 
EEF1A1P10 7 0.127 0.0143 NA NA 
PTEN 10 -0.127 0.0143 0.196 0.0043 
ORAI3 16 -0.127 0.0143 NA NA 
MTATP8P1 1 -0.127 0.0144 NA NA 
CNN3 1 0.127 0.0144 -0.235 0.0006 
CCL17 16 0.126 0.0145 NA NA 
LSP1P3 5 0.126 0.0146 NA NA 
SGOL1 3 -0.126 0.0146 NA NA 
RASAL3 19 -0.126 0.0147 NA NA 
BSCL2 11 -0.126 0.0147 NA NA 
CASKIN1 16 0.126 0.0148 NA NA 
RPL23AP38 3 0.126 0.0148 NA NA 
SNAI1 20 0.126 0.0148 NA NA 
SERBP1P1 X -0.126 0.0149 NA NA 
OGDHL 10 -0.126 0.0149 NA NA 
DQX1 2 0.126 0.0149 NA NA 
NUDT19 19 -0.126 0.0150 NA NA 
TNFRSF11B 8 0.126 0.0151 NA NA 
SLCO3A1 15 0.126 0.0152 0.597 0 
CNKSR1 1 0.126 0.0152 NA NA 
TANK 2 0.126 0.0153 -0.005 0.9389 
PPAP2B 1 0.125 0.0153 -0.211 0.0021 
SNHG14 15 -0.125 0.0153 NA NA 
LRBA 4 -0.125 0.0153 -0.191 0.0053 
NSUN3 3 -0.125 0.0154 -0.060 0.3883 
SFXN4 10 -0.125 0.0154 NA NA 
NPM1P33 2 0.125 0.0155 NA NA 
TSG101 11 0.125 0.0155 -0.014 0.8361 
PPP4R2 3 -0.125 0.0155 -0.065 0.3495 
LGALS9C 17 -0.125 0.0155 NA NA 
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PALLD 4 0.125 0.0156 0.095 0.1706 
LAMP5 20 -0.125 0.0157 NA NA 
ZNF706 8 -0.125 0.0157 0.143 0.0377 
ABHD6 3 -0.125 0.0157 0.019 0.7816 
RPS12P23 13 0.125 0.0157 NA NA 
LMNTD2 11 -0.125 0.0157 NA NA 
YIPF6 X 0.125 0.0158 -0.094 0.1754 
ADM 11 0.125 0.0159 0.209 0.0023 
EPHA1-AS1 7 0.125 0.0159 NA NA 
RPL32 3 0.125 0.0160 0.065 0.3501 
KIF4B 5 -0.125 0.0160 NA NA 
ACTG1P14 9 0.125 0.0160 NA NA 
ATP5J2 7 0.125 0.0160 0.026 0.7021 
GPR183 13 -0.125 0.0160 NA NA 
PITPNC1 17 0.124 0.0162 0.271 6.77E-05 
RPL36AP26 7 0.124 0.0162 NA NA 
CPS1 2 0.124 0.0162 -0.135 0.0495 
RTKN 2 0.124 0.0163 NA NA 
CEACAM21 19 -0.124 0.0163 NA NA 
NOC4L 12 0.124 0.0164 -0.032 0.6481 
DLL4 15 0.124 0.0165 NA NA 
NFAM1 22 -0.124 0.0165 NA NA 
IL12B 5 0.124 0.0166 NA NA 
BCL2A1 15 0.124 0.0167 0.366 4.50E-08 
CXCR4 2 0.124 0.0167 0.239 0.0005 
RAP1BP1 9 0.124 0.0167 NA NA 
VOPP1 7 0.124 0.0168 NA NA 
RPL7P48 17 -0.124 0.0168 NA NA 
PIAS2 18 -0.124 0.0170 -0.060 0.3886 
ZMYM4 1 0.123 0.0170 0.106 0.1243 
SH2D3C 9 -0.123 0.0171 NA NA 
RAB42 1 0.123 0.0171 NA NA 
LRRC8C 1 -0.123 0.0172 NA NA 
PSMB10 16 -0.123 0.0172 0.285 2.70E-05 
TNFRSF8 1 0.123 0.0172 0.289 1.96E-05 
LGALS14 19 -0.123 0.0172 NA NA 
FITM1 14 -0.123 0.0173 NA NA 
HTR2B 2 0.123 0.0174 0.118 0.0880 
SMIM7 19 -0.123 0.0174 NA NA 
FAM222B 17 0.123 0.0174 NA NA 
SLC44A2 19 -0.123 0.0175 NA NA 
ZNF355P 21 0.123 0.0177 NA NA 
C2orf44 2 0.123 0.0177 -0.097 0.1608 
GAPT 5 0.123 0.0177 NA NA 
NCKAP5 2 0.123 0.0178 NA NA 
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HYOU1 11 -0.123 0.0178 -0.010 0.8886 
KCNK5 6 -0.123 0.0178 -0.289 1.94E-05 
TMC4 19 0.123 0.0178 NA NA 
TMX1 14 0.123 0.0179 NA NA 
WWC3 X -0.123 0.0179 0.051 0.4621 
ANXA2P2 9 0.122 0.0180 0.409 6.58E-10 
PPP2R2A 8 -0.122 0.0180 0.150 0.0291 
JDP2 14 0.122 0.0180 NA NA 
NLRP3 1 0.122 0.0181 0.484 8.37E-14 
LCA5 6 0.122 0.0182 NA NA 
CENPJ 13 -0.122 0.0184 -0.331 8.84E-07 
TCF19 6 0.122 0.0185 NA NA 
GYS1 19 -0.122 0.0186 0.196 0.0043 
CD300C 17 -0.122 0.0186 0.189 0.0059 
ANKRA2 5 -0.122 0.0188 0.139 0.0433 
RBBP7 X 0.121 0.0189 -0.108 0.1177 
SEC24B-AS1 4 -0.121 0.0189 NA NA 
ANKRD16 10 0.121 0.0190 NA NA 
YBX1P2 7 -0.121 0.0191 NA NA 
RNF144A 2 -0.121 0.0191 NA NA 
GPCPD1 20 -0.121 0.0191 NA NA 
GPR63 6 -0.121 0.0192 NA NA 
UBE2G1 17 0.121 0.0192 0.099 0.1505 
SRSF10 1 0.121 0.0192 NA NA 
B4GALT1 9 -0.121 0.0192 -0.022 0.7495 
GBP1 1 -0.121 0.0193 0.389 4.85E-09 
RPS21P4 4 0.121 0.0193 NA NA 
RXRA 9 0.121 0.0194 0.151 0.0285 
RPS17P2 5 0.121 0.0194 NA NA 
TXNL1 18 -0.121 0.0195 -0.130 0.0597 
TRABD2A 2 0.121 0.0195 NA NA 
ARAP1-AS1 11 -0.121 0.0196 NA NA 
MAPK6 15 -0.121 0.0197 0.120 0.0822 
SLC18A2 10 0.121 0.0197 NA NA 
SRP54 14 -0.121 0.0198 0.183 0.0076 
MTCH2 11 -0.121 0.0198 0.049 0.4827 
RBMXP4 4 -0.121 0.0198 NA NA 
ZSCAN30 18 -0.121 0.0199 NA NA 
SOWAHD X 0.120 0.0200 NA NA 
HNRNPA1P33 10 0.120 0.0201 NA NA 
ABI1 10 0.120 0.0201 0.122 0.0761 
ADD2 2 0.120 0.0202 -0.229 0.0008 
UBR3 2 -0.120 0.0202 NA NA 
PRORSD1P 2 -0.120 0.0202 NA NA 
LIPH 3 -0.120 0.0203 NA NA 
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MED10 5 -0.120 0.0203 NA NA 
C11orf24 11 -0.120 0.0204 -0.095 0.1696 
ICK 6 0.120 0.0205 0.151 0.0285 
STPG1 1 -0.120 0.0206 NA NA 
ANXA11 10 0.120 0.0206 0.346 2.44E-07 
FNIP2 4 -0.120 0.0206 NA NA 
FAM207A 21 0.120 0.0208 NA NA 
BCAP29 7 -0.120 0.0209 -0.182 0.0081 
ANKDD1A 15 0.120 0.0209 0.014 0.8412 
RDH14 2 0.119 0.0210 -0.093 0.1766 
DNAJC3 13 -0.119 0.0211 0.177 0.0099 
PMAIP1 18 -0.119 0.0211 -0.237 0.0005 
FCHO2 5 0.119 0.0211 NA NA 
ADSL 22 -0.119 0.0211 0.200 0.0035 
IGLV1-47 22 0.119 0.0212 NA NA 
SAPCD2 9 0.119 0.0212 NA NA 
MAPK1 22 0.119 0.0214 0.033 0.6381 
NPM1P35 11 0.119 0.0214 NA NA 
TNFRSF1B 1 -0.119 0.0214 0.437 3.14E-11 
GPR55 2 0.119 0.0215 NA NA 
PLAU 10 0.119 0.0216 NA NA 
DZIP3 3 -0.119 0.0216 -0.191 0.0054 
RALY 20 -0.119 0.0216 -0.093 0.1794 
APAF1 12 0.119 0.0216 0.534 0 
SARS2 19 0.119 0.0217 NA NA 
ELK1 X -0.119 0.0217 0.250 0.0002 
RBM17P4 15 -0.119 0.0218 NA NA 
ACTG1P11 Y 0.119 0.0218 NA NA 
RAB13 1 0.119 0.0219 -0.170 0.0136 
PPFIA4 1 -0.119 0.0220 0.306 6.11E-06 
RPL23P2 21 0.119 0.0220 NA NA 
AHCYL2 7 0.119 0.0220 NA NA 
TUBE1 6 -0.119 0.0220 NA NA 
SBNO2 19 0.118 0.0221 NA NA 
IPCEF1 6 -0.118 0.0221 NA NA 
FAM167A 8 -0.118 0.0222 NA NA 
KIZ 20 -0.118 0.0222 NA NA 
PDCL 9 -0.118 0.0222 -0.011 0.8771 
FAM60A 12 0.118 0.0223 0.005 0.9474 
TIMM8B 11 -0.118 0.0223 0.067 0.3301 
C16orf87 16 -0.118 0.0224 NA NA 
CXorf21 X 0.118 0.0224 0.149 0.0300 
ARPC1B 7 -0.118 0.0225 0.239 0.0005 
UBE2E3 2 -0.118 0.0225 -0.225 0.0010 
HSPD1P3 8 0.118 0.0225 NA NA 
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NUP54 4 -0.118 0.0225 -0.027 0.6990 
CYCS 7 0.118 0.0229 -0.133 0.0537 
CD300A 17 -0.118 0.0230 0.131 0.0584 
FAM105A 5 -0.118 0.0231 0.620 0 
TAPT1-AS1 4 0.117 0.0233 NA NA 
LRRC47 1 -0.117 0.0233 0.146 0.0344 
IGLC6 22 0.117 0.0233 NA NA 
GTF2E2 8 0.117 0.0234 0.169 0.0142 
GPR153 1 0.117 0.0235 -0.067 0.3360 
NEK8 17 0.117 0.0235 NA NA 
ECE1 1 0.117 0.0235 0.113 0.1032 
TMEM38A 19 0.117 0.0235 NA NA 
LYL1 19 0.117 0.0236 -0.211 0.0020 
SLC28A3 9 -0.117 0.0238 0.043 0.5303 
TPCN1 12 -0.117 0.0238 0.451 5.98E-12 
LINC00865 10 0.117 0.0239 NA NA 
ALDH6A1 14 -0.117 0.0239 -0.206 0.0026 
IGHV3-7 14 0.117 0.0240 NA NA 
DPY19L2P1 7 0.117 0.0240 NA NA 
SH3BP5-AS1 3 0.117 0.0241 NA NA 
CFLAR 2 0.117 0.0241 0.379 1.36E-08 
KIAA0040 1 0.117 0.0243 0.099 0.1514 
PRLR 5 0.117 0.0243 NA NA 
C10orf12 10 -0.117 0.0244 NA NA 
NDUFA2 5 -0.116 0.0244 0.018 0.7970 
CDCA8 1 -0.116 0.0245 -0.226 0.0010 
ABHD17AP4 22 0.116 0.0245 NA NA 
NSD1 5 0.116 0.0246 0.114 0.0975 
AHNAK2 14 0.116 0.0247 NA NA 
THOP1 19 0.116 0.0248 NA NA 
SPRYD7 13 -0.116 0.0249 NA NA 
TMOD2 15 0.116 0.0249 NA NA 
TNFRSF17 16 0.116 0.0250 -0.234 0.0006 
SLAIN1 13 -0.116 0.0250 NA NA 
TMEM156 4 0.116 0.0251 -0.119 0.0837 
LY75 2 0.116 0.0251 0.199 0.0036 
HMGN2P7 3 -0.116 0.0251 NA NA 
ANKH 5 -0.116 0.0251 0.014 0.8454 
NPNT 4 0.116 0.0253 NA NA 
MAP4K4 2 0.116 0.0253 0.222 0.0012 
ZSCAN16 6 -0.116 0.0253 NA NA 
ZFP36L2 2 0.116 0.0254 0.091 0.1903 
YEATS2 3 0.116 0.0254 -0.023 0.7451 
SMIM13 6 -0.116 0.0254 NA NA 
ABHD4 14 -0.116 0.0255 -0.101 0.1456 
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HSPA4 5 -0.116 0.0256 0.010 0.8798 
EEF1A1P28 7 0.115 0.0257 NA NA 
LETM1 4 -0.115 0.0258 -0.018 0.7915 
WIPI1 17 -0.115 0.0258 0.112 0.1032 
RNPC3 1 0.115 0.0258 NA NA 
RPS27L 15 -0.115 0.0258 0.085 0.2184 
RPL34P34 19 0.115 0.0259 NA NA 
NHP2P1 10 -0.115 0.0260 NA NA 
TEAD4 12 0.115 0.0261 NA NA 
ADARB1 21 0.115 0.0261 0.068 0.3290 
RWDD2A 6 -0.115 0.0262 NA NA 
XAF1 17 0.115 0.0262 NA NA 
PIK3CD-AS1 1 0.115 0.0262 NA NA 
CD69 12 -0.115 0.0263 -0.093 0.1779 
TMEM132A 11 0.115 0.0263 NA NA 
ARHGAP25 2 0.115 0.0263 0.172 0.0126 
MED26 19 -0.115 0.0263 NA NA 
TPGS2 18 -0.115 0.0263 NA NA 
SSR2 1 -0.115 0.0265 0.197 0.0041 
ZSCAN18 19 -0.115 0.0265 NA NA 
TXNDC5 6 0.115 0.0267 -0.286 2.50E-05 
FABP5P3 7 0.115 0.0267 NA NA 
ADCK4 19 -0.115 0.0267 NA NA 
MYH6 14 0.115 0.0267 NA NA 
GALK2 15 -0.115 0.0269 0.015 0.8337 
FAM53B 10 0.115 0.0269 0.122 0.0778 
AMMECR1 X -0.115 0.0270 -0.009 0.8982 
EXD3 9 -0.114 0.0271 NA NA 
LRP6 12 0.114 0.0272 -0.134 0.0519 
IMPDH1P10 2 0.114 0.0272 NA NA 
PLEKHM1P 17 -0.114 0.0272 NA NA 
DHX30 3 -0.114 0.0273 -0.018 0.7984 
RGS6 14 -0.114 0.0274 NA NA 
PPIF 10 -0.114 0.0275 0.167 0.0153 
AMOTL1 11 0.114 0.0276 NA NA 
CLSPN 1 0.114 0.0276 NA NA 
SNX10 7 0.114 0.0277 0.137 0.0470 
NOL7 6 -0.114 0.0278 -0.042 0.5477 
CHPF2 7 -0.114 0.0278 NA NA 
DNAH14 1 0.114 0.0278 NA NA 
OXA1L 14 -0.114 0.0279 0.274 5.34E-05 
RPL3P12 X 0.114 0.0279 NA NA 
AMT 3 -0.114 0.0279 -0.081 0.2422 
CMPK1 1 -0.114 0.0280 NA NA 
ECH1 19 -0.114 0.0280 -0.137 0.0473 
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ZNF121 19 -0.114 0.0280 NA NA 
DEPDC4 12 0.114 0.0281 NA NA 
CD9 12 0.114 0.0282 0.098 0.1558 
IRF8 16 -0.114 0.0282 0.053 0.4412 
DNAJB6 7 -0.114 0.0282 -0.039 0.5703 
SGOL1-AS1 3 -0.114 0.0283 NA NA 
ANO10 3 0.114 0.0283 NA NA 
HSPA5 9 -0.114 0.0283 0.053 0.4395 
MTTP 4 0.114 0.0284 NA NA 
HHAT 1 -0.114 0.0284 -0.171 0.0130 
FBXL19 16 0.114 0.0284 NA NA 
DET1 15 0.114 0.0284 0.059 0.3943 
ZNF569 19 -0.113 0.0284 NA NA 
GDF11 12 -0.113 0.0284 NA NA 
LINC00342 2 0.113 0.0285 NA NA 
QPCTL 19 -0.113 0.0286 NA NA 
CEP250 20 0.113 0.0287 NA NA 
SECISBP2 9 0.113 0.0288 0.058 0.3985 
MYC 8 0.113 0.0289 -0.133 0.0545 
EEF1A1P8 3 0.113 0.0290 NA NA 
TBC1D22A 22 0.113 0.0290 0.179 0.0092 
DNAJB11 3 -0.113 0.0290 NA NA 
MEA1 6 -0.113 0.0290 -0.207 0.0025 
IGFBP4 17 0.113 0.0291 -0.171 0.0129 
ATP8B1 18 -0.113 0.0291 -0.057 0.4087 
PODXL2 3 0.113 0.0293 NA NA 
FAM160A1 4 0.113 0.0294 NA NA 
TCEA1P4 9 -0.113 0.0294 NA NA 
HES1 3 0.113 0.0295 -0.201 0.0034 
NME3 16 -0.113 0.0295 NA NA 
HADHA 2 -0.113 0.0296 0.176 0.0102 
IRGQ 19 -0.113 0.0296 NA NA 
RPL7P19 5 0.113 0.0296 NA NA 
ADTRP 6 0.113 0.0297 NA NA 
RPSAP14 X 0.113 0.0298 NA NA 
DNLZ 9 0.113 0.0298 NA NA 
IST1 16 0.112 0.0298 NA NA 
FAM160A2 11 -0.112 0.0299 NA NA 
AJUBA 14 -0.112 0.0299 NA NA 
LHFP 13 0.112 0.0299 -0.135 0.0504 
KCTD3 1 0.112 0.0300 -0.094 0.1718 
AMZ2 17 -0.112 0.0300 0.065 0.3501 
RPL35AP35 17 -0.112 0.0301 NA NA 
PSTPIP2 18 -0.112 0.0303 0.224 0.0010 
KIF13B 8 -0.112 0.0304 0.205 0.0028 
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SUB1P3 16 0.112 0.0304 NA NA 
DYNC1LI2 16 -0.112 0.0304 0.319 2.23E-06 
PRKX X -0.112 0.0304 0.295 1.33E-05 
RPL7AP3 14 0.112 0.0305 NA NA 
PSMA6P1 Y 0.112 0.0305 NA NA 
FSTL3 19 0.112 0.0308 NA NA 
SLC45A3 1 0.112 0.0308 NA NA 
RGMB 5 0.112 0.0308 NA NA 
CAMSAP2 1 0.112 0.0310 NA NA 
NXT2 X -0.112 0.0311 -0.099 0.1535 
CYP51A1P2 13 -0.112 0.0311 NA NA 
MYL12BP1 15 0.112 0.0311 NA NA 
OSGIN2 8 -0.112 0.0312 0.185 0.0069 
RPL19P20 X 0.112 0.0313 NA NA 
PLAC8 4 0.111 0.0314 -0.058 0.4004 
UCN 2 -0.111 0.0314 0.006 0.9338 
FUT8 14 0.111 0.0314 -0.201 0.0034 
GSTP1 11 -0.111 0.0314 0.048 0.4894 
ZNF641 12 0.111 0.0315 NA NA 
RRM2P3 X 0.111 0.0315 NA NA 
TFEB 6 0.111 0.0315 0.102 0.1403 
XPOT 12 -0.111 0.0315 0.043 0.5346 
C14orf105 14 0.111 0.0315 NA NA 
MRPL13 8 -0.111 0.0316 -0.004 0.9535 
ZNF649 19 -0.111 0.0316 NA NA 
NME4 16 0.111 0.0316 -0.365 4.57E-08 
PGAM1P7 X 0.111 0.0316 NA NA 
IGLV1-51 22 0.111 0.0316 NA NA 
CHCHD4 3 0.111 0.0317 NA NA 
ZNF680 7 -0.111 0.0318 NA NA 
TPBG 6 -0.111 0.0319 -0.119 0.0856 
ZNF248 10 0.111 0.0320 0.017 0.8116 
CUL7 6 -0.111 0.0320 NA NA 
UBXN6 19 -0.111 0.0321 NA NA 
SPSB3 16 -0.111 0.0321 0.117 0.0907 
TRIM13 13 0.111 0.0321 0.034 0.6285 
TSGA10 2 -0.111 0.0323 NA NA 
FHL2 2 -0.111 0.0323 -0.304 6.67E-06 
CD4 12 0.111 0.0323 0.739 0 
EDN1 6 0.111 0.0323 NA NA 
C19orf52 19 -0.111 0.0323 NA NA 
WDR62 19 -0.111 0.0324 NA NA 
PLEKHA8 7 0.111 0.0324 NA NA 
RFNG 17 -0.111 0.0325 0.074 0.2869 
ABCC5 3 0.111 0.0325 0.010 0.8807 
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GFM2 5 -0.111 0.0325 NA NA 
CDH24 14 -0.111 0.0326 NA NA 
SWT1 1 0.111 0.0326 NA NA 
GPR150 5 -0.111 0.0326 NA NA 
PLS1 3 0.111 0.0326 -0.274 5.63E-05 
ZFP30 19 -0.111 0.0326 -0.065 0.3506 
LONP1 19 -0.111 0.0327 NA NA 
C7orf26 7 -0.111 0.0327 0.034 0.6231 
RABGAP1L 1 0.111 0.0327 0.229 0.0008 
CHST12 7 -0.111 0.0328 -0.260 0.0001 
SIKE1 1 0.111 0.0328 NA NA 
STRBP 9 -0.111 0.0329 NA NA 
XKR9 8 -0.110 0.0329 NA NA 
IGLC7 22 0.110 0.0329 NA NA 
ADRB1 10 -0.110 0.0329 NA NA 
SLC25A26 3 -0.110 0.0329 NA NA 
HCAR2 12 0.110 0.0330 NA NA 
TANC2 17 -0.110 0.0331 NA NA 
RPS2P46 17 -0.110 0.0331 NA NA 
VCL 10 0.110 0.0331 0.168 0.0143 
PHLPP1 18 -0.110 0.0332 NA NA 
SUGP2 19 -0.110 0.0332 NA NA 
UBE2MP1 16 -0.110 0.0332 NA NA 
MSTO2P 1 -0.110 0.0333 NA NA 
PCTP 17 -0.110 0.0333 0.036 0.6047 
MBD2 18 -0.110 0.0334 0.285 2.72E-05 
KIN 10 0.110 0.0335 0.190 0.0057 
YBEY 21 -0.110 0.0336 NA NA 
TMEM200A 6 0.110 0.0336 NA NA 
POU5F1P4 1 0.110 0.0337 NA NA 
IGLC3 22 0.110 0.0338 NA NA 
RPL37P23 19 0.110 0.0339 NA NA 
ANAPC1 2 -0.110 0.0340 0.003 0.9644 
PPP1R11P1 1 0.110 0.0341 NA NA 
RPS20P24 9 0.110 0.0341 NA NA 
IFNG 12 -0.110 0.0343 -0.138 0.0459 
TTC38 22 -0.110 0.0343 NA NA 
CNR1 6 0.110 0.0344 -0.201 0.0034 
FAM212B-
AS1 1 -0.110 0.0344 NA NA 
NACAP3 12 0.109 0.0346 NA NA 
C10orf128 10 0.109 0.0346 NA NA 
DARS-AS1 2 0.109 0.0346 NA NA 
AMZ2P1 17 -0.109 0.0347 NA NA 
KLF13 15 0.109 0.0348 NA NA 
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NPM1P22 13 0.109 0.0348 NA NA 
SLC44A1 9 0.109 0.0348 NA NA 
RIT1 1 0.109 0.0348 0.069 0.3197 
SRIP3 Y -0.109 0.0350 NA NA 
RAPGEF1 9 0.109 0.0350 0.111 0.1076 
CAPN2 1 0.109 0.0350 0.427 8.87E-11 
RCL1 9 -0.109 0.0351 -0.306 5.99E-06 
C1orf162 1 0.109 0.0351 NA NA 
ZNF135 19 -0.109 0.0351 NA NA 
SERBP1P5 4 -0.109 0.0352 NA NA 
AIM2 1 0.109 0.0352 -0.047 0.4947 
POC1A 3 -0.109 0.0352 NA NA 
TMEM67 8 -0.109 0.0353 NA NA 
FA2H 16 0.109 0.0353 NA NA 
FAM3C 7 -0.109 0.0353 -0.282 3.17E-05 
DDN 12 0.109 0.0354 NA NA 
SLAMF1 1 0.109 0.0354 0.171 0.0129 
FAM199X X -0.109 0.0355 NA NA 
TMEM107 17 -0.109 0.0355 NA NA 
RPL6P27 18 -0.109 0.0355 NA NA 
DEAF1 11 0.109 0.0357 NA NA 
FAM129B 9 -0.109 0.0357 NA NA 
RGS19 20 -0.109 0.0358 0.300 9.45E-06 
QPCT 2 -0.109 0.0358 0.442 1.64E-11 
STK17B 2 -0.109 0.0359 0.402 1.38E-09 
ATG13 11 -0.109 0.0361 NA NA 
NME9 3 -0.109 0.0361 NA NA 
HNRNPLP1 6 0.109 0.0361 NA NA 
RNF24 20 -0.109 0.0362 0.175 0.0109 
SEPT10 2 0.109 0.0362 NA NA 
PTOV1 19 -0.108 0.0363 -0.083 0.2314 
ALG13 X 0.108 0.0365 -0.064 0.3571 
FAM219A 9 0.108 0.0365 NA NA 
NPM1P46 2 0.108 0.0366 NA NA 
NLK 17 0.108 0.0367 -0.167 0.0150 
CD44 11 0.108 0.0367 0.472 4.27E-13 
NOL8P1 4 0.108 0.0367 NA NA 
ELL 19 -0.108 0.0367 NA NA 
JUP 17 0.108 0.0369 -0.068 0.3242 
CYBRD1 2 -0.108 0.0370 -0.152 0.0272 
FTSJ2 7 -0.108 0.0370 0.187 0.0065 
PRKRIRP3 10 -0.108 0.0371 NA NA 
ZNF277 7 0.108 0.0371 NA NA 
IPO7 11 0.108 0.0371 0.139 0.0435 
SHOC2 10 -0.108 0.0373 0.013 0.8561 
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ZNF653 19 0.108 0.0375 NA NA 
HCFC1R1 16 0.108 0.0376 -0.101 0.1427 
AFG3L2P1 8 -0.108 0.0376 NA NA 
RPL15P20 16 0.108 0.0376 NA NA 
KCNA1 12 -0.108 0.0377 NA NA 
RHOBTB3 5 -0.108 0.0377 -0.365 4.75E-08 
IGLC2 22 0.108 0.0378 NA NA 
TNKS2 10 -0.108 0.0379 0.266 9.13E-05 
LRFN4 11 0.108 0.0380 NA NA 
PHB2 12 0.107 0.0380 0.028 0.6889 
SPTLC1P5 13 -0.107 0.0380 NA NA 
RPL3P10 8 0.107 0.0380 NA NA 
TBCA 5 0.107 0.0381 0.141 0.0411 
GAPDHP69 13 0.107 0.0381 NA NA 
SREK1IP1 5 0.107 0.0382 NA NA 
AUH 9 -0.107 0.0383 -0.156 0.0235 
SLC16A1 1 0.107 0.0383 -0.171 0.0128 
PUS7 7 0.107 0.0384 -0.043 0.5362 
KCNMB3P1 22 -0.107 0.0384 NA NA 
PIGBOS1 15 -0.107 0.0385 NA NA 
UBA52P3 14 0.107 0.0386 NA NA 
KIAA1462 10 0.107 0.0386 -0.273 5.79E-05 
PLEK 2 0.107 0.0388 -0.151 0.0287 
RPL7L1P9 2 0.107 0.0389 NA NA 
MAF1 8 -0.107 0.0389 NA NA 
SLC3A2 11 -0.107 0.0392 0.081 0.2423 
MORF4L1 15 -0.107 0.0393 0.055 0.4297 
MTRF1LP1 11 0.107 0.0393 NA NA 
MTX1P1 1 -0.107 0.0393 NA NA 
MGST3 1 0.107 0.0394 0.048 0.4867 
RPS12P26 15 0.107 0.0394 NA NA 
HGS 17 -0.107 0.0395 0.045 0.5193 
RPL31P63 X 0.107 0.0396 NA NA 
FANCM 14 -0.106 0.0398 NA NA 
SPATA3-AS1 2 0.106 0.0398 NA NA 
PPP2R4 9 0.106 0.0399 -0.021 0.7669 
MTND2P28 1 -0.106 0.0399 NA NA 
AKR1B1P1 1 -0.106 0.0399 NA NA 
KBTBD8 3 0.106 0.0400 NA NA 
RBMX2 X -0.106 0.0400 0.146 0.0337 
SMG1P4 16 -0.106 0.0401 NA NA 
SOCS2 12 0.106 0.0403 -0.267 8.84E-05 
RNF180 5 0.106 0.0403 NA NA 
AAGAB 15 -0.106 0.0404 NA NA 
HOXB3 17 0.106 0.0405 -0.128 0.0635 
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SEPT10P1 8 0.106 0.0407 NA NA 
YKT6 7 -0.106 0.0407 0.160 0.0202 
HECA 6 -0.106 0.0409 0.247 0.0003 
MDFIC 7 0.106 0.0410 0.289 2.04E-05 
ZIK1 19 -0.106 0.0411 NA NA 
CYSLTR1 X 0.106 0.0411 -0.115 0.0953 
SLC2A3P4 8 0.106 0.0412 NA NA 
STARD13 13 0.106 0.0414 -0.008 0.9067 
RPL34P18 8 0.106 0.0414 NA NA 
PIFO 1 -0.106 0.0415 NA NA 
GMEB1 1 0.106 0.0415 NA NA 
FBXL5 4 -0.106 0.0415 0.401 1.51E-09 
MIB1 18 -0.106 0.0415 NA NA 
RAPGEF5 7 0.106 0.0416 NA NA 
C9orf41 9 -0.106 0.0417 NA NA 
FOXN3P1 X 0.106 0.0417 NA NA 
SLC41A2 12 0.105 0.0419 NA NA 
MGAT3 22 0.105 0.0419 NA NA 
TPRG1 3 0.105 0.0419 NA NA 
GEMIN8P4 1 -0.105 0.0420 NA NA 
TGM2 20 0.105 0.0420 -0.121 0.0786 
SH3PXD2B 5 0.105 0.0420 NA NA 
PCSK4 19 -0.105 0.0422 NA NA 
HIPK1-AS1 1 0.105 0.0422 NA NA 
DTX1 12 -0.105 0.0422 NA NA 
HSPD1P6 3 0.105 0.0422 NA NA 
HMGN2P3 16 -0.105 0.0422 NA NA 
JMJD4 1 -0.105 0.0422 -0.078 0.2564 
FAM91A3P 1 -0.105 0.0423 NA NA 
FANCF 11 0.105 0.0423 -0.029 0.6732 
SLC30A7 1 -0.105 0.0424 NA NA 
SH3KBP1 X 0.105 0.0425 NA NA 
OSBPL7 17 -0.105 0.0425 NA NA 
RPS15AP38 22 0.105 0.0425 NA NA 
FABP3 1 0.105 0.0425 0.000 0.9964 
IGSF10 3 0.105 0.0426 NA NA 
NID1 1 -0.105 0.0426 0.367 3.92E-08 
TULP2 19 0.105 0.0427 NA NA 
UNC13D 17 -0.105 0.0427 NA NA 
TMEM129 4 -0.105 0.0428 NA NA 
SURF4 9 -0.105 0.0428 NA NA 
ACTBP11 1 -0.105 0.0430 NA NA 
MRPL39 21 -0.105 0.0431 -0.006 0.9294 
HHLA2 3 0.105 0.0435 NA NA 
VPS36 13 -0.105 0.0435 NA NA 
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AQP9 15 0.105 0.0435 0.436 3.37E-11 
CARM1 19 0.105 0.0436 -0.074 0.2841 
GRHPR 9 0.105 0.0436 0.008 0.9104 
TUBBP2 13 -0.105 0.0437 NA NA 
SLC16A7 12 -0.104 0.0437 0.260 0.0001 
POU5F1P3 12 0.104 0.0439 NA NA 
RPL7P59 7 0.104 0.0439 NA NA 
RPL3P6 5 0.104 0.0440 NA NA 
ATIC 2 0.104 0.0440 -0.090 0.1950 
EFNA4 1 0.104 0.0441 -0.151 0.0288 
CYP1B1-AS1 2 0.104 0.0441 NA NA 
IGSF8 1 0.104 0.0442 NA NA 
PDE4C 19 -0.104 0.0442 0.043 0.5300 
FAM27C 9 0.104 0.0442 NA NA 
NPM1P21 8 0.104 0.0442 NA NA 
ZDBF2 2 -0.104 0.0444 NA NA 
TRIO 5 0.104 0.0444 -0.153 0.0266 
GOLGA6L9 15 -0.104 0.0446 NA NA 
MAD1L1 7 -0.104 0.0446 NA NA 
MFSD6 2 -0.104 0.0446 NA NA 
LINC01320 2 0.104 0.0447 NA NA 
KIAA1524 3 -0.104 0.0448 NA NA 
CLIP2 7 0.104 0.0448 NA NA 
LMTK2 7 0.104 0.0448 -0.100 0.1479 
BIN2 12 0.104 0.0449 0.322 1.79E-06 
SCIN 7 0.104 0.0450 0.019 0.7793 
BTK X 0.104 0.0450 -0.085 0.2162 
IRF3 19 -0.104 0.0450 0.065 0.3448 
PET117 20 -0.104 0.0451 NA NA 
FIRRE X 0.104 0.0453 NA NA 
CDC14B 9 0.104 0.0453 0.076 0.2709 
TMEM263 12 -0.104 0.0454 NA NA 
CHCHD5 2 -0.104 0.0454 NA NA 
NDUFAF3 3 0.104 0.0454 NA NA 
FOXM1 12 -0.104 0.0455 -0.101 0.1452 
CDKN2D 19 0.104 0.0456 -0.044 0.5237 
PRR11 17 -0.104 0.0456 0.011 0.8772 
PDE4B 1 0.104 0.0456 0.212 0.0020 
MIA 19 0.103 0.0458 NA NA 
POU5F1 6 0.103 0.0458 0.067 0.3357 
FRMD8 11 -0.103 0.0459 NA NA 
NUDT16L1 16 -0.103 0.0460 NA NA 
PSMD6 3 -0.103 0.0460 0.094 0.1721 
ERCC5 13 -0.103 0.0460 0.216 0.0016 
SRP68P3 17 0.103 0.0461 NA NA 
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ATP5G3 2 -0.103 0.0461 0.066 0.3431 
MED21 12 0.103 0.0462 NA NA 
CD200 3 0.103 0.0462 -0.319 2.23E-06 
GPX4 19 0.103 0.0463 0.019 0.7831 
MYLK-AS1 3 0.103 0.0463 NA NA 
NECAB1 8 0.103 0.0463 NA NA 
BAX 19 -0.103 0.0463 0.226 0.0010 
LMCD1 3 0.103 0.0463 NA NA 
MPRIPP1 3 -0.103 0.0464 NA NA 
RAB18 10 -0.103 0.0464 NA NA 
PYCARD-AS1 16 0.103 0.0464 NA NA 
ST13P6 8 -0.103 0.0464 NA NA 
CTTNBP2NL 1 0.103 0.0466 0.022 0.7501 
HMGB1P4 2 0.103 0.0467 NA NA 
TNFAIP6 2 0.103 0.0469 0.224 0.0011 
CCNA2 4 -0.103 0.0469 -0.222 0.0012 
BCO1 16 0.103 0.0470 NA NA 
C1orf106 1 0.103 0.0470 NA NA 
KIAA1671 22 0.103 0.0470 NA NA 
GLDCP1 4 0.103 0.0471 NA NA 
ZNF195 11 0.103 0.0472 -0.067 0.3301 
TMEM237 2 0.103 0.0473 NA NA 
KIF9-AS1 3 -0.103 0.0475 NA NA 
ZNF568 19 -0.103 0.0475 NA NA 
PCAT6 1 -0.103 0.0476 NA NA 
HSD17B4 5 -0.103 0.0476 0.116 0.0941 
HKR1 19 -0.103 0.0476 NA NA 
DEK 6 -0.103 0.0476 0.048 0.4898 
RHBDL1 16 -0.103 0.0477 NA NA 
TADA2B 4 -0.103 0.0477 NA NA 
EEF1E1 6 0.103 0.0477 -0.008 0.9067 
PRKCDBP 11 0.103 0.0477 NA NA 
CEP128 14 0.103 0.0477 NA NA 
MTMR9 8 -0.103 0.0478 0.269 7.79E-05 
ANKRD29 18 0.102 0.0479 NA NA 
ANXA2P1 4 0.102 0.0480 0.058 0.4044 
RIPK2 8 0.102 0.0480 0.030 0.6632 
H3F3A 1 0.102 0.0480 -0.063 0.3640 
ABCD2 12 0.102 0.0481 0.140 0.0417 
APEX2 X -0.102 0.0481 NA NA 
SRGN 10 0.102 0.0482 NA NA 
RPL21P134 X -0.102 0.0482 NA NA 
CD47 3 -0.102 0.0482 0.119 0.0855 
GAB1 4 0.102 0.0482 -0.286 2.44E-05 
SIRPA 20 0.102 0.0483 0.395 2.60E-09 
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TMCO1 1 0.102 0.0483 0.153 0.0260 
STMN3 20 0.102 0.0484 NA NA 
RPL34P33 19 0.102 0.0485 NA NA 
MED13L 12 0.102 0.0485 NA NA 
ARHGAP11B 15 -0.102 0.0486 NA NA 
NOTCH2 1 0.102 0.0486 0.258 0.0002 
SMARCE1P6 2 0.102 0.0486 NA NA 
ACSL3 2 -0.102 0.0487 0.084 0.2269 
ZNF816 19 0.102 0.0487 NA NA 
NPM1P19 20 0.102 0.0487 NA NA 
LDHAP2 1 0.102 0.0488 NA NA 
DAAM2 6 0.102 0.0488 NA NA 
CBX3P1 11 0.102 0.0490 NA NA 
SETD3 14 -0.102 0.0490 0.194 0.0046 
DGKZP1 13 -0.102 0.0490 NA NA 
HMGB3P24 9 -0.102 0.0491 NA NA 
UBA7 3 -0.102 0.0491 NA NA 
PLEKHG2 19 0.102 0.0492 NA NA 
FAM227B 15 -0.102 0.0492 NA NA 
COPB1 11 -0.102 0.0493 0.171 0.0130 
PHF10 6 0.102 0.0493 0.244 0.0004 
KISS1R 19 0.102 0.0495 NA NA 
NTNG2 9 0.102 0.0495 NA NA 
GPR34 X 0.102 0.0495 NA NA 
PTPRO 12 0.102 0.0495 0.389 4.97E-09 
TLR4 9 0.102 0.0495 0.380 1.22E-08 
CMC2 16 -0.102 0.0495 NA NA 
PLD4 14 0.102 0.0495 NA NA 
ZBED3 5 0.102 0.0496 NA NA 
TFR2 7 -0.102 0.0496 -0.352 1.45E-07 
PTMAP4 12 0.102 0.0497 NA NA 
TMED4 7 -0.102 0.0497 NA NA 
ATG16L2 11 -0.102 0.0497 NA NA 
KIF4A X -0.102 0.0498 -0.238 0.0005 
LRP10 14 -0.102 0.0498 0.105 0.1277 
ZNF25 10 -0.102 0.0499 NA NA 
AP1S3 2 -0.102 0.0500 NA NA 
UPB1 22 0.102 0.0500 NA NA 
LMAN1 18 -0.102 0.0500 -0.087 0.2105 
ZFP36L1 14 -0.102 0.0500 0.341 3.69E-07 
PTPRC 1 0.102 0.0501 0.308 5.18E-06 
EIF3LP1 14 -0.102 0.0501 NA NA 
FAM129A 1 0.102 0.0501 0.337 5.49E-07 
AMD1 6 -0.101 0.0502 -0.120 0.0830 
BOLA3-AS1 2 0.101 0.0503 NA NA 
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GLE1 9 -0.101 0.0504 NA NA 
ZNF264 19 -0.101 0.0506 0.193 0.0049 
PCGF3 4 0.101 0.0506 0.127 0.0657 
SERTAD2 2 0.101 0.0506 -0.011 0.8747 
NFE2L3 7 0.101 0.0507 0.119 0.0833 
MLLT3 9 -0.101 0.0507 -0.120 0.0826 
IGLV1-44 22 0.101 0.0507 NA NA 
RPS18P13 19 0.101 0.0508 NA NA 
ACSL5 10 0.101 0.0508 0.221 0.0013 
ZNF611 19 -0.101 0.0509 0.031 0.6578 
TPT1P6 6 0.101 0.0509 NA NA 
SELPLG 12 0.101 0.0509 0.515 1.11E-15 
MICU1 10 0.101 0.0510 NA NA 
CLPB 11 -0.101 0.0510 NA NA 
TMED6 16 -0.101 0.0511 NA NA 
PTPN1 20 0.101 0.0513 0.168 0.0149 
PHBP11 1 0.101 0.0513 NA NA 
ANXA3 4 0.101 0.0514 0.061 0.3788 
DLGAP1-AS2 18 0.101 0.0516 NA NA 
RALGPS2 1 0.101 0.0517 -0.170 0.0133 
SCAP 3 -0.101 0.0517 0.073 0.2923 
C11orf63 11 0.101 0.0519 0.082 0.2373 
RPS6KA5 14 0.101 0.0519 0.237 0.0005 
CASP9 1 -0.101 0.0519 0.033 0.6386 
FBXW7 4 0.101 0.0519 0.279 4.01E-05 
EP300 22 0.101 0.0519 0.186 0.0067 
TBL3 16 -0.101 0.0519 NA NA 
SYNPO2 4 -0.101 0.0520 -0.001 0.9840 
ZNF736 7 -0.101 0.0520 NA NA 
QPRT 16 -0.101 0.0520 NA NA 
CCDC13 3 0.101 0.0521 NA NA 
RPL23 17 -0.101 0.0522 0.038 0.5856 
LEAP2 5 0.101 0.0522 NA NA 
ACTL10 20 -0.101 0.0523 NA NA 
ANKS3 16 -0.101 0.0524 NA NA 
DGKE 17 -0.101 0.0524 -0.007 0.9231 
SORT1 1 -0.100 0.0525 0.403 1.26E-09 
SMEK1 14 -0.100 0.0525 0.216 0.0016 
ABRACL 6 -0.100 0.0526 NA NA 
NPM1P6 8 -0.100 0.0526 NA NA 
AICDA 12 0.100 0.0526 NA NA 
B3GNTL1 17 0.100 0.0528 NA NA 
TROAP 12 -0.100 0.0529 NA NA 
WDFY2 13 0.100 0.0529 NA NA 
RAB42P1 14 0.100 0.0529 NA NA 
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NOP9 14 -0.100 0.0530 NA NA 
ZNF324B 19 -0.100 0.0531 NA NA 
ARPC3 12 0.100 0.0531 0.307 5.62E-06 
ZWILCH 15 -0.100 0.0533 -0.305 6.66E-06 
EEF1A1P25 3 0.100 0.0533 NA NA 
ARHGEF7 13 -0.100 0.0533 0.113 0.1030 
FLOT2 17 0.100 0.0535 0.200 0.0034 
LINC00426 13 0.100 0.0535 NA NA 
HMGA1P3 12 0.100 0.0535 NA NA 
SEMA7A 15 -0.100 0.0537 NA NA 
LCMT1-AS2 16 -0.100 0.0539 NA NA 
DROSHA 5 -0.100 0.0540 NA NA 
GAPDHP1 X -0.100 0.0540 NA NA 
MYBPC2 19 0.100 0.0540 NA NA 
FAM72A 1 -0.100 0.0541 NA NA 
RPS3AP22 5 0.100 0.0542 NA NA 
SRIP2 X -0.100 0.0543 NA NA 
CLK1 2 0.100 0.0544 0.122 0.0759 
GNPNAT1 14 -0.100 0.0544 NA NA 
CCNE1 19 -0.100 0.0544 -0.090 0.1908 
MAP3K15 X 0.100 0.0544 0.019 0.7840 
KHSRP 19 -0.100 0.0544 0.010 0.8828 
ARAP1 11 -0.100 0.0544 NA NA 
TBXAS1 7 0.100 0.0546 0.295 1.36E-05 
TMEM109 11 0.100 0.0546 0.085 0.2197 
KTI12 1 -0.100 0.0546 NA NA 
C16orf13 16 -0.100 0.0547 NA NA 
HAUS1P1 5 0.100 0.0547 NA NA 
SHB 9 0.100 0.0547 0.071 0.3069 
SYTL3 6 -0.100 0.0548 NA NA 
PARP14 3 0.100 0.0549 NA NA 
HCP5 6 0.099 0.0549 NA NA 
RPL17P43 17 0.099 0.0549 NA NA 
ITGA6 2 0.099 0.0549 0.115 0.0966 
PCP4L1 1 0.099 0.0550 NA NA 
KDM2A 11 0.099 0.0550 NA NA 
TEKT4 2 -0.099 0.0550 NA NA 
AFTPH 2 -0.099 0.0551 0.148 0.0316 
ALDOC 17 -0.099 0.0552 -0.076 0.2749 
PPP1R21 2 -0.099 0.0553 NA NA 
KIF23 15 -0.099 0.0553 NA NA 
ATP1A1-AS1 1 0.099 0.0554 NA NA 
IFIH1 2 0.099 0.0554 0.236 0.0005 
ELMO1 7 0.099 0.0555 0.057 0.4063 
GATAD2B 1 -0.099 0.0556 NA NA 
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DIABLO 12 0.099 0.0558 0.093 0.1795 
DDB2 11 -0.099 0.0558 0.152 0.0276 
SRSF6 20 -0.099 0.0560 NA NA 
FLI1 11 0.099 0.0560 0.159 0.0211 
STK40 1 -0.099 0.0560 NA NA 
VN1R1 19 -0.099 0.0561 NA NA 
RASSF7 11 0.099 0.0562 0.094 0.1739 
RPS2P4 14 -0.099 0.0562 NA NA 
DDX3X X -0.099 0.0563 0.041 0.5520 
ADAM19 5 0.099 0.0564 0.205 0.0028 
CUL5 11 -0.099 0.0564 0.156 0.0237 
MRPS36P1 3 -0.099 0.0566 NA NA 
EFNA5 5 0.099 0.0567 NA NA 
C6orf136 6 -0.099 0.0568 NA NA 
IGLC1 22 0.099 0.0568 NA NA 
NET1 10 -0.099 0.0569 -0.097 0.1595 
ERBB2 17 -0.099 0.0569 -0.175 0.0109 
MRPL51 12 -0.099 0.0570 NA NA 
EPRS 1 -0.099 0.0571 0.094 0.1730 
KCMF1 2 -0.099 0.0571 0.219 0.0014 
PDE4A 19 -0.099 0.0572 0.309 4.62E-06 
ZNF565 19 -0.099 0.0573 NA NA 
TFAP2A 6 0.099 0.0573 NA NA 
MBP 18 0.099 0.0573 0.242 0.0004 
CD160 1 -0.098 0.0575 -0.104 0.1328 
UCK2 1 0.098 0.0575 -0.255 0.0002 
BCL2L11 2 -0.098 0.0577 -0.059 0.3925 
GRAMD1C 3 0.098 0.0577 -0.293 1.51E-05 
AP2A2 11 0.098 0.0577 0.126 0.0679 
NELFA 4 0.098 0.0577 NA NA 
DLGAP5 14 -0.098 0.0578 NA NA 
HSPA9P1 2 -0.098 0.0578 NA NA 
GAPDHP63 6 0.098 0.0579 NA NA 
RPL21P119 16 -0.098 0.0580 NA NA 
TRMT5 14 -0.098 0.0581 -0.030 0.6609 
ATP11A 13 0.098 0.0581 0.457 2.83E-12 
BIK 22 0.098 0.0581 0.101 0.1453 
LDHAP1 4 0.098 0.0581 NA NA 
PTPN2P1 1 0.098 0.0582 NA NA 
TEC 4 -0.098 0.0584 NA NA 
STAM-AS1 10 0.098 0.0584 NA NA 
P2RY10 X -0.098 0.0585 0.051 0.4582 
PCOLCE 7 -0.098 0.0585 NA NA 
DACT3 19 0.098 0.0586 NA NA 
TMEM117 12 0.098 0.0586 NA NA 
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FUNDC2 X -0.098 0.0587 NA NA 
C11orf65 11 -0.098 0.0587 NA NA 
ACTG1 17 -0.098 0.0587 0.214 0.0018 
STX12 1 0.098 0.0588 0.406 9.00E-10 
BCL2L13 22 0.098 0.0588 0.094 0.1719 
SNX18 5 -0.098 0.0588 NA NA 
ZNF134 19 -0.098 0.0588 0.055 0.4243 
BRI3 7 0.098 0.0588 NA NA 
HNRNPA1P35 2 0.098 0.0589 NA NA 
PDK2 17 0.098 0.0590 NA NA 
TMEM2 9 -0.098 0.0591 0.301 8.71E-06 
SUV39H2 10 -0.098 0.0591 -0.104 0.1310 
GNA11 19 0.098 0.0591 -0.086 0.2131 
STAG3L4 7 -0.098 0.0592 NA NA 
C1orf123 1 0.098 0.0592 0.203 0.0031 
PHBP21 16 0.098 0.0593 NA NA 
LBR 1 0.098 0.0593 0.014 0.8433 
SLC39A7 6 -0.098 0.0594 0.012 0.8593 
SEMA6A-AS1 5 0.098 0.0594 NA NA 
CCSER2 10 0.098 0.0594 NA NA 
SIN3B 19 -0.098 0.0594 0.285 2.55E-05 
TUBB 6 -0.098 0.0595 -0.267 8.71E-05 
EBNA1BP2 1 0.098 0.0595 -0.232 0.0007 
ZNF853 7 -0.098 0.0595 NA NA 
REL 2 0.098 0.0595 0.070 0.3122 
CCSER1 4 -0.098 0.0596 NA NA 
PABPC1P4 12 0.098 0.0596 NA NA 
CBR3 21 0.098 0.0596 0.108 0.1187 
KIF6 6 0.098 0.0596 NA NA 
TMEM170A 16 -0.098 0.0598 NA NA 
XPO6 16 -0.098 0.0599 0.242 0.0004 
HMGN4 6 0.097 0.0600 0.208 0.0024 
ATP5G2 12 -0.097 0.0600 0.068 0.3221 
BBS10 12 0.097 0.0600 0.090 0.1952 
MCTP2 15 -0.097 0.0601 -0.374 2.04E-08 
PPP2R5C 14 0.097 0.0601 0.201 0.0034 
FAM49B 8 -0.097 0.0603 0.202 0.0032 
ERICH3 1 -0.097 0.0603 NA NA 
E2F2 1 0.097 0.0604 -0.169 0.0141 
RNPS1 16 -0.097 0.0604 0.014 0.8357 
TCEB2P2 11 0.097 0.0604 NA NA 
NDUFA10 2 -0.097 0.0604 0.164 0.0175 
ARHGEF1 19 -0.097 0.0606 0.290 1.88E-05 
KRT18P34 3 -0.097 0.0606 NA NA 
PRKAA1 5 -0.097 0.0607 -0.010 0.8836 
Appendix 
The Role of the Interleukin-6 Pathway in Asthma | 185 
MTND1P23 1 -0.097 0.0607 NA NA 
DHX8 17 -0.097 0.0608 0.263 0.0001 
RPL21P2 20 0.097 0.0609 NA NA 
ANKFY1 17 0.097 0.0610 NA NA 
YBX1P1 14 -0.097 0.0611 NA NA 
ITGA3 17 0.097 0.0612 NA NA 
PAQR4 16 0.097 0.0613 NA NA 
LAT 16 -0.097 0.0613 0.295 1.31E-05 
PEG10 7 0.097 0.0613 -0.236 0.0006 
PSME2P2 13 0.097 0.0615 NA NA 
RWDD4P2 7 0.097 0.0615 NA NA 
RPEL1 10 0.097 0.0615 NA NA 
RAD54L 1 -0.097 0.0615 -0.284 2.75E-05 
MUC12 7 0.097 0.0616 NA NA 
RCN3 19 0.097 0.0616 0.006 0.9261 
UCHL5 1 -0.097 0.0617 -0.059 0.3977 
CHID1 11 -0.097 0.0617 NA NA 
ECI2 6 -0.097 0.0618 NA NA 
DIP2A 21 -0.097 0.0619 0.069 0.3181 
CDKN2C 1 -0.097 0.0619 NA NA 
COX6C 8 -0.097 0.0619 -0.007 0.9174 
PRR14L 22 0.097 0.0619 NA NA 
CCNC 6 -0.097 0.0620 0.150 0.0289 
ERHP1 7 0.097 0.0620 NA NA 
EID1 15 0.097 0.0621 -0.087 0.2056 
IMPACT 18 -0.097 0.0622 0.101 0.1444 
LUC7L 16 0.097 0.0624 0.102 0.1411 
LINC00937 12 0.097 0.0624 NA NA 
MEST 7 0.097 0.0624 -0.255 0.0002 
KIF21B 1 0.097 0.0625 0.158 0.0216 
SNAI3 16 0.097 0.0625 NA NA 
LSP1 11 0.096 0.0627 0.369 3.29E-08 
RIMKLA 1 -0.096 0.0627 NA NA 
IER5 1 0.096 0.0628 0.117 0.0897 
COL18A1 21 -0.096 0.0628 -0.052 0.4515 
ANKRD13A 12 0.096 0.0628 NA NA 
ZNF674-AS1 X 0.096 0.0628 NA NA 
ANKRD44 2 0.096 0.0629 NA NA 
PRTFDC1 10 0.096 0.0629 NA NA 
TNFRSF21 6 0.096 0.0630 -0.249 0.0003 
KDM3B 5 0.096 0.0631 NA NA 
RPS10P3 9 -0.096 0.0631 NA NA 
NDUFC1 4 0.096 0.0632 0.023 0.7409 
GRIN2D 19 0.096 0.0632 NA NA 
PNMA1 14 0.096 0.0632 0.007 0.9218 
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SPARC 5 0.096 0.0632 -0.004 0.9577 
GPLD1 6 0.096 0.0632 -0.162 0.0187 
MRPS18AP1 3 0.096 0.0633 NA NA 
ILDR2 1 0.096 0.0633 NA NA 
HSPE1 2 -0.096 0.0634 -0.048 0.4839 
ZBTB4 17 -0.096 0.0634 NA NA 
DACT1 14 0.096 0.0634 0.058 0.4025 
ZG16B 16 -0.096 0.0634 NA NA 
C12orf74 12 0.096 0.0636 NA NA 
GIMAP1 7 -0.096 0.0637 NA NA 
IMPAD1 8 -0.096 0.0637 NA NA 
CCNB2 15 -0.096 0.0638 -0.280 3.62E-05 
MARCH9 12 0.096 0.0638 NA NA 
CXXC5 5 0.096 0.0639 NA NA 
SLC9A7P1 12 0.096 0.0641 NA NA 
ADAMTS12 5 0.096 0.0643 NA NA 
RSBN1 1 0.096 0.0643 0.145 0.0358 
NAMPTP1 10 0.096 0.0645 NA NA 
APOL2 22 0.096 0.0646 0.190 0.0057 
FAR2 12 -0.096 0.0646 NA NA 
TRAF3IP2 6 -0.096 0.0647 -0.072 0.2974 
TERF1P4 X -0.096 0.0647 NA NA 
CD83 6 0.096 0.0647 0.064 0.3542 
RASGRP4 19 0.096 0.0648 NA NA 
KPNA3 13 -0.096 0.0648 0.028 0.6852 
CCDC18 1 -0.096 0.0649 NA NA 
NPM1P25 10 0.096 0.0650 NA NA 
MZT1 13 -0.096 0.0650 NA NA 
SPATA9 5 -0.096 0.0651 NA NA 
SLC29A2 11 -0.096 0.0651 NA NA 
ACPP 3 0.096 0.0654 0.360 7.26E-08 
FAM171B 2 0.095 0.0655 NA NA 
CLSTN3 12 -0.095 0.0655 -0.032 0.6390 
METTL6 3 -0.095 0.0656 NA NA 
ARSG 17 -0.095 0.0656 NA NA 
AP1S1 7 -0.095 0.0658 0.048 0.4901 
MTA3 2 0.095 0.0658 NA NA 
HNRNPA1P51 2 0.095 0.0658 NA NA 
PRKACA 19 -0.095 0.0659 0.451 5.45E-12 
COG3 13 -0.095 0.0659 NA NA 
LILRB4 19 0.095 0.0660 0.015 0.8341 
IFI6 1 0.095 0.0660 -0.316 2.91E-06 
SLC9A7 X 0.095 0.0660 -0.279 3.83E-05 
P2RX5 17 0.095 0.0661 -0.136 0.0486 
TMEM86B 19 -0.095 0.0661 NA NA 
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ATF7 12 0.095 0.0662 0.031 0.6571 
CCDC51 3 0.095 0.0662 -0.180 0.0088 
SH2B1 16 0.095 0.0662 NA NA 
LSM6 4 -0.095 0.0664 0.219 0.0014 
RNASE6 14 0.095 0.0665 0.242 0.0004 
ARHGEF38 4 0.095 0.0667 NA NA 
HMGA1P6 13 0.095 0.0667 NA NA 
CLCN5 X 0.095 0.0668 0.132 0.0559 
SLC30A6 2 0.095 0.0668 NA NA 
H2AFJ 12 0.095 0.0669 -0.168 0.0144 
GTF2H2 5 -0.095 0.0670 0.112 0.1040 
RDH13 19 -0.095 0.0670 NA NA 
ASS1 9 -0.095 0.0670 NA NA 
ST20 15 0.095 0.0671 NA NA 
FCHSD2 11 0.095 0.0671 0.086 0.2149 
RPS11P5 12 0.095 0.0671 NA NA 
NDNL2 15 -0.095 0.0671 NA NA 
RINL 19 -0.095 0.0672 NA NA 
MAN1A2 1 0.095 0.0672 0.150 0.0294 
NDUFA4L2 12 0.095 0.0673 NA NA 
RITA1 12 -0.095 0.0673 NA NA 
RPSAP4 14 0.095 0.0673 NA NA 
TARSL2 15 -0.095 0.0673 NA NA 
CD58 1 0.095 0.0674 0.175 0.0109 
RANGAP1 22 -0.095 0.0674 NA NA 
MITD1 2 0.095 0.0675 NA NA 
ITIH1 3 -0.095 0.0676 NA NA 
CENPN 16 -0.095 0.0676 -0.291 1.77E-05 
ELF4 X 0.095 0.0676 0.360 7.77E-08 
ACBD5 10 0.095 0.0677 NA NA 
LMTK3 19 -0.095 0.0679 NA NA 
H1FX 3 0.095 0.0679 0.066 0.3383 
KCTD12 13 0.095 0.0679 0.481 1.35E-13 
COQ10A 12 0.095 0.0680 NA NA 
RNF169 11 0.095 0.0680 NA NA 
MAP2K2 19 -0.095 0.0680 -0.100 0.1493 
RPS23P2 4 0.095 0.0682 NA NA 
UBE2V1 20 -0.095 0.0682 -0.089 0.1967 
HSP90AB3P 4 -0.095 0.0683 NA NA 
PPIB 15 -0.094 0.0683 -0.061 0.3795 
RPLP1P6 5 0.094 0.0683 NA NA 
DDT 22 0.094 0.0684 0.089 0.1999 
PLEKHG3 14 0.094 0.0687 NA NA 
ARHGAP6 X 0.094 0.0687 -0.009 0.8946 
CTAGE1 18 0.094 0.0689 NA NA 
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XPO4 13 -0.094 0.0689 0.173 0.0117 
EFNA3 1 -0.094 0.0689 NA NA 
RHOU 1 0.094 0.0690 NA NA 
PER1 17 -0.094 0.0690 0.087 0.2074 
IL18 11 -0.094 0.0694 -0.047 0.4981 
C3orf67 3 0.094 0.0695 NA NA 
SLC46A1 17 -0.094 0.0695 NA NA 
AIM1 6 -0.094 0.0695 0.393 3.41E-09 
FLII 17 -0.094 0.0695 0.202 0.0031 
CCDC85B 11 0.094 0.0695 -0.068 0.3291 
BRD4 19 -0.094 0.0696 -0.030 0.6631 
JMJD1C 10 -0.094 0.0696 0.209 0.0023 
LIMD1-AS1 3 0.094 0.0696 NA NA 
TSPYL1 6 -0.094 0.0697 -0.084 0.2266 
SETD6 16 0.094 0.0700 0.058 0.4036 
HMGN2P5 15 -0.094 0.0700 NA NA 
ATP10D 4 -0.094 0.0700 0.031 0.6588 
MAPK6PS4 8 -0.094 0.0701 NA NA 
ITGB3 17 0.094 0.0702 -0.039 0.5778 
ZNF322P1 9 0.094 0.0702 NA NA 
SLC26A1 4 0.094 0.0703 NA NA 
IFI16 1 0.094 0.0703 0.179 0.0091 
STYX 14 -0.094 0.0703 NA NA 
SGCB 4 0.094 0.0703 -0.055 0.4296 
PRKAR1A 17 -0.094 0.0703 0.168 0.0147 
ESF1 20 -0.094 0.0703 0.070 0.3117 
MCM6 2 0.094 0.0704 -0.148 0.0319 
DTD1 20 -0.094 0.0707 NA NA 
SIDT1 3 -0.094 0.0707 0.051 0.4594 
RPS20 8 -0.094 0.0708 0.043 0.5320 
C16orf74 16 0.094 0.0709 NA NA 
SH3D21 1 -0.094 0.0709 NA NA 
GLIS2 16 0.094 0.0710 NA NA 
SNORD3B-2 17 0.094 0.0711 NA NA 
EEF1A1P16 12 0.094 0.0711 NA NA 
NPHP4 1 -0.094 0.0711 NA NA 
RPSA 3 -0.094 0.0712 NA NA 
CAPRIN2 12 -0.093 0.0713 NA NA 
RAB8A 19 -0.093 0.0714 0.108 0.1193 
WDR83OS 19 -0.093 0.0714 NA NA 
NXPH3 17 0.093 0.0714 NA NA 
FRMD4B 3 0.093 0.0715 0.080 0.2478 
APOL6 22 0.093 0.0716 0.261 0.0001 
PPP1CC 12 0.093 0.0716 0.081 0.2424 
CAPN7 3 -0.093 0.0717 0.182 0.0082 
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ZNF426 19 -0.093 0.0718 NA NA 
BRD7P2 3 -0.093 0.0718 NA NA 
IL17RA 22 -0.093 0.0718 0.622 0 
KRT8P46 4 0.093 0.0719 NA NA 
KLF9 9 -0.093 0.0719 0.244 0.0003 
ID3 1 0.093 0.0719 0.054 0.4393 
TMC6 17 -0.093 0.0719 0.175 0.0109 
LCN10 9 -0.093 0.0721 NA NA 
TBP 6 -0.093 0.0722 0.167 0.0152 
TTC13 1 -0.093 0.0722 0.245 0.0003 
TAF11 6 -0.093 0.0723 0.011 0.8692 
BAP1 3 -0.093 0.0723 -0.081 0.2438 
PIKFYVE 2 0.093 0.0723 NA NA 
SATL1 X 0.093 0.0725 0.051 0.4611 
ZNF962P 13 0.093 0.0725 NA NA 
VGLL4 3 0.093 0.0725 0.026 0.7100 
POLR1A 2 0.093 0.0726 NA NA 
ITSN2 2 0.093 0.0727 0.192 0.0050 
GIGYF2 2 -0.093 0.0728 NA NA 
ADRB2 5 0.093 0.0728 0.059 0.3959 
RUSC1-AS1 1 -0.093 0.0729 NA NA 
BASP1 5 0.093 0.0729 -0.100 0.1488 
OLA1P2 17 0.093 0.0729 NA NA 
PREPL 2 -0.093 0.0731 0.110 0.1112 
SLC5A3 21 0.093 0.0731 0.165 0.0165 
ASNSP4 8 -0.093 0.0732 NA NA 
NRAS 1 -0.093 0.0732 -0.041 0.5566 
GPT2 16 -0.093 0.0732 NA NA 
EDNRB 13 0.093 0.0734 -0.091 0.1903 
FCER1G 1 -0.093 0.0735 0.127 0.0646 
BTBD2 19 -0.093 0.0735 NA NA 
ACTG1P17 15 -0.093 0.0735 NA NA 
ZNF529 19 -0.093 0.0736 -0.092 0.1825 
SLC35A5 3 -0.093 0.0736 0.237 0.0005 
IRF2BPL 14 0.093 0.0737 NA NA 
LIN7C 11 -0.093 0.0738 0.085 0.2185 
ACTN4P1 4 0.093 0.0738 NA NA 
VPS37B 12 0.093 0.0738 -0.202 0.0032 
SENCR 11 0.093 0.0742 NA NA 
IFI44L 1 0.093 0.0742 0.271 6.59E-05 
CNOT6 5 -0.093 0.0743 0.030 0.6610 
MCTP1 5 -0.092 0.0744 0.232 0.0007 
GOLGA6L4 15 -0.092 0.0745 NA NA 
MNDA 1 0.092 0.0746 0.333 7.19E-07 
TSEN34 19 0.092 0.0746 0.358 8.93E-08 
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POLB 8 -0.092 0.0747 0.204 0.0029 
TMEM154 4 0.092 0.0748 NA NA 
TOM1 22 -0.092 0.0749 NA NA 
DCHS2 4 0.092 0.0749 NA NA 
ZNF821 16 -0.092 0.0749 NA NA 
CCDC81 11 0.092 0.0750 NA NA 
DCBLD2 3 -0.092 0.0750 -0.189 0.0060 
CC2D1A 19 -0.092 0.0750 -0.021 0.7566 
NDUFV1 11 -0.092 0.0750 0.085 0.2212 
VLDLR-AS1 9 -0.092 0.0750 NA NA 
SLC12A7 5 0.092 0.0751 0.340 4.16E-07 
PSMB9 6 0.092 0.0752 0.253 0.0002 
FBXO33 14 -0.092 0.0755 NA NA 
RUNX1 21 0.092 0.0755 0.137 0.0463 
VPS25 17 -0.092 0.0755 NA NA 
PMS2CL 7 -0.092 0.0757 NA NA 
CPA4 7 0.092 0.0757 NA NA 
DBI 2 -0.092 0.0757 0.145 0.0356 
BLCAP 20 -0.092 0.0758 0.145 0.0357 
FOXP1 3 0.092 0.0758 0.364 5.34E-08 
SSH3 11 -0.092 0.0759 0.073 0.2919 
HINT1 5 -0.092 0.0759 0.012 0.8636 
MTM1 X -0.092 0.0760 0.323 1.62E-06 
PEX12 17 0.092 0.0760 -0.125 0.0707 
SF3B1 2 0.092 0.0760 0.226 0.0010 
PLEKHF1 19 -0.092 0.0761 NA NA 
RPS24P17 16 0.092 0.0761 NA NA 
IFI30 19 -0.092 0.0762 0.368 3.72E-08 
ZNF608 5 -0.092 0.0762 NA NA 
RPL7P37 10 0.092 0.0762 NA NA 
SGMS1 10 -0.092 0.0763 NA NA 
FABP5P2 13 0.092 0.0763 NA NA 
RGS1 1 -0.092 0.0763 0.106 0.1246 
GATC 12 -0.092 0.0765 NA NA 
MARCH8 10 0.092 0.0765 NA NA 
IRS1 2 0.092 0.0765 0.143 0.0382 
LIMK2 22 -0.092 0.0765 0.341 3.81E-07 
PNKP 19 -0.092 0.0766 -0.156 0.0238 
PDXP 22 -0.092 0.0766 NA NA 
ORC3 6 0.092 0.0770 NA NA 
PCED1B-AS1 12 0.092 0.0770 NA NA 
SRSF5 14 -0.092 0.0771 NA NA 
RPS2P6 18 0.092 0.0771 NA NA 
CHAC1 15 -0.092 0.0771 NA NA 
ZNF682 19 -0.092 0.0772 -0.083 0.2305 
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JAM2 21 -0.092 0.0774 NA NA 
DSC3 18 -0.092 0.0775 NA NA 
MCMBP 10 0.092 0.0775 NA NA 
SLC35E2B 1 -0.091 0.0776 NA NA 
GPR68 14 -0.091 0.0777 -0.014 0.8436 
TSPAN12 7 -0.091 0.0778 NA NA 
IQCD 12 -0.091 0.0778 NA NA 
C1orf52 1 -0.091 0.0779 NA NA 
ZHX2 8 0.091 0.0779 -0.047 0.4937 
KDM1B 6 0.091 0.0780 NA NA 
HMGB2 4 -0.091 0.0780 -0.097 0.1590 
PDE12 3 -0.091 0.0780 NA NA 
BCL2L14 12 0.091 0.0780 NA NA 
MPC1 6 -0.091 0.0781 NA NA 
SLC29A4 7 -0.091 0.0781 NA NA 
FFAR2 19 0.091 0.0782 NA NA 
C10orf55 10 0.091 0.0782 NA NA 
FAM175B 10 0.091 0.0782 NA NA 
SLC52A1 17 -0.091 0.0782 NA NA 
OAT 10 -0.091 0.0784 -0.097 0.1602 
PLGRKT 9 -0.091 0.0784 NA NA 
ZNF219 14 0.091 0.0784 -0.195 0.0045 
SDSL 12 0.091 0.0786 NA NA 
RBM8B 14 -0.091 0.0787 NA NA 
ANKHD1 5 0.091 0.0787 0.221 0.0012 
RGS10 10 0.091 0.0787 0.250 0.0002 
CLK4 5 0.091 0.0788 0.149 0.0307 
GMPSP1 4 -0.091 0.0788 NA NA 
PEX3 6 -0.091 0.0788 0.079 0.2531 
CDH23 10 0.091 0.0791 NA NA 
RPL7AP6 14 -0.091 0.0791 NA NA 
JAG1 20 -0.091 0.0792 0.159 0.0212 
ARL8B 3 0.091 0.0792 0.205 0.0028 
DHX9P1 13 0.091 0.0793 NA NA 
SNHG17 20 -0.091 0.0794 NA NA 
HSDL2 9 -0.091 0.0796 0.083 0.2283 
TMED10 14 -0.091 0.0796 0.132 0.0555 
RABGGTB 1 -0.091 0.0797 0.071 0.3064 
CHEK1 11 0.091 0.0798 -0.333 7.14E-07 
FAM3C2 X -0.091 0.0798 NA NA 
PDXDC1 16 0.091 0.0801 NA NA 
RAB15 14 0.091 0.0801 NA NA 
DRAM1 12 0.091 0.0801 NA NA 
LINC00094 9 -0.091 0.0802 NA NA 
AZIN1 8 -0.091 0.0802 0.145 0.0357 
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PSMA1 11 0.091 0.0802 0.124 0.0717 
CECR1 22 0.091 0.0803 0.436 3.17E-11 
BCLAF1 6 -0.091 0.0803 0.099 0.1533 
ARID5B 10 0.091 0.0804 -0.047 0.4927 
C17orf75 17 -0.091 0.0804 0.020 0.7713 
PA2G4P2 20 0.091 0.0806 NA NA 
HIP1R 12 0.091 0.0806 NA NA 
BCL10 1 0.091 0.0806 0.117 0.0890 
CCDC101 16 0.091 0.0806 0.142 0.0398 
UBE2SP1 17 -0.091 0.0807 NA NA 
NXPH4 12 0.091 0.0808 0.012 0.8583 
TMEM189 20 0.091 0.0808 NA NA 
FAM103A2P 6 -0.091 0.0809 NA NA 
TMEM14A 6 -0.090 0.0810 -0.218 0.0015 
PARL 3 -0.090 0.0810 0.256 0.0002 
SVIL 10 0.090 0.0810 0.475 2.81E-13 
SRD5A1 5 -0.090 0.0811 0.325 1.45E-06 
SPAG16 2 0.090 0.0812 -0.235 0.0006 
PPA2 4 -0.090 0.0813 0.097 0.1593 
NCKAP1 2 0.090 0.0813 -0.083 0.2290 
ZNF337 20 -0.090 0.0814 0.157 0.0224 
MLX 17 0.090 0.0816 0.364 5.13E-08 
CCR1 3 0.089 0.0861 0.477 2.27E-13 
SLC16A6 17 -0.088 0.0887 0.318 2.45E-06 
CDK5R1 17 -0.088 0.0902 0.349 2.01E-07 
BAG3 10 0.087 0.0916 0.383 8.55E-09 
TNFAIP2 14 0.087 0.0928 0.330 9.33E-07 
TDRD7 9 0.087 0.0932 0.337 5.51E-07 
MKNK1 1 0.087 0.0932 0.332 7.77E-07 
F2R 5 -0.087 0.0951 -0.354 1.29E-07 
FAS 10 -0.086 0.0955 0.339 4.56E-07 
NUMB 14 0.086 0.0956 0.407 8.03E-10 
MKKS 20 -0.086 0.0957 0.456 3.04E-12 
NINJ1 9 -0.086 0.0978 0.375 1.87E-08 
KIAA0513 16 -0.085 0.1004 0.486 6.79E-14 
SLC27A2 15 -0.085 0.1022 -0.323 1.63E-06 
IL11RA 9 0.084 0.1056 0.328 1.08E-06 
CD209 19 0.083 0.1081 0.364 5.06E-08 
SNN 16 0.083 0.1084 0.445 1.19E-11 
ZNF516 18 -0.083 0.1103 0.392 3.76E-09 
GLG1 16 -0.083 0.1104 0.393 3.18E-09 
MICAL3 22 0.081 0.1167 -0.394 3.10E-09 
STX2 12 0.081 0.1183 0.352 1.47E-07 
LTB4R 14 0.081 0.1187 0.382 9.33E-09 
ZDHHC7 16 -0.081 0.1188 0.424 1.34E-10 
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HSPA6 1 0.081 0.1192 0.332 7.77E-07 
TK2 16 -0.081 0.1200 0.451 5.52E-12 
CREBL2 12 -0.080 0.1216 0.469 5.98E-13 
LY96 8 0.080 0.1218 0.532 0 
NECAP2 1 0.080 0.1227 0.476 2.40E-13 
GNPDA1 5 -0.080 0.1229 0.561 0 
SGK3 8 -0.080 0.1235 0.368 3.73E-08 
HDAC4 2 0.079 0.1281 0.430 6.39E-11 
FGL2 7 0.079 0.1284 0.487 6.06E-14 
SULT1A2 16 0.078 0.1305 0.433 4.74E-11 
TCIRG1 11 -0.078 0.1320 0.361 6.79E-08 
ATP6AP1 X 0.078 0.1333 0.394 3.09E-09 
CD86 3 0.077 0.1356 0.399 1.78E-09 
GIMAP6 7 -0.077 0.1362 0.359 8.32E-08 
RAB20 13 0.077 0.1373 0.354 1.30E-07 
GADD45B 19 -0.077 0.1377 0.386 6.69E-09 
ZNF711 X 0.077 0.1392 -0.396 2.59E-09 
TOB1 17 -0.076 0.1419 0.497 1.47E-14 
KCNQ1 11 -0.076 0.1427 0.328 1.09E-06 
TBL1X X 0.075 0.1457 0.493 2.44E-14 
SLFN12 17 0.075 0.1458 0.367 4.08E-08 
SLC16A3 17 0.075 0.1472 0.352 1.50E-07 
JUNB 19 0.075 0.1473 0.413 4.08E-10 
CYP1B1 2 0.075 0.1482 0.475 2.90E-13 
SIGLEC5 19 0.075 0.1493 0.405 1.03E-09 
CRYL1 13 -0.075 0.1495 0.475 2.76E-13 
SEMA6C 1 -0.075 0.1497 0.378 1.37E-08 
LRRC8D 1 -0.075 0.1498 0.438 2.77E-11 
PELI1 2 0.075 0.1501 0.319 2.23E-06 
GAS7 17 -0.074 0.1522 0.338 5.05E-07 
CAPZB 1 -0.074 0.1537 0.415 3.51E-10 
CTSA 20 0.073 0.1573 0.366 4.34E-08 
MOSPD2 X -0.073 0.1582 0.368 3.57E-08 
SLC7A7 14 0.073 0.1583 0.346 2.44E-07 
SMYD3 1 -0.073 0.1585 -0.331 9.01E-07 
SH2B3 12 0.073 0.1589 0.331 8.38E-07 
PRKCA 17 -0.073 0.1595 0.504 5.11E-15 
FZD7 2 0.073 0.1608 -0.329 1.01E-06 
RAD51AP1 12 0.073 0.1616 -0.342 3.44E-07 
PPARD 6 0.072 0.1648 0.337 5.55E-07 
KIF1B 1 -0.072 0.1655 0.351 1.68E-07 
STAT6 12 0.072 0.1662 0.415 3.43E-10 
EPHX2 8 0.072 0.1663 0.343 3.17E-07 
TNFSF13 17 0.071 0.1685 0.501 8.88E-15 
ACTN1 14 -0.071 0.1705 0.421 1.75E-10 
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PIAS1 15 -0.071 0.1705 0.380 1.21E-08 
NUSAP1 15 -0.071 0.1737 -0.321 1.99E-06 
FRAT2 10 -0.070 0.1748 0.438 2.77E-11 
CD93 20 -0.070 0.1763 0.401 1.48E-09 
TGFBR2 3 -0.070 0.1775 0.384 8.36E-09 
TRAF3IP3 1 0.070 0.1779 0.365 4.78E-08 
RASSF2 20 0.070 0.1785 0.394 3.00E-09 
DISC1 1 0.070 0.1790 0.673 0 
SLC11A1 2 0.069 0.1816 0.358 8.85E-08 
OSTF1 9 0.069 0.1852 0.335 6.39E-07 
CD48 1 -0.069 0.1856 0.431 6.23E-11 
GCH1 14 -0.069 0.1860 0.401 1.46E-09 
DDAH1 1 0.068 0.1880 -0.355 1.12E-07 
RUFY2 10 0.068 0.1901 0.419 2.24E-10 
CDC42BPA 1 0.068 0.1923 -0.357 9.63E-08 
CNIH4 1 0.067 0.1947 0.499 1.11E-14 
RPS6KA4 11 0.067 0.1984 0.466 8.85E-13 
PHC2 1 0.066 0.2004 0.320 2.14E-06 
ARL4C 2 -0.066 0.2020 0.373 2.36E-08 
AHR 7 0.066 0.2028 0.383 8.85E-09 
DOK2 8 -0.066 0.2031 0.457 2.91E-12 
CORO1A 16 -0.066 0.2039 0.437 3.00E-11 
FCGRT 19 0.065 0.2119 0.481 1.31E-13 
AOAH 7 0.064 0.2152 0.327 1.15E-06 
STX6 1 0.064 0.2155 0.352 1.50E-07 
GRN 17 0.064 0.2178 0.445 1.12E-11 
SCRN3 2 0.064 0.2205 0.406 9.07E-10 
MAL 2 -0.063 0.2269 0.414 3.73E-10 
ITPK1 14 0.062 0.2317 0.327 1.17E-06 
ATG7 3 -0.062 0.2329 0.505 4.88E-15 
IL6ST 5 0.062 0.2347 0.518 6.66E-16 
IL16 15 -0.062 0.2357 0.409 6.70E-10 
VIM 10 0.061 0.2362 0.438 2.72E-11 
RAB27A 15 -0.061 0.2363 0.357 9.43E-08 
TLR2 4 -0.061 0.2377 0.534 0 
LILRA6 19 0.061 0.2402 0.317 2.52E-06 
PPT1 1 0.061 0.2430 0.517 8.88E-16 
PPFIA1 11 0.060 0.2452 0.333 7.39E-07 
CKS2 9 -0.060 0.2494 -0.394 2.93E-09 
SERPINB8 18 0.059 0.2530 0.426 1.01E-10 
MYD88 3 0.059 0.2540 0.440 2.13E-11 
CD46 1 -0.059 0.2542 0.345 2.67E-07 
SH3BP2 4 0.059 0.2548 0.318 2.47E-06 
REEP5 5 -0.059 0.2555 0.380 1.13E-08 
PRRG4 11 -0.059 0.2561 0.343 3.21E-07 
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NCF2 1 0.059 0.2587 0.526 2.22E-16 
PLCL1 2 -0.058 0.2613 0.494 2.31E-14 
TRIM38 6 0.058 0.2635 0.337 5.24E-07 
MCM2 3 0.058 0.2650 -0.359 8.27E-08 
UPP1 7 0.058 0.2655 0.498 1.20E-14 
ST7 7 0.058 0.2665 -0.343 3.23E-07 
GALNS 16 -0.057 0.2733 0.351 1.71E-07 
TBC1D4 13 0.057 0.2734 0.377 1.63E-08 
APOL3 22 0.057 0.2743 0.418 2.52E-10 
NFE2L2 2 0.056 0.2767 0.373 2.36E-08 
GNG10 9 0.056 0.2803 0.322 1.79E-06 
CAB39 2 0.056 0.2828 0.351 1.69E-07 
F5 1 0.056 0.2837 0.580 0 
TNFAIP3 6 0.056 0.2841 0.359 8.32E-08 
SLC15A3 11 0.056 0.2850 0.445 1.22E-11 
OSBPL11 3 0.055 0.2921 0.320 2.05E-06 
SLC6A6 3 0.055 0.2925 0.322 1.82E-06 
PEA15 1 -0.055 0.2932 0.328 1.12E-06 
KDELC1 13 0.054 0.2995 -0.388 5.37E-09 
PCYOX1L 5 -0.054 0.3010 0.323 1.58E-06 
SYNJ1 21 0.053 0.3040 0.482 1.14E-13 
CKLF 16 -0.053 0.3093 0.400 1.58E-09 
CLTB 5 -0.053 0.3093 0.318 2.40E-06 
PDGFD 11 -0.053 0.3118 -0.406 9.01E-10 
SNX27 1 -0.052 0.3128 0.561 0 
N4BP1 16 0.052 0.3128 0.435 3.66E-11 
FBN1 15 0.052 0.3146 -0.324 1.56E-06 
MX2 21 0.052 0.3153 0.573 0 
NPTN 15 -0.052 0.3154 0.423 1.51E-10 
PIK3CD 1 0.052 0.3192 0.352 1.51E-07 
LPXN 11 -0.052 0.3197 0.394 3.14E-09 
IRAK4 12 -0.051 0.3222 0.332 8.19E-07 
LDLRAP1 1 0.051 0.3245 0.349 2.04E-07 
TBC1D2B 15 0.051 0.3266 0.426 1.02E-10 
GIT2 12 -0.051 0.3271 0.333 7.24E-07 
CRK 17 0.051 0.3277 0.349 1.91E-07 
HERC3 4 -0.051 0.3286 0.373 2.22E-08 
SLC25A44 1 -0.050 0.3348 0.331 8.60E-07 
DEGS1 1 0.050 0.3376 0.331 8.63E-07 
FTH1 11 0.050 0.3398 0.442 1.75E-11 
CHMP4A 14 0.049 0.3412 0.336 5.89E-07 
SNAP23 15 -0.049 0.3417 0.338 4.92E-07 
NETO2 16 -0.049 0.3422 0.399 1.78E-09 
WDFY3 4 -0.049 0.3449 0.428 8.30E-11 
WARS 14 0.049 0.3449 0.415 3.49E-10 
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STX10 19 0.049 0.3467 0.358 9.24E-08 
CAMKK2 12 0.049 0.3481 0.359 8.51E-08 
IL13RA1 X 0.049 0.3483 0.412 4.78E-10 
ZFYVE16 5 0.048 0.3531 0.341 3.70E-07 
SERPINA1 14 0.048 0.3551 0.424 1.35E-10 
TIMELESS 12 -0.048 0.3595 -0.323 1.59E-06 
DPEP2 16 0.047 0.3614 0.459 2.08E-12 
S100A6 1 0.047 0.3615 0.477 2.25E-13 
ARHGEF11 1 0.047 0.3653 0.618 0 
COG5 7 0.047 0.3664 0.323 1.68E-06 
ALDOA 16 -0.047 0.3682 0.335 6.05E-07 
MTUS1 8 -0.046 0.3736 0.361 7.04E-08 
EVI2B 17 0.046 0.3737 0.378 1.47E-08 
CERK 22 0.046 0.3743 0.460 2.03E-12 
GCSH 16 -0.046 0.3744 -0.348 2.14E-07 
IER3 6 0.046 0.3769 0.456 2.98E-12 
GIMAP5 7 -0.046 0.3788 0.409 6.36E-10 
GLCE 15 0.045 0.3863 0.334 6.93E-07 
AMPD2 1 -0.045 0.3893 0.351 1.65E-07 
TMEM43 3 -0.045 0.3908 0.318 2.39E-06 
TRIM14 9 0.044 0.3936 0.437 2.93E-11 
RNASET2 6 0.044 0.3959 0.424 1.31E-10 
PRMT2 21 -0.044 0.3962 0.359 8.14E-08 
OAS3 12 0.044 0.3969 0.461 1.62E-12 
CNDP2 18 0.044 0.3991 0.351 1.58E-07 
DLG5 10 -0.044 0.3992 -0.320 2.07E-06 
SIRT7 17 -0.044 0.3994 0.325 1.39E-06 
NLRP1 17 0.043 0.4069 0.518 6.66E-16 
HEATR3 16 -0.043 0.4131 0.440 2.15E-11 
SERPINI1 3 -0.042 0.4135 -0.424 1.23E-10 
CFP X -0.042 0.4209 0.494 2.20E-14 
MYH9 22 0.042 0.4227 0.349 1.91E-07 
PEPD 19 0.042 0.4235 0.349 1.92E-07 
CHMP7 8 0.041 0.4249 0.326 1.27E-06 
ALDH5A1 6 -0.041 0.4267 -0.327 1.17E-06 
OSTM1 6 0.041 0.4275 0.339 4.41E-07 
ERO1L 14 0.041 0.4283 0.345 2.81E-07 
STX16 20 -0.041 0.4285 0.383 8.52E-09 
ARL6IP5 3 0.041 0.4310 0.349 2.02E-07 
SORL1 11 -0.041 0.4326 0.417 2.69E-10 
SLC16A5 17 0.041 0.4328 0.443 1.40E-11 
MAN2B1 19 -0.041 0.4331 0.425 1.21E-10 
MAN1C1 1 0.041 0.4348 0.534 0 
RAD51 15 -0.040 0.4367 -0.408 7.00E-10 
PDE3B 11 -0.040 0.4378 0.375 1.93E-08 
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DTL 1 0.040 0.4381 -0.357 9.61E-08 
HTRA2 2 -0.040 0.4384 -0.341 3.83E-07 
MAN2C1 15 0.040 0.4401 0.364 5.25E-08 
EVI2A 17 0.040 0.4429 0.546 0 
PDXK 21 -0.040 0.4433 0.505 4.88E-15 
MINA 3 0.040 0.4445 0.439 2.45E-11 
GINS2 16 0.040 0.4450 -0.351 1.71E-07 
NDST2 10 -0.040 0.4453 0.348 2.04E-07 
SEMA4A 1 0.040 0.4463 0.519 6.66E-16 
ANKS1A 6 0.039 0.4491 0.338 5.10E-07 
LILRB2 19 0.039 0.4506 0.344 3.09E-07 
STAT1 2 0.039 0.4525 0.429 7.25E-11 
STK10 5 0.039 0.4537 0.354 1.24E-07 
NUP62 19 -0.039 0.4567 0.330 9.46E-07 
CEBPB 20 0.039 0.4570 0.379 1.24E-08 
USP4 3 -0.039 0.4583 0.378 1.38E-08 
TRIM36 5 -0.038 0.4622 0.458 2.50E-12 
LACTB2 8 -0.038 0.4652 0.320 2.09E-06 
PFKFB3 10 -0.038 0.4670 0.323 1.62E-06 
SGSH 17 -0.038 0.4671 0.521 4.44E-16 
UBE2D1 10 0.038 0.4693 0.398 2.05E-09 
SCO2 22 0.037 0.4722 0.475 2.78E-13 
NCAPG 4 -0.037 0.4722 -0.319 2.17E-06 
SMPD4 2 -0.037 0.4738 0.318 2.49E-06 
SQRDL 15 -0.037 0.4744 0.488 4.80E-14 
RHOG 11 -0.037 0.4745 0.394 2.93E-09 
ZDHHC18 1 0.037 0.4751 0.396 2.52E-09 
MYO5A 15 0.037 0.4768 0.348 2.07E-07 
SAMHD1 20 0.037 0.4768 0.609 0 
CSAD 12 0.037 0.4803 0.324 1.48E-06 
GNS 12 -0.037 0.4806 0.382 1.02E-08 
CHAF1B 21 -0.037 0.4808 -0.417 2.74E-10 
S100A11 1 0.036 0.4861 0.458 2.45E-12 
ALDH2 12 0.036 0.4868 0.373 2.20E-08 
USP3 15 -0.036 0.4873 0.425 1.11E-10 
MX1 21 0.036 0.4875 0.317 2.58E-06 
PYGB 20 -0.036 0.4885 0.323 1.62E-06 
ZNF200 16 0.036 0.4911 0.338 4.84E-07 
ICAM1 19 0.036 0.4915 0.413 4.24E-10 
SOCS3 17 -0.036 0.4922 0.463 1.35E-12 
KLHL23 2 0.036 0.4938 -0.381 1.06E-08 
LCP2 5 0.035 0.4945 0.401 1.51E-09 
CTSS 1 0.035 0.4955 0.423 1.48E-10 
CPD 17 -0.035 0.4956 0.344 2.89E-07 
MTF1 1 0.035 0.4956 0.356 1.06E-07 
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KIAA1467 12 0.035 0.4962 -0.342 3.48E-07 
WAS X 0.035 0.4993 0.461 1.76E-12 
HIPK3 11 -0.035 0.4994 0.399 1.90E-09 
LEPROTL1 8 -0.035 0.5047 0.360 7.67E-08 
CRIP1 14 0.035 0.5057 0.378 1.41E-08 
ITM2B 13 -0.034 0.5066 0.399 1.90E-09 
TNFSF10 3 0.034 0.5084 0.493 2.46E-14 
MKL1 22 0.034 0.5088 0.408 7.42E-10 
PHACTR2 6 0.034 0.5149 0.361 7.01E-08 
CASP1 11 -0.034 0.5170 0.557 0 
OAS2 12 0.034 0.5180 0.412 4.69E-10 
TLR1 4 0.034 0.5181 0.448 8.07E-12 
ZCCHC14 16 -0.033 0.5192 0.340 4.27E-07 
HIST1H3D 6 0.033 0.5223 -0.347 2.37E-07 
PLP2 X 0.033 0.5256 0.395 2.62E-09 
TMEM30A 6 -0.033 0.5260 0.331 8.51E-07 
HEXB 5 -0.033 0.5271 0.455 3.56E-12 
KIAA1324 1 -0.033 0.5277 0.323 1.66E-06 
GLIPR1 12 0.032 0.5338 0.351 1.63E-07 
WDR7 18 0.032 0.5354 0.320 2.14E-06 
DMXL2 15 -0.032 0.5383 0.407 8.09E-10 
MPPE1 18 -0.032 0.5408 0.329 9.91E-07 
IMPDH1 7 0.032 0.5413 0.334 7.08E-07 
SEC23B 20 -0.032 0.5415 0.364 5.36E-08 
ACVR2A 2 0.032 0.5418 0.437 2.85E-11 
MNT 17 0.032 0.5422 0.331 8.83E-07 
PDLIM5 4 -0.032 0.5429 0.362 6.00E-08 
DGKA 12 0.032 0.5435 0.395 2.83E-09 
PAK1 11 0.031 0.5490 0.337 5.54E-07 
SLC17A5 6 0.031 0.5493 0.405 9.98E-10 
VNN2 6 -0.031 0.5510 0.424 1.36E-10 
GSTK1 7 0.031 0.5526 0.379 1.32E-08 
POLR3G 5 -0.031 0.5532 -0.386 6.39E-09 
EXT1 8 -0.031 0.5558 0.408 7.26E-10 
PTPRE 10 -0.031 0.5567 0.420 1.93E-10 
AGTPBP1 9 0.030 0.5584 0.391 4.25E-09 
ANXA5 4 0.030 0.5622 0.481 1.34E-13 
IL10RB 21 0.030 0.5624 0.389 5.06E-09 
SLC2A3 12 0.030 0.5630 0.360 7.57E-08 
ABCB1 7 -0.030 0.5666 -0.394 2.89E-09 
STOML2 9 0.030 0.5688 -0.346 2.42E-07 
FHIT 3 -0.030 0.5696 0.346 2.50E-07 
TM9SF4 20 -0.030 0.5700 0.390 4.59E-09 
DPYD 1 0.029 0.5713 0.434 4.11E-11 
WWP1 8 -0.029 0.5744 0.381 1.06E-08 
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MYL6B 12 -0.029 0.5744 -0.429 7.74E-11 
ATP1A1 1 -0.029 0.5786 0.457 2.79E-12 
POLE2 14 -0.028 0.5843 -0.331 8.73E-07 
MEGF9 9 0.028 0.5849 0.431 5.70E-11 
RBMS1 2 -0.028 0.5860 0.440 2.12E-11 
WASF1 6 0.028 0.5879 -0.388 5.24E-09 
DNASE1L1 X 0.028 0.5903 0.321 1.96E-06 
TPP1 11 -0.028 0.5931 0.398 1.94E-09 
GSTA4 6 0.028 0.5943 -0.355 1.14E-07 
STK38L 12 0.028 0.5956 0.324 1.53E-06 
PSAP 10 -0.027 0.5984 0.323 1.66E-06 
NDRG1 8 -0.027 0.5991 0.428 8.57E-11 
ATP6V1B2 8 0.027 0.5999 0.440 2.04E-11 
DPP4 2 0.027 0.6065 0.322 1.71E-06 
RNH1 11 0.027 0.6072 0.425 1.13E-10 
TOR1AIP1 1 -0.027 0.6088 0.434 4.41E-11 
GPSM3 6 -0.026 0.6140 0.473 3.74E-13 
TNFSF12 17 -0.026 0.6142 0.407 7.69E-10 
ITGB2 21 -0.026 0.6168 0.477 2.10E-13 
FLNA X 0.026 0.6199 0.324 1.47E-06 
CSF1R 5 0.025 0.6285 0.462 1.58E-12 
CDK6 7 -0.025 0.6293 -0.358 8.83E-08 
PILRA 7 -0.025 0.6321 0.423 1.37E-10 
NSF 17 0.025 0.6324 0.374 2.08E-08 
ST6GALNAC2 17 -0.025 0.6333 0.383 8.79E-09 
LRCH4 7 -0.025 0.6338 0.373 2.22E-08 
PTAFR 1 0.025 0.6350 0.476 2.57E-13 
GPR65 14 -0.025 0.6364 0.336 5.57E-07 
RNF44 5 -0.024 0.6394 0.319 2.16E-06 
PIK3R3 1 0.024 0.6398 -0.361 6.92E-08 
PIK3CB 3 -0.024 0.6450 0.323 1.69E-06 
FBN2 5 -0.024 0.6454 0.330 9.39E-07 
KLHL22 22 0.024 0.6463 0.325 1.44E-06 
LRPAP1 4 0.024 0.6469 0.343 3.30E-07 
SLC9A6 X -0.024 0.6475 0.328 1.11E-06 
ID2 2 -0.023 0.6582 0.324 1.57E-06 
FGD6 12 0.023 0.6589 0.343 3.19E-07 
GNAI2 3 -0.023 0.6591 0.361 6.74E-08 
ARF5 7 -0.023 0.6623 0.351 1.71E-07 
TBC1D8 2 0.022 0.6682 0.361 6.96E-08 
RGL1 1 -0.022 0.6692 0.699 0 
STX3 11 0.022 0.6695 0.362 6.24E-08 
CLEC4A 12 0.022 0.6728 0.503 6.22E-15 
CYBA 16 -0.022 0.6761 0.334 6.59E-07 
HLA-B 6 0.022 0.6768 0.338 4.96E-07 
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HMMR 5 0.022 0.6772 -0.322 1.74E-06 
NAGA 22 0.021 0.6821 0.525 2.22E-16 
EHD4 15 0.021 0.6837 0.507 3.55E-15 
NOD2 16 0.021 0.6846 0.648 0 
SLC7A6 16 0.021 0.6848 0.348 2.14E-07 
DOCK4 7 0.021 0.6877 0.374 2.11E-08 
DBN1 5 -0.021 0.6879 -0.326 1.27E-06 
SETX 9 0.021 0.6880 0.330 9.10E-07 
ENTPD6 20 -0.021 0.6897 0.330 9.75E-07 
MYH10 17 -0.021 0.6907 -0.368 3.46E-08 
LILRB1 19 0.021 0.6910 0.425 1.09E-10 
NPC2 14 0.021 0.6918 0.319 2.32E-06 
SMARCD3 7 -0.021 0.6929 0.512 1.78E-15 
TIAM1 21 -0.021 0.6930 0.661 0 
C1GALT1C1 X 0.021 0.6930 0.317 2.70E-06 
LRP1 12 0.020 0.6953 0.486 6.62E-14 
ACAA1 3 0.020 0.6971 0.351 1.70E-07 
MTMR11 1 0.020 0.6975 0.546 0 
DYNLT1 6 -0.020 0.6980 0.354 1.21E-07 
TGOLN2 2 -0.020 0.6983 0.433 4.83E-11 
FYB 5 -0.020 0.6983 0.511 1.78E-15 
TAPBPL 12 0.020 0.7003 0.322 1.74E-06 
CBX6 22 0.020 0.7020 0.322 1.75E-06 
PSEN1 14 -0.020 0.7038 0.364 5.45E-08 
CTBS 1 -0.020 0.7043 0.409 6.40E-10 
TFDP2 3 -0.020 0.7043 -0.424 1.32E-10 
ARNTL 11 0.020 0.7070 0.415 3.46E-10 
GIMAP4 7 0.019 0.7102 0.536 0 
ENTPD1 10 0.019 0.7106 0.419 2.35E-10 
PMM1 22 -0.019 0.7119 0.385 7.17E-09 
AGER 6 -0.019 0.7149 0.318 2.44E-06 
GLRX 5 -0.019 0.7171 0.429 7.13E-11 
ZNF217 20 -0.019 0.7186 0.338 5.09E-07 
RPS6KA3 X -0.019 0.7190 0.401 1.53E-09 
CYP27A1 2 0.019 0.7193 0.517 8.88E-16 
CREB5 7 0.019 0.7211 0.494 2.22E-14 
AIP 11 -0.018 0.7232 0.319 2.27E-06 
ZYX 7 -0.018 0.7233 0.461 1.75E-12 
CYLD 16 0.018 0.7235 0.322 1.81E-06 
CLN3 16 0.018 0.7268 0.359 8.34E-08 
IL10RA 11 0.018 0.7286 0.441 1.91E-11 
RPS6KA1 1 0.018 0.7309 0.364 4.98E-08 
ANXA1 9 -0.018 0.7320 0.431 5.98E-11 
CTSH 15 -0.018 0.7340 0.343 3.22E-07 
TCF4 18 -0.018 0.7351 -0.324 1.53E-06 
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ATF6 1 0.018 0.7356 0.326 1.31E-06 
PGS1 17 -0.017 0.7380 0.365 4.60E-08 
LAMP3 3 -0.017 0.7404 0.407 7.88E-10 
KIAA0125 14 0.017 0.7404 -0.386 6.64E-09 
C1orf21 1 0.017 0.7425 -0.319 2.26E-06 
IL27RA 19 -0.017 0.7428 0.400 1.67E-09 
SASH1 6 -0.017 0.7437 0.434 4.23E-11 
DLEU1 13 0.017 0.7452 -0.330 9.47E-07 
PXN 12 0.017 0.7456 0.437 2.87E-11 
LGALS1 22 0.017 0.7457 0.349 1.94E-07 
COL5A1 9 0.017 0.7475 -0.328 1.11E-06 
MAP2K1 15 -0.017 0.7476 0.415 3.58E-10 
BLM 15 0.016 0.7509 -0.357 9.65E-08 
RASA4 7 0.016 0.7515 0.443 1.51E-11 
BSPRY 9 -0.016 0.7521 -0.359 7.92E-08 
EDEM3 1 -0.016 0.7521 0.413 4.38E-10 
TYK2 19 -0.016 0.7523 0.403 1.21E-09 
TRPS1 8 -0.016 0.7529 0.331 8.93E-07 
TSPAN14 10 0.016 0.7535 0.361 6.70E-08 
GDAP2 1 0.016 0.7562 0.360 7.22E-08 
TNFRSF10B 8 -0.016 0.7565 0.431 5.62E-11 
TRADD 16 0.016 0.7568 0.351 1.69E-07 
RCBTB2 13 -0.016 0.7610 0.492 2.73E-14 
HMHA1 19 -0.016 0.7639 0.369 3.40E-08 
ITGAL 16 0.015 0.7670 0.367 3.81E-08 
CKAP4 12 0.015 0.7789 0.453 4.37E-12 
TLE4 9 0.015 0.7792 0.363 5.62E-08 
PLCB2 15 -0.014 0.7812 0.410 5.75E-10 
KIAA0319L 1 -0.014 0.7816 0.400 1.68E-09 
RNF13 3 0.014 0.7872 0.329 1.00E-06 
MAP3K1 5 0.014 0.7883 0.363 5.72E-08 
ACVR1B 12 0.014 0.7885 0.335 6.22E-07 
TUBD1 17 0.014 0.7893 0.332 8.30E-07 
TAP1 6 0.014 0.7897 0.324 1.51E-06 
ANXA2 15 0.014 0.7907 0.365 4.65E-08 
GLB1 3 -0.014 0.7915 0.520 4.44E-16 
GABBR1 6 0.014 0.7927 0.443 1.48E-11 
LRRFIP1 2 0.014 0.7949 0.378 1.37E-08 
ATP6V0E1 5 -0.013 0.7950 0.354 1.24E-07 
UROS 10 -0.013 0.7967 -0.334 6.72E-07 
KLF4 9 0.013 0.7976 0.340 4.06E-07 
ARHGAP26 5 -0.013 0.7997 0.358 9.17E-08 
TIMP1 X -0.013 0.8003 0.441 1.91E-11 
GGA3 17 0.013 0.8006 0.320 2.15E-06 
PAWR 12 0.013 0.8058 -0.398 1.95E-09 
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SPATS2 12 0.012 0.8102 -0.373 2.35E-08 
ARRB2 17 0.012 0.8105 0.578 0 
YWHAB 20 -0.012 0.8106 0.400 1.60E-09 
LAPTM5 1 0.012 0.8106 0.344 2.94E-07 
MTO1 6 0.012 0.8118 0.332 7.86E-07 
YPEL1 22 -0.012 0.8128 -0.430 6.92E-11 
MTMR2 11 -0.012 0.8138 -0.344 2.88E-07 
AZI2 3 -0.012 0.8165 0.363 5.47E-08 
MTMR14 3 0.012 0.8175 0.343 3.27E-07 
WDR1 4 -0.011 0.8272 0.374 2.15E-08 
TSPO 22 -0.011 0.8290 0.474 3.27E-13 
LAMC1 1 -0.011 0.8311 -0.354 1.30E-07 
PACSIN2 22 -0.011 0.8346 0.361 7.10E-08 
WEE1 11 0.010 0.8409 -0.509 2.83E-15 
TPK1 7 -0.010 0.8431 0.538 0 
WAPAL 10 -0.010 0.8434 0.353 1.34E-07 
IRS2 13 0.010 0.8446 0.323 1.63E-06 
SEL1L 14 -0.010 0.8486 0.334 6.61E-07 
AKAP13 15 0.010 0.8519 0.383 9.03E-09 
HIST1H1C 6 0.010 0.8521 -0.359 8.08E-08 
SCML1 X -0.009 0.8552 0.459 2.21E-12 
CRTAP 3 0.009 0.8552 0.321 1.97E-06 
MTHFS 15 0.009 0.8561 0.324 1.55E-06 
M6PR 12 0.009 0.8583 0.391 3.91E-09 
VPS54 2 0.009 0.8602 0.323 1.65E-06 
SULT1A4 16 -0.009 0.8616 0.333 7.63E-07 
ADI1 2 -0.009 0.8621 0.352 1.55E-07 
MAK 6 0.009 0.8623 0.343 3.17E-07 
OS9 12 -0.009 0.8645 0.411 5.44E-10 
TREX1 3 -0.009 0.8647 0.337 5.50E-07 
MAP3K3 17 0.009 0.8657 0.523 4.44E-16 
UBL3 13 -0.009 0.8672 0.410 5.94E-10 
PHF7 3 -0.009 0.8684 -0.374 2.17E-08 
TGFBI 5 -0.009 0.8688 0.456 2.95E-12 
HSPBAP1 3 -0.008 0.8702 0.415 3.43E-10 
MIPEP 13 0.008 0.8710 -0.335 6.35E-07 
CD28 2 0.008 0.8730 0.335 6.52E-07 
VANGL1 1 0.008 0.8733 -0.322 1.78E-06 
NAIP 5 0.008 0.8740 0.492 2.84E-14 
FRAT1 10 -0.008 0.8804 0.422 1.59E-10 
NXF1 11 -0.008 0.8845 0.342 3.66E-07 
VASH1 14 0.007 0.8858 0.423 1.51E-10 
FKBP15 9 -0.007 0.8868 0.495 1.91E-14 
MTCH1 6 0.007 0.8885 0.349 1.88E-07 
CECR5 22 0.007 0.8895 0.421 1.76E-10 
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ARHGEF10L 1 0.007 0.8902 0.514 1.33E-15 
PLAUR 19 -0.007 0.8930 0.346 2.54E-07 
LAP3 4 -0.007 0.8933 0.363 5.47E-08 
SAT1 X 0.007 0.8938 0.395 2.60E-09 
NUP214 9 0.007 0.8951 0.498 1.29E-14 
ARPC5 1 -0.007 0.8954 0.349 1.98E-07 
FAM45B X -0.007 0.8968 0.342 3.45E-07 
PSMC3IP 17 -0.007 0.8970 0.364 5.20E-08 
PGK1 X -0.007 0.8984 0.401 1.51E-09 
IFNGR1 6 0.007 0.8993 0.342 3.56E-07 
IFNAR2 21 -0.007 0.9000 0.434 4.11E-11 
SERPINB2 18 0.007 0.9001 0.362 6.45E-08 
APOBEC3A 22 0.006 0.9005 0.344 2.94E-07 
AAK1 2 -0.006 0.9014 0.371 2.78E-08 
PLK4 4 0.006 0.9020 -0.347 2.40E-07 
MTMR6 13 -0.006 0.9027 0.384 7.95E-09 
DHFR 5 0.006 0.9043 -0.331 8.78E-07 
CSTB 21 0.006 0.9116 0.438 2.80E-11 
UBQLN2 X 0.006 0.9131 0.350 1.80E-07 
HMOX1 22 -0.006 0.9143 0.357 9.61E-08 
OCEL1 19 -0.005 0.9157 0.358 8.60E-08 
DHX16 6 -0.005 0.9199 0.323 1.65E-06 
RNASEL 1 0.005 0.9216 0.479 1.58E-13 
BTN2A1 6 0.005 0.9263 0.329 1.06E-06 
ALDH3A2 17 0.005 0.9266 0.492 2.89E-14 
NFKB1 4 0.005 0.9280 0.425 1.17E-10 
CEBPD 8 0.005 0.9300 0.384 7.72E-09 
NPEPL1 20 0.005 0.9305 0.323 1.60E-06 
HBEGF 5 -0.004 0.9317 0.499 1.11E-14 
SORBS1 10 -0.004 0.9355 -0.327 1.21E-06 
ELOVL6 4 -0.004 0.9366 -0.358 9.01E-08 
CORO2A 9 -0.004 0.9381 0.406 8.49E-10 
CNN2 19 0.004 0.9392 0.325 1.36E-06 
CAP1 1 -0.004 0.9398 0.375 1.94E-08 
MGAT1 5 -0.004 0.9404 0.472 4.26E-13 
DECR1 8 -0.004 0.9416 0.318 2.39E-06 
TFCP2 12 0.004 0.9426 0.336 5.85E-07 
SULT1A1 16 0.004 0.9439 0.429 7.39E-11 
DHRS4 14 -0.004 0.9461 0.318 2.36E-06 
ATRN 20 -0.003 0.9467 0.343 3.19E-07 
INPP4A 2 -0.003 0.9499 0.371 2.63E-08 
SLC35A1 6 -0.003 0.9503 0.420 1.90E-10 
CAMTA2 17 0.003 0.9519 0.455 3.53E-12 
SERINC5 5 0.003 0.9530 0.503 6.66E-15 
C5AR1 19 0.003 0.9532 0.345 2.81E-07 
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DSG2 18 0.003 0.9534 -0.334 6.74E-07 
HCLS1 3 0.003 0.9548 0.370 3.02E-08 
NAGK 2 -0.003 0.9550 0.494 2.31E-14 
VAMP3 1 -0.003 0.9552 0.387 6.22E-09 
CST3 20 0.003 0.9558 0.501 8.44E-15 
VPS45 1 0.003 0.9573 0.341 3.87E-07 
RETSAT 2 -0.003 0.9574 0.320 2.12E-06 
SNX1 15 0.003 0.9587 0.397 2.15E-09 
PRNP 20 -0.002 0.9625 0.344 2.91E-07 
ERP29 12 0.002 0.9702 0.325 1.37E-06 
SFXN3 10 0.002 0.9729 0.324 1.53E-06 
WDHD1 14 0.002 0.9738 -0.375 1.95E-08 
NRBF2 10 0.002 0.9739 0.395 2.64E-09 
RRAS2 11 0.002 0.9769 -0.375 1.87E-08 
LILRA1 19 0.001 0.9777 0.396 2.47E-09 
PADI2 1 -0.001 0.9778 0.400 1.63E-09 
TMEM127 2 -0.001 0.9786 0.340 4.09E-07 
KLHL2 4 0.001 0.9828 0.329 1.04E-06 
COTL1 16 -0.001 0.9848 0.454 4.23E-12 
DAZAP2 12 0.001 0.9878 0.358 8.84E-08 
CCDC109B 4 -0.001 0.9887 0.352 1.50E-07 
ULK2 17 0.000 0.9943 0.424 1.25E-10 
VASP 19 0.000 0.9943 0.338 4.92E-07 
ALDH3B1 11 0.000 0.9945 0.343 3.35E-07 
ACVR1 2 0.000 0.9951 0.502 7.11E-15 
HTATIP2 11 0.000 0.9958 0.321 1.91E-06 
HCK 20 0.000 0.9962 0.335 6.19E-07 
PHF20L1 8 0.000 0.9965 0.333 7.69E-07 
S100A10 1 0.000 0.9974 0.561 0 
SLC31A2 9 0.000 0.9978 0.456 3.27E-12 
RASGRP3 2 0.000 0.9997 -0.322 1.84E-06 
VIPR1 3 NA NA 0.736 0 
CD163 12 NA NA 0.591 0 
PCSK5 9 NA NA 0.570 0 
RTN1 14 NA NA 0.556 0 
CACNA2D3 3 NA NA 0.555 0 
CRISPLD2 16 NA NA 0.544 0 
FBP1 9 NA NA 0.530 0 
HNMT 2 NA NA 0.520 4.44E-16 
ZNF467 7 NA NA 0.519 4.44E-16 
ASGR2 17 NA NA 0.519 6.66E-16 
TLR5 1 NA NA 0.518 6.66E-16 
TREM1 6 NA NA 0.518 8.88E-16 
TMEM176A 7 NA NA 0.503 6.22E-15 
SIGLEC1 20 NA NA 0.500 9.77E-15 
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LGALS2 22 NA NA 0.496 1.69E-14 
ADAMTSL4 1 NA NA 0.494 2.26E-14 
SECTM1 17 NA NA 0.493 2.53E-14 
SULT1B1 4 NA NA 0.493 2.53E-14 
VSIG4 X NA NA 0.491 3.22E-14 
VENTX 10 NA NA 0.491 3.29E-14 
FCN1 9 NA NA 0.491 3.31E-14 
MS4A6A 11 NA NA 0.489 4.55E-14 
FCGR1B 1 NA NA 0.487 6.15E-14 
KBTBD11 8 NA NA 0.474 3.40E-13 
FCGR1A 1 NA NA 0.473 3.71E-13 
CD14 5 NA NA 0.469 6.09E-13 
CCR2 3 NA NA 0.467 8.00E-13 
CSF2RA X NA NA 0.467 8.23E-13 
TMEM176B 7 NA NA 0.466 9.20E-13 
MRC1 10 NA NA 0.461 1.73E-12 
MAPK10 4 NA NA 0.453 4.34E-12 
STEAP4 7 NA NA 0.453 4.40E-12 
P2RY13 3 NA NA 0.452 5.20E-12 
CLEC4E 12 NA NA 0.452 5.36E-12 
FPR1 19 NA NA 0.439 2.24E-11 
SEZ6L 22 NA NA 0.433 4.46E-11 
IL1RN 2 NA NA 0.433 4.60E-11 
MEFV 16 NA NA 0.433 4.67E-11 
TLR8 X NA NA 0.432 5.37E-11 
PPARGC1A 4 NA NA 0.428 7.94E-11 
RNASE4 14 NA NA 0.427 9.46E-11 
CSTA 3 NA NA 0.419 2.31E-10 
IGSF6 16 NA NA 0.415 3.36E-10 
VNN3 6 NA NA 0.407 8.35E-10 
CSF3R 1 NA NA 0.406 8.54E-10 
DSG1 18 NA NA 0.404 1.13E-09 
CLEC7A 12 NA NA 0.388 5.59E-09 
THBD 20 NA NA 0.382 9.82E-09 
CLEC10A 17 NA NA 0.381 1.10E-08 
SMPDL3A 6 NA NA 0.372 2.43E-08 
FCAR 19 NA NA 0.372 2.50E-08 
CACNA1I 22 NA NA 0.368 3.51E-08 
TGFA 2 NA NA 0.362 6.11E-08 
EPB41L3 18 NA NA 0.359 8.34E-08 
CPVL 7 NA NA 0.358 8.56E-08 
CALCA 11 NA NA 0.358 8.74E-08 
MAFB 20 NA NA 0.356 1.11E-07 
STAB1 3 NA NA 0.354 1.27E-07 
ICOS 2 NA NA 0.353 1.37E-07 
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CD5 11 NA NA 0.346 2.58E-07 
GNAQ 9 NA NA 0.345 2.69E-07 
SLA 8 NA NA 0.344 3.00E-07 
CDA 1 NA NA 0.344 3.01E-07 
HAL 12 NA NA 0.339 4.41E-07 
EGLN2 19 NA NA 0.337 5.49E-07 
CLEC1A 12 NA NA 0.336 5.57E-07 
HK3 5 NA NA 0.334 6.82E-07 
LILRA5 19 NA NA 0.333 7.62E-07 
S100A12 1 NA NA 0.332 7.97E-07 
NBPF14 1 NA NA 0.328 1.13E-06 
RIN2 20 NA NA 0.326 1.30E-06 
BCL6 3 NA NA 0.324 1.49E-06 
NBPF10 1 NA NA 0.321 1.90E-06 
CEBPA 19 NA NA 0.321 1.97E-06 
SLC8A1 2 NA NA 0.317 2.67E-06 
CFH 1 NA NA -0.317 2.61E-06 
MPDZ 9 NA NA -0.318 2.51E-06 
SPTA1 1 NA NA -0.318 2.38E-06 
CRYGD 2 NA NA -0.319 2.20E-06 
CRHBP 5 NA NA -0.321 1.93E-06 
HIST1H2BE 6 NA NA -0.323 1.63E-06 
GSTM5 1 NA NA -0.324 1.50E-06 
MPPED2 11 NA NA -0.324 1.48E-06 
MYOZ3 5 NA NA -0.325 1.46E-06 
HMGA2 12 NA NA -0.325 1.45E-06 
HIST1H2BF 6 NA NA -0.325 1.38E-06 
NPR3 5 NA NA -0.329 9.83E-07 
HIST1H2BI 6 NA NA -0.330 9.52E-07 
TEK 9 NA NA -0.331 8.60E-07 
IGLL1 22 NA NA -0.331 8.59E-07 
HIST1H2BH 6 NA NA -0.336 6.03E-07 
COBLL1 2 NA NA -0.336 5.86E-07 
ENAH 1 NA NA -0.336 5.66E-07 
ADAMTS3 4 NA NA -0.338 5.01E-07 
KHDRBS2 6 NA NA -0.339 4.62E-07 
KLF1 19 NA NA -0.339 4.38E-07 
AGTR1 3 NA NA -0.349 1.97E-07 
HIST1H4C 6 NA NA -0.352 1.48E-07 
HIST1H3C 6 NA NA -0.355 1.20E-07 
HOXA10 7 NA NA -0.358 9.16E-08 
AKR1C2 10 NA NA -0.359 8.42E-08 
MYT1L 2 NA NA -0.360 7.55E-08 
FAT4 4 NA NA -0.360 7.26E-08 
JAKMIP2 5 NA NA -0.361 6.68E-08 
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NUDT11 X NA NA -0.363 5.90E-08 
CYTL1 4 NA NA -0.366 4.35E-08 
TFPI 2 NA NA -0.371 2.66E-08 
AKR1C3 10 NA NA -0.398 2.01E-09 
TSPAN13 7 NA NA -0.432 5.59E-11 
 
 
 
Supplementary Table 4.2. eQTLs for genes co-expressed with IL6R. 
*Proxy SNPs were chosen based on an r2 > 0.8. Abbreviations: BP, base pair; Chr, chromosome; 
SNP, single nucleotide polymorphism. 
No SNP Chr bp 
Gene 
regulated by 
a risk SNP Proxy SNP* P-value Sample Study 
1 rs9611485 22 41060886 EP300 rs9611462 0 Lung 194 
 rs9611485 22 41060886 PMM1 rs9611485 4.67E-06 LCLs 
181
 
2 rs324011 12 57108399 STAT6 rs12368672 9.81E-198 Whole-Blood 195 
3 rs8003392 14 76672868 VASH1 rs10873292 9.81E-198 Whole-Blood 195 
4 rs4911214 20 32299661 TM9SF4 rs6141641 3.03E-184 Whole-Blood 195 
5 rs4778892 15 81312048 IL16 rs3726 1.57E-183 Whole-Blood 195 
6 rs10197862 2 102350089 IL18RAP rs10197862 2.82E-137 Whole-Blood 195 
 rs10197862 2 102350089 IL18R1 rs950881 0.0003 Whole-Blood 
195
 
7 rs731945 19 18456229 ELL rs731945 1.27E-135 Whole-Blood 195 
8 rs2267076 22 24434627 UPB1 rs1008931 4.45E-98 Whole-Blood 195 
9 rs785472 1 46052616 PIK3R3 rs1707321 3.04E-62 Whole-Blood 197 
10 rs4833095 4 38798089 TLR1 rs12233670 2.80E-57 Whole-Blood 197 
11 rs7223589 17 31401266 EVI2A rs10512434 1.32E-56 Whole-Blood 195 
 rs7223589 17 31401266 EVI2B rs2525570 2.15E-06 Whole-Blood 
195
 
12 rs11602465 11 9943274 ADM rs12421179 5.90E-56 Whole-Blood 195 
13 rs13020280 2 223941421 WDFY1 rs6734908 1.83E-43 Whole-Blood 195 
14 rs10845506 12 12282676 LRP6 rs1071994 2.51E-40 Whole-Blood 197 
15 rs9289837 3 151388204 MED12L rs13327359 2.42E-37 Whole-Blood 195 
 rs9289837 3 151388204 P2RY13 rs7637803 2.01E-14 Whole-Blood 
195
 
16 rs6790914 3 49168885 USP4 rs10865954 3.57E-33 Whole-Blood 195 
 rs6790914 3 49168885 NDUFAF3 rs10865954 0.0034 Whole-Blood 
195
 
17 rs7155696 14 35027548 SRP54 rs12890307 1.98E-27 Whole-Blood 195 
18 rs12502586 4 15724941 FBXL5 rs12502586 6.06E-19 Whole-Blood 195 
19 rs162328 2 38091546 CYP1B1 rs4670814 6.33E-18 Whole-Blood 195 
20 rs17061789 3 60014239 FHIT rs17061789 8.06E-18 Whole-Blood 195 
21 rs7234644 18 56770128 TXNL1 rs7234644 9.19E-17 Whole-Blood 195 
22 rs13212921 6 27237643 BTN2A1 rs13217285 1.72E-15 LCLs 181 
23 rs11265424 1 160530060 SLAMF1 rs6670721 2.96E-15 Whole-Blood 195 
24 rs17710743 19 41569079 CEACAM21 rs16975338 4.76E-14 Whole-Blood 195 
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25 rs56872707 5 80898586 DHFR rs13159448 1.42E-13 LCLs 181 
26 rs10101062 8 123112091 ZHX2 rs7012815 1.78E-13 Whole-Blood 195 
27 rs4942758 13 48213854 ITM2B rs551034 2.18E-13 Whole-Blood 195 
28 rs6949090 7 67432703 STAG3L4 rs10233061 2.99E-12 PBMCs 193 
29 rs2357792 16 50734311 NOD2 rs7342715 3.45E-11 PBMCs 193 
30 rs7185536 16 67958261 SLC7A6 rs1107767 4.94E-11 PBMCs 193 
 rs7185536 16 67958261 PSMB10 rs1133090 3.35E-07 Whole-Blood 
197
 
31 rs11000805 10 73903593 NDST2 rs17741873 2.68E-10 Whole-Blood 195 
32 rs1464510 3 188394766 BCL6 rs9864529 5.22E-10 PBMCs 193 
33 rs12757280 1 150753573 CTSS rs55972172 1.35E-09 LCLs 181 
34 rs9890550 17 75018845 SLC16A5 rs12449492 7.19E-09 Whole-Blood 195 
35 rs28631821 14 55379269 DLGAP5 rs7147136 1.02E-08 LCLs 181 
36 rs2419618 10 112316082 ACSL5 rs2419618 1.28E-08 LCLs 181 
37 rs931702 3 113215905 SIDT1 rs931702 3.10E-08 LCLs 181 
38 rs13416555 2 8301605 ID2 rs891058 6.05E-08 PBMCs 193 
39 rs9630721 17 6947049 ASGR2 rs9630722 6.08E-08 Whole-Blood 195 
40 rs1757460 15 41498262 NUSAP1 rs1757457 8.65E-08 LCLs 181 
41 rs9298557 8 56981127 IMPAD1 rs9298557 1.03E-07 Lung 194 
42 rs3827279 22 17115039 IL17RA rs3827278 3.33E-07 Lung 194 
43 rs10501420 11 74784992 RNF169 rs17133608 3.49E-07 PBMCs 193 
44 rs11167763 5 142055901 NDFIP1 rs6884380 5.45E-07 LCLs 181 
45 rs4653051 1 33333327 PHC2 rs4653015 1.05E-06 Whole-Blood 197 
46 rs12048743 1 205145745 DSTYK rs1572993 1.15E-06 Monocytes 189 
47 rs7946115 11 65598721 FRMD8 rs10791820 1.61E-06 LCLs 181 
48 rs12709916 19 49817730 PTOV1 rs12709916 1.96E-06 LCLs 181 
49 rs4725618 7 143425331 ZYX rs6951852 2.43E-06 Whole-Blood 195 
50 rs758206 7 140204661 TBXAS1 rs6956540 2.70E-06 Whole-Blood 195 
51 rs2797414 1 113752816 RSBN1 rs6537798 3.09E-06 Whole-Blood 195 
52 rs2071595 6 31539285 HLA-B rs3219184 3.98E-06 LCLs 181 
53 rs25987 5 14712600 FAM105A rs31926 5.06E-06 Lung 194 
54 rs6511788 19 12369223 MAN2B1 rs10411986 5.22E-06 LCLs 181 
55 rs2453570 17 19474180 ALDH3A2 rs2428584 6.11E-06 Whole-Blood 195 
56 rs10245342 7 64627050 ZNF736 rs4313046 6.23E-06 LCLs 181 
57 rs1163073 10 103263177 SH3PXD2A rs7911488 1.33E-05 Whole-Blood 195 
58 rs10431490 12 51931787 SMAGP rs10783481 2.15E-05 Monocytes 189 
59 rs2033466 5 151701814 SPARC rs2033466 2.28E-05 Whole-Blood 195 
60 rs2167524 18 54644208 MBD2 rs1077553 5.15E-05 Lung 194 
61 rs2435206 17 45980745 NSF rs2435211 9.38E-05 LCLS 190 
62 rs7039317 9 34964538 STOML2 rs10972275 9.58E-05 Whole-Blood 195 
63 rs540178 9 117547445 TLR4 rs540178 0.0002 Whole-Blood 195 
64 rs13268953 8 28197719 KIF13B rs13268953 0.0002 Monocytes 189 
65 rs9989026 12 7105855 CD163 rs6487290 0.0002 Monocytes 189 
66 rs13256893 8 89664751 RIPK2 rs13256893 0.0003 Whole-Blood 195 
67 rs34097828 14 94321337 SERPINA1 rs3748320 0.0003 Whole-Blood 195 
68 rs2071390 16 30070046 CORO1A rs2071390 0.0003 Whole-Blood 195 
69 rs2251083 10 133461697 ECHS1 rs2255518 0.0003 Whole-Blood 195 
70 rs3918188 7 151005693 TMEM176A rs3918188 0.0004 Whole-Blood 195 
71 rs7596735 2 44105567 PREPL rs7596735 0.0004 Whole-Blood 195 
72 rs2391391 1 94986370 CNN3 rs2391391 0.0004 B-cells 189 
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73 rs6792409 3 69465422 FRMD4B rs17432953 0.0004 Whole-Blood 195 
74 rs4687721 3 51564238 PPM1M rs11719995 0.0005 Monocytes 189 
75 rs1501534 1 37221817 MTF1 rs1566599 0.0006 B-cells 189 
76 rs35259724 12 113124090 OAS3 rs17643821 0.0006 B-cells 189 
77 rs2932967 4 23813502 PPARGC1A rs2932965 0.0006 Whole-Blood 195 
78 rs4944804 11 72809485 ARAP1 rs663015 0.0009 Whole-Blood 195 
79 rs1253118 14 59497301 RTN1 rs956901 0.0016 Whole-Blood 195 
80 rs1288354 1 53134678 C1orf123 rs1288354 0.0017 Whole-Blood 195 
81 rs6544629 2 43142628 ZFP36L2 rs12105183 0.0022 Whole-Blood 195 
82 rs17125240 8 17751387 MTUS1 rs3862101 0.0026 Whole-Blood 195 
83 rs6134069 20 10882886 JAG1 rs6134067 0.0027 Whole-Blood 195 
84 rs7246816 19 15403849 BRD4 rs3826863 0.0031 Whole-Blood 195 
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